Eigene Vorlage

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Mepolizumab (Nucala) – HES

GlaxoSmithKline GmbH & Co. KG

Separater Anhang 4-G zu Modul 4C

Tabellen und Abbildungen

Stand: 24.11.2021

Inhaltsverzeichnis

15 Subgruppenanalysen zu Anteil Patienten mit einem HES-Schub aus RCT mit dem zu bewertenden Arzneimittel (Woche 20-32)

16 Subgruppenanalysen zu Zeit bis zum ersten HES-Schub aus RCT mit dem zu bewertenden Arzneimittel

17 Subgruppenanalysen zu Rate an HES-Schüben aus RCT mit dem zu bewertenden Arzneimittel

18 Subgruppenanalysen zu Veränderung des Gesamt-BFI Scores aus RCT mit dem zu bewertenden Arzneimittel

19 Subgruppenanalysen zu Veränderung des BFI Item 3 aus RCT mit dem zu bewertenden Arzneimittel

20 Subgruppenanalysen zu Veränderung der HES-DS aus RCT mit dem zu bewertenden Arzneimittel

21 Subgruppenanalysen zu Gesamtansprechen auf die Therapie aus RCT mit dem zu bewertenden Arzneimittel

22 Subgruppenanalysen zu Veränderung in der Schwere der Symptome (durch den Patienten beurteilt) aus RCT mit dem zu bewertenden Arzneimittel

23 Subgruppenanalysen zu Veränderung der modifizierten MSAS-SF aus RCT mit dem zu bewertenden Arzneimittel

24 Subgruppenanalysen zu Veränderung des PROMIS – Körperliche Funktion Score aus RCT mit dem zu bewertenden Arzneimittel

25 Subgruppenanalysen zu Veränderung des PROMIS – Schlaf Score aus RCT mit dem zu bewertenden Arzneimittel

26 Subgruppenanalysen zu SF-36 Responder (Physical Component Summary Scores ≥5 Punkte) aus RCT mit dem zu bewertenden Arzneimittel

27 Subgruppenanalysen zu SF-36 Responder (Mental Component Summary Scores ≥ 5 Punkte) aus RCT mit dem zu bewertenden Arzneimittel

28 Subgruppenanalysen zu WPAI (Versäumte Arbeitszeit aufgrund aufgrund von Krankheit) aus RCT mit dem zu bewertenden Arzneimittel

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	BFI Total	n	49	50
		Mean	3.92	4.23
		SD	2.610	2.565
		Median	3.67	4.11
		Min.	0.0	0.1
		Max.	8.4	9.1
Week 1	BFI Total	n	46	50
		Mean	3.73	3.88
		SD	2.563	2.529
		Median	3.56	3.83
		Min.	0.0	0.0
		Max.	10.0	9.4
	Change from Baseline	n	43	46
		Mean	-0.33	-0.19
		SD	1.681	1.293
		Median	-0.22	-0.06
		Min.	-8.0	-3.0
		Max.	2.9	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 2	BFI Total	n	48	48
		Mean	3.55	3.56
		SD	2.444	2.454
		Median	3.67	3.06
		Min.	0.0	0.0
		Max.	9.8	8.6
	Change from Baseline	n	45	46
		Mean	-0.34	-0.60
		SD	1.350	1.318
		Median	-0.22	-0.39
		Min.	-3.8	-2.9
		Max.	2.1	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 3	BFI Total	n	48	49
		Mean	3.29	3.24
		SD	2.440	2.529
		Median	3.17	2.56
		Min.	0.0	0.0
		Max.	10.0	9.3
	Change from Baseline	n	45	45
		Mean	-0.41	-0.90
		SD	1.207	2.155
		Median	-0.22	-0.33
		Min.	-4.2	-7.2
		Max.	1.6	2.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 4	BFI Total	n	47	49
		Mean	3.15	3.31
		SD	2.508	2.355
		Median	3.00	2.78
		Min.	0.0	0.0
		Max.	10.0	9.0
	Change from Baseline	n	43	47
		Mean	-0.58	-0.82
		SD	1.923	1.916
		Median	-0.11	-0.44
		Min.	-8.2	-6.2
		Max.	2.9	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 5	BFI Total	n	35	43
		Mean	3.08	2.97
		SD	2.771	2.480
		Median	2.22	1.89
		Min.	0.0	0.0
		Max.	10.0	9.0
	Change from Baseline	n	35	41
		Mean	-0.92	-1.12
		SD	1.868	2.104
		Median	-0.56	-0.67
		Min.	-5.8	-6.2
		Max.	2.1	2.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 6	BFI Total	n	44	50
		Mean	3.60	3.47
		SD	2.646	2.463
		Median	3.39	3.67
		Min.	0.0	0.0
		Max.	10.0	9.3
	Change from Baseline	n	44	48
		Mean	-0.53	-0.84
		SD	1.612	2.217
		Median	-0.39	-0.33
		Min.	-5.8	-6.9
		Max.	1.8	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 7	BFI Total	n	46	51
		Mean	3.21	3.44
		SD	2.560	2.690
		Median	3.06	3.00
		Min.	0.0	0.0
		Max.	10.0	8.9
	Change from Baseline	n	43	48
		Mean	-0.56	-0.90
		SD	1.965	1.964
		Median	0.00	-0.67
		Min.	-5.9	-6.7
		Max.	3.8	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	BFI Total	n	45	47
		Mean	3.03	3.40
		SD	2.582	2.455
		Median	2.67	3.00
		Min.	0.0	0.0
		Max.	8.3	8.2
	Change from Baseline	n	42	46
		Mean	-0.64	-0.69
		SD	1.640	2.261
		Median	-0.11	-0.22
		Min.	-6.7	-6.3
		Max.	1.9	6.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 9	BFI Total	n	38	42
		Mean	2.68	3.21
		SD	2.353	2.390
		Median	2.28	2.67
		Min.	0.0	0.0
		Max.	6.8	8.0
	Change from Baseline	n	37	39
		Mean	-0.79	-0.74
		SD	1.980	1.903
		Median	-0.11	-0.33
		Min.	-6.3	-5.8
		Max.	2.2	2.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 10	BFI Total	n	44	49
		Mean	3.23	3.32
		SD	2.495	2.464
		Median	3.00	3.11
		Min.	0.0	0.0
		Max.	9.7	8.4
	Change from Baseline	n	42	47
		Mean	-0.73	-0.96
		SD	1.906	1.901
		Median	-0.17	-0.67
		Min.	-6.7	-6.7
		Max.	2.0	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 11	BFI Total	n	39	43
		Mean	3.21	3.11
		SD	2.552	2.475
		Median	3.11	2.33
		Min.	0.0	0.0
		Max.	9.8	8.7
	Change from Baseline	n	39	40
		Mean	-0.74	-0.96
		SD	1.922	2.064
		Median	-0.33	-0.67
		Min.	-6.0	-6.3
		Max.	2.9	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 12	BFI Total	n	42	46
		Mean	3.08	3.35
		SD	2.431	2.453
		Median	2.78	2.94
		Min.	0.0	0.0
		Max.	9.9	8.2
	Change from Baseline	n	41	42
		Mean	-0.83	-0.79
		SD	1.947	2.044
		Median	-0.33	-0.61
		Min.	-6.6	-6.4
		Max.	2.4	6.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 13	BFI Total	n	31	40
		Mean	2.78	3.57
		SD	2.634	2.325
		Median	2.33	3.06
		Min.	0.0	0.3
		Max.	10.0	8.0
	Change from Baseline	n	31	37
		Mean	-1.25	-0.76
		SD	1.929	2.069
		Median	-0.78	-0.11
		Min.	-5.7	-6.3
		Max.	2.6	2.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 14	BFI Total	n	45	47
		Mean	2.95	3.13
		SD	2.526	2.392
		Median	2.78	2.67
		Min.	0.0	0.0
		Max.	9.1	8.4
	Change from Baseline	n	43	45
		Mean	-0.91	-0.89
		SD	2.075	1.699
		Median	-0.22	-0.78
		Min.	-6.1	-5.7
		Max.	2.6	2.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 15	BFI Total	n	38	45
		Mean	3.61	3.35
		SD	2.464	2.552
		Median	3.56	2.78
		Min.	0.0	0.0
		Max.	9.6	9.6
	Change from Baseline	n	38	42
		Mean	-0.25	-0.67
		SD	2.070	2.140
		Median	-0.06	-0.83
		Min.	-5.9	-6.0
		Max.	4.7	7.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	BFI Total	n	45	47
		Mean	3.04	3.06
		SD	2.399	2.338
		Median	2.44	2.33
		Min.	0.0	0.0
		Max.	8.0	8.3
	Change from Baseline	n	44	44
		Mean	-0.96	-1.02
		SD	1.822	1.663
		Median	-0.33	-0.94
		Min.	-5.9	-6.1
		Max.	2.3	3.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 17	BFI Total	n	33	33
		Mean	2.54	2.82
		SD	2.030	1.887
		Median	2.00	2.33
		Min.	0.0	0.0
		Max.	6.9	8.1
	Change from Baseline	n	31	30
		Mean	-0.83	-1.40
		SD	1.721	1.520
		Median	-0.44	-1.67
		Min.	-5.8	-4.4
		Max.	1.7	1.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 18	BFI Total	n	40	44
		Mean	2.86	3.09
		SD	2.443	2.247
		Median	2.28	2.78
		Min.	0.0	0.0
		Max.	8.6	8.0
	Change from Baseline	n	39	41
		Mean	-0.83	-1.04
		SD	1.970	1.965
		Median	0.00	-0.89
		Min.	-5.2	-4.9
		Max.	2.1	5.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 19	BFI Total	n	45	47
		Mean	3.20	3.03
		SD	2.644	2.085
		Median	2.89	2.78
		Min.	0.0	0.0
		Max.	9.0	7.9
	Change from Baseline	n	44	46
		Mean	-0.59	-1.13
		SD	2.003	2.032
		Median	-0.22	-1.28
		Min.	-6.0	-6.2
		Max.	2.6	3.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 20	BFI Total	n	43	43
		Mean	3.10	2.66
		SD	2.786	2.160
		Median	2.33	2.33
		Min.	0.0	0.0
		Max.	9.9	8.6
	Change from Baseline	n	43	41
		Mean	-0.58	-1.17
		SD	1.927	1.931
		Median	0.00	-1.00
		Min.	-5.0	-6.0
		Max.	3.7	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 21	BFI Total	n	39	40
		Mean	3.08	2.74
		SD	2.732	2.460
		Median	2.11	2.22
		Min.	0.0	0.0
		Max.	10.0	7.8
	Change from Baseline	n	38	38
		Mean	-0.63	-1.42
		SD	2.010	2.234
		Median	-0.11	-0.94
		Min.	-6.3	-6.1
		Max.	3.3	3.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 22	BFI Total	n	41	46
		Mean	3.16	2.94
		SD	2.663	2.391
		Median	2.44	2.50
		Min.	0.0	0.0
		Max.	9.9	8.9
	Change from Baseline	n	41	43
		Mean	-0.52	-1.34
		SD	1.897	2.060
		Median	0.00	-1.44
		Min.	-5.2	-5.8
		Max.	1.8	3.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 23	BFI Total	n	39	42
		Mean	3.19	2.91
		SD	2.976	2.526
		Median	2.44	2.11
		Min.	0.0	0.0
		Max.	10.0	8.6
	Change from Baseline	n	38	40
		Mean	-0.63	-1.23
		SD	2.018	1.874
		Median	-0.11	-1.11
		Min.	-5.6	-5.8
		Max.	4.2	3.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	BFI Total	n	40	41
		Mean	2.91	2.82
		SD	2.623	2.536
		Median	2.17	2.22
		Min.	0.0	0.0
		Max.	7.8	8.8
	Change from Baseline	n	39	38
		Mean	-1.04	-1.33
		SD	2.016	2.074
		Median	-0.33	-1.17
		Min.	-5.9	-6.3
		Max.	1.9	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 25	BFI Total	n	39	38
		Mean	2.79	2.56
		SD	2.247	1.986
		Median	2.22	2.00
		Min.	0.0	0.0
		Max.	8.0	7.6
	Change from Baseline	n	38	36
		Mean	-0.76	-1.21
		SD	2.225	2.263
		Median	-0.33	-1.22
		Min.	-5.3	-6.2
		Max.	3.2	5.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 26	BFI Total	n	42	41
		Mean	2.83	2.54
		SD	2.374	1.959
		Median	2.44	2.00
		Min.	0.0	0.0
		Max.	8.0	7.8
	Change from Baseline	n	40	39
		Mean	-1.14	-1.47
		SD	1.993	2.101
		Median	-0.44	-1.44
		Min.	-5.9	-7.1
		Max.	1.6	3.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 27	BFI Total	n	41	47
		Mean	2.99	2.68
		SD	2.468	2.252
		Median	2.56	2.11
		Min.	0.0	0.0
		Max.	8.3	8.0
	Change from Baseline	n	40	44
		Mean	-0.68	-1.56
		SD	2.008	1.996
		Median	-0.11	-1.17
		Min.	-5.7	-9.1
		Max.	2.3	1.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 28	BFI Total	n	43	44
		Mean	2.98	3.04
		SD	2.648	2.557
		Median	2.89	2.72
		Min.	0.0	0.0
		Max.	8.9	8.0
	Change from Baseline	n	41	41
		Mean	-0.81	-0.99
		SD	1.711	1.949
		Median	-0.33	-0.89
		Min.	-4.3	-5.8
		Max.	2.1	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 29	BFI Total	n	31	34
		Mean	2.72	2.59
		SD	2.355	2.276
		Median	2.67	1.83
		Min.	0.0	0.0
		Max.	7.7	8.0
	Change from Baseline	n	31	34
		Mean	-1.01	-1.89
		SD	2.134	2.003
		Median	0.00	-1.33
		Min.	-6.2	-6.4
		Max.	1.8	0.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 30	BFI Total	n	43	45
		Mean	2.87	2.69
		SD	2.576	2.141
		Median	2.56	2.22
		Min.	0.0	0.0
		Max.	8.2	7.0
	Change from Baseline	n	41	43
		Mean	-0.98	-1.35
		SD	2.208	2.197
		Median	-0.33	-1.56
		Min.	-6.4	-6.3
		Max.	3.0	6.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 31	BFI Total	n	42	45
		Mean	3.30	2.94
		SD	2.494	2.241
		Median	3.06	2.44
		Min.	0.0	0.0
		Max.	8.4	8.1
	Change from Baseline	n	41	44
		Mean	-0.50	-1.05
		SD	2.032	2.245
		Median	0.00	-0.89
		Min.	-5.6	-6.1
		Max.	3.4	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.41
Summary of Total BFI Score

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	BFI Total	n	37	37
		Mean	3.16	2.53
		SD	2.700	2.260
		Median	2.56	1.78
		Min.	0.0	0.0
		Max.	8.8	7.8
	Change from Baseline	n	36	36
		Mean	-0.76	-1.55
		SD	2.157	1.911
		Median	-0.17	-1.11
		Min.	-6.2	-6.1
		Max.	2.0	1.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.49
Analysis of Change from Baseline in Total BFI Score
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	49	50
n [2]	43	47
LS Mean (SE)	3.38 (0.268)	3.12 (0.258)
LS Mean Change (SE)	-0.56 (0.268)	-0.82 (0.258)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.26
95% CI		(-1.00, 0.48)
p-value		0.487
Corrected Hedges g [3]		-0.15
95% CI		(-0.56, 0.27)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Population: Intent-to-Treat

Table 90.49
Analysis of Change from Baseline in Total BFI Score
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	49	50
n [2]	42	46
LS Mean (SE)	3.19 (0.270)	3.24 (0.261)
LS Mean Change (SE)	-0.75 (0.270)	-0.71 (0.261)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.04
95% CI		(-0.70, 0.79)
p-value		0.906
Corrected Hedges g [3]		0.03
95% CI		(-0.39, 0.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.49
Analysis of Change from Baseline in Total BFI Score
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	49	50
n [2]	41	42
LS Mean (SE)	3.17 (0.272)	3.23 (0.266)
LS Mean Change (SE)	-0.78 (0.272)	-0.72 (0.266)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.06
95% CI		(-0.70, 0.81)
p-value		0.881
Corrected Hedges g [3]		0.03
95% CI		(-0.40, 0.46)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Population: Intent-to-Treat

Table 90.49
Analysis of Change from Baseline in Total BFI Score
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	49	50
n [2]	44	44
LS Mean (SE)	2.99 (0.229)	3.03 (0.228)
LS Mean Change (SE)	-0.95 (0.229)	-0.91 (0.228)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.04
95% CI		(-0.61, 0.68)
p-value		0.910
Corrected Hedges g [3]		0.02
95% CI		(-0.39, 0.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Table 90.49
Analysis of Change from Baseline in Total BFI Score
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	49	50
n [2]	43	41
LS Mean (SE)	3.28 (0.273)	2.77 (0.274)
LS Mean Change (SE)	-0.66 (0.273)	-1.17 (0.274)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.51
95% CI		(-1.28, 0.26)
p-value		0.190
Corrected Hedges g [3]		-0.29
95% CI		(-0.72, 0.14)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

Population: Intent-to-Treat

Table 90.49
Analysis of Change from Baseline in Total BFI Score
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	49	50
n [2]	39	38
LS Mean (SE)	3.06 (0.274)	2.74 (0.275)
LS Mean Change (SE)	-0.88 (0.274)	-1.20 (0.275)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.32
95% CI		(-1.09, 0.45)
p-value		0.416
Corrected Hedges g [3]		-0.18
95% CI		(-0.63, 0.26)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.49
Analysis of Change from Baseline in Total BFI Score
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	49	50
n [2]	41	41
LS Mean (SE)	3.21 (0.265)	3.08 (0.265)
LS Mean Change (SE)	-0.74 (0.265)	-0.86 (0.265)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.13
95% CI		(-0.87, 0.62)
p-value		0.732
Corrected Hedges g [3]		-0.08
95% CI		(-0.51, 0.36)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Population: Intent-to-Treat

Table 90.49
Analysis of Change from Baseline in Total BFI Score
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	49	50
n [2]	36	36
LS Mean (SE)	3.39 (0.286)	2.75 (0.286)
LS Mean Change (SE)	-0.56 (0.286)	-1.19 (0.286)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.64
95% CI		(-1.44, 0.17)
p-value		0.118
Corrected Hedges g [3]		-0.37
95% CI		(-0.83, 0.10)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	BFI Item 3	n	54	54
		Mean	4.39	4.74
		SD	2.666	2.575
		Median	4.69	4.46
		Min.	0.0	0.0
		Max.	9.6	9.3
Week 1	BFI Item 3	n	54	54
		Mean	4.03	4.45
		SD	2.635	2.651
		Median	3.99	4.33
		Min.	0.0	0.0
		Max.	9.7	9.9
	Change from Baseline	n	54	54
		Mean	-0.36	-0.30
		SD	1.360	1.140
		Median	-0.43	-0.29
		Min.	-3.8	-3.0
		Max.	3.6	2.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 2	BFI Item 3	n	54	54
		Mean	3.88	4.08
		SD	2.569	2.517
		Median	4.00	4.08
		Min.	0.0	0.0
		Max.	9.8	9.4
	Change from Baseline	n	54	54
		Mean	-0.51	-0.66
		SD	1.374	1.266
		Median	-0.43	-0.57
		Min.	-4.7	-3.8
		Max.	3.4	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 3	BFI Item 3	n	54	54
		Mean	3.69	3.93
		SD	2.593	2.530
		Median	3.38	3.45
		Min.	0.0	0.0
		Max.	10.0	8.2
	Change from Baseline	n	54	54
		Mean	-0.70	-0.82
		SD	1.655	1.726
		Median	-0.43	-0.43
		Min.	-5.5	-6.7
		Max.	3.3	1.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 4	BFI Item 3	n	54	54
		Mean	3.63	3.82
		SD	2.666	2.476
		Median	3.13	3.32
		Min.	0.0	0.0
		Max.	10.0	9.0
	Change from Baseline	n	54	54
		Mean	-0.76	-0.92
		SD	1.783	1.772
		Median	-0.45	-0.68
		Min.	-6.3	-6.9
		Max.	2.0	1.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 5	BFI Item 3	n	47	50
		Mean	3.82	3.87
		SD	2.901	2.682
		Median	3.57	3.07
		Min.	0.0	0.0
		Max.	10.0	8.4
	Change from Baseline	n	47	50
		Mean	-0.67	-1.05
		SD	1.861	1.963
		Median	-0.18	-0.71
		Min.	-4.3	-7.5
		Max.	2.9	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 6	BFI Item 3	n	51	54
		Mean	3.92	3.97
		SD	2.654	2.662
		Median	4.00	3.57
		Min.	0.0	0.0
		Max.	10.0	8.8
	Change from Baseline	n	51	54
		Mean	-0.41	-0.77
		SD	1.718	2.006
		Median	0.00	-0.50
		Min.	-4.4	-7.5
		Max.	5.0	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 7	BFI Item 3	n	52	54
		Mean	3.74	3.86
		SD	2.713	2.635
		Median	3.43	3.00
		Min.	0.0	0.0
		Max.	9.4	8.5
	Change from Baseline	n	52	54
		Mean	-0.63	-0.88
		SD	1.682	2.013
		Median	-0.43	-0.83
		Min.	-4.3	-7.7
		Max.	3.1	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	BFI Item 3	n	52	54
		Mean	3.67	4.00
		SD	2.707	2.555
		Median	3.07	3.90
		Min.	0.0	0.0
		Max.	9.0	8.3
	Change from Baseline	n	52	54
		Mean	-0.71	-0.75
		SD	1.687	2.165
		Median	-0.52	-0.69
		Min.	-5.0	-7.3
		Max.	2.0	4.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 9	BFI Item 3	n	47	50
		Mean	3.61	3.99
		SD	2.737	2.555
		Median	3.20	3.10
		Min.	0.0	0.0
		Max.	8.6	9.0
	Change from Baseline	n	47	50
		Mean	-0.62	-0.63
		SD	1.592	1.846
		Median	-0.29	-0.59
		Min.	-4.5	-7.0
		Max.	2.9	3.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 10	BFI Item 3	n	51	52
		Mean	3.72	3.83
		SD	2.602	2.565
		Median	3.14	3.41
		Min.	0.0	0.0
		Max.	8.8	10.0
	Change from Baseline	n	51	52
		Mean	-0.63	-0.82
		SD	1.681	2.139
		Median	-0.36	-0.57
		Min.	-5.3	-6.8
		Max.	3.2	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 11	BFI Item 3	n	49	52
		Mean	3.72	4.12
		SD	2.624	2.753
		Median	3.14	3.79
		Min.	0.0	0.3
		Max.	8.9	10.0
	Change from Baseline	n	49	52
		Mean	-0.73	-0.57
		SD	1.839	2.368
		Median	-0.43	-0.69
		Min.	-4.4	-6.8
		Max.	3.7	4.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 12	BFI Item 3	n	51	53
		Mean	3.73	3.98
		SD	2.658	2.611
		Median	3.50	4.00
		Min.	0.0	0.0
		Max.	9.3	10.0
	Change from Baseline	n	51	53
		Mean	-0.59	-0.73
		SD	1.693	2.227
		Median	0.00	-0.54
		Min.	-4.8	-7.5
		Max.	3.0	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 13	BFI Item 3	n	43	48
		Mean	3.81	3.97
		SD	2.801	2.547
		Median	4.00	3.83
		Min.	0.0	0.5
		Max.	9.2	10.0
	Change from Baseline	n	43	48
		Mean	-0.87	-0.84
		SD	1.774	2.248
		Median	-0.71	-0.32
		Min.	-4.9	-7.0
		Max.	2.7	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 14	BFI Item 3	n	50	53
		Mean	3.50	4.03
		SD	2.745	2.535
		Median	3.14	4.00
		Min.	0.0	0.4
		Max.	9.0	10.0
	Change from Baseline	n	50	53
		Mean	-0.78	-0.68
		SD	1.933	2.161
		Median	-0.52	-0.43
		Min.	-5.4	-7.3
		Max.	4.0	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 15	BFI Item 3	n	50	53
		Mean	3.70	4.01
		SD	2.634	2.540
		Median	3.43	3.86
		Min.	0.0	0.0
		Max.	9.3	10.0
	Change from Baseline	n	50	53
		Mean	-0.57	-0.71
		SD	1.899	2.188
		Median	-0.21	-0.50
		Min.	-5.5	-6.3
		Max.	4.0	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	BFI Item 3	n	51	52
		Mean	3.78	3.86
		SD	2.742	2.484
		Median	3.29	3.13
		Min.	0.0	0.0
		Max.	9.2	10.0
	Change from Baseline	n	51	52
		Mean	-0.54	-0.82
		SD	1.871	2.132
		Median	-0.29	-0.54
		Min.	-4.4	-6.6
		Max.	3.4	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 17	BFI Item 3	n	41	42
		Mean	3.43	3.93
		SD	2.899	2.519
		Median	2.40	3.86
		Min.	0.0	0.1
		Max.	9.8	10.0
	Change from Baseline	n	41	42
		Mean	-0.69	-0.84
		SD	1.857	2.284
		Median	-0.29	-0.73
		Min.	-4.9	-6.5
		Max.	2.8	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 18	BFI Item 3	n	48	51
		Mean	3.67	3.63
		SD	2.805	2.411
		Median	3.25	3.43
		Min.	0.0	0.0
		Max.	9.5	10.0
	Change from Baseline	n	48	51
		Mean	-0.64	-1.03
		SD	1.859	2.148
		Median	-0.21	-1.14
		Min.	-5.1	-6.0
		Max.	4.1	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 19	BFI Item 3	n	48	51
		Mean	3.85	3.62
		SD	2.859	2.539
		Median	3.46	3.29
		Min.	0.0	0.0
		Max.	9.7	10.0
	Change from Baseline	n	48	51
		Mean	-0.46	-1.04
		SD	1.786	2.418
		Median	-0.17	-0.83
		Min.	-4.7	-6.7
		Max.	3.6	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 20	BFI Item 3	n	48	52
		Mean	3.82	3.53
		SD	2.968	2.465
		Median	3.85	2.62
		Min.	0.0	0.0
		Max.	9.8	10.0
	Change from Baseline	n	48	52
		Mean	-0.48	-1.11
		SD	1.803	2.313
		Median	-0.21	-0.85
		Min.	-4.7	-6.0
		Max.	4.3	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 21	BFI Item 3	n	46	46
		Mean	3.69	3.68
		SD	2.902	2.446
		Median	3.21	3.17
		Min.	0.0	0.0
		Max.	9.3	10.0
	Change from Baseline	n	46	46
		Mean	-0.54	-1.15
		SD	1.701	2.349
		Median	-0.29	-0.96
		Min.	-3.8	-6.5
		Max.	2.7	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 22	BFI Item 3	n	47	51
		Mean	3.77	3.43
		SD	2.851	2.400
		Median	3.43	2.86
		Min.	0.0	0.0
		Max.	9.0	9.5
	Change from Baseline	n	47	51
		Mean	-0.48	-1.24
		SD	1.979	2.280
		Median	-0.14	-1.17
		Min.	-4.7	-6.0
		Max.	4.1	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 23	BFI Item 3	n	47	49
		Mean	3.84	3.32
		SD	3.036	2.649
		Median	4.00	2.43
		Min.	0.0	0.0
		Max.	10.0	10.0
	Change from Baseline	n	47	49
		Mean	-0.46	-1.39
		SD	2.033	2.409
		Median	-0.19	-1.20
		Min.	-5.0	-6.3
		Max.	4.1	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	BFI Item 3	n	47	48
		Mean	3.75	3.44
		SD	3.001	2.600
		Median	3.33	2.60
		Min.	0.0	0.0
		Max.	10.0	10.0
	Change from Baseline	n	47	48
		Mean	-0.45	-1.24
		SD	2.013	2.450
		Median	0.00	-0.93
		Min.	-4.6	-6.3
		Max.	4.0	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 25	BFI Item 3	n	45	44
		Mean	3.84	3.29
		SD	2.682	2.506
		Median	3.17	2.34
		Min.	0.0	0.0
		Max.	9.3	9.0
	Change from Baseline	n	45	44
		Mean	-0.58	-1.10
		SD	2.124	2.572
		Median	0.00	-0.51
		Min.	-4.5	-6.8
		Max.	3.2	5.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 26	BFI Item 3	n	49	50
		Mean	3.72	3.62
		SD	2.958	2.617
		Median	3.14	2.93
		Min.	0.0	0.0
		Max.	10.0	10.0
	Change from Baseline	n	49	50
		Mean	-0.64	-1.06
		SD	1.986	2.694
		Median	-0.29	-0.86
		Min.	-4.5	-8.5
		Max.	4.3	5.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 27	BFI Item 3	n	50	50
		Mean	3.96	3.59
		SD	3.021	2.584
		Median	3.83	2.69
		Min.	0.0	0.0
		Max.	10.0	10.0
	Change from Baseline	n	50	50
		Mean	-0.45	-1.09
		SD	2.068	2.509
		Median	-0.12	-0.58
		Min.	-5.0	-8.8
		Max.	4.4	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 28	BFI Item 3	n	48	50
		Mean	4.13	3.67
		SD	2.900	2.771
		Median	3.86	3.25
		Min.	0.0	0.0
		Max.	10.0	10.0
	Change from Baseline	n	48	50
		Mean	-0.12	-1.02
		SD	1.860	2.535
		Median	-0.08	-0.81
		Min.	-5.5	-8.2
		Max.	4.3	4.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 29	BFI Item 3	n	44	40
		Mean	3.68	3.44
		SD	2.544	2.592
		Median	3.30	2.45
		Min.	0.0	0.0
		Max.	9.0	8.5
	Change from Baseline	n	44	40
		Mean	-0.47	-1.45
		SD	1.807	2.306
		Median	-0.21	-0.93
		Min.	-5.3	-7.2
		Max.	3.4	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 30	BFI Item 3	n	47	51
		Mean	3.83	3.68
		SD	2.773	2.674
		Median	3.50	2.75
		Min.	0.0	0.0
		Max.	9.0	10.0
	Change from Baseline	n	47	51
		Mean	-0.41	-0.99
		SD	2.038	2.709
		Median	-0.21	-0.86
		Min.	-5.5	-6.8
		Max.	5.0	6.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 31	BFI Item 3	n	47	51
		Mean	4.08	3.62
		SD	2.915	2.547
		Median	4.14	2.75
		Min.	0.0	0.0
		Max.	9.2	10.0
	Change from Baseline	n	47	51
		Mean	-0.24	-1.04
		SD	1.932	2.467
		Median	0.00	-0.86
		Min.	-5.4	-6.5
		Max.	3.4	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.23
Summary of Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Treatment Policy Estimand)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	BFI Item 3	n	47	50
		Mean	3.98	3.51
		SD	2.947	2.644
		Median	3.83	3.00
		Min.	0.0	0.0
		Max.	9.5	10.0
	Change from Baseline	n	47	50
		Mean	-0.30	-1.12
		SD	1.955	2.384
		Median	0.00	-0.82
		Min.	-5.7	-6.2
		Max.	2.9	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.32
Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	3.71 (0.233)	3.64 (0.235)
LS Mean Change (SE)	-0.79 (0.233)	-0.86 (0.235)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.07
95% CI		(-0.73, 0.59)
p-value		0.842
Corrected Hedges g [3]		-0.04
95% CI		(-0.42, 0.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.32
Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	54
LS Mean (SE)	3.75 (0.249)	3.83 (0.248)
LS Mean Change (SE)	-0.75 (0.249)	-0.68 (0.248)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.08
95% CI		(-0.63, 0.78)
p-value		0.832
Corrected Hedges g [3]		0.04
95% CI		(-0.34, 0.42)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.32
Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	53
LS Mean (SE)	3.79 (0.259)	3.88 (0.256)
LS Mean Change (SE)	-0.71 (0.259)	-0.62 (0.256)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.09
95% CI		(-0.63, 0.82)
p-value		0.801
Corrected Hedges g [3]		0.05
95% CI		(-0.34, 0.43)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.



Population: Intent-to-Treat

Table 90.32
Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	52
LS Mean (SE)	3.84 (0.262)	3.78 (0.260)
LS Mean Change (SE)	-0.66 (0.262)	-0.73 (0.260)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.06
95% CI		(-0.80, 0.67)
p-value		0.862
Corrected Hedges g [3]		-0.03
95% CI		(-0.42, 0.35)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.32
Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	52
LS Mean (SE)	3.95 (0.276)	3.48 (0.272)
LS Mean Change (SE)	-0.55 (0.276)	-1.02 (0.272)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.47
95% CI		(-1.24, 0.30)
p-value		0.232
Corrected Hedges g [3]		-0.24
95% CI		(-0.63, 0.15)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.



Population: Intent-to-Treat

Table 90.32
Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	48
LS Mean (SE)	3.96 (0.296)	3.46 (0.292)
LS Mean Change (SE)	-0.54 (0.296)	-1.05 (0.292)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.51
95% CI		(-1.33, 0.32)
p-value		0.228
Corrected Hedges g [3]		-0.25
95% CI		(-0.65, 0.16)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.32
Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	50
LS Mean (SE)	4.34 (0.295)	3.61 (0.290)
LS Mean Change (SE)	-0.16 (0.295)	-0.89 (0.290)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.73
95% CI		(-1.56, 0.09)
p-value		0.080
Corrected Hedges g [3]		-0.36
95% CI		(-0.76, 0.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.32
Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	50
LS Mean (SE)	4.21 (0.288)	3.47 (0.283)
LS Mean Change (SE)	-0.29 (0.288)	-1.04 (0.283)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.75
95% CI		(-1.55, 0.06)
p-value		0.068
Corrected Hedges g [3]		-0.37
95% CI		(-0.77, 0.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Most Bothersome Symptom Score	n	54	54
		Mean	4.26	4.61
		SD	2.248	2.630
		Median	4.37	4.18
		Min.	0.0	0.3
		Max.	9.2	9.4
		Subjects with no reported symptoms	1 (2%)	0
Week 1	Most Bothersome Symptom Score	n	54	54
		Mean	3.52	4.01
		SD	2.117	2.442
		Median	3.73	3.65
		Min.	0.0	0.1
		Max.	9.5	9.7
		Subjects with no reported symptoms	2 (4%)	0

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 1	Change from Baseline	n	54	54
		Mean	-0.74	-0.60
		SD	1.117	1.153
		Median	-0.37	-0.46
		Min.	-4.2	-3.7
		Max.	1.4	2.7
Week 2	Most Bothersome Symptom Score	n	54	54
		Mean	3.48	3.42
		SD	2.039	2.293
		Median	3.56	2.60
		Min.	0.0	0.0
		Max.	9.3	9.1
		Subjects with no reported symptoms	1 (2%)	1 (2%)
	Change from Baseline	n	54	54
		Mean	-0.78	-1.19
		SD	1.118	1.944
		Median	-0.51	-0.88
		Min.	-4.2	-7.3
		Max.	1.0	2.3

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 3	Most Bothersome Symptom Score	n	54	54
		Mean	3.36	3.25
		SD	2.136	2.317
		Median	3.31	2.46
		Min.	0.0	0.0
		Max.	9.3	8.3
		Subjects with no reported symptoms	2 (4%)	2 (4%)
	Change from Baseline	n	54	54
		Mean	-0.89	-1.36
		SD	1.218	2.270
		Median	-0.70	-0.96
		Min.	-4.5	-8.3
		Max.	0.9	2.5

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 4	Most Bothersome Symptom Score	n	54	54
		Mean	3.32	3.31
		SD	2.195	2.356
		Median	3.50	2.70
		Min.	0.0	0.0
		Max.	9.7	9.0
		Subjects with no reported symptoms	2 (4%)	1 (2%)
	Change from Baseline	n	54	54
		Mean	-0.93	-1.30
		SD	1.418	2.338
		Median	-0.73	-0.60
		Min.	-5.7	-8.3
		Max.	1.3	1.7

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 5	Most Bothersome Symptom Score	n	47	50
		Mean	3.20	3.22
		SD	2.202	2.354
		Median	3.17	2.46
		Min.	0.0	0.0
		Max.	9.7	8.8
		Subjects with no reported symptoms	2 (4%)	2 (4%)
	Change from Baseline	n	47	50
		Mean	-1.18	-1.57
		SD	1.356	2.319
		Median	-0.98	-0.86
		Min.	-4.9	-8.3
		Max.	1.0	2.3

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 6	Most Bothersome Symptom Score	n	51	54
		Mean	3.29	3.25
		SD	2.225	2.412
		Median	3.50	2.71
		Min.	0.0	0.0
		Max.	9.7	8.9
		Subjects with no reported symptoms	2 (4%)	1 (2%)
	Change from Baseline	n	51	54
		Mean	-0.93	-1.35
		SD	1.463	2.598
		Median	-0.71	-0.64
		Min.	-5.9	-8.4
		Max.	1.0	3.7

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 7	Most Bothersome Symptom Score	n	52	54
		Mean	3.47	3.11
		SD	2.430	2.373
		Median	3.66	2.42
		Min.	0.0	0.0
		Max.	8.7	8.1
		Subjects with no reported symptoms	4 (7%)	3 (6%)
	Change from Baseline	n	52	54
		Mean	-0.79	-1.50
		SD	1.757	2.481
		Median	-0.74	-0.80
		Min.	-5.9	-8.3
		Max.	5.0	3.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Most Bothersome Symptom Score	n	52	54
		Mean	3.38	3.06
		SD	2.260	2.367
		Median	3.39	2.72
		Min.	0.0	0.0
		Max.	7.9	8.3
		Subjects with no reported symptoms	2 (4%)	2 (4%)
	Change from Baseline	n	52	54
		Mean	-0.88	-1.55
		SD	1.467	2.531
		Median	-1.00	-0.98
		Min.	-5.1	-8.3
		Max.	2.8	3.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 9	Most Bothersome Symptom Score	n	47	50
		Mean	3.24	2.87
		SD	2.528	2.284
		Median	2.71	2.34
		Min.	0.0	0.0
		Max.	8.5	8.4
		Subjects with no reported symptoms	4 (7%)	3 (6%)
	Change from Baseline	n	47	50
		Mean	-0.87	-1.60
		SD	1.558	2.405
		Median	-0.71	-1.00
		Min.	-5.5	-8.3
		Max.	2.3	3.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 10	Most Bothersome Symptom Score	n	51	52
		Mean	3.25	3.11
		SD	2.293	2.201
		Median	3.14	2.55
		Min.	0.0	0.1
		Max.	8.8	8.4
		Subjects with no reported symptoms	3 (6%)	0
	Change from Baseline	n	51	52
		Mean	-0.97	-1.40
		SD	1.691	2.488
		Median	-0.73	-0.76
		Min.	-5.7	-8.1
		Max.	1.8	3.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 11	Most Bothersome Symptom Score	n	49	52
		Mean	3.28	3.14
		SD	2.244	2.399
		Median	3.00	2.13
		Min.	0.0	0.0
		Max.	9.0	9.1
		Subjects with no reported symptoms	2 (4%)	1 (2%)
	Change from Baseline	n	49	52
		Mean	-0.98	-1.42
		SD	1.640	2.596
		Median	-0.78	-0.86
		Min.	-5.9	-8.3
		Max.	1.1	3.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 12	Most Bothersome Symptom Score	n	51	53
		Mean	3.26	3.21
		SD	2.240	2.335
		Median	3.07	2.83
		Min.	0.0	0.0
		Max.	8.7	8.8
		Subjects with no reported symptoms	2 (4%)	1 (2%)
	Change from Baseline	n	51	53
		Mean	-0.91	-1.36
		SD	1.530	2.637
		Median	-0.52	-0.93
		Min.	-4.1	-7.9
		Max.	2.4	3.7

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 13	Most Bothersome Symptom Score	n	43	48
		Mean	3.15	3.26
		SD	2.129	2.273
		Median	3.05	2.87
		Min.	0.0	0.0
		Max.	8.4	8.6
		Subjects with no reported symptoms	2 (4%)	2 (4%)
	Change from Baseline	n	43	48
		Mean	-1.24	-1.42
		SD	1.728	2.500
		Median	-1.02	-0.96
		Min.	-4.7	-7.9
		Max.	3.0	3.4

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 14	Most Bothersome Symptom Score	n	50	53
		Mean	2.97	3.07
		SD	2.166	2.172
		Median	2.81	2.81
		Min.	0.0	0.0
		Max.	8.7	8.4
		Subjects with no reported symptoms	3 (6%)	3 (6%)
	Change from Baseline	n	50	53
		Mean	-1.21	-1.49
		SD	1.732	2.315
		Median	-1.01	-0.86
		Min.	-6.7	-7.9
		Max.	1.9	3.0

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 15	Most Bothersome Symptom Score	n	50	53
		Mean	3.03	3.16
		SD	2.101	2.303
		Median	3.12	2.67
		Min.	0.0	0.0
		Max.	8.5	8.0
		Subjects with no reported symptoms	3 (6%)	3 (6%)
	Change from Baseline	n	50	53
		Mean	-1.15	-1.40
		SD	1.641	2.257
		Median	-0.81	-0.92
		Min.	-6.6	-7.9
		Max.	1.9	2.7

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Most Bothersome Symptom Score	n	51	52
		Mean	3.09	3.02
		SD	2.081	2.270
		Median	3.67	2.33
		Min.	0.0	0.0
		Max.	8.2	8.2
		Subjects with no reported symptoms	4 (7%)	2 (4%)
	Change from Baseline	n	51	52
		Mean	-1.09	-1.54
		SD	1.709	2.233
		Median	-0.76	-0.97
		Min.	-5.9	-7.8
		Max.	1.3	2.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 17	Most Bothersome Symptom Score	n	41	42
		Mean	3.06	3.10
		SD	2.270	2.316
		Median	2.86	2.40
		Min.	0.0	0.0
		Max.	8.3	8.8
		Subjects with no reported symptoms	2 (4%)	1 (2%)
	Change from Baseline	n	41	42
		Mean	-1.10	-1.65
		SD	1.849	2.269
		Median	-1.07	-0.98
		Min.	-6.4	-7.9
		Max.	3.2	3.1

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 18	Most Bothersome Symptom Score	n	48	51
		Mean	3.09	2.96
		SD	2.166	2.229
		Median	3.31	2.44
		Min.	0.0	0.0
		Max.	8.4	7.9
		Subjects with no reported symptoms	4 (7%)	1 (2%)
	Change from Baseline	n	48	51
		Mean	-1.08	-1.54
		SD	1.798	2.284
		Median	-0.81	-1.20
		Min.	-6.7	-7.3
		Max.	3.0	4.2

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 19	Most Bothersome Symptom Score	n	48	51
		Mean	3.14	2.94
		SD	2.207	2.241
		Median	3.38	2.29
		Min.	0.0	0.0
		Max.	8.1	8.6
		Subjects with no reported symptoms	6 (11%)	1 (2%)
	Change from Baseline	n	48	51
		Mean	-1.03	-1.56
		SD	1.775	2.296
		Median	-0.83	-1.33
		Min.	-6.9	-7.3
		Max.	2.7	4.0

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 20	Most Bothersome Symptom Score	n	48	52
		Mean	3.19	2.89
		SD	2.290	2.286
		Median	3.49	2.49
		Min.	0.0	0.0
		Max.	8.1	8.7
		Subjects with no reported symptoms	4 (7%)	3 (6%)
	Change from Baseline	n	48	52
		Mean	-0.98	-1.59
		SD	1.640	2.394
		Median	-0.96	-1.05
		Min.	-5.7	-7.6
		Max.	2.8	2.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on PPD up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 21	Most Bothersome Symptom Score	n	46	46
		Mean	3.11	2.85
		SD	2.283	2.304
		Median	3.17	2.18
		Min.	0.0	0.0
		Max.	8.3	8.5
		Subjects with no reported symptoms	4 (7%)	2 (4%)
	Change from Baseline	n	46	46
		Mean	-1.01	-1.86
		SD	1.731	2.403
		Median	-0.89	-1.21
		Min.	-5.3	-7.9
		Max.	3.0	2.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 22	Most Bothersome Symptom Score	n	47	51
		Mean	3.09	2.67
		SD	2.228	2.092
		Median	3.28	2.17
		Min.	0.0	0.0
		Max.	8.2	7.9
		Subjects with no reported symptoms	3 (6%)	3 (6%)
	Change from Baseline	n	47	51
		Mean	-1.10	-1.87
		SD	1.563	2.227
		Median	-1.03	-1.40
		Min.	-5.9	-7.9
		Max.	1.4	2.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 23	Most Bothersome Symptom Score	n	47	49
		Mean	3.14	2.79
		SD	2.292	2.258
		Median	3.00	2.08
		Min.	0.0	0.0
		Max.	8.4	7.9
		Subjects with no reported symptoms	4 (7%)	3 (6%)
	Change from Baseline	n	47	49
		Mean	-1.11	-1.80
		SD	1.847	2.418
		Median	-0.86	-1.33
		Min.	-6.9	-7.9
		Max.	2.8	3.3

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Most Bothersome Symptom Score	n	47	48
		Mean	3.02	2.83
		SD	2.306	2.236
		Median	2.90	2.24
		Min.	0.0	0.0
		Max.	8.3	7.8
		Subjects with no reported symptoms	5 (9%)	3 (6%)
	Change from Baseline	n	47	48
		Mean	-1.12	-1.77
		SD	1.886	2.577
		Median	-0.80	-1.46
		Min.	-6.9	-7.9
		Max.	1.5	4.1

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 25	Most Bothersome Symptom Score	n	45	44
		Mean	3.00	2.74
		SD	2.221	1.995
		Median	2.90	2.18
		Min.	0.0	0.0
		Max.	8.8	7.1
		Subjects with no reported symptoms	4 (7%)	3 (6%)
	Change from Baseline	n	45	44
		Mean	-1.39	-1.51
		SD	1.884	2.370
		Median	-0.86	-1.05
		Min.	-6.9	-7.9
		Max.	1.4	4.4

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on PPD up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 26	Most Bothersome Symptom Score	n	49	50
		Mean	2.96	2.94
		SD	2.214	2.246
		Median	2.64	2.05
		Min.	0.0	0.0
		Max.	9.3	8.7
		Subjects with no reported symptoms	5 (9%)	2 (4%)
	Change from Baseline	n	49	50
		Mean	-1.30	-1.59
		SD	1.851	2.477
		Median	-0.90	-1.06
		Min.	-6.9	-7.9
		Max.	1.3	6.7

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on PPD up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 27	Most Bothersome Symptom Score	n	50	50
		Mean	3.11	3.06
		SD	2.282	2.326
		Median	3.15	2.14
		Min.	0.0	0.0
		Max.	9.2	9.1
		Subjects with no reported symptoms	6 (11%)	2 (4%)
	Change from Baseline	n	50	50
		Mean	-1.14	-1.47
		SD	1.864	2.495
		Median	-0.66	-1.23
		Min.	-6.9	-7.9
		Max.	1.2	7.1

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 28	Most Bothersome Symptom Score	n	48	50
		Mean	3.13	2.94
		SD	2.395	2.268
		Median	3.04	2.17
		Min.	0.0	0.0
		Max.	9.3	7.9
		Subjects with no reported symptoms	5 (9%)	3 (6%)
	Change from Baseline	n	48	50
		Mean	-1.00	-1.59
		SD	1.966	2.330
		Median	-0.54	-1.27
		Min.	-6.9	-7.9
		Max.	2.5	4.1

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 29	Most Bothersome Symptom Score	n	44	40
		Mean	2.87	2.51
		SD	2.194	2.022
		Median	2.53	1.93
		Min.	0.0	0.0
		Max.	7.9	7.2
		Subjects with no reported symptoms	6 (11%)	1 (2%)
	Change from Baseline	n	44	40
		Mean	-1.10	-2.26
		SD	1.923	2.591
		Median	-0.79	-1.36
		Min.	-6.9	-7.6
		Max.	1.8	2.5

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on PPD p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 30	Most Bothersome Symptom Score	n	47	51
		Mean	2.96	2.51
		SD	2.304	2.131
		Median	2.67	1.86
		Min.	0.0	0.0
		Max.	9.2	8.3
		Subjects with no reported symptoms	5 (9%)	2 (4%)
	Change from Baseline	n	47	51
		Mean	-1.23	-1.99
		SD	1.849	2.435
		Median	-1.03	-1.24
		Min.	-6.9	-7.8
		Max.	1.9	2.2

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 31	Most Bothersome Symptom Score	n	47	51
		Mean	3.08	2.59
		SD	2.350	2.124
		Median	2.83	1.86
		Min.	0.0	0.0
		Max.	9.5	7.7
		Subjects with no reported symptoms	5 (9%)	3 (6%)
	Change from Baseline	n	47	51
		Mean	-1.10	-1.91
		SD	1.831	2.349
		Median	-0.71	-1.24
		Min.	-6.6	-7.9
		Max.	1.7	1.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.35
Summary of Most Bothersome HES Symptom Severity Score (HES-DS)

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Most Bothersome Symptom Score	n	47	50
		Mean	3.25	2.70
		SD	2.360	2.174
		Median	3.08	2.25
		Min.	0.0	0.0
		Max.	9.4	7.7
		Subjects with no reported symptoms	4 (7%)	4 (7%)
	Change from Baseline	n	47	50
		Mean	-0.88	-1.80
		SD	1.899	2.392
		Median	-0.28	-1.27
		Min.	-6.5	-7.9
		Max.	2.2	1.9

Note:
1. The mean of up to 3 most bothersome symptoms identified by subjects at Visit 2 (Week 0) is used as the most bothersome symptom score. Subject PPD reported 4 most bothersome symptoms.
2. The mean of the available assessments on p to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
3. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.40
Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	3.43 (0.232)	3.11 (0.233)
LS Mean Change (SE)	-0.95 (0.232)	-1.27 (0.233)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.32
95% CI		(-0.97, 0.34)
p-value		0.337
Corrected Hedges g [3]		-0.19
95% CI		(-0.56, 0.19)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.40
Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	54
LS Mean (SE)	3.50 (0.252)	2.86 (0.251)
LS Mean Change (SE)	-0.87 (0.252)	-1.51 (0.251)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.64
95% CI		(-1.35, 0.07)
p-value		0.078
Corrected Hedges g [3]		-0.35
95% CI		(-0.73, 0.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.40
Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	53
LS Mean (SE)	3.43 (0.257)	3.09 (0.256)
LS Mean Change (SE)	-0.95 (0.257)	-1.28 (0.256)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.33
95% CI		(-1.06, 0.39)
p-value		0.360
Corrected Hedges g [3]		-0.18
95% CI		(-0.56, 0.21)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.40
Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	52
LS Mean (SE)	3.25 (0.229)	2.91 (0.227)
LS Mean Change (SE)	-1.12 (0.229)	-1.46 (0.227)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.34
95% CI		(-0.98, 0.31)
p-value		0.304
Corrected Hedges g [3]		-0.20
95% CI		(-0.59, 0.18)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.40
Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	52
LS Mean (SE)	3.36 (0.251)	2.85 (0.247)
LS Mean Change (SE)	-1.01 (0.251)	-1.52 (0.247)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.51
95% CI		(-1.21, 0.20)
p-value		0.155
Corrected Hedges g [3]		-0.29
95% CI		(-0.68, 0.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.40
Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	48
LS Mean (SE)	3.25 (0.268)	2.81 (0.265)
LS Mean Change (SE)	-1.12 (0.268)	-1.56 (0.265)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.44
95% CI		(-1.19, 0.31)
p-value		0.248
Corrected Hedges g [3]		-0.24
95% CI		(-0.64, 0.17)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.40
Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	50
LS Mean (SE)	3.38 (0.267)	2.89 (0.263)
LS Mean Change (SE)	-0.99 (0.267)	-1.48 (0.263)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.49
95% CI		(-1.24, 0.26)
p-value		0.195
Corrected Hedges g [3]		-0.26
95% CI		(-0.66, 0.13)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.40
Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	50
LS Mean (SE)	3.37 (0.259)	2.68 (0.255)
LS Mean Change (SE)	-1.01 (0.259)	-1.70 (0.255)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.69
95% CI		(-1.42, 0.03)
p-value		0.062
Corrected Hedges g [3]		-0.38
95% CI		(-0.78, 0.02)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Symptom Severity Score	n	54	54
		Mean	3.08	3.86
		SD	2.682	2.486
		Median	2.37	3.48
		Min.	0.0	0.0
		Max.	9.0	9.1
		Subjects with no reported symptoms	11 (20%)	2 (4%)
Week 1	Symptom Severity Score	n	54	54
		Mean	2.75	3.41
		SD	2.394	2.588
		Median	2.17	2.69
		Min.	0.0	0.0
		Max.	8.9	9.6
		Subjects with no reported symptoms	10 (19%)	5 (9%)

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 1	Change from Baseline	n	54	54
		Mean	-0.33	-0.45
		SD	1.161	1.269
		Median	-0.15	-0.21
		Min.	-4.8	-3.3
		Max.	1.6	2.3
Week 2	Symptom Severity Score	n	54	54
		Mean	2.61	3.25
		SD	2.371	2.591
		Median	2.00	2.64
		Min.	0.0	0.0
		Max.	9.0	9.6
		Subjects with no reported symptoms	9 (17%)	7 (13%)
	Change from Baseline	n	54	54
		Mean	-0.47	-0.62
		SD	1.350	1.391
		Median	-0.05	-0.27
		Min.	-4.8	-3.8
		Max.	2.4	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 3	Symptom Severity Score	n	54	54
		Mean	2.51	3.06
		SD	2.434	2.550
		Median	1.85	2.39
		Min.	0.0	0.0
		Max.	9.0	9.3
		Subjects with no reported symptoms	10 (19%)	6 (11%)
	Change from Baseline	n	54	54
		Mean	-0.58	-0.80
		SD	1.272	1.597
		Median	-0.15	-0.83
		Min.	-4.0	-6.1
		Max.	2.3	2.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 4	Symptom Severity Score	n	54	54
		Mean	2.63	3.04
		SD	2.575	2.477
		Median	2.21	2.63
		Min.	0.0	0.0
		Max.	9.4	9.9
		Subjects with no reported symptoms	14 (26%)	7 (13%)
	Change from Baseline	n	54	54
		Mean	-0.45	-0.83
		SD	1.411	1.777
		Median	-0.04	-0.14
		Min.	-4.7	-6.3
		Max.	3.0	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 5	Symptom Severity Score	n	47	50
		Mean	2.74	2.95
		SD	2.665	2.433
		Median	2.00	2.54
		Min.	0.0	0.0
		Max.	9.4	8.6
		Subjects with no reported symptoms	10 (19%)	8 (15%)
	Change from Baseline	n	47	50
		Mean	-0.42	-0.96
		SD	1.597	1.602
		Median	0.00	-0.66
		Min.	-5.1	-6.8
		Max.	3.1	1.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 6	Symptom Severity Score	n	51	54
		Mean	2.93	3.03
		SD	2.581	2.491
		Median	2.80	2.52
		Min.	0.0	0.0
		Max.	9.3	8.3
		Subjects with no reported symptoms	9 (17%)	6 (11%)
	Change from Baseline	n	51	54
		Mean	-0.08	-0.83
		SD	1.751	1.843
		Median	0.00	-0.75
		Min.	-3.9	-7.2
		Max.	6.3	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 7	Symptom Severity Score	n	52	54
		Mean	2.80	2.93
		SD	2.530	2.407
		Median	2.20	2.27
		Min.	0.0	0.0
		Max.	8.4	7.8
		Subjects with no reported symptoms	8 (15%)	8 (15%)
	Change from Baseline	n	52	54
		Mean	-0.27	-0.93
		SD	1.734	1.840
		Median	0.00	-0.79
		Min.	-3.5	-7.4
		Max.	7.0	1.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Symptom Severity Score	n	52	54
		Mean	2.80	2.93
		SD	2.581	2.483
		Median	2.42	2.14
		Min.	0.0	0.0
		Max.	8.7	8.3
		Subjects with no reported symptoms	10 (19%)	9 (17%)
	Change from Baseline	n	52	54
		Mean	-0.28	-0.94
		SD	1.446	1.863
		Median	0.00	-0.71
		Min.	-3.2	-6.7
		Max.	3.6	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 9	Symptom Severity Score	n	47	50
		Mean	2.67	2.85
		SD	2.561	2.456
		Median	2.20	2.54
		Min.	0.0	0.0
		Max.	8.0	8.3
		Subjects with no reported symptoms	11 (20%)	8 (15%)
	Change from Baseline	n	47	50
		Mean	-0.20	-0.93
		SD	1.519	1.912
		Median	0.00	-0.43
		Min.	-3.5	-6.5
		Max.	4.0	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 10	Symptom Severity Score	n	51	52
		Mean	2.66	2.82
		SD	2.610	2.375
		Median	2.00	2.38
		Min.	0.0	0.0
		Max.	8.3	8.0
		Subjects with no reported symptoms	11 (20%)	9 (17%)
	Change from Baseline	n	51	52
		Mean	-0.36	-0.93
		SD	1.495	2.105
		Median	0.00	-0.85
		Min.	-4.0	-7.1
		Max.	2.9	3.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 11	Symptom Severity Score	n	49	52
		Mean	2.85	3.08
		SD	2.532	2.593
		Median	2.20	2.36
		Min.	0.0	0.0
		Max.	9.1	8.9
		Subjects with no reported symptoms	8 (15%)	7 (13%)
	Change from Baseline	n	49	52
		Mean	-0.25	-0.71
		SD	1.573	2.168
		Median	0.00	-0.81
		Min.	-3.9	-7.3
		Max.	2.7	6.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 12	Symptom Severity Score	n	51	53
		Mean	2.64	3.20
		SD	2.643	2.599
		Median	2.00	2.71
		Min.	0.0	0.0
		Max.	9.9	8.9
		Subjects with no reported symptoms	11 (20%)	9 (17%)
	Change from Baseline	n	51	53
		Mean	-0.38	-0.62
		SD	1.553	2.208
		Median	0.00	-0.67
		Min.	-3.7	-7.3
		Max.	3.0	6.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 13	Symptom Severity Score	n	43	48
		Mean	2.74	3.00
		SD	2.655	2.557
		Median	2.00	2.58
		Min.	0.0	0.0
		Max.	9.6	8.1
		Subjects with no reported symptoms	8 (15%)	8 (15%)
	Change from Baseline	n	43	48
		Mean	-0.56	-0.85
		SD	1.679	2.270
		Median	-0.29	-0.83
		Min.	-3.9	-7.5
		Max.	3.5	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 14	Symptom Severity Score	n	50	53
		Mean	2.51	2.82
		SD	2.621	2.510
		Median	2.07	2.29
		Min.	0.0	0.0
		Max.	9.0	8.3
		Subjects with no reported symptoms	13 (24%)	11 (20%)
	Change from Baseline	n	50	53
		Mean	-0.56	-1.00
		SD	1.597	2.176
		Median	-0.19	-0.83
		Min.	-3.8	-7.2
		Max.	2.2	3.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 15	Symptom Severity Score	n	50	53
		Mean	2.47	3.17
		SD	2.601	2.516
		Median	1.86	3.17
		Min.	0.0	0.0
		Max.	8.8	8.7
		Subjects with no reported symptoms	13 (24%)	9 (17%)
	Change from Baseline	n	50	53
		Mean	-0.59	-0.65
		SD	1.690	2.033
		Median	-0.18	-0.80
		Min.	-5.0	-6.3
		Max.	2.6	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Symptom Severity Score	n	51	52
		Mean	2.61	2.90
		SD	2.632	2.402
		Median	2.00	2.39
		Min.	0.0	0.0
		Max.	8.1	7.9
		Subjects with no reported symptoms	14 (26%)	10 (19%)
	Change from Baseline	n	51	52
		Mean	-0.41	-0.89
		SD	1.701	1.976
		Median	0.00	-0.67
		Min.	-5.3	-6.8
		Max.	2.9	4.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 17	Symptom Severity Score	n	41	42
		Mean	2.45	2.79
		SD	2.788	2.426
		Median	1.40	2.37
		Min.	0.0	0.0
		Max.	9.0	8.0
		Subjects with no reported symptoms	11 (20%)	10 (19%)
	Change from Baseline	n	41	42
		Mean	-0.51	-0.94
		SD	1.657	1.767
		Median	0.00	-0.70
		Min.	-4.6	-4.7
		Max.	1.6	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 18	Symptom Severity Score	n	48	51
		Mean	2.60	2.62
		SD	2.505	2.346
		Median	2.08	2.29
		Min.	0.0	0.0
		Max.	8.7	8.0
		Subjects with no reported symptoms	12 (22%)	9 (17%)
	Change from Baseline	n	48	51
		Mean	-0.48	-1.12
		SD	1.603	2.034
		Median	0.00	-0.80
		Min.	-3.8	-7.3
		Max.	2.5	2.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 19	Symptom Severity Score	n	48	51
		Mean	2.62	2.63
		SD	2.665	2.514
		Median	2.23	2.00
		Min.	0.0	0.0
		Max.	8.4	8.5
		Subjects with no reported symptoms	11 (20%)	8 (15%)
	Change from Baseline	n	48	51
		Mean	-0.45	-1.10
		SD	1.643	2.285
		Median	0.00	-1.00
		Min.	-4.0	-7.1
		Max.	2.7	4.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 20	Symptom Severity Score	n	48	52
		Mean	2.62	2.58
		SD	2.580	2.489
		Median	2.17	2.00
		Min.	0.0	0.0
		Max.	8.8	8.7
		Subjects with no reported symptoms	11 (20%)	10 (19%)
	Change from Baseline	n	48	52
		Mean	-0.46	-1.17
		SD	1.453	2.083
		Median	-0.14	-0.86
		Min.	-3.7	-7.3
		Max.	2.5	3.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 21	Symptom Severity Score	n	46	46
		Mean	2.74	2.68
		SD	2.757	2.386
		Median	2.38	2.00
		Min.	0.0	0.0
		Max.	9.0	8.0
		Subjects with no reported symptoms	11 (20%)	7 (13%)
	Change from Baseline	n	46	46
		Mean	-0.32	-1.27
		SD	1.572	2.067
		Median	0.00	-1.17
		Min.	-4.1	-6.3
		Max.	3.6	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 22	Symptom Severity Score	n	47	51
		Mean	2.38	2.53
		SD	2.473	2.280
		Median	2.00	2.17
		Min.	0.0	0.0
		Max.	9.0	8.0
		Subjects with no reported symptoms	13 (24%)	10 (19%)
	Change from Baseline	n	47	51
		Mean	-0.60	-1.28
		SD	1.564	1.958
		Median	0.00	-1.37
		Min.	-4.6	-6.5
		Max.	2.1	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 23	Symptom Severity Score	n	47	49
		Mean	2.54	2.68
		SD	2.664	2.623
		Median	2.14	1.71
		Min.	0.0	0.0
		Max.	9.0	8.6
		Subjects with no reported symptoms	12 (22%)	7 (13%)
	Change from Baseline	n	47	49
		Mean	-0.60	-1.12
		SD	1.710	2.245
		Median	0.00	-1.17
		Min.	-5.6	-6.9
		Max.	2.4	4.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Symptom Severity Score	n	47	48
		Mean	2.57	2.59
		SD	2.572	2.401
		Median	2.29	2.00
		Min.	0.0	0.0
		Max.	9.0	8.0
		Subjects with no reported symptoms	14 (26%)	9 (17%)
	Change from Baseline	n	47	48
		Mean	-0.46	-1.17
		SD	1.846	2.244
		Median	0.00	-1.14
		Min.	-5.6	-7.0
		Max.	3.6	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 25	Symptom Severity Score	n	45	44
		Mean	2.41	2.40
		SD	2.422	2.280
		Median	2.33	2.00
		Min.	0.0	0.0
		Max.	9.0	8.4
		Subjects with no reported symptoms	12 (22%)	9 (17%)
	Change from Baseline	n	45	44
		Mean	-0.58	-0.95
		SD	1.903	2.050
		Median	0.00	-0.92
		Min.	-5.3	-6.6
		Max.	3.3	3.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 26	Symptom Severity Score	n	49	50
		Mean	2.32	2.62
		SD	2.593	2.417
		Median	1.71	2.00
		Min.	0.0	0.0
		Max.	9.3	8.0
		Subjects with no reported symptoms	15 (28%)	9 (17%)
	Change from Baseline	n	49	50
		Mean	-0.82	-1.11
		SD	1.724	2.230
		Median	-0.05	-1.00
		Min.	-5.3	-7.7
		Max.	2.1	3.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 27	Symptom Severity Score	n	50	50
		Mean	2.48	2.66
		SD	2.641	2.434
		Median	1.79	2.00
		Min.	0.0	0.0
		Max.	9.0	8.0
		Subjects with no reported symptoms	15 (28%)	7 (13%)
	Change from Baseline	n	50	50
		Mean	-0.60	-1.07
		SD	1.737	2.320
		Median	0.00	-0.93
		Min.	-5.0	-8.8
		Max.	3.4	2.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 28	Symptom Severity Score	n	48	50
		Mean	2.48	2.68
		SD	2.632	2.306
		Median	2.00	2.00
		Min.	0.0	0.0
		Max.	9.0	8.2
		Subjects with no reported symptoms	14 (26%)	8 (15%)
	Change from Baseline	n	48	50
		Mean	-0.51	-1.05
		SD	1.755	2.171
		Median	0.00	-0.86
		Min.	-4.6	-7.0
		Max.	3.8	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 29	Symptom Severity Score	n	44	40
		Mean	2.43	2.57
		SD	2.451	2.363
		Median	1.82	1.83
		Min.	0.0	0.0
		Max.	8.0	8.0
		Subjects with no reported symptoms	12 (22%)	7 (13%)
	Change from Baseline	n	44	40
		Mean	-0.46	-1.44
		SD	1.877	2.423
		Median	0.00	-1.07
		Min.	-4.7	-7.3
		Max.	2.4	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 30	Symptom Severity Score	n	47	51
		Mean	2.40	2.69
		SD	2.573	2.327
		Median	1.60	2.00
		Min.	0.0	0.0
		Max.	9.4	8.0
		Subjects with no reported symptoms	12 (22%)	9 (17%)
	Change from Baseline	n	47	51
		Mean	-0.58	-1.04
		SD	1.718	2.179
		Median	0.00	-1.00
		Min.	-4.9	-7.0
		Max.	2.4	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 31	Symptom Severity Score	n	47	51
		Mean	2.77	2.71
		SD	2.729	2.364
		Median	1.86	2.00
		Min.	0.0	0.0
		Max.	9.2	8.0
		Subjects with no reported symptoms	12 (22%)	7 (13%)
	Change from Baseline	n	47	51
		Mean	-0.37	-1.02
		SD	1.777	2.378
		Median	0.00	-0.71
		Min.	-4.6	-7.2
		Max.	4.3	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Muscle/Joint Pain Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Symptom Severity Score	n	47	50
		Mean	2.87	2.45
		SD	2.910	2.276
		Median	2.00	2.00
		Min.	0.0	0.0
		Max.	9.3	8.0
		Subjects with no reported symptoms	12 (22%)	9 (17%)
	Change from Baseline	n	47	50
		Mean	-0.15	-1.24
		SD	1.730	2.216
		Median	0.00	-0.96
		Min.	-4.0	-7.3
		Max.	4.0	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Symptom Severity Score	n	54	54
		Mean	1.98	2.65
		SD	2.371	2.820
		Median	1.14	1.38
		Min.	0.0	0.0
		Max.	10.0	8.9
		Subjects with no reported symptoms	15 (28%)	11 (20%)
Week 1	Symptom Severity Score	n	54	54
		Mean	1.66	2.27
		SD	2.237	2.529
		Median	1.00	1.50
		Min.	0.0	0.0
		Max.	10.0	8.4
		Subjects with no reported symptoms	19 (35%)	17 (31%)

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 1	Change from Baseline	n	54	54
		Mean	-0.32	-0.38
		SD	0.816	1.527
		Median	-0.06	-0.21
		Min.	-2.8	-5.1
		Max.	1.6	5.0
Week 2	Symptom Severity Score	n	54	54
		Mean	1.68	2.03
		SD	2.185	2.473
		Median	1.07	1.00
		Min.	0.0	0.0
		Max.	10.0	8.4
		Subjects with no reported symptoms	20 (37%)	15 (28%)
	Change from Baseline	n	54	54
		Mean	-0.29	-0.62
		SD	0.930	1.735
		Median	0.00	-0.13
		Min.	-2.8	-7.0
		Max.	2.1	4.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 3	Symptom Severity Score	n	54	54
		Mean	1.65	2.04
		SD	2.185	2.299
		Median	1.00	1.00
		Min.	0.0	0.0
		Max.	10.0	8.8
		Subjects with no reported symptoms	19 (35%)	15 (28%)
	Change from Baseline	n	54	54
		Mean	-0.33	-0.61
		SD	1.006	2.071
		Median	0.00	-0.07
		Min.	-3.0	-7.0
		Max.	1.6	4.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 4	Symptom Severity Score	n	54	54
		Mean	1.54	1.90
		SD	2.227	2.188
		Median	0.64	1.00
		Min.	0.0	0.0
		Max.	10.0	7.8
		Subjects with no reported symptoms	21 (39%)	17 (31%)
	Change from Baseline	n	54	54
		Mean	-0.44	-0.75
		SD	1.018	1.902
		Median	0.00	-0.14
		Min.	-3.3	-7.0
		Max.	1.6	2.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 5	Symptom Severity Score	n	47	50
		Mean	1.66	1.93
		SD	2.277	2.246
		Median	0.71	0.92
		Min.	0.0	0.0
		Max.	10.0	7.6
		Subjects with no reported symptoms	18 (33%)	15 (28%)
	Change from Baseline	n	47	50
		Mean	-0.48	-0.87
		SD	1.532	1.925
		Median	0.00	-0.30
		Min.	-4.9	-7.0
		Max.	3.4	2.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 6	Symptom Severity Score	n	51	54
		Mean	1.58	2.02
		SD	2.163	2.288
		Median	1.00	1.17
		Min.	0.0	0.0
		Max.	10.0	8.2
		Subjects with no reported symptoms	19 (35%)	19 (35%)
	Change from Baseline	n	51	54
		Mean	-0.39	-0.63
		SD	1.433	2.109
		Median	0.00	-0.15
		Min.	-3.7	-6.9
		Max.	2.5	5.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 7	Symptom Severity Score	n	52	54
		Mean	1.56	1.94
		SD	2.189	2.026
		Median	0.50	1.29
		Min.	0.0	0.0
		Max.	10.0	6.9
		Subjects with no reported symptoms	23 (43%)	15 (28%)
	Change from Baseline	n	52	54
		Mean	-0.39	-0.71
		SD	1.666	2.235
		Median	0.00	-0.31
		Min.	-4.6	-6.9
		Max.	3.3	4.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Symptom Severity Score	n	52	54
		Mean	1.43	1.89
		SD	2.091	2.055
		Median	0.79	1.10
		Min.	0.0	0.0
		Max.	10.0	7.1
		Subjects with no reported symptoms	21 (39%)	17 (31%)
	Change from Baseline	n	52	54
		Mean	-0.52	-0.76
		SD	1.721	2.202
		Median	0.00	-0.29
		Min.	-5.7	-6.8
		Max.	3.1	5.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 9	Symptom Severity Score	n	47	50
		Mean	1.41	1.55
		SD	2.151	2.120
		Median	0.17	0.64
		Min.	0.0	0.0
		Max.	10.0	7.2
		Subjects with no reported symptoms	20 (37%)	18 (33%)
	Change from Baseline	n	47	50
		Mean	-0.50	-0.91
		SD	1.772	2.002
		Median	0.00	-0.29
		Min.	-7.0	-6.7
		Max.	1.9	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 10	Symptom Severity Score	n	51	52
		Mean	1.59	1.57
		SD	2.187	2.012
		Median	0.86	0.62
		Min.	0.0	0.0
		Max.	10.0	7.3
		Subjects with no reported symptoms	16 (30%)	19 (35%)
	Change from Baseline	n	51	52
		Mean	-0.40	-0.97
		SD	1.817	2.030
		Median	0.00	-0.29
		Min.	-5.9	-7.1
		Max.	2.7	1.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 11	Symptom Severity Score	n	49	52
		Mean	1.57	1.63
		SD	2.168	2.174
		Median	0.86	0.46
		Min.	0.0	0.0
		Max.	10.0	7.8
		Subjects with no reported symptoms	16 (30%)	19 (35%)
	Change from Baseline	n	49	52
		Mean	-0.38	-0.93
		SD	1.826	2.102
		Median	0.00	-0.29
		Min.	-6.3	-7.1
		Max.	4.0	3.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 12	Symptom Severity Score	n	51	53
		Mean	1.54	1.73
		SD	2.147	2.121
		Median	0.75	0.50
		Min.	0.0	0.0
		Max.	9.9	6.5
		Subjects with no reported symptoms	17 (31%)	24 (44%)
	Change from Baseline	n	51	53
		Mean	-0.35	-0.89
		SD	1.733	2.188
		Median	0.00	-0.29
		Min.	-6.3	-7.3
		Max.	4.0	3.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 13	Symptom Severity Score	n	43	48
		Mean	1.60	1.71
		SD	2.275	2.052
		Median	1.00	0.92
		Min.	0.0	0.0
		Max.	9.8	6.0
		Subjects with no reported symptoms	15 (28%)	19 (35%)
	Change from Baseline	n	43	48
		Mean	-0.55	-0.96
		SD	1.942	2.385
		Median	0.00	-0.15
		Min.	-7.7	-7.5
		Max.	4.1	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 14	Symptom Severity Score	n	50	53
		Mean	1.46	1.71
		SD	2.048	2.084
		Median	0.79	1.00
		Min.	0.0	0.0
		Max.	9.0	7.1
		Subjects with no reported symptoms	16 (30%)	19 (35%)
	Change from Baseline	n	50	53
		Mean	-0.46	-0.91
		SD	1.918	2.244
		Median	0.00	-0.20
		Min.	-7.0	-7.7
		Max.	4.4	2.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 15	Symptom Severity Score	n	50	53
		Mean	1.57	1.72
		SD	2.087	2.168
		Median	1.00	1.00
		Min.	0.0	0.0
		Max.	8.8	7.2
		Subjects with no reported symptoms	21 (39%)	22 (41%)
	Change from Baseline	n	50	53
		Mean	-0.34	-0.90
		SD	1.812	2.266
		Median	0.00	-0.29
		Min.	-5.4	-7.0
		Max.	3.9	4.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Symptom Severity Score	n	51	52
		Mean	1.46	1.49
		SD	2.033	1.925
		Median	0.57	0.44
		Min.	0.0	0.0
		Max.	8.6	6.5
		Subjects with no reported symptoms	22 (41%)	23 (43%)
	Change from Baseline	n	51	52
		Mean	-0.42	-1.08
		SD	1.945	2.238
		Median	0.00	-0.29
		Min.	-7.1	-7.0
		Max.	4.3	2.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 17	Symptom Severity Score	n	41	42
		Mean	1.56	1.36
		SD	2.329	1.815
		Median	0.67	0.34
		Min.	0.0	0.0
		Max.	9.0	6.6
		Subjects with no reported symptoms	18 (33%)	17 (31%)
	Change from Baseline	n	41	42
		Mean	-0.47	-1.43
		SD	2.189	2.443
		Median	0.00	-0.43
		Min.	-7.7	-7.9
		Max.	4.3	2.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 18	Symptom Severity Score	n	48	51
		Mean	1.41	1.23
		SD	2.044	1.633
		Median	0.79	0.40
		Min.	0.0	0.0
		Max.	9.0	5.5
		Subjects with no reported symptoms	21 (39%)	20 (37%)
	Change from Baseline	n	48	51
		Mean	-0.58	-1.34
		SD	1.797	2.444
		Median	0.00	-0.33
		Min.	-6.9	-8.3
		Max.	1.9	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 19	Symptom Severity Score	n	48	51
		Mean	1.43	1.46
		SD	2.104	1.718
		Median	0.50	1.00
		Min.	0.0	0.0
		Max.	8.5	6.4
		Subjects with no reported symptoms	19 (35%)	18 (33%)
	Change from Baseline	n	48	51
		Mean	-0.56	-1.10
		SD	1.931	2.235
		Median	0.00	-0.29
		Min.	-6.0	-7.9
		Max.	3.1	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 20	Symptom Severity Score	n	48	52
		Mean	1.62	1.38
		SD	2.271	1.796
		Median	0.83	0.82
		Min.	0.0	0.0
		Max.	9.0	7.2
		Subjects with no reported symptoms	18 (33%)	22 (41%)
	Change from Baseline	n	48	52
		Mean	-0.38	-1.16
		SD	2.331	2.330
		Median	0.00	-0.29
		Min.	-6.6	-8.0
		Max.	7.0	2.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 21	Symptom Severity Score	n	46	46
		Mean	1.64	1.31
		SD	2.268	1.750
		Median	0.70	1.00
		Min.	0.0	0.0
		Max.	9.0	7.0
		Subjects with no reported symptoms	16 (30%)	19 (35%)
	Change from Baseline	n	46	46
		Mean	-0.26	-1.53
		SD	2.113	2.491
		Median	0.00	-0.38
		Min.	-5.0	-7.9
		Max.	5.7	2.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 22	Symptom Severity Score	n	47	51
		Mean	1.57	1.16
		SD	2.220	1.606
		Median	0.43	0.40
		Min.	0.0	0.0
		Max.	9.0	6.2
		Subjects with no reported symptoms	19 (35%)	22 (41%)
	Change from Baseline	n	47	51
		Mean	-0.45	-1.41
		SD	1.979	2.420
		Median	0.00	-0.33
		Min.	-7.7	-7.9
		Max.	3.4	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 23	Symptom Severity Score	n	47	49
		Mean	1.76	1.20
		SD	2.437	1.663
		Median	1.00	0.50
		Min.	0.0	0.0
		Max.	9.0	6.7
		Subjects with no reported symptoms	18 (33%)	19 (35%)
	Change from Baseline	n	47	49
		Mean	-0.17	-1.44
		SD	2.242	2.527
		Median	0.00	-0.33
		Min.	-6.3	-7.9
		Max.	7.3	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Symptom Severity Score	n	47	48
		Mean	1.63	1.23
		SD	2.366	1.753
		Median	0.29	0.45
		Min.	0.0	0.0
		Max.	8.9	7.0
		Subjects with no reported symptoms	19 (35%)	21 (39%)
	Change from Baseline	n	47	48
		Mean	-0.34	-1.35
		SD	2.292	2.644
		Median	0.00	-0.35
		Min.	-7.4	-7.9
		Max.	4.9	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 25	Symptom Severity Score	n	45	44
		Mean	1.57	1.03
		SD	2.323	1.404
		Median	0.29	0.36
		Min.	0.0	0.0
		Max.	9.0	5.3
		Subjects with no reported symptoms	21 (39%)	21 (39%)
	Change from Baseline	n	45	44
		Mean	-0.60	-1.24
		SD	2.267	2.574
		Median	0.00	-0.23
		Min.	-7.4	-8.3
		Max.	4.1	2.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 26	Symptom Severity Score	n	49	50
		Mean	1.59	1.30
		SD	2.433	1.606
		Median	0.20	0.63
		Min.	0.0	0.0
		Max.	9.3	5.6
		Subjects with no reported symptoms	22 (41%)	20 (37%)
	Change from Baseline	n	49	50
		Mean	-0.48	-1.31
		SD	2.318	2.704
		Median	0.00	-0.31
		Min.	-7.6	-8.3
		Max.	6.3	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 27	Symptom Severity Score	n	50	50
		Mean	1.84	1.24
		SD	2.501	1.632
		Median	0.80	0.53
		Min.	0.0	0.0
		Max.	9.3	6.3
		Subjects with no reported symptoms	22 (41%)	19 (35%)
	Change from Baseline	n	50	50
		Mean	-0.19	-1.37
		SD	2.312	2.632
		Median	0.00	-0.29
		Min.	-7.7	-8.3
		Max.	6.0	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 28	Symptom Severity Score	n	48	50
		Mean	1.76	1.19
		SD	2.667	1.610
		Median	0.36	0.50
		Min.	0.0	0.0
		Max.	10.0	6.8
		Subjects with no reported symptoms	22 (41%)	20 (37%)
	Change from Baseline	n	48	50
		Mean	-0.18	-1.42
		SD	2.602	2.590
		Median	0.00	-0.35
		Min.	-7.7	-8.3
		Max.	9.0	3.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 29	Symptom Severity Score	n	44	40
		Mean	1.42	1.03
		SD	2.118	1.570
		Median	0.00	0.25
		Min.	0.0	0.0
		Max.	8.5	6.5
		Subjects with no reported symptoms	24 (44%)	19 (35%)
	Change from Baseline	n	44	40
		Mean	-0.50	-1.80
		SD	2.199	2.790
		Median	0.00	-0.38
		Min.	-7.2	-8.3
		Max.	3.3	1.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 30	Symptom Severity Score	n	47	51
		Mean	1.50	1.20
		SD	2.343	1.712
		Median	0.00	0.20
		Min.	0.0	0.0
		Max.	9.6	5.8
		Subjects with no reported symptoms	24 (44%)	25 (46%)
	Change from Baseline	n	47	51
		Mean	-0.52	-1.36
		SD	2.061	2.503
		Median	0.00	-0.29
		Min.	-6.4	-7.9
		Max.	2.7	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 31	Symptom Severity Score	n	47	51
		Mean	1.67	1.21
		SD	2.518	1.695
		Median	0.29	0.33
		Min.	0.0	0.0
		Max.	9.8	5.9
		Subjects with no reported symptoms	21 (39%)	22 (41%)
	Change from Baseline	n	47	51
		Mean	-0.37	-1.36
		SD	2.329	2.457
		Median	0.00	-0.33
		Min.	-7.1	-7.4
		Max.	4.7	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Chills or Sweats Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Symptom Severity Score	n	47	50
		Mean	1.75	1.21
		SD	2.440	1.686
		Median	0.50	0.00
		Min.	0.0	0.0
		Max.	10.0	5.4
		Subjects with no reported symptoms	20 (37%)	26 (48%)
	Change from Baseline	n	47	50
		Mean	-0.28	-1.29
		SD	2.044	2.422
		Median	0.00	-0.31
		Min.	-5.0	-7.4
		Max.	2.9	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Symptom Severity Score	n	54	54
		Mean	2.63	3.12
		SD	2.412	2.836
		Median	2.27	2.79
		Min.	0.0	0.0
		Max.	8.6	10.0
		Subjects with no reported symptoms	12 (22%)	11 (20%)
Week 1	Symptom Severity Score	n	54	54
		Mean	2.37	2.91
		SD	2.295	2.826
		Median	1.43	1.93
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	11 (20%)	12 (22%)

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 1	Change from Baseline	n	54	54
		Mean	-0.26	-0.21
		SD	1.254	1.231
		Median	0.00	0.00
		Min.	-3.0	-2.4
		Max.	4.7	4.8
Week 2	Symptom Severity Score	n	54	54
		Mean	2.34	2.73
		SD	2.389	2.699
		Median	1.62	2.27
		Min.	0.0	0.0
		Max.	8.8	10.0
		Subjects with no reported symptoms	13 (24%)	10 (19%)
	Change from Baseline	n	54	54
		Mean	-0.29	-0.39
		SD	1.522	1.428
		Median	0.00	-0.07
		Min.	-3.2	-6.0
		Max.	6.5	4.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 3	Symptom Severity Score	n	54	54
		Mean	2.35	2.67
		SD	2.311	2.627
		Median	1.64	2.14
		Min.	0.0	0.0
		Max.	8.8	10.0
		Subjects with no reported symptoms	14 (26%)	11 (20%)
	Change from Baseline	n	54	54
		Mean	-0.28	-0.45
		SD	1.583	1.685
		Median	0.00	-0.05
		Min.	-4.8	-6.9
		Max.	5.9	3.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 4	Symptom Severity Score	n	54	54
		Mean	2.31	2.63
		SD	2.369	2.629
		Median	1.61	1.79
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	14 (26%)	9 (17%)
	Change from Baseline	n	54	54
		Mean	-0.33	-0.49
		SD	1.570	1.635
		Median	-0.07	-0.14
		Min.	-3.9	-7.1
		Max.	5.7	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 5	Symptom Severity Score	n	47	50
		Mean	2.28	2.71
		SD	2.448	2.700
		Median	1.43	2.00
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	13 (24%)	12 (22%)
	Change from Baseline	n	47	50
		Mean	-0.33	-0.50
		SD	1.837	1.583
		Median	-0.14	0.00
		Min.	-5.1	-5.9
		Max.	6.1	2.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 6	Symptom Severity Score	n	51	54
		Mean	2.15	2.74
		SD	2.338	2.686
		Median	1.29	2.07
		Min.	0.0	0.0
		Max.	9.2	10.0
		Subjects with no reported symptoms	13 (24%)	12 (22%)
	Change from Baseline	n	51	54
		Mean	-0.40	-0.38
		SD	1.726	1.926
		Median	-0.14	0.00
		Min.	-5.3	-7.1
		Max.	5.1	4.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 7	Symptom Severity Score	n	52	54
		Mean	2.40	2.53
		SD	2.534	2.623
		Median	1.36	1.66
		Min.	0.0	0.0
		Max.	7.9	10.0
		Subjects with no reported symptoms	15 (28%)	13 (24%)
	Change from Baseline	n	52	54
		Mean	-0.21	-0.60
		SD	1.847	1.777
		Median	0.00	-0.15
		Min.	-6.3	-7.6
		Max.	5.7	4.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Symptom Severity Score	n	52	54
		Mean	2.42	2.58
		SD	2.519	2.570
		Median	1.43	1.77
		Min.	0.0	0.0
		Max.	8.4	10.0
		Subjects with no reported symptoms	15 (28%)	12 (22%)
	Change from Baseline	n	52	54
		Mean	-0.19	-0.54
		SD	1.981	1.813
		Median	0.00	0.00
		Min.	-6.3	-7.1
		Max.	7.3	4.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 9	Symptom Severity Score	n	47	50
		Mean	2.50	2.40
		SD	2.676	2.631
		Median	1.17	1.18
		Min.	0.0	0.0
		Max.	8.0	10.0
		Subjects with no reported symptoms	13 (24%)	10 (19%)
	Change from Baseline	n	47	50
		Mean	-0.14	-0.65
		SD	1.815	1.869
		Median	-0.14	-0.24
		Min.	-6.3	-6.9
		Max.	6.5	3.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 10	Symptom Severity Score	n	51	52
		Mean	2.54	2.51
		SD	2.653	2.665
		Median	1.43	1.51
		Min.	0.0	0.0
		Max.	8.4	10.0
		Subjects with no reported symptoms	14 (26%)	13 (24%)
	Change from Baseline	n	51	52
		Mean	-0.08	-0.51
		SD	1.860	1.748
		Median	0.00	-0.07
		Min.	-6.3	-6.3
		Max.	6.3	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 11	Symptom Severity Score	n	49	52
		Mean	2.48	2.55
		SD	2.680	2.571
		Median	1.29	1.64
		Min.	0.0	0.0
		Max.	8.9	10.0
		Subjects with no reported symptoms	13 (24%)	13 (24%)
	Change from Baseline	n	49	52
		Mean	-0.13	-0.43
		SD	1.849	1.930
		Median	0.00	0.00
		Min.	-6.3	-7.1
		Max.	5.9	4.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 12	Symptom Severity Score	n	51	53
		Mean	2.30	2.58
		SD	2.600	2.569
		Median	1.25	1.83
		Min.	0.0	0.0
		Max.	8.6	10.0
		Subjects with no reported symptoms	15 (28%)	12 (22%)
	Change from Baseline	n	51	53
		Mean	-0.24	-0.50
		SD	1.787	1.943
		Median	0.00	0.00
		Min.	-6.3	-7.0
		Max.	5.4	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 13	Symptom Severity Score	n	43	48
		Mean	2.31	2.65
		SD	2.421	2.671
		Median	1.86	1.83
		Min.	0.0	0.0
		Max.	8.5	10.0
		Subjects with no reported symptoms	12 (22%)	8 (15%)
	Change from Baseline	n	43	48
		Mean	-0.49	-0.44
		SD	1.937	1.747
		Median	-0.07	0.00
		Min.	-6.3	-5.9
		Max.	4.8	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 14	Symptom Severity Score	n	50	53
		Mean	2.33	2.58
		SD	2.492	2.668
		Median	1.75	1.86
		Min.	0.0	0.0
		Max.	8.3	10.0
		Subjects with no reported symptoms	17 (31%)	15 (28%)
	Change from Baseline	n	50	53
		Mean	-0.20	-0.51
		SD	1.849	1.946
		Median	0.00	0.00
		Min.	-6.3	-6.1
		Max.	5.2	5.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 15	Symptom Severity Score	n	50	53
		Mean	2.28	2.62
		SD	2.700	2.717
		Median	1.07	2.00
		Min.	0.0	0.0
		Max.	8.4	10.0
		Subjects with no reported symptoms	17 (31%)	14 (26%)
	Change from Baseline	n	50	53
		Mean	-0.25	-0.47
		SD	1.906	1.641
		Median	0.00	-0.14
		Min.	-6.3	-6.4
		Max.	5.4	2.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Symptom Severity Score	n	51	52
		Mean	2.23	2.41
		SD	2.408	2.566
		Median	1.83	2.00
		Min.	0.0	0.0
		Max.	8.1	10.0
		Subjects with no reported symptoms	17 (31%)	12 (22%)
	Change from Baseline	n	51	52
		Mean	-0.31	-0.57
		SD	1.915	1.707
		Median	0.00	0.00
		Min.	-6.3	-6.7
		Max.	4.7	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 17	Symptom Severity Score	n	41	42
		Mean	2.37	2.52
		SD	2.578	2.740
		Median	1.80	1.70
		Min.	0.0	0.0
		Max.	8.3	10.0
		Subjects with no reported symptoms	13 (24%)	11 (20%)
	Change from Baseline	n	41	42
		Mean	-0.13	-0.95
		SD	1.759	1.946
		Median	0.00	-0.28
		Min.	-6.3	-7.9
		Max.	6.1	1.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 18	Symptom Severity Score	n	48	51
		Mean	2.52	2.24
		SD	2.600	2.594
		Median	2.29	1.67
		Min.	0.0	0.0
		Max.	8.7	10.0
		Subjects with no reported symptoms	14 (26%)	14 (26%)
	Change from Baseline	n	48	51
		Mean	-0.10	-0.80
		SD	2.004	1.743
		Median	0.00	0.00
		Min.	-6.3	-6.3
		Max.	5.7	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 19	Symptom Severity Score	n	48	51
		Mean	2.51	2.35
		SD	2.657	2.599
		Median	2.29	1.86
		Min.	0.0	0.0
		Max.	8.7	10.0
		Subjects with no reported symptoms	13 (24%)	13 (24%)
	Change from Baseline	n	48	51
		Mean	-0.12	-0.70
		SD	2.050	1.683
		Median	0.00	-0.43
		Min.	-6.1	-6.6
		Max.	5.9	2.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 20	Symptom Severity Score	n	48	52
		Mean	2.43	2.35
		SD	2.729	2.647
		Median	1.27	1.63
		Min.	0.0	0.0
		Max.	8.8	10.0
		Subjects with no reported symptoms	16 (30%)	16 (30%)
	Change from Baseline	n	48	52
		Mean	-0.20	-0.70
		SD	2.094	1.784
		Median	0.00	-0.25
		Min.	-6.0	-6.5
		Max.	5.7	3.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 21	Symptom Severity Score	n	46	46
		Mean	2.46	2.44
		SD	2.783	2.678
		Median	1.50	1.71
		Min.	0.0	0.0
		Max.	8.8	10.0
		Subjects with no reported symptoms	14 (26%)	14 (26%)
	Change from Baseline	n	46	46
		Mean	-0.21	-0.72
		SD	2.037	1.710
		Median	0.00	-0.15
		Min.	-4.9	-6.8
		Max.	6.1	1.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 22	Symptom Severity Score	n	47	51
		Mean	2.33	2.09
		SD	2.690	2.474
		Median	1.14	1.57
		Min.	0.0	0.0
		Max.	9.5	10.0
		Subjects with no reported symptoms	16 (30%)	17 (31%)
	Change from Baseline	n	47	51
		Mean	-0.20	-0.96
		SD	1.942	1.732
		Median	0.00	-0.27
		Min.	-5.6	-6.3
		Max.	5.0	1.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 23	Symptom Severity Score	n	47	49
		Mean	2.48	2.33
		SD	2.741	2.651
		Median	1.86	1.40
		Min.	0.0	0.0
		Max.	8.8	10.0
		Subjects with no reported symptoms	16 (30%)	14 (26%)
	Change from Baseline	n	47	49
		Mean	-0.19	-0.70
		SD	2.004	1.683
		Median	0.00	-0.33
		Min.	-6.3	-6.6
		Max.	5.9	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Symptom Severity Score	n	47	48
		Mean	2.41	2.18
		SD	2.803	2.583
		Median	1.00	1.07
		Min.	0.0	0.0
		Max.	8.5	10.0
		Subjects with no reported symptoms	16 (30%)	16 (30%)
	Change from Baseline	n	47	48
		Mean	-0.21	-0.73
		SD	2.080	1.731
		Median	0.00	0.00
		Min.	-5.9	-5.9
		Max.	5.9	2.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 25	Symptom Severity Score	n	45	44
		Mean	2.36	1.75
		SD	2.572	2.178
		Median	1.57	1.00
		Min.	0.0	0.0
		Max.	8.8	10.0
		Subjects with no reported symptoms	14 (26%)	15 (28%)
	Change from Baseline	n	45	44
		Mean	-0.36	-0.78
		SD	1.989	1.548
		Median	0.00	-0.33
		Min.	-5.7	-5.6
		Max.	5.9	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 26	Symptom Severity Score	n	49	50
		Mean	2.45	2.25
		SD	2.794	2.535
		Median	1.43	1.43
		Min.	0.0	0.0
		Max.	9.3	10.0
		Subjects with no reported symptoms	15 (28%)	16 (30%)
	Change from Baseline	n	49	50
		Mean	-0.25	-0.78
		SD	2.002	1.657
		Median	0.00	-0.18
		Min.	-6.0	-5.6
		Max.	6.7	2.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 27	Symptom Severity Score	n	50	50
		Mean	2.50	2.38
		SD	2.790	2.536
		Median	1.79	1.86
		Min.	0.0	0.0
		Max.	9.2	10.0
		Subjects with no reported symptoms	16 (30%)	15 (28%)
	Change from Baseline	n	50	50
		Mean	-0.21	-0.64
		SD	2.122	1.619
		Median	0.00	-0.14
		Min.	-6.3	-5.6
		Max.	5.6	2.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 28	Symptom Severity Score	n	48	50
		Mean	2.44	2.28
		SD	2.758	2.684
		Median	1.54	1.41
		Min.	0.0	0.0
		Max.	8.8	10.0
		Subjects with no reported symptoms	17 (31%)	16 (30%)
	Change from Baseline	n	48	50
		Mean	-0.19	-0.75
		SD	2.060	1.548
		Median	0.00	-0.21
		Min.	-6.3	-5.6
		Max.	6.4	1.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 29	Symptom Severity Score	n	44	40
		Mean	2.36	2.45
		SD	2.697	2.874
		Median	1.08	1.33
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	14 (26%)	12 (22%)
	Change from Baseline	n	44	40
		Mean	-0.03	-0.61
		SD	2.153	1.729
		Median	0.00	-0.14
		Min.	-6.3	-6.3
		Max.	7.4	2.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 30	Symptom Severity Score	n	47	51
		Mean	2.45	2.15
		SD	2.693	2.549
		Median	1.71	1.40
		Min.	0.0	0.0
		Max.	8.8	10.0
		Subjects with no reported symptoms	17 (31%)	15 (28%)
	Change from Baseline	n	47	51
		Mean	-0.08	-0.89
		SD	2.029	1.747
		Median	0.00	-0.29
		Min.	-6.3	-6.4
		Max.	6.9	1.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 31	Symptom Severity Score	n	47	51
		Mean	2.66	2.18
		SD	2.844	2.543
		Median	2.14	1.29
		Min.	0.0	0.0
		Max.	9.5	10.0
		Subjects with no reported symptoms	15 (28%)	15 (28%)
	Change from Baseline	n	47	51
		Mean	-0.02	-0.86
		SD	2.017	1.680
		Median	0.00	-0.14
		Min.	-6.3	-6.6
		Max.	7.2	1.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Abdominal Pain/Bloating Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Symptom Severity Score	n	47	50
		Mean	2.65	2.06
		SD	2.732	2.453
		Median	1.83	1.42
		Min.	0.0	0.0
		Max.	9.2	10.0
		Subjects with no reported symptoms	15 (28%)	15 (28%)
	Change from Baseline	n	47	50
		Mean	0.02	-0.86
		SD	2.031	1.752
		Median	0.00	-0.14
		Min.	-6.3	-6.0
		Max.	6.9	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Symptom Severity Score	n	54	54
		Mean	3.23	4.08
		SD	2.795	3.217
		Median	2.75	3.21
		Min.	0.0	0.0
		Max.	9.1	10.0
		Subjects with no reported symptoms	11 (20%)	6 (11%)
Week 1	Symptom Severity Score	n	54	54
		Mean	2.90	3.41
		SD	2.658	2.740
		Median	2.75	2.77
		Min.	0.0	0.0
		Max.	9.4	10.0
		Subjects with no reported symptoms	14 (26%)	7 (13%)

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 1	Change from Baseline	n	54	54
		Mean	-0.33	-0.67
		SD	1.145	1.569
		Median	-0.05	-0.33
		Min.	-3.6	-6.1
		Max.	2.8	5.4
Week 2	Symptom Severity Score	n	54	54
		Mean	2.79	2.81
		SD	2.677	2.626
		Median	2.03	2.00
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	13 (24%)	8 (15%)
	Change from Baseline	n	54	54
		Mean	-0.44	-1.27
		SD	1.048	2.154
		Median	0.00	-0.87
		Min.	-3.2	-8.2
		Max.	1.7	5.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 3	Symptom Severity Score	n	54	54
		Mean	2.76	2.64
		SD	2.579	2.559
		Median	2.33	1.93
		Min.	0.0	0.0
		Max.	9.2	10.0
		Subjects with no reported symptoms	12 (22%)	11 (20%)
	Change from Baseline	n	54	54
		Mean	-0.47	-1.44
		SD	1.001	2.441
		Median	-0.19	-0.57
		Min.	-3.5	-8.3
		Max.	1.7	4.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 4	Symptom Severity Score	n	54	54
		Mean	2.56	2.56
		SD	2.582	2.524
		Median	1.71	1.86
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	12 (22%)	9 (17%)
	Change from Baseline	n	54	54
		Mean	-0.67	-1.52
		SD	1.527	2.533
		Median	-0.21	-0.98
		Min.	-6.4	-8.5
		Max.	1.6	4.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 5	Symptom Severity Score	n	47	50
		Mean	2.76	2.54
		SD	2.469	2.584
		Median	2.50	2.07
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	8 (15%)	10 (19%)
	Change from Baseline	n	47	50
		Mean	-0.69	-1.74
		SD	1.443	2.823
		Median	-0.14	-1.14
		Min.	-4.6	-8.9
		Max.	1.3	3.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 6	Symptom Severity Score	n	51	54
		Mean	2.90	2.40
		SD	2.476	2.628
		Median	2.50	1.46
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	9 (17%)	13 (24%)
	Change from Baseline	n	51	54
		Mean	-0.41	-1.68
		SD	1.540	2.898
		Median	-0.03	-0.85
		Min.	-5.9	-8.9
		Max.	2.3	5.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 7	Symptom Severity Score	n	52	54
		Mean	2.84	2.35
		SD	2.889	2.552
		Median	2.07	1.59
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	12 (22%)	16 (30%)
	Change from Baseline	n	52	54
		Mean	-0.43	-1.73
		SD	1.803	2.851
		Median	0.00	-1.13
		Min.	-5.9	-8.8
		Max.	5.1	4.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Symptom Severity Score	n	52	54
		Mean	2.77	2.44
		SD	2.729	2.578
		Median	2.54	1.66
		Min.	0.0	0.0
		Max.	9.8	10.0
		Subjects with no reported symptoms	13 (24%)	13 (24%)
	Change from Baseline	n	52	54
		Mean	-0.50	-1.64
		SD	1.684	2.956
		Median	0.00	-0.87
		Min.	-5.1	-8.8
		Max.	4.3	5.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 9	Symptom Severity Score	n	47	50
		Mean	2.74	2.04
		SD	2.911	2.445
		Median	2.00	1.15
		Min.	0.0	0.0
		Max.	9.7	10.0
		Subjects with no reported symptoms	12 (22%)	18 (33%)
	Change from Baseline	n	47	50
		Mean	-0.40	-1.85
		SD	1.620	3.004
		Median	0.00	-1.07
		Min.	-5.5	-8.8
		Max.	4.0	4.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 10	Symptom Severity Score	n	51	52
		Mean	2.64	2.30
		SD	2.660	2.538
		Median	1.80	1.00
		Min.	0.0	0.0
		Max.	9.7	10.0
		Subjects with no reported symptoms	12 (22%)	12 (22%)
	Change from Baseline	n	51	52
		Mean	-0.56	-1.65
		SD	1.749	3.047
		Median	0.00	-0.90
		Min.	-5.7	-8.8
		Max.	2.9	4.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 11	Symptom Severity Score	n	49	52
		Mean	2.60	2.40
		SD	2.664	2.716
		Median	2.00	1.41
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	10 (19%)	15 (28%)
	Change from Baseline	n	49	52
		Mean	-0.74	-1.55
		SD	1.870	2.859
		Median	-0.14	-0.75
		Min.	-7.0	-8.8
		Max.	2.0	3.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 12	Symptom Severity Score	n	51	53
		Mean	2.67	2.31
		SD	2.663	2.645
		Median	2.00	1.33
		Min.	0.0	0.0
		Max.	9.6	10.0
		Subjects with no reported symptoms	11 (20%)	16 (30%)
	Change from Baseline	n	51	53
		Mean	-0.56	-1.71
		SD	1.837	2.928
		Median	0.00	-1.00
		Min.	-7.1	-8.8
		Max.	2.4	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 13	Symptom Severity Score	n	43	48
		Mean	2.74	2.22
		SD	2.744	2.607
		Median	2.14	1.23
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	11 (20%)	18 (33%)
	Change from Baseline	n	43	48
		Mean	-0.76	-1.96
		SD	2.189	2.975
		Median	0.00	-1.10
		Min.	-7.1	-8.9
		Max.	3.3	2.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 14	Symptom Severity Score	n	50	53
		Mean	2.54	2.21
		SD	2.687	2.521
		Median	1.85	1.57
		Min.	0.0	0.0
		Max.	9.4	10.0
		Subjects with no reported symptoms	12 (22%)	17 (31%)
	Change from Baseline	n	50	53
		Mean	-0.73	-1.82
		SD	2.187	2.880
		Median	0.00	-0.98
		Min.	-7.1	-8.9
		Max.	3.5	3.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 15	Symptom Severity Score	n	50	53
		Mean	2.38	2.32
		SD	2.545	2.541
		Median	2.00	1.20
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	14 (26%)	17 (31%)
	Change from Baseline	n	50	53
		Mean	-0.89	-1.70
		SD	1.962	2.850
		Median	-0.15	-1.00
		Min.	-7.1	-8.9
		Max.	3.1	4.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Symptom Severity Score	n	51	52
		Mean	2.42	2.18
		SD	2.484	2.473
		Median	1.86	1.31
		Min.	0.0	0.0
		Max.	8.9	10.0
		Subjects with no reported symptoms	12 (22%)	15 (28%)
	Change from Baseline	n	51	52
		Mean	-0.82	-1.77
		SD	2.005	2.808
		Median	0.00	-1.12
		Min.	-6.6	-8.8
		Max.	2.8	4.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 17	Symptom Severity Score	n	41	42
		Mean	2.42	2.17
		SD	2.769	2.528
		Median	1.29	1.14
		Min.	0.0	0.0
		Max.	9.8	10.0
		Subjects with no reported symptoms	11 (20%)	11 (20%)
	Change from Baseline	n	41	42
		Mean	-0.86	-2.12
		SD	2.328	2.717
		Median	-0.29	-1.14
		Min.	-6.8	-8.8
		Max.	4.9	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 18	Symptom Severity Score	n	48	51
		Mean	2.62	1.92
		SD	2.655	2.246
		Median	2.00	1.14
		Min.	0.0	0.0
		Max.	9.3	10.0
		Subjects with no reported symptoms	11 (20%)	14 (26%)
	Change from Baseline	n	48	51
		Mean	-0.73	-2.08
		SD	2.251	2.754
		Median	0.00	-1.29
		Min.	-7.1	-8.8
		Max.	4.4	4.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 19	Symptom Severity Score	n	48	51
		Mean	2.71	2.01
		SD	2.733	2.178
		Median	2.14	1.17
		Min.	0.0	0.0
		Max.	9.7	9.0
		Subjects with no reported symptoms	13 (24%)	15 (28%)
	Change from Baseline	n	48	51
		Mean	-0.63	-1.99
		SD	2.315	2.760
		Median	0.00	-1.29
		Min.	-7.1	-8.8
		Max.	4.8	4.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 20	Symptom Severity Score	n	48	52
		Mean	2.71	1.88
		SD	2.749	2.197
		Median	2.07	1.14
		Min.	0.0	0.0
		Max.	9.5	10.0
		Subjects with no reported symptoms	13 (24%)	16 (30%)
	Change from Baseline	n	48	52
		Mean	-0.63	-2.11
		SD	2.110	2.634
		Median	-0.10	-1.20
		Min.	-7.1	-8.8
		Max.	4.6	2.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 21	Symptom Severity Score	n	46	46
		Mean	2.57	1.87
		SD	2.542	2.306
		Median	1.92	1.14
		Min.	0.0	0.0
		Max.	9.3	10.0
		Subjects with no reported symptoms	10 (19%)	16 (30%)
	Change from Baseline	n	46	46
		Mean	-0.60	-2.44
		SD	1.908	2.762
		Median	-0.14	-1.45
		Min.	-5.3	-8.9
		Max.	4.5	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 22	Symptom Severity Score	n	47	51
		Mean	2.56	1.75
		SD	2.591	2.152
		Median	2.00	1.00
		Min.	0.0	0.0
		Max.	8.7	10.0
		Subjects with no reported symptoms	12 (22%)	13 (24%)
	Change from Baseline	n	47	51
		Mean	-0.75	-2.32
		SD	1.920	2.655
		Median	0.00	-1.29
		Min.	-7.1	-8.9
		Max.	2.3	1.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 23	Symptom Severity Score	n	47	49
		Mean	2.66	1.69
		SD	2.853	2.109
		Median	2.14	1.00
		Min.	0.0	0.0
		Max.	9.7	10.0
		Subjects with no reported symptoms	15 (28%)	12 (22%)
	Change from Baseline	n	47	49
		Mean	-0.76	-2.46
		SD	2.275	2.652
		Median	0.00	-1.50
		Min.	-7.1	-8.9
		Max.	4.8	1.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Symptom Severity Score	n	47	48
		Mean	2.50	1.79
		SD	2.791	2.138
		Median	2.00	1.14
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	16 (30%)	12 (22%)
	Change from Baseline	n	47	48
		Mean	-0.83	-2.29
		SD	2.163	2.726
		Median	0.00	-1.48
		Min.	-7.1	-8.9
		Max.	2.9	1.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 25	Symptom Severity Score	n	45	44
		Mean	2.55	1.61
		SD	2.596	1.675
		Median	2.00	1.15
		Min.	0.0	0.0
		Max.	9.0	6.0
		Subjects with no reported symptoms	12 (22%)	11 (20%)
	Change from Baseline	n	45	44
		Mean	-0.80	-2.11
		SD	2.132	2.841
		Median	0.00	-1.36
		Min.	-7.1	-8.9
		Max.	2.5	5.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 26	Symptom Severity Score	n	49	50
		Mean	2.50	1.94
		SD	2.659	2.113
		Median	2.00	1.14
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	17 (31%)	11 (20%)
	Change from Baseline	n	49	50
		Mean	-0.88	-2.13
		SD	2.062	2.865
		Median	-0.14	-1.20
		Min.	-7.1	-8.9
		Max.	2.3	4.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 27	Symptom Severity Score	n	50	50
		Mean	2.65	1.94
		SD	2.780	2.186
		Median	2.23	1.15
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	18 (33%)	13 (24%)
	Change from Baseline	n	50	50
		Mean	-0.68	-2.12
		SD	2.270	2.621
		Median	-0.07	-1.20
		Min.	-7.1	-8.9
		Max.	5.9	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 28	Symptom Severity Score	n	48	50
		Mean	2.78	1.91
		SD	3.042	2.204
		Median	2.00	1.17
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	16 (30%)	13 (24%)
	Change from Baseline	n	48	50
		Mean	-0.51	-2.15
		SD	2.451	2.793
		Median	0.00	-1.24
		Min.	-7.0	-8.9
		Max.	5.1	1.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 29	Symptom Severity Score	n	44	40
		Mean	2.25	1.69
		SD	2.384	2.118
		Median	2.00	1.00
		Min.	0.0	0.0
		Max.	7.8	8.0
		Subjects with no reported symptoms	15 (28%)	12 (22%)
	Change from Baseline	n	44	40
		Mean	-0.91	-2.59
		SD	2.171	3.066
		Median	-0.04	-1.27
		Min.	-6.9	-9.0
		Max.	3.1	1.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 30	Symptom Severity Score	n	47	51
		Mean	2.44	1.82
		SD	2.569	2.194
		Median	2.00	1.00
		Min.	0.0	0.0
		Max.	9.0	9.9
		Subjects with no reported symptoms	16 (30%)	14 (26%)
	Change from Baseline	n	47	51
		Mean	-0.87	-2.18
		SD	2.010	2.810
		Median	-0.14	-1.14
		Min.	-6.9	-9.3
		Max.	3.3	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 31	Symptom Severity Score	n	47	51
		Mean	2.53	1.86
		SD	2.646	2.252
		Median	2.00	1.00
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	14 (26%)	18 (33%)
	Change from Baseline	n	47	51
		Mean	-0.83	-2.14
		SD	2.065	2.786
		Median	0.00	-1.33
		Min.	-6.6	-9.9
		Max.	2.9	2.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Breathing Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Symptom Severity Score	n	47	50
		Mean	2.59	2.03
		SD	2.641	2.375
		Median	1.67	1.18
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	14 (26%)	17 (31%)
	Change from Baseline	n	47	50
		Mean	-0.69	-1.89
		SD	2.311	2.823
		Median	0.00	-1.13
		Min.	-6.8	-10.0
		Max.	3.0	4.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Symptom Severity Score	n	54	54
		Mean	2.90	3.51
		SD	2.827	3.043
		Median	2.21	3.00
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	13 (24%)	4 (7%)
Week 1	Symptom Severity Score	n	54	54
		Mean	2.66	2.95
		SD	2.570	2.732
		Median	2.00	2.62
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	11 (20%)	8 (15%)

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 1	Change from Baseline	n	54	54
		Mean	-0.24	-0.56
		SD	1.298	1.269
		Median	0.00	-0.14
		Min.	-3.2	-5.1
		Max.	3.7	2.7
Week 2	Symptom Severity Score	n	54	54
		Mean	2.72	2.64
		SD	2.701	2.569
		Median	2.00	2.00
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	14 (26%)	9 (17%)
	Change from Baseline	n	54	54
		Mean	-0.18	-0.87
		SD	1.622	1.890
		Median	0.00	-0.15
		Min.	-4.1	-8.0
		Max.	5.7	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 3	Symptom Severity Score	n	54	54
		Mean	2.68	2.41
		SD	2.658	2.378
		Median	2.00	1.64
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	12 (22%)	11 (20%)
	Change from Baseline	n	54	54
		Mean	-0.22	-1.10
		SD	1.704	2.238
		Median	-0.04	-0.23
		Min.	-5.0	-8.6
		Max.	5.0	2.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 4	Symptom Severity Score	n	54	54
		Mean	2.72	2.41
		SD	2.655	2.357
		Median	1.96	1.73
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	12 (22%)	9 (17%)
	Change from Baseline	n	54	54
		Mean	-0.18	-1.11
		SD	1.823	2.277
		Median	0.00	-0.37
		Min.	-6.0	-8.8
		Max.	7.3	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 5	Symptom Severity Score	n	47	50
		Mean	2.64	2.44
		SD	2.526	2.479
		Median	2.43	1.67
		Min.	0.0	0.0
		Max.	10.0	10.0
		Subjects with no reported symptoms	10 (19%)	10 (19%)
	Change from Baseline	n	47	50
		Mean	-0.35	-1.23
		SD	1.720	2.372
		Median	0.00	-0.34
		Min.	-4.3	-7.5
		Max.	5.6	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 6	Symptom Severity Score	n	51	54
		Mean	2.52	2.33
		SD	2.538	2.276
		Median	2.00	1.76
		Min.	0.0	0.0
		Max.	9.8	10.0
		Subjects with no reported symptoms	14 (26%)	9 (17%)
	Change from Baseline	n	51	54
		Mean	-0.38	-1.18
		SD	1.534	2.360
		Median	0.00	-0.31
		Min.	-5.3	-7.1
		Max.	4.3	3.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 7	Symptom Severity Score	n	52	54
		Mean	2.42	2.53
		SD	2.612	2.254
		Median	1.54	1.71
		Min.	0.0	0.0
		Max.	9.7	9.8
		Subjects with no reported symptoms	14 (26%)	7 (13%)
	Change from Baseline	n	52	54
		Mean	-0.45	-0.98
		SD	1.769	2.415
		Median	-0.14	-0.50
		Min.	-5.7	-7.0
		Max.	5.3	4.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Symptom Severity Score	n	52	54
		Mean	2.43	2.44
		SD	2.549	2.213
		Median	1.67	2.00
		Min.	0.0	0.0
		Max.	8.8	9.6
		Subjects with no reported symptoms	13 (24%)	8 (15%)
	Change from Baseline	n	52	54
		Mean	-0.44	-1.07
		SD	1.769	2.387
		Median	-0.15	-0.39
		Min.	-5.7	-7.0
		Max.	4.4	2.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 9	Symptom Severity Score	n	47	50
		Mean	2.63	2.06
		SD	2.868	2.132
		Median	1.50	1.27
		Min.	0.0	0.0
		Max.	8.7	8.6
		Subjects with no reported symptoms	14 (26%)	9 (17%)
	Change from Baseline	n	47	50
		Mean	-0.18	-1.38
		SD	1.689	2.533
		Median	0.00	-0.31
		Min.	-5.7	-7.6
		Max.	4.3	2.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 10	Symptom Severity Score	n	51	52
		Mean	2.31	2.02
		SD	2.573	2.038
		Median	1.33	1.45
		Min.	0.0	0.0
		Max.	8.8	8.0
		Subjects with no reported symptoms	14 (26%)	11 (20%)
	Change from Baseline	n	51	52
		Mean	-0.48	-1.36
		SD	1.816	2.469
		Median	0.00	-0.64
		Min.	-6.5	-7.6
		Max.	3.0	3.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 11	Symptom Severity Score	n	49	52
		Mean	2.28	2.33
		SD	2.578	2.289
		Median	1.40	2.00
		Min.	0.0	0.0
		Max.	8.8	8.8
		Subjects with no reported symptoms	17 (31%)	8 (15%)
	Change from Baseline	n	49	52
		Mean	-0.67	-1.06
		SD	1.720	2.519
		Median	-0.20	-0.58
		Min.	-5.9	-8.1
		Max.	2.9	6.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 12	Symptom Severity Score	n	51	53
		Mean	2.23	2.43
		SD	2.539	2.352
		Median	1.33	1.57
		Min.	0.0	0.0
		Max.	8.7	9.0
		Subjects with no reported symptoms	17 (31%)	8 (15%)
	Change from Baseline	n	51	53
		Mean	-0.63	-1.02
		SD	1.737	2.663
		Median	-0.29	-0.57
		Min.	-5.9	-7.8
		Max.	3.8	6.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 13	Symptom Severity Score	n	43	48
		Mean	2.34	2.32
		SD	2.332	2.345
		Median	1.14	1.85
		Min.	0.0	0.0
		Max.	8.3	10.0
		Subjects with no reported symptoms	8 (15%)	8 (15%)
	Change from Baseline	n	43	48
		Mean	-0.77	-1.21
		SD	1.825	2.533
		Median	-0.57	-0.24
		Min.	-5.9	-7.6
		Max.	2.8	4.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 14	Symptom Severity Score	n	50	53
		Mean	2.33	2.14
		SD	2.595	2.305
		Median	1.35	1.43
		Min.	0.0	0.0
		Max.	9.0	9.6
		Subjects with no reported symptoms	14 (26%)	12 (22%)
	Change from Baseline	n	50	53
		Mean	-0.59	-1.30
		SD	2.014	2.334
		Median	-0.14	-0.71
		Min.	-6.5	-8.0
		Max.	6.1	3.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 15	Symptom Severity Score	n	50	53
		Mean	2.39	2.27
		SD	2.573	2.241
		Median	1.14	1.43
		Min.	0.0	0.0
		Max.	8.3	9.9
		Subjects with no reported symptoms	15 (28%)	9 (17%)
	Change from Baseline	n	50	53
		Mean	-0.53	-1.17
		SD	1.783	2.223
		Median	-0.15	-0.86
		Min.	-6.7	-8.0
		Max.	3.6	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Symptom Severity Score	n	51	52
		Mean	2.35	2.21
		SD	2.439	2.213
		Median	1.43	1.46
		Min.	0.0	0.0
		Max.	8.8	10.0
		Subjects with no reported symptoms	16 (30%)	9 (17%)
	Change from Baseline	n	51	52
		Mean	-0.51	-1.18
		SD	1.716	2.219
		Median	0.00	-0.43
		Min.	-6.5	-8.0
		Max.	2.7	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 17	Symptom Severity Score	n	41	42
		Mean	2.23	2.48
		SD	2.694	2.300
		Median	1.00	2.00
		Min.	0.0	0.0
		Max.	9.5	10.0
		Subjects with no reported symptoms	12 (22%)	6 (11%)
	Change from Baseline	n	41	42
		Mean	-0.60	-1.39
		SD	2.206	2.361
		Median	0.00	-0.43
		Min.	-6.0	-7.6
		Max.	5.1	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 18	Symptom Severity Score	n	48	51
		Mean	2.47	2.20
		SD	2.607	2.091
		Median	1.76	1.57
		Min.	0.0	0.0
		Max.	9.3	8.8
		Subjects with no reported symptoms	13 (24%)	10 (19%)
	Change from Baseline	n	48	51
		Mean	-0.54	-1.24
		SD	2.035	2.262
		Median	-0.07	-0.69
		Min.	-6.4	-7.6
		Max.	4.8	3.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 19	Symptom Severity Score	n	48	51
		Mean	2.40	2.33
		SD	2.554	2.276
		Median	1.53	2.00
		Min.	0.0	0.0
		Max.	8.3	10.0
		Subjects with no reported symptoms	13 (24%)	10 (19%)
	Change from Baseline	n	48	51
		Mean	-0.62	-1.11
		SD	1.843	2.621
		Median	-0.14	-0.71
		Min.	-6.7	-6.7
		Max.	3.6	7.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 20	Symptom Severity Score	n	48	52
		Mean	2.57	2.36
		SD	2.545	2.330
		Median	1.86	1.75
		Min.	0.0	0.0
		Max.	8.8	9.0
		Subjects with no reported symptoms	12 (22%)	11 (20%)
	Change from Baseline	n	48	52
		Mean	-0.44	-1.06
		SD	1.895	2.632
		Median	0.00	-0.29
		Min.	-6.7	-7.9
		Max.	3.6	4.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 21	Symptom Severity Score	n	46	46
		Mean	2.46	2.43
		SD	2.562	2.187
		Median	1.83	1.90
		Min.	0.0	0.0
		Max.	9.0	8.6
		Subjects with no reported symptoms	12 (22%)	6 (11%)
	Change from Baseline	n	46	46
		Mean	-0.64	-1.21
		SD	2.069	2.583
		Median	-0.29	-0.43
		Min.	-6.5	-8.1
		Max.	4.2	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 22	Symptom Severity Score	n	47	51
		Mean	2.43	2.28
		SD	2.457	2.075
		Median	2.00	1.86
		Min.	0.0	0.0
		Max.	9.0	8.0
		Subjects with no reported symptoms	12 (22%)	9 (17%)
	Change from Baseline	n	47	51
		Mean	-0.56	-1.21
		SD	1.746	2.475
		Median	0.00	-0.40
		Min.	-6.7	-8.1
		Max.	3.1	3.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 23	Symptom Severity Score	n	47	49
		Mean	2.36	2.29
		SD	2.477	2.049
		Median	2.00	2.00
		Min.	0.0	0.0
		Max.	9.0	7.0
		Subjects with no reported symptoms	14 (26%)	10 (19%)
	Change from Baseline	n	47	49
		Mean	-0.72	-1.29
		SD	2.033	2.438
		Median	0.00	-0.43
		Min.	-6.7	-8.1
		Max.	4.4	2.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Symptom Severity Score	n	47	48
		Mean	2.31	2.29
		SD	2.519	1.967
		Median	1.71	1.83
		Min.	0.0	0.0
		Max.	8.7	6.7
		Subjects with no reported symptoms	15 (28%)	9 (17%)
	Change from Baseline	n	47	48
		Mean	-0.74	-1.23
		SD	1.990	2.477
		Median	0.00	-0.23
		Min.	-6.7	-8.1
		Max.	3.3	2.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 25	Symptom Severity Score	n	45	44
		Mean	2.22	2.16
		SD	2.161	1.852
		Median	2.00	1.73
		Min.	0.0	0.0
		Max.	8.9	6.1
		Subjects with no reported symptoms	11 (20%)	8 (15%)
	Change from Baseline	n	45	44
		Mean	-0.74	-0.93
		SD	2.078	1.990
		Median	0.00	-0.15
		Min.	-6.7	-7.6
		Max.	3.5	1.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 26	Symptom Severity Score	n	49	50
		Mean	2.30	2.36
		SD	2.429	2.077
		Median	2.00	2.00
		Min.	0.0	0.0
		Max.	9.5	8.8
		Subjects with no reported symptoms	14 (26%)	8 (15%)
	Change from Baseline	n	49	50
		Mean	-0.72	-1.15
		SD	2.174	2.554
		Median	0.00	-0.44
		Min.	-6.7	-8.1
		Max.	3.9	5.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 27	Symptom Severity Score	n	50	50
		Mean	2.35	2.42
		SD	2.546	2.253
		Median	2.00	1.83
		Min.	0.0	0.0
		Max.	9.5	8.2
		Subjects with no reported symptoms	17 (31%)	10 (19%)
	Change from Baseline	n	50	50
		Mean	-0.61	-1.09
		SD	2.410	2.428
		Median	0.00	-0.15
		Min.	-6.7	-8.1
		Max.	8.0	5.2

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 28	Symptom Severity Score	n	48	50
		Mean	2.59	2.29
		SD	2.671	2.042
		Median	2.07	1.92
		Min.	0.0	0.0
		Max.	10.0	7.3
		Subjects with no reported symptoms	14 (26%)	10 (19%)
	Change from Baseline	n	48	50
		Mean	-0.41	-1.22
		SD	2.271	2.298
		Median	0.00	-0.47
		Min.	-6.7	-8.1
		Max.	5.5	4.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 29	Symptom Severity Score	n	44	40
		Mean	2.41	2.38
		SD	2.301	2.074
		Median	2.00	1.67
		Min.	0.0	0.0
		Max.	8.8	8.0
		Subjects with no reported symptoms	11 (20%)	6 (11%)
	Change from Baseline	n	44	40
		Mean	-0.55	-1.30
		SD	2.347	2.610
		Median	-0.07	-0.73
		Min.	-6.7	-8.1
		Max.	4.0	4.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 30	Symptom Severity Score	n	47	51
		Mean	2.32	2.14
		SD	2.682	2.022
		Median	1.67	1.60
		Min.	0.0	0.0
		Max.	9.8	8.5
		Subjects with no reported symptoms	16 (30%)	10 (19%)
	Change from Baseline	n	47	51
		Mean	-0.66	-1.30
		SD	2.401	2.207
		Median	0.00	-0.57
		Min.	-6.7	-8.1
		Max.	4.8	1.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 31	Symptom Severity Score	n	47	51
		Mean	2.34	2.10
		SD	2.700	2.058
		Median	1.43	1.20
		Min.	0.0	0.0
		Max.	10.0	7.6
		Subjects with no reported symptoms	15 (28%)	10 (19%)
	Change from Baseline	n	47	51
		Mean	-0.62	-1.35
		SD	2.254	2.210
		Median	0.00	-0.57
		Min.	-6.7	-8.1
		Max.	4.7	1.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Nasal or Sinus Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Symptom Severity Score	n	47	50
		Mean	2.68	2.19
		SD	2.901	2.218
		Median	2.00	1.63
		Min.	0.0	0.0
		Max.	10.0	8.0
		Subjects with no reported symptoms	15 (28%)	11 (20%)
	Change from Baseline	n	47	50
		Mean	-0.25	-1.19
		SD	2.407	2.310
		Median	0.00	-0.23
		Min.	-6.7	-8.1
		Max.	7.5	2.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Symptom Severity Score	n	54	54
		Mean	3.37	2.94
		SD	3.143	2.800
		Median	2.50	2.14
		Min.	0.0	0.0
		Max.	9.0	9.3
		Subjects with no reported symptoms	11 (20%)	12 (22%)
Week 1	Symptom Severity Score	n	54	54
		Mean	3.11	2.36
		SD	2.878	2.521
		Median	2.33	1.54
		Min.	0.0	0.0
		Max.	9.2	8.1
		Subjects with no reported symptoms	14 (26%)	13 (24%)

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 1	Change from Baseline	n	54	54
		Mean	-0.26	-0.58
		SD	1.329	1.408
		Median	0.00	-0.08
		Min.	-4.2	-6.6
		Max.	3.4	1.4
Week 2	Symptom Severity Score	n	54	54
		Mean	3.17	2.33
		SD	2.832	2.307
		Median	2.24	1.71
		Min.	0.0	0.0
		Max.	9.5	8.0
		Subjects with no reported symptoms	10 (19%)	14 (26%)
	Change from Baseline	n	54	54
		Mean	-0.20	-0.60
		SD	1.327	1.661
		Median	-0.14	0.00
		Min.	-4.2	-7.3
		Max.	3.2	1.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 3	Symptom Severity Score	n	54	54
		Mean	2.93	2.14
		SD	2.880	2.391
		Median	1.79	1.50
		Min.	0.0	0.0
		Max.	10.0	8.3
		Subjects with no reported symptoms	15 (28%)	15 (28%)
	Change from Baseline	n	54	54
		Mean	-0.44	-0.80
		SD	1.415	1.782
		Median	-0.15	-0.21
		Min.	-4.5	-8.3
		Max.	2.7	3.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 4	Symptom Severity Score	n	54	54
		Mean	2.96	2.07
		SD	2.933	2.387
		Median	2.10	1.07
		Min.	0.0	0.0
		Max.	9.5	8.3
		Subjects with no reported symptoms	16 (30%)	14 (26%)
	Change from Baseline	n	54	54
		Mean	-0.41	-0.86
		SD	1.651	1.834
		Median	-0.29	-0.27
		Min.	-3.9	-8.3
		Max.	4.7	2.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 5	Symptom Severity Score	n	47	50
		Mean	2.87	1.94
		SD	2.889	2.448
		Median	2.00	1.00
		Min.	0.0	0.0
		Max.	9.3	8.3
		Subjects with no reported symptoms	13 (24%)	20 (37%)
	Change from Baseline	n	47	50
		Mean	-0.49	-1.11
		SD	1.916	1.966
		Median	-0.17	-0.54
		Min.	-4.7	-8.3
		Max.	4.9	2.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 6	Symptom Severity Score	n	51	54
		Mean	2.77	2.14
		SD	2.748	2.325
		Median	1.57	1.31
		Min.	0.0	0.0
		Max.	9.0	8.7
		Subjects with no reported symptoms	13 (24%)	12 (22%)
	Change from Baseline	n	51	54
		Mean	-0.42	-0.80
		SD	1.799	2.119
		Median	0.00	-0.23
		Min.	-5.1	-8.4
		Max.	3.9	3.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 7	Symptom Severity Score	n	52	54
		Mean	2.96	2.06
		SD	2.757	2.305
		Median	2.57	1.31
		Min.	0.0	0.0
		Max.	8.6	8.1
		Subjects with no reported symptoms	14 (26%)	13 (24%)
	Change from Baseline	n	52	54
		Mean	-0.29	-0.87
		SD	2.063	2.068
		Median	0.00	-0.43
		Min.	-4.7	-8.3
		Max.	5.0	3.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Symptom Severity Score	n	52	54
		Mean	2.76	1.98
		SD	2.548	2.168
		Median	2.37	1.21
		Min.	0.0	0.0
		Max.	8.0	8.3
		Subjects with no reported symptoms	13 (24%)	10 (19%)
	Change from Baseline	n	52	54
		Mean	-0.49	-0.96
		SD	1.996	2.107
		Median	-0.23	-0.54
		Min.	-5.7	-8.3
		Max.	4.1	3.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 9	Symptom Severity Score	n	47	50
		Mean	2.49	2.08
		SD	2.598	2.420
		Median	1.67	1.10
		Min.	0.0	0.0
		Max.	8.3	8.4
		Subjects with no reported symptoms	12 (22%)	17 (31%)
	Change from Baseline	n	47	50
		Mean	-0.59	-0.74
		SD	2.187	2.296
		Median	-0.14	-0.42
		Min.	-6.4	-8.3
		Max.	5.5	3.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 10	Symptom Severity Score	n	51	52
		Mean	2.48	1.97
		SD	2.656	2.445
		Median	1.33	1.00
		Min.	0.0	0.0
		Max.	8.6	8.6
		Subjects with no reported symptoms	15 (28%)	20 (37%)
	Change from Baseline	n	51	52
		Mean	-0.74	-0.81
		SD	2.292	2.248
		Median	-0.29	-0.40
		Min.	-6.4	-8.1
		Max.	5.4	4.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 11	Symptom Severity Score	n	49	52
		Mean	2.61	2.12
		SD	2.684	2.506
		Median	1.60	1.27
		Min.	0.0	0.0
		Max.	10.0	9.2
		Subjects with no reported symptoms	13 (24%)	16 (30%)
	Change from Baseline	n	49	52
		Mean	-0.58	-0.82
		SD	2.176	2.371
		Median	-0.29	-0.20
		Min.	-5.9	-8.3
		Max.	5.7	3.9

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 12	Symptom Severity Score	n	51	53
		Mean	2.55	2.12
		SD	2.559	2.360
		Median	1.71	1.33
		Min.	0.0	0.0
		Max.	10.0	8.8
		Subjects with no reported symptoms	14 (26%)	14 (26%)
	Change from Baseline	n	51	53
		Mean	-0.60	-0.76
		SD	2.216	2.426
		Median	0.00	-0.14
		Min.	-6.1	-7.9
		Max.	5.7	4.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 13	Symptom Severity Score	n	43	48
		Mean	2.36	2.44
		SD	2.543	2.441
		Median	1.14	2.17
		Min.	0.0	0.0
		Max.	10.0	8.2
		Subjects with no reported symptoms	13 (24%)	15 (28%)
	Change from Baseline	n	43	48
		Mean	-0.92	-0.39
		SD	2.245	2.483
		Median	-0.67	0.00
		Min.	-5.5	-7.0
		Max.	4.1	5.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 14	Symptom Severity Score	n	50	53
		Mean	2.38	2.27
		SD	2.519	2.318
		Median	1.27	1.50
		Min.	0.0	0.0
		Max.	10.0	8.0
		Subjects with no reported symptoms	16 (30%)	13 (24%)
	Change from Baseline	n	50	53
		Mean	-0.71	-0.61
		SD	2.255	2.286
		Median	-0.23	-0.25
		Min.	-5.5	-7.0
		Max.	4.7	5.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 15	Symptom Severity Score	n	50	53
		Mean	2.48	2.28
		SD	2.535	2.356
		Median	1.68	1.50
		Min.	0.0	0.0
		Max.	10.0	8.0
		Subjects with no reported symptoms	14 (26%)	14 (26%)
	Change from Baseline	n	50	53
		Mean	-0.61	-0.60
		SD	2.088	2.416
		Median	-0.14	-0.17
		Min.	-6.3	-7.0
		Max.	4.0	7.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Symptom Severity Score	n	51	52
		Mean	2.50	2.24
		SD	2.629	2.415
		Median	1.60	1.29
		Min.	0.0	0.0
		Max.	10.0	8.2
		Subjects with no reported symptoms	17 (31%)	11 (20%)
	Change from Baseline	n	51	52
		Mean	-0.65	-0.69
		SD	2.245	2.377
		Median	-0.14	-0.21
		Min.	-7.1	-6.9
		Max.	4.6	7.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 17	Symptom Severity Score	n	41	42
		Mean	2.44	2.23
		SD	2.635	2.336
		Median	1.33	1.75
		Min.	0.0	0.0
		Max.	9.4	8.5
		Subjects with no reported symptoms	13 (24%)	10 (19%)
	Change from Baseline	n	41	42
		Mean	-0.57	-0.67
		SD	2.106	2.244
		Median	-0.17	-0.14
		Min.	-6.4	-7.0
		Max.	4.1	3.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 18	Symptom Severity Score	n	48	51
		Mean	2.44	2.36
		SD	2.427	2.607
		Median	2.15	1.43
		Min.	0.0	0.0
		Max.	9.0	8.7
		Subjects with no reported symptoms	15 (28%)	16 (30%)
	Change from Baseline	n	48	51
		Mean	-0.58	-0.39
		SD	2.190	2.445
		Median	-0.15	-0.17
		Min.	-5.9	-7.0
		Max.	4.0	7.7

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 19	Symptom Severity Score	n	48	51
		Mean	2.45	2.11
		SD	2.465	2.363
		Median	1.69	1.20
		Min.	0.0	0.0
		Max.	9.0	8.6
		Subjects with no reported symptoms	13 (24%)	14 (26%)
	Change from Baseline	n	48	51
		Mean	-0.58	-0.64
		SD	2.143	2.291
		Median	0.00	-0.25
		Min.	-6.1	-6.9
		Max.	3.6	7.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 20	Symptom Severity Score	n	48	52
		Mean	2.50	2.03
		SD	2.566	2.288
		Median	1.71	1.42
		Min.	0.0	0.0
		Max.	10.0	8.7
		Subjects with no reported symptoms	14 (26%)	16 (30%)
	Change from Baseline	n	48	52
		Mean	-0.53	-0.74
		SD	2.013	2.080
		Median	-0.07	-0.30
		Min.	-5.1	-7.2
		Max.	5.0	3.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 21	Symptom Severity Score	n	46	46
		Mean	2.59	2.08
		SD	2.643	2.424
		Median	2.08	1.00
		Min.	0.0	0.0
		Max.	9.8	9.3
		Subjects with no reported symptoms	13 (24%)	15 (28%)
	Change from Baseline	n	46	46
		Mean	-0.40	-0.81
		SD	2.001	2.143
		Median	0.00	-0.35
		Min.	-5.1	-7.6
		Max.	3.9	3.3

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 22	Symptom Severity Score	n	47	51
		Mean	2.51	2.15
		SD	2.531	2.334
		Median	2.00	1.40
		Min.	0.0	0.0
		Max.	9.2	9.0
		Subjects with no reported symptoms	15 (28%)	14 (26%)
	Change from Baseline	n	47	51
		Mean	-0.55	-0.67
		SD	2.129	2.109
		Median	0.00	-0.25
		Min.	-5.1	-6.0
		Max.	4.3	4.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 23	Symptom Severity Score	n	47	49
		Mean	2.60	2.24
		SD	2.680	2.526
		Median	2.00	1.33
		Min.	0.0	0.0
		Max.	9.5	8.0
		Subjects with no reported symptoms	12 (22%)	17 (31%)
	Change from Baseline	n	47	49
		Mean	-0.49	-0.63
		SD	2.286	2.611
		Median	0.00	-0.17
		Min.	-5.6	-7.1
		Max.	5.1	6.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Symptom Severity Score	n	47	48
		Mean	2.48	2.39
		SD	2.567	2.655
		Median	1.67	1.29
		Min.	0.0	0.0
		Max.	9.0	9.4
		Subjects with no reported symptoms	11 (20%)	14 (26%)
	Change from Baseline	n	47	48
		Mean	-0.44	-0.53
		SD	2.295	2.720
		Median	0.00	-0.37
		Min.	-6.0	-7.2
		Max.	4.1	8.4

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 25	Symptom Severity Score	n	45	44
		Mean	2.60	2.58
		SD	2.619	2.785
		Median	2.00	1.71
		Min.	0.0	0.0
		Max.	9.0	9.8
		Subjects with no reported symptoms	13 (24%)	14 (26%)
	Change from Baseline	n	45	44
		Mean	-0.83	-0.11
		SD	2.472	2.637
		Median	0.00	0.00
		Min.	-6.1	-5.8
		Max.	3.7	8.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 26	Symptom Severity Score	n	49	50
		Mean	2.50	2.39
		SD	2.506	2.618
		Median	1.67	1.36
		Min.	0.0	0.0
		Max.	9.0	8.5
		Subjects with no reported symptoms	12 (22%)	14 (26%)
	Change from Baseline	n	49	50
		Mean	-0.64	-0.42
		SD	2.248	2.409
		Median	0.00	-0.17
		Min.	-6.6	-5.5
		Max.	4.7	7.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 27	Symptom Severity Score	n	50	50
		Mean	2.47	2.40
		SD	2.662	2.662
		Median	1.55	1.63
		Min.	0.0	0.0
		Max.	9.0	10.0
		Subjects with no reported symptoms	14 (26%)	16 (30%)
	Change from Baseline	n	50	50
		Mean	-0.74	-0.41
		SD	2.177	2.535
		Median	-0.15	-0.17
		Min.	-7.0	-6.4
		Max.	3.5	9.0

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 28	Symptom Severity Score	n	48	50
		Mean	2.42	2.38
		SD	2.560	2.603
		Median	1.50	1.62
		Min.	0.0	0.0
		Max.	9.0	9.6
		Subjects with no reported symptoms	11 (20%)	14 (26%)
	Change from Baseline	n	48	50
		Mean	-0.57	-0.43
		SD	2.348	2.464
		Median	0.00	-0.14
		Min.	-7.0	-6.9
		Max.	4.9	8.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 29	Symptom Severity Score	n	44	40
		Mean	2.58	1.90
		SD	2.543	2.172
		Median	2.00	1.00
		Min.	0.0	0.0
		Max.	9.0	6.8
		Subjects with no reported symptoms	11 (20%)	13 (24%)
	Change from Baseline	n	44	40
		Mean	-0.31	-1.03
		SD	2.162	2.720
		Median	0.00	-0.15
		Min.	-6.1	-7.6
		Max.	5.7	5.1

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 30	Symptom Severity Score	n	47	51
		Mean	2.67	2.00
		SD	2.742	2.452
		Median	2.00	1.00
		Min.	0.0	0.0
		Max.	9.6	9.0
		Subjects with no reported symptoms	12 (22%)	19 (35%)
	Change from Baseline	n	47	51
		Mean	-0.40	-0.75
		SD	2.227	2.461
		Median	0.00	-0.29
		Min.	-6.1	-7.6
		Max.	4.4	5.5

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 31	Symptom Severity Score	n	47	51
		Mean	2.67	2.00
		SD	2.773	2.309
		Median	1.86	1.14
		Min.	0.0	0.0
		Max.	9.2	7.9
		Subjects with no reported symptoms	14 (26%)	17 (31%)
	Change from Baseline	n	47	51
		Mean	-0.42	-0.75
		SD	2.163	2.317
		Median	0.00	-0.43
		Min.	-6.1	-6.7
		Max.	6.0	5.6

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Table 2.38
Summary of HES Symptom Severity Score (HES-DS) by Symptom

Symptom: Worst Level of Skin Symptoms Summary

Analysis Time Point	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Symptom Severity Score	n	47	50
		Mean	2.68	2.17
		SD	2.685	2.403
		Median	2.17	1.20
		Min.	0.0	0.0
		Max.	8.7	8.7
		Subjects with no reported symptoms	11 (20%)	14 (26%)
	Change from Baseline	n	47	50
		Mean	-0.31	-0.64
		SD	2.104	2.519
		Median	0.00	-0.17
		Min.	-5.8	-7.1
		Max.	5.7	5.8

Note:
1. The mean of the available assessments on the 7 days up to and including the date of each study visit is used as the value for that visit. For time points between visits i.e week 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, 14, 15, 17, 18, 19, 21, 22, 23, 25, 26, 27, 29, 30, 31, the number of available assessments depends on the elapsed time between visits.
2. Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.44
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	22	32
n [2]	18	30
LS Mean (SE)	3.82 (0.402)	2.50 (0.314)
LS Mean Change (SE)	-0.76 (0.402)	-2.08 (0.314)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.32
95% CI		(-2.35, -0.29)
p-value		0.013
Corrected Hedges g [3]		-0.76
95% CI		(-1.36, -0.15)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.45
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	30	26
n [2]	29	24
LS Mean (SE)	3.24 (0.302)	3.08 (0.331)
LS Mean Change (SE)	-1.21 (0.302)	-1.37 (0.331)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.16
95% CI		(-1.07, 0.74)
p-value		0.722
Corrected Hedges g [3]		-0.10
95% CI		(-0.64, 0.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.45
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	24	28
n [2]	18	26
LS Mean (SE)	3.62 (0.431)	2.25 (0.381)
LS Mean Change (SE)	-0.67 (0.431)	-2.04 (0.381)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.37
95% CI		(-2.54, -0.21)
p-value		0.022
Corrected Hedges g [3]		-0.71
95% CI		(-1.33, -0.09)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.46
Subgroup Analysis of Change from Baseline in
Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32
p-values for Subgroup-by-Treatment Interactions

Subgroup	Treatment by subgroup interaction p-value
Age (12-<18, 18-64, >=65 Years)	0.420
Gender (Male, Female)	0.018
Region (Europe, Rest of World)	0.464
Duration of disease (<2.76, >=2.76 Years) [1]	0.242
Baseline blood eosinophils (<1.5, >=1.5 10^9/L)	0.191

[1] 2.76 is the median in the ITT population.
Note: Interaction p-values obtained from separate mixed models repeated measures with covariates of treatment, region, baseline, baseline OCS dose, visit, subgroup plus interaction terms for visit-by-baseline, visit-by-treatment and subgroup-by-treatment. Region covariate is categorised as Argentina, Mexico and Brazil; USA; Rest of World; except for the region subgroup model where region is categorised as Europe; Rest of World.

Protocol: 200622
Population: Intent-to-Treat

Table 90.47
Analysis of Proportion of Subjects with an Improvement of >=1.5 in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	54	54
Responder	15 (28%)	22 (41%)
Non-Responder	39 (72%)	32 (59%)
Missing response	7 (13%)	4 (7%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.60 (0.24,1.51)
p-value		0.279
Inverse unadjusted odds ratio (95% CI) [3]		0.56 (0.23,1.35)
Inverse relative risk (95% CI) [4]		0.68 (0.36,1.17)
Risk difference (95% CI) [4]		-0.13 (-0.31,0.05)
Fisher's Exact p-value (2-sided)		0.224

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Muscle/Joint Pain Summary
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	2.89 (0.210)	2.69 (0.211)
LS Mean Change (SE)	-0.53 (0.210)	-0.73 (0.211)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.20
95% CI		(-0.80, 0.40)
p-value		0.506
Corrected Hedges g [3]		-0.13
95% CI		(-0.51, 0.25)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Muscle/Joint Pain Summary
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	54
LS Mean (SE)	3.04 (0.220)	2.59 (0.219)
LS Mean Change (SE)	-0.38 (0.220)	-0.83 (0.219)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.45
95% CI		(-1.07, 0.17)
p-value		0.157
Corrected Hedges g [3]		-0.28
95% CI		(-0.66, 0.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Muscle/Joint Pain Summary
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	53
LS Mean (SE)	2.87 (0.257)	2.96 (0.255)
LS Mean Change (SE)	-0.55 (0.257)	-0.46 (0.255)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.09
95% CI		(-0.63, 0.81)
p-value		0.805
Corrected Hedges g [3]		0.05
95% CI		(-0.34, 0.43)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Muscle/Joint Pain Summary
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	52
LS Mean (SE)	2.84 (0.243)	2.70 (0.241)
LS Mean Change (SE)	-0.58 (0.243)	-0.72 (0.241)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.14
95% CI		(-0.83, 0.54)
p-value		0.684
Corrected Hedges g [3]		-0.08
95% CI		(-0.47, 0.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Muscle/Joint Pain Summary
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	52
LS Mean (SE)	2.91 (0.243)	2.41 (0.239)
LS Mean Change (SE)	-0.51 (0.243)	-1.01 (0.239)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.50
95% CI		(-1.18, 0.18)
p-value		0.149
Corrected Hedges g [3]		-0.29
95% CI		(-0.69, 0.10)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Muscle/Joint Pain Summary
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	48
LS Mean (SE)	2.96 (0.268)	2.50 (0.265)
LS Mean Change (SE)	-0.45 (0.268)	-0.91 (0.265)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.46
95% CI		(-1.21, 0.29)
p-value		0.228
Corrected Hedges g [3]		-0.25
95% CI		(-0.65, 0.15)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Muscle/Joint Pain Summary
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	50
LS Mean (SE)	2.86 (0.259)	2.52 (0.255)
LS Mean Change (SE)	-0.55 (0.259)	-0.90 (0.255)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.34
95% CI		(-1.07, 0.39)
p-value		0.355
Corrected Hedges g [3]		-0.19
95% CI		(-0.58, 0.21)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Muscle/Joint Pain Summary
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	50
LS Mean (SE)	3.15 (0.273)	2.39 (0.268)
LS Mean Change (SE)	-0.27 (0.273)	-1.03 (0.268)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.76
95% CI		(-1.52, 0.01)
p-value		0.052
Corrected Hedges g [3]		-0.40
95% CI		(-0.80, 0.00)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Chills or Sweats Summary
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	1.77 (0.176)	1.60 (0.176)
LS Mean Change (SE)	-0.51 (0.176)	-0.68 (0.176)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.17
95% CI		(-0.67, 0.33)
p-value		0.505
Corrected Hedges g [3]		-0.13
95% CI		(-0.51, 0.25)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Chills or Sweats Summary
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	54
LS Mean (SE)	1.65 (0.219)	1.65 (0.218)
LS Mean Change (SE)	-0.63 (0.219)	-0.63 (0.218)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.00
95% CI		(-0.61, 0.62)
p-value		0.994
Corrected Hedges g [3]		0.00
95% CI		(-0.38, 0.38)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Chills or Sweats Summary
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	53
LS Mean (SE)	1.78 (0.221)	1.51 (0.219)
LS Mean Change (SE)	-0.50 (0.221)	-0.77 (0.219)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.26
95% CI		(-0.88, 0.36)
p-value		0.403
Corrected Hedges g [3]		-0.16
95% CI		(-0.55, 0.22)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Chills or Sweats Summary
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	52
LS Mean (SE)	1.66 (0.221)	1.32 (0.220)
LS Mean Change (SE)	-0.61 (0.221)	-0.95 (0.220)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.34
95% CI		(-0.96, 0.28)
p-value		0.282
Corrected Hedges g [3]		-0.21
95% CI		(-0.60, 0.17)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Chills or Sweats Summary
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	52
LS Mean (SE)	1.77 (0.249)	1.28 (0.245)
LS Mean Change (SE)	-0.51 (0.249)	-1.00 (0.245)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.49
95% CI		(-1.19, 0.21)
p-value		0.165
Corrected Hedges g [3]		-0.28
95% CI		(-0.67, 0.12)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Chills or Sweats Summary
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	48
LS Mean (SE)	1.82 (0.263)	1.08 (0.260)
LS Mean Change (SE)	-0.46 (0.263)	-1.20 (0.260)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.74
95% CI		(-1.47, 0.00)
p-value		0.051
Corrected Hedges g [3]		-0.41
95% CI		(-0.81, 0.00)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Chills or Sweats Summary
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	50
LS Mean (SE)	1.92 (0.283)	1.05 (0.279)
LS Mean Change (SE)	-0.36 (0.283)	-1.23 (0.279)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.87
95% CI		(-1.67, -0.08)
p-value		0.031
Corrected Hedges g [3]		-0.44
95% CI		(-0.84, -0.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Chills or Sweats Summary
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	50
LS Mean (SE)	1.87 (0.245)	1.09 (0.242)
LS Mean Change (SE)	-0.41 (0.245)	-1.19 (0.242)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.78
95% CI		(-1.47, -0.09)
p-value		0.026
Corrected Hedges g [3]		-0.46
95% CI		(-0.86, -0.05)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Abdominal Pain/Bloating Summary
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	2.47 (0.200)	2.37 (0.201)
LS Mean Change (SE)	-0.35 (0.200)	-0.45 (0.201)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.10
95% CI		(-0.67, 0.47)
p-value		0.727
Corrected Hedges g [3]		-0.07
95% CI		(-0.44, 0.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Abdominal Pain/Bloating Summary
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	54
LS Mean (SE)	2.61 (0.237)	2.34 (0.236)
LS Mean Change (SE)	-0.21 (0.237)	-0.49 (0.236)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.28
95% CI		(-0.94, 0.39)
p-value		0.414
Corrected Hedges g [3]		-0.16
95% CI		(-0.54, 0.22)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Abdominal Pain/Bloating Summary
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	53
LS Mean (SE)	2.55 (0.231)	2.37 (0.230)
LS Mean Change (SE)	-0.27 (0.231)	-0.46 (0.230)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.19
95% CI		(-0.84, 0.46)
p-value		0.565
Corrected Hedges g [3]		-0.11
95% CI		(-0.50, 0.27)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Abdominal Pain/Bloating Summary
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	52
LS Mean (SE)	2.47 (0.220)	2.28 (0.219)
LS Mean Change (SE)	-0.35 (0.220)	-0.54 (0.219)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.19
95% CI		(-0.82, 0.43)
p-value		0.535
Corrected Hedges g [3]		-0.12
95% CI		(-0.51, 0.26)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Abdominal Pain/Bloating Summary
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	52
LS Mean (SE)	2.60 (0.245)	2.19 (0.242)
LS Mean Change (SE)	-0.22 (0.245)	-0.64 (0.242)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.41
95% CI		(-1.10, 0.27)
p-value		0.236
Corrected Hedges g [3]		-0.24
95% CI		(-0.63, 0.16)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Abdominal Pain/Bloating Summary
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	48
LS Mean (SE)	2.66 (0.250)	2.17 (0.248)
LS Mean Change (SE)	-0.16 (0.250)	-0.65 (0.248)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.50
95% CI		(-1.20, 0.21)
p-value		0.164
Corrected Hedges g [3]		-0.29
95% CI		(-0.69, 0.12)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Abdominal Pain/Bloating Summary
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	50
LS Mean (SE)	2.72 (0.246)	2.11 (0.243)
LS Mean Change (SE)	-0.10 (0.246)	-0.71 (0.243)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.61
95% CI		(-1.29, 0.08)
p-value		0.084
Corrected Hedges g [3]		-0.35
95% CI		(-0.75, 0.05)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Abdominal Pain/Bloating Summary
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	50
LS Mean (SE)	2.77 (0.247)	2.07 (0.244)
LS Mean Change (SE)	-0.05 (0.247)	-0.75 (0.244)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.70
95% CI		(-1.39, 0.00)
p-value		0.049
Corrected Hedges g [3]		-0.40
95% CI		(-0.81, 0.00)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Breathing Symptoms Summary
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	2.85 (0.238)	2.24 (0.239)
LS Mean Change (SE)	-0.81 (0.238)	-1.41 (0.239)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.60
95% CI		(-1.28, 0.07)
p-value		0.079
Corrected Hedges g [3]		-0.34
95% CI		(-0.72, 0.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Breathing Symptoms Summary
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	54
LS Mean (SE)	3.00 (0.278)	2.14 (0.277)
LS Mean Change (SE)	-0.65 (0.278)	-1.52 (0.277)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.86
95% CI		(-1.65, -0.08)
p-value		0.031
Corrected Hedges g [3]		-0.42
95% CI		(-0.81, -0.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Breathing Symptoms Summary
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	53
LS Mean (SE)	2.90 (0.279)	2.10 (0.277)
LS Mean Change (SE)	-0.75 (0.279)	-1.55 (0.277)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.80
95% CI		(-1.58, -0.01)
p-value		0.046
Corrected Hedges g [3]		-0.40
95% CI		(-0.78, -0.01)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Breathing Symptoms Summary
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	52
LS Mean (SE)	2.63 (0.262)	2.00 (0.261)
LS Mean Change (SE)	-1.03 (0.262)	-1.66 (0.261)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.63
95% CI		(-1.37, 0.11)
p-value		0.094
Corrected Hedges g [3]		-0.33
95% CI		(-0.72, 0.06)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Breathing Symptoms Summary
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	52
LS Mean (SE)	2.88 (0.254)	1.74 (0.251)
LS Mean Change (SE)	-0.77 (0.254)	-1.92 (0.251)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.15
95% CI		(-1.86, -0.43)
p-value		0.002
Corrected Hedges g [3]		-0.64
95% CI		(-1.04, -0.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Breathing Symptoms Summary
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	48
LS Mean (SE)	2.76 (0.272)	1.69 (0.269)
LS Mean Change (SE)	-0.90 (0.272)	-1.97 (0.269)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.07
95% CI		(-1.83, -0.30)
p-value		0.007
Corrected Hedges g [3]		-0.57
95% CI		(-0.98, -0.16)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Breathing Symptoms Summary
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	50
LS Mean (SE)	3.03 (0.298)	1.84 (0.294)
LS Mean Change (SE)	-0.62 (0.298)	-1.82 (0.294)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.20
95% CI		(-2.03, -0.36)
p-value		0.005
Corrected Hedges g [3]		-0.57
95% CI		(-0.98, -0.17)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Breathing Symptoms Summary
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	50
LS Mean (SE)	2.83 (0.276)	1.92 (0.272)
LS Mean Change (SE)	-0.82 (0.276)	-1.73 (0.272)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.91
95% CI		(-1.68, -0.13)
p-value		0.022
Corrected Hedges g [3]		-0.47
95% CI		(-0.88, -0.07)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Nasal or Sinus Symptoms Summary
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	2.92 (0.239)	2.19 (0.240)
LS Mean Change (SE)	-0.29 (0.239)	-1.01 (0.240)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.72
95% CI		(-1.40, -0.05)
p-value		0.036
Corrected Hedges g [3]		-0.41
95% CI		(-0.79, -0.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Nasal or Sinus Symptoms Summary
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	54
LS Mean (SE)	2.66 (0.238)	2.24 (0.236)
LS Mean Change (SE)	-0.54 (0.238)	-0.96 (0.236)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.41
95% CI		(-1.08, 0.26)
p-value		0.222
Corrected Hedges g [3]		-0.24
95% CI		(-0.62, 0.14)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Nasal or Sinus Symptoms Summary
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	53
LS Mean (SE)	2.45 (0.257)	2.30 (0.254)
LS Mean Change (SE)	-0.76 (0.257)	-0.90 (0.254)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.14
95% CI		(-0.86, 0.58)
p-value		0.699
Corrected Hedges g [3]		-0.08
95% CI		(-0.46, 0.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Nasal or Sinus Symptoms Summary
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	52
LS Mean (SE)	2.57 (0.218)	2.09 (0.216)
LS Mean Change (SE)	-0.63 (0.218)	-1.11 (0.216)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.48
95% CI		(-1.09, 0.13)
p-value		0.123
Corrected Hedges g [3]		-0.31
95% CI		(-0.69, 0.08)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Nasal or Sinus Symptoms Summary
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	52
LS Mean (SE)	2.70 (0.264)	2.31 (0.258)
LS Mean Change (SE)	-0.51 (0.264)	-0.90 (0.258)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.39
95% CI		(-1.12, 0.35)
p-value		0.296
Corrected Hedges g [3]		-0.21
95% CI		(-0.60, 0.18)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Nasal or Sinus Symptoms Summary
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	48
LS Mean (SE)	2.53 (0.243)	2.16 (0.240)
LS Mean Change (SE)	-0.67 (0.243)	-1.04 (0.240)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.37
95% CI		(-1.06, 0.31)
p-value		0.278
Corrected Hedges g [3]		-0.22
95% CI		(-0.63, 0.18)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Nasal or Sinus Symptoms Summary
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	50
LS Mean (SE)	2.82 (0.257)	2.14 (0.253)
LS Mean Change (SE)	-0.38 (0.257)	-1.06 (0.253)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.68
95% CI		(-1.40, 0.04)
p-value		0.064
Corrected Hedges g [3]		-0.38
95% CI		(-0.78, 0.02)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Nasal or Sinus Symptoms Summary
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	50
LS Mean (SE)	2.88 (0.280)	2.13 (0.273)
LS Mean Change (SE)	-0.32 (0.280)	-1.07 (0.273)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.75
95% CI		(-1.53, 0.03)
p-value		0.059
Corrected Hedges g [3]		-0.39
95% CI		(-0.79, 0.01)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Skin Symptoms Summary
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	2.68 (0.215)	2.13 (0.215)
LS Mean Change (SE)	-0.32 (0.215)	-0.86 (0.215)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.54
95% CI		(-1.15, 0.07)
p-value		0.080
Corrected Hedges g [3]		-0.34
95% CI		(-0.72, 0.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Skin Symptoms Summary
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	54
LS Mean (SE)	2.63 (0.229)	2.03 (0.226)
LS Mean Change (SE)	-0.37 (0.229)	-0.96 (0.226)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.59
95% CI		(-1.24, 0.05)
p-value		0.070
Corrected Hedges g [3]		-0.36
95% CI		(-0.74, 0.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Skin Symptoms Summary
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	53
LS Mean (SE)	2.48 (0.265)	2.22 (0.262)
LS Mean Change (SE)	-0.51 (0.265)	-0.77 (0.262)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.26
95% CI		(-1.01, 0.48)
p-value		0.481
Corrected Hedges g [3]		-0.14
95% CI		(-0.52, 0.25)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Skin Symptoms Summary
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	52
LS Mean (SE)	2.42 (0.271)	2.34 (0.268)
LS Mean Change (SE)	-0.57 (0.271)	-0.65 (0.268)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.09
95% CI		(-0.84, 0.67)
p-value		0.824
Corrected Hedges g [3]		-0.04
95% CI		(-0.43, 0.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Skin Symptoms Summary
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	52
LS Mean (SE)	2.53 (0.242)	2.25 (0.237)
LS Mean Change (SE)	-0.46 (0.242)	-0.75 (0.237)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.29
95% CI		(-0.96, 0.39)
p-value		0.402
Corrected Hedges g [3]		-0.17
95% CI		(-0.56, 0.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Skin Symptoms Summary
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	48
LS Mean (SE)	2.53 (0.298)	2.50 (0.294)
LS Mean Change (SE)	-0.47 (0.298)	-0.49 (0.294)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.02
95% CI		(-0.86, 0.81)
p-value		0.956
Corrected Hedges g [3]		-0.01
95% CI		(-0.41, 0.39)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Skin Symptoms Summary
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	48	50
LS Mean (SE)	2.45 (0.289)	2.56 (0.283)
LS Mean Change (SE)	-0.55 (0.289)	-0.43 (0.283)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.11
95% CI		(-0.69, 0.92)
p-value		0.782
Corrected Hedges g [3]		0.06
95% CI		(-0.34, 0.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.48
Analysis of Change from Baseline in HES Symptom Severity Score (HES-DS) by Symptom
(Mixed Model Repeated Measures)

Symptom: Worst Level of Skin Symptoms Summary
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	47	50
LS Mean (SE)	2.58 (0.280)	2.33 (0.275)
LS Mean Change (SE)	-0.41 (0.280)	-0.66 (0.275)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.25
95% CI		(-1.04, 0.53)
p-value		0.522
Corrected Hedges g [3]		-0.13
95% CI		(-0.53, 0.27)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Protocol: 200622
Population: Intent-to-Treat

Table 2.44
Summary of Clinician-Rated Overall Response to Therapy

Visit		Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 4	n	51		51	
	Significantly improved (1)	2	(4%)	10	(20%)
	Moderately improved (2)	8	(16%)	9	(18%)
	Mildly improved (3)	8	(16%)	10	(20%)
	No change (4)	26	(51%)	18	(35%)
	Mildly worse (5)	5	(10%)	1	(2%)
	Moderately worse (6)	2	(4%)	2	(4%)
	Significantly worse (7)	0		1	(2%)
Week 8	n	49		47	
	Significantly improved (1)	6	(12%)	12	(26%)
	Moderately improved (2)	6	(12%)	6	(13%)
	Mildly improved (3)	10	(20%)	7	(15%)
	No change (4)	20	(41%)	17	(36%)
	Mildly worse (5)	4	(8%)	3	(6%)
	Moderately worse (6)	3	(6%)	1	(2%)
	Significantly worse (7)	0		1	(2%)
Week 12	n	46		45	
	Significantly improved (1)	5	(11%)	13	(29%)
	Moderately improved (2)	9	(20%)	6	(13%)
	Mildly improved (3)	6	(13%)	11	(24%)
	No change (4)	17	(37%)	11	(24%)
	Mildly worse (5)	7	(15%)	4	(9%)
	Moderately worse (6)	2	(4%)	0	
	Significantly worse (7)	0		0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.44
Summary of Clinician-Rated Overall Response to Therapy

Visit		Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 16	n	44		43	
	Significantly improved (1)	5	(11%)	15	(35%)
	Moderately improved (2)	4	(9%)	7	(16%)
	Mildly improved (3)	11	(25%)	11	(26%)
	No change (4)	15	(34%)	7	(16%)
	Mildly worse (5)	5	(11%)	3	(7%)
	Moderately worse (6)	4	(9%)	0	
	Significantly worse (7)	0		0	
Week 20	n	41		42	
	Significantly improved (1)	5	(12%)	12	(29%)
	Moderately improved (2)	5	(12%)	10	(24%)
	Mildly improved (3)	8	(20%)	8	(19%)
	No change (4)	16	(39%)	9	(21%)
	Mildly worse (5)	5	(12%)	3	(7%)
	Moderately worse (6)	2	(5%)	0	
	Significantly worse (7)	0		0	
Week 24	n	42		42	
	Significantly improved (1)	3	(7%)	13	(31%)
	Moderately improved (2)	11	(26%)	7	(17%)
	Mildly improved (3)	6	(14%)	8	(19%)
	No change (4)	14	(33%)	9	(21%)
	Mildly worse (5)	6	(14%)	4	(10%)
	Moderately worse (6)	2	(5%)	0	
	Significantly worse (7)	0		1	(2%)

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.44
Summary of Clinician-Rated Overall Response to Therapy

Visit		Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 28	n	42		43	
	Significantly improved (1)	8	(19%)	16	(37%)
	Moderately improved (2)	4	(10%)	8	(19%)
	Mildly improved (3)	8	(19%)	5	(12%)
	No change (4)	17	(40%)	8	(19%)
	Mildly worse (5)	4	(10%)	3	(7%)
	Moderately worse (6)	1	(2%)	3	(7%)
	Significantly worse (7)	0		0	
Week 32	n	41		41	
	Significantly improved (1)	3	(7%)	18	(44%)
	Moderately improved (2)	8	(20%)	3	(7%)
	Mildly improved (3)	11	(27%)	7	(17%)
	No change (4)	12	(29%)	7	(17%)
	Mildly worse (5)	6	(15%)	3	(7%)
	Moderately worse (6)	0		3	(7%)
	Significantly worse (7)	1	(2%)	0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.46
Summary of Subject-Rated Overall Response to Therapy

Visit		Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 4	n	51		51	
	Significantly improved (1)	2	(4%)	12	(24%)
	Moderately improved (2)	9	(18%)	5	(10%)
	Mildly improved (3)	16	(31%)	11	(22%)
	No change (4)	18	(35%)	17	(33%)
	Mildly worse (5)	3	(6%)	4	(8%)
	Moderately worse (6)	1	(2%)	2	(4%)
	Significantly worse (7)	2	(4%)	0	
Week 8	n	49		47	
	Significantly improved (1)	6	(12%)	13	(28%)
	Moderately improved (2)	9	(18%)	6	(13%)
	Mildly improved (3)	8	(16%)	8	(17%)
	No change (4)	22	(45%)	17	(36%)
	Mildly worse (5)	3	(6%)	1	(2%)
	Moderately worse (6)	1	(2%)	1	(2%)
	Significantly worse (7)	0		1	(2%)
Week 12	n	46		45	
	Significantly improved (1)	7	(15%)	13	(29%)
	Moderately improved (2)	5	(11%)	7	(16%)
	Mildly improved (3)	12	(26%)	8	(18%)
	No change (4)	16	(35%)	13	(29%)
	Mildly worse (5)	4	(9%)	2	(4%)
	Moderately worse (6)	1	(2%)	1	(2%)
	Significantly worse (7)	1	(2%)	1	(2%)

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.46
Summary of Subject-Rated Overall Response to Therapy

Visit		Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 16	n	44		44	
	Significantly improved (1)	5	(11%)	12	(27%)
	Moderately improved (2)	13	(30%)	5	(11%)
	Mildly improved (3)	6	(14%)	16	(36%)
	No change (4)	19	(43%)	9	(20%)
	Mildly worse (5)	1	(2%)	2	(5%)
	Moderately worse (6)	0		0	
	Significantly worse (7)	0		0	
Week 20	n	44		42	
	Significantly improved (1)	5	(11%)	13	(31%)
	Moderately improved (2)	10	(23%)	6	(14%)
	Mildly improved (3)	12	(27%)	13	(31%)
	No change (4)	14	(32%)	8	(19%)
	Mildly worse (5)	1	(2%)	2	(5%)
	Moderately worse (6)	2	(5%)	0	
	Significantly worse (7)	0		0	
Week 24	n	43		42	
	Significantly improved (1)	5	(12%)	15	(36%)
	Moderately improved (2)	11	(26%)	7	(17%)
	Mildly improved (3)	7	(16%)	7	(17%)
	No change (4)	16	(37%)	12	(29%)
	Mildly worse (5)	2	(5%)	1	(2%)
	Moderately worse (6)	2	(5%)	0	
	Significantly worse (7)	0		0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.46
Summary of Subject-Rated Overall Response to Therapy

Visit		Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 28	n	43		43	
	Significantly improved (1)	3	(7%)	13	(30%)
	Moderately improved (2)	8	(19%)	11	(26%)
	Mildly improved (3)	9	(21%)	7	(16%)
	No change (4)	20	(47%)	9	(21%)
	Mildly worse (5)	1	(2%)	1	(2%)
	Moderately worse (6)	2	(5%)	1	(2%)
	Significantly worse (7)	0		1	(2%)
Week 32	n	41		42	
	Significantly improved (1)	7	(17%)	12	(29%)
	Moderately improved (2)	7	(17%)	9	(21%)
	Mildly improved (3)	9	(22%)	12	(29%)
	No change (4)	13	(32%)	8	(19%)
	Mildly worse (5)	4	(10%)	1	(2%)
	Moderately worse (6)	1	(2%)	0	
	Significantly worse (7)	0		0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.48
Summary of Subject-Rated Symptom Severity

Visit			Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Baseline	SSR Score	n	54		54	
		None (0)	5	(9%)	4	(7%)
		Mild (1)	12	(22%)	11	(20%)
		Moderate (2)	19	(35%)	21	(39%)
		Severe (3)	16	(30%)	15	(28%)
		Very severe (4)	2	(4%)	3	(6%)
Week 4	SSR Score	n	51		51	
		None (0)	8	(16%)	5	(10%)
		Mild (1)	12	(24%)	21	(41%)
		Moderate (2)	23	(45%)	18	(35%)
		Severe (3)	5	(10%)	7	(14%)
		Very severe (4)	3	(6%)	0	
	Change from Baseline	n	51		51	
		4 point improvement (-4)	0		0	
		3 point improvement (-3)	0		1	(2%)
		2 point improvement (-2)	6	(12%)	7	(14%)
		1 point improvement (-1)	14	(27%)	16	(31%)
		No change (0)	21	(41%)	20	(39%)
		1 point worsening (1)	9	(18%)	6	(12%)
		2 point worsening (2)	1	(2%)	1	(2%)
		3 point worsening (3)	0		0	
		4 point worsening (4)	0		0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.48
Summary of Subject-Rated Symptom Severity

Visit			Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 8	SSR Score	n	49		47	
		None (0)	4	(8%)	9	(19%)
		Mild (1)	13	(27%)	16	(34%)
		Moderate (2)	26	(53%)	14	(30%)
		Severe (3)	6	(12%)	6	(13%)
		Very severe (4)	0		2	(4%)
	Change from Baseline	n	49		47	
		4 point improvement (-4)	0		1	(2%)
		3 point improvement (-3)	0		3	(6%)
		2 point improvement (-2)	3	(6%)	7	(15%)
		1 point improvement (-1)	19	(39%)	11	(23%)
		No change (0)	18	(37%)	17	(36%)
		1 point worsening (1)	8	(16%)	4	(9%)
		2 point worsening (2)	1	(2%)	2	(4%)
		3 point worsening (3)	0		2	(4%)
		4 point worsening (4)	0		0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.48
Summary of Subject-Rated Symptom Severity

Visit			Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 12	SSR Score	n	46		45	
		None (0)	9	(20%)	8	(18%)
		Mild (1)	10	(22%)	14	(31%)
		Moderate (2)	20	(43%)	17	(38%)
		Severe (3)	6	(13%)	4	(9%)
		Very severe (4)	1	(2%)	2	(4%)
	Change from Baseline	n	46		45	
		4 point improvement (-4)	0		0	
		3 point improvement (-3)	1	(2%)	4	(9%)
		2 point improvement (-2)	5	(11%)	4	(9%)
		1 point improvement (-1)	16	(35%)	14	(31%)
		No change (0)	19	(41%)	15	(33%)
		1 point worsening (1)	3	(7%)	6	(13%)
		2 point worsening (2)	2	(4%)	1	(2%)
		3 point worsening (3)	0		0	
		4 point worsening (4)	0		1	(2%)

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.48
Summary of Subject-Rated Symptom Severity

Visit			Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 16	SSR Score	n	45		44	
		None (0)	8	(18%)	7	(16%)
		Mild (1)	12	(27%)	15	(34%)
		Moderate (2)	18	(40%)	17	(39%)
		Severe (3)	7	(16%)	5	(11%)
		Very severe (4)	0		0	
	Change from Baseline	n	45		44	
		4 point improvement (-4)	0		0	
		3 point improvement (-3)	2	(4%)	3	(7%)
		2 point improvement (-2)	4	(9%)	7	(16%)
		1 point improvement (-1)	18	(40%)	13	(30%)
		No change (0)	11	(24%)	13	(30%)
		1 point worsening (1)	8	(18%)	6	(14%)
		2 point worsening (2)	2	(4%)	0	
		3 point worsening (3)	0		2	(5%)
		4 point worsening (4)	0		0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.48
Summary of Subject-Rated Symptom Severity

Visit			Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 20	SSR Score	n	45		42	
		None (0)	10	(22%)	7	(17%)
		Mild (1)	14	(31%)	17	(40%)
		Moderate (2)	15	(33%)	15	(36%)
		Severe (3)	5	(11%)	3	(7%)
		Very severe (4)	1	(2%)	0	
	Change from Baseline	n	45		42	
		4 point improvement (-4)	0		1	(2%)
		3 point improvement (-3)	0		2	(5%)
		2 point improvement (-2)	7	(16%)	8	(19%)
		1 point improvement (-1)	18	(40%)	10	(24%)
		No change (0)	15	(33%)	15	(36%)
		1 point worsening (1)	2	(4%)	4	(10%)
		2 point worsening (2)	3	(7%)	2	(5%)
		3 point worsening (3)	0		0	
		4 point worsening (4)	0		0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.48
Summary of Subject-Rated Symptom Severity

Visit			Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 24	SSR Score	n	43		42	
		None (0)	6	(14%)	4	(10%)
		Mild (1)	18	(42%)	21	(50%)
		Moderate (2)	11	(26%)	10	(24%)
		Severe (3)	7	(16%)	6	(14%)
		Very severe (4)	1	(2%)	1	(2%)
	Change from Baseline	n	43		42	
		4 point improvement (-4)	0		0	
		3 point improvement (-3)	1	(2%)	2	(5%)
		2 point improvement (-2)	8	(19%)	7	(17%)
		1 point improvement (-1)	10	(23%)	10	(24%)
		No change (0)	17	(40%)	17	(40%)
		1 point worsening (1)	5	(12%)	4	(10%)
		2 point worsening (2)	2	(5%)	2	(5%)
		3 point worsening (3)	0		0	
		4 point worsening (4)	0		0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.48
Summary of Subject-Rated Symptom Severity

Visit			Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 28	SSR Score	n	43		43	
		None (0)	6	(14%)	6	(14%)
		Mild (1)	16	(37%)	14	(33%)
		Moderate (2)	14	(33%)	17	(40%)
		Severe (3)	5	(12%)	4	(9%)
		Very severe (4)	2	(5%)	2	(5%)
	Change from Baseline	n	43		43	
		4 point improvement (-4)	0		0	
		3 point improvement (-3)	0		4	(9%)
		2 point improvement (-2)	7	(16%)	5	(12%)
		1 point improvement (-1)	12	(28%)	9	(21%)
		No change (0)	18	(42%)	16	(37%)
		1 point worsening (1)	4	(9%)	6	(14%)
		2 point worsening (2)	2	(5%)	2	(5%)
		3 point worsening (3)	0		0	
		4 point worsening (4)	0		1	(2%)

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.48
Summary of Subject-Rated Symptom Severity

Visit			Placebo (N=54)		Mepolizumab 300mg SC (N=54)	
Week 32	SSR Score	n	41		42	
		None (0)	6	(15%)	8	(19%)
		Mild (1)	14	(34%)	15	(36%)
		Moderate (2)	16	(39%)	16	(38%)
		Severe (3)	5	(12%)	2	(5%)
		Very severe (4)	0		1	(2%)
	Change from Baseline	n	41		42	
		4 point improvement (-4)	0		0	
		3 point improvement (-3)	1	(2%)	7	(17%)
		2 point improvement (-2)	5	(12%)	1	(2%)
		1 point improvement (-1)	16	(39%)	14	(33%)
		No change (0)	13	(32%)	10	(24%)
		1 point worsening (1)	4	(10%)	9	(21%)
		2 point worsening (2)	2	(5%)	1	(2%)
		3 point worsening (3)	0		0	
		4 point worsening (4)	0		0	

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Total Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Total Score	n	54	54
		Mean	0.97	1.03
		SD	0.614	0.552
		Median	0.95	1.00
		Min.	0.0	0.1
		Max.	2.5	2.5
Week 4	Total Score	n	51	51
		Mean	0.79	0.73
		SD	0.660	0.535
		Median	0.68	0.63
		Min.	0.0	0.0
		Max.	2.9	2.3
	Change from Baseline	n	51	51
		Mean	-0.16	-0.28
		SD	0.394	0.466
		Median	-0.14	-0.15
		Min.	-1.2	-1.5
		Max.	0.5	0.6
Week 8	Total Score	n	49	47
		Mean	0.79	0.76
		SD	0.638	0.505
		Median	0.69	0.74
		Min.	0.0	0.1
		Max.	2.7	2.2

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Total Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Change from Baseline	n	49	47
		Mean	-0.17	-0.25
		SD	0.396	0.489
		Median	-0.13	-0.25
		Min.	-1.0	-1.3
		Max.	0.7	1.4
Week 16	Total Score	n	46	44
		Mean	0.75	0.65
		SD	0.578	0.474
		Median	0.72	0.62
		Min.	0.0	0.0
		Max.	2.4	1.8
	Change from Baseline	n	46	44
		Mean	-0.21	-0.34
		SD	0.449	0.406
		Median	-0.16	-0.23
		Min.	-1.7	-1.4
		Max.	0.8	0.2
Week 24	Total Score	n	45	42
		Mean	0.81	0.63
		SD	0.658	0.484
		Median	0.61	0.54
		Min.	0.0	0.0
		Max.	2.6	1.8

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Total Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Change from Baseline	n	45	42
		Mean	-0.14	-0.37
		SD	0.467	0.484
		Median	-0.11	-0.34
		Min.	-1.1	-1.7
		Max.	1.2	0.4
Week 32	Total Score	n	41	42
		Mean	0.82	0.61
		SD	0.679	0.550
		Median	0.60	0.54
		Min.	0.0	0.0
		Max.	2.6	2.5
	Change from Baseline	n	41	42
		Mean	-0.17	-0.35
		SD	0.476	0.469
		Median	-0.09	-0.31
		Min.	-1.2	-1.2
		Max.	0.8	1.0

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Global Distress Index

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Global Distress Index	n	54	54
		Mean	1.21	1.36
		SD	0.743	0.764
		Median	1.27	1.30
		Min.	0.0	0.0
		Max.	3.0	3.4
Week 4	Global Distress Index	n	51	51
		Mean	1.03	1.00
		SD	0.837	0.781
		Median	0.80	0.94
		Min.	0.0	0.0
		Max.	3.1	3.2
	Change from Baseline	n	51	51
		Mean	-0.16	-0.35
		SD	0.505	0.719
		Median	-0.10	-0.18
		Min.	-1.4	-2.0
		Max.	0.8	0.7
Week 8	Global Distress Index	n	49	47
		Mean	0.99	1.00
		SD	0.789	0.757
		Median	0.96	0.96
		Min.	0.0	0.0
		Max.	2.9	3.0

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Global Distress Index

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Change from Baseline	n	49	47
		Mean	-0.20	-0.35
		SD	0.584	0.645
		Median	-0.10	-0.24
		Min.	-1.3	-1.7
		Max.	1.2	1.4
Week 16	Global Distress Index	n	46	44
		Mean	0.94	0.85
		SD	0.716	0.723
		Median	0.84	0.86
		Min.	0.0	0.0
		Max.	2.6	2.9
	Change from Baseline	n	46	44
		Mean	-0.25	-0.47
		SD	0.606	0.505
		Median	-0.20	-0.32
		Min.	-1.8	-1.7
		Max.	1.3	0.4
Week 24	Global Distress Index	n	45	42
		Mean	1.01	0.83
		SD	0.787	0.766
		Median	0.84	0.68
		Min.	0.0	0.0
		Max.	2.8	2.8

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Global Distress Index

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Change from Baseline	n	45	42
		Mean	-0.20	-0.48
		SD	0.642	0.612
		Median	-0.22	-0.41
		Min.	-1.4	-1.8
		Max.	1.3	0.9
Week 32	Global Distress Index	n	41	42
		Mean	1.03	0.84
		SD	0.829	0.791
		Median	0.96	0.62
		Min.	0.0	0.0
		Max.	2.9	3.2
	Change from Baseline	n	41	42
		Mean	-0.22	-0.45
		SD	0.640	0.609
		Median	-0.24	-0.45
		Min.	-1.4	-1.7
		Max.	1.3	1.1

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Physical Symptom Subscale Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Physical Symptom Subscale Score	n	54	54
		Mean	0.89	0.98
		SD	0.641	0.603
		Median	0.87	0.93
		Min.	0.0	0.0
		Max.	2.5	2.7
Week 4	Physical Symptom Subscale Score	n	51	51
		Mean	0.75	0.71
		SD	0.647	0.547
		Median	0.60	0.73
		Min.	0.0	0.0
		Max.	2.7	2.4
	Change from Baseline	n	51	51
		Mean	-0.12	-0.24
		SD	0.434	0.483
		Median	-0.07	-0.13
		Min.	-1.1	-1.8
		Max.	0.9	0.7
Week 8	Physical Symptom Subscale Score	n	49	47
		Mean	0.70	0.71
		SD	0.609	0.582
		Median	0.60	0.60
		Min.	0.0	0.0
		Max.	2.5	2.4

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Physical Symptom Subscale Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Change from Baseline	n	49	47
		Mean	-0.16	-0.23
		SD	0.395	0.648
		Median	-0.13	-0.20
		Min.	-1.0	-1.5
		Max.	0.7	1.3
Week 16	Physical Symptom Subscale Score	n	46	44
		Mean	0.67	0.57
		SD	0.551	0.493
		Median	0.63	0.47
		Min.	0.0	0.0
		Max.	2.1	2.0
	Change from Baseline	n	46	44
		Mean	-0.22	-0.36
		SD	0.480	0.444
		Median	-0.20	-0.30
		Min.	-1.8	-1.5
		Max.	0.6	0.4
Week 24	Physical Symptom Subscale Score	n	45	42
		Mean	0.70	0.57
		SD	0.633	0.503
		Median	0.67	0.43
		Min.	0.0	0.0
		Max.	2.3	1.7

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Physical Symptom Subscale Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Change from Baseline	n	45	42
		Mean	-0.19	-0.35
		SD	0.582	0.532
		Median	-0.20	-0.30
		Min.	-1.5	-1.7
		Max.	1.5	0.7
Week 32	Physical Symptom Subscale Score	n	41	42
		Mean	0.77	0.56
		SD	0.669	0.534
		Median	0.67	0.47
		Min.	0.0	0.0
		Max.	2.3	2.3
	Change from Baseline	n	41	42
		Mean	-0.16	-0.37
		SD	0.539	0.591
		Median	-0.00	-0.27
		Min.	-1.3	-1.9
		Max.	0.9	1.1

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Psychological Symptom Subscale Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Psychological Symptom Subscale Score	n	54	54
		Mean	1.33	1.42
		SD	0.938	0.934
		Median	1.20	1.37
		Min.	0.0	0.0
		Max.	3.7	3.9
Week 4	Psychological Symptom Subscale Score	n	51	51
		Mean	1.11	1.06
		SD	1.016	0.911
		Median	0.93	1.00
		Min.	0.0	0.0
		Max.	3.3	3.2
	Change from Baseline	n	51	51
		Mean	-0.19	-0.33
		SD	0.653	0.787
		Median	-0.17	-0.13
		Min.	-2.1	-2.3
		Max.	1.2	1.1
Week 8	Psychological Symptom Subscale Score	n	49	47
		Mean	1.06	1.12
		SD	1.038	0.894
		Median	0.60	1.00
		Min.	0.0	0.0
		Max.	3.2	3.2

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Psychological Symptom Subscale Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Change from Baseline	n	49	47
		Mean	-0.24	-0.28
		SD	0.792	0.624
		Median	-0.17	-0.20
		Min.	-2.6	-1.7
		Max.	1.5	1.6
Week 16	Psychological Symptom Subscale Score	n	46	44
		Mean	1.05	1.00
		SD	0.950	0.910
		Median	0.78	1.00
		Min.	0.0	0.0
		Max.	3.2	3.4
	Change from Baseline	n	46	44
		Mean	-0.25	-0.38
		SD	0.727	0.715
		Median	-0.27	-0.33
		Min.	-2.0	-1.9
		Max.	1.4	1.4
Week 24	Psychological Symptom Subscale Score	n	45	42
		Mean	1.16	0.93
		SD	1.047	0.882
		Median	0.87	0.78
		Min.	0.0	0.0
		Max.	3.5	3.4

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 2.50
Summary of MSAS-SF Total and Subscale Scores

Endpoint: Psychological Symptom Subscale Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Change from Baseline	n	45	42
		Mean	-0.16	-0.45
		SD	0.876	0.790
		Median	-0.17	-0.33
		Min.	-2.1	-2.0
		Max.	2.5	1.3
Week 32	Psychological Symptom Subscale Score	n	41	42
		Mean	1.13	0.92
		SD	1.029	0.971
		Median	0.67	0.73
		Min.	0.0	0.0
		Max.	3.6	3.4
	Change from Baseline	n	41	42
		Mean	-0.23	-0.40
		SD	0.777	0.830
		Median	-0.17	-0.45
		Min.	-1.6	-1.9
		Max.	2.0	1.3

Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Total Score
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	51	51
LS Mean (SE)	0.81 (0.059)	0.71 (0.059)
LS Mean Change (SE)	-0.17 (0.059)	-0.27 (0.059)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.10
95% CI		(-0.27, 0.06)
p-value		0.223
Corrected Hedges g [3]		-0.24
95% CI		(-0.63, 0.15)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Total Score
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	49	47
LS Mean (SE)	0.81 (0.058)	0.74 (0.059)
LS Mean Change (SE)	-0.17 (0.058)	-0.23 (0.059)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.06
95% CI		(-0.23, 0.10)
p-value		0.453
Corrected Hedges g [3]		-0.15
95% CI		(-0.55, 0.25)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Total Score
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	46	44
LS Mean (SE)	0.76 (0.056)	0.66 (0.057)
LS Mean Change (SE)	-0.22 (0.056)	-0.32 (0.057)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.10
95% CI		(-0.26, 0.06)
p-value		0.204
Corrected Hedges g [3]		-0.27
95% CI		(-0.68, 0.15)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Total Score
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	45	42
LS Mean (SE)	0.82 (0.064)	0.66 (0.066)
LS Mean Change (SE)	-0.16 (0.064)	-0.32 (0.066)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.16
95% CI		(-0.34, 0.03)
p-value		0.095
Corrected Hedges g [3]		-0.36
95% CI		(-0.78, 0.06)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Total Score
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	41	42
LS Mean (SE)	0.80 (0.069)	0.64 (0.070)
LS Mean Change (SE)	-0.17 (0.069)	-0.34 (0.070)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.16
95% CI		(-0.36, 0.03)
p-value		0.104
Corrected Hedges g [3]		-0.36
95% CI		(-0.79, 0.08)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Global Distress Index
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	51	51
LS Mean (SE)	1.08 (0.084)	0.94 (0.084)
LS Mean Change (SE)	-0.18 (0.084)	-0.33 (0.084)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.15
95% CI		(-0.38, 0.09)
p-value		0.219
Corrected Hedges g [3]		-0.24
95% CI		(-0.63, 0.15)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Global Distress Index
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	49	47
LS Mean (SE)	1.04 (0.083)	0.96 (0.085)
LS Mean Change (SE)	-0.22 (0.083)	-0.31 (0.085)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.09
95% CI		(-0.32, 0.15)
p-value		0.463
Corrected Hedges g [3]		-0.15
95% CI		(-0.55, 0.25)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Global Distress Index
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	46	44
LS Mean (SE)	0.99 (0.076)	0.84 (0.078)
LS Mean Change (SE)	-0.27 (0.076)	-0.42 (0.078)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.15
95% CI		(-0.37, 0.07)
p-value		0.172
Corrected Hedges g [3]		-0.29
95% CI		(-0.71, 0.13)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Global Distress Index
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	45	42
LS Mean (SE)	1.04 (0.086)	0.84 (0.088)
LS Mean Change (SE)	-0.22 (0.086)	-0.42 (0.088)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.20
95% CI		(-0.44, 0.05)
p-value		0.113
Corrected Hedges g [3]		-0.34
95% CI		(-0.77, 0.08)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Global Distress Index
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	41	42
LS Mean (SE)	1.03 (0.091)	0.85 (0.091)
LS Mean Change (SE)	-0.23 (0.091)	-0.41 (0.091)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.18
95% CI		(-0.44, 0.08)
p-value		0.166
Corrected Hedges g [3]		-0.31
95% CI		(-0.74, 0.13)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Physical Symptom Subscale Score
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	51	51
LS Mean (SE)	0.78 (0.060)	0.68 (0.060)
LS Mean Change (SE)	-0.13 (0.060)	-0.23 (0.060)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.10
95% CI		(-0.27, 0.07)
p-value		0.262
Corrected Hedges g [3]		-0.22
95% CI		(-0.61, 0.17)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Physical Symptom Subscale Score
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	49	47
LS Mean (SE)	0.73 (0.068)	0.69 (0.069)
LS Mean Change (SE)	-0.17 (0.068)	-0.22 (0.069)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.04
95% CI		(-0.23, 0.15)
p-value		0.673
Corrected Hedges g [3]		-0.09
95% CI		(-0.49, 0.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Physical Symptom Subscale Score
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	46	44
LS Mean (SE)	0.68 (0.056)	0.56 (0.057)
LS Mean Change (SE)	-0.23 (0.056)	-0.35 (0.057)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.12
95% CI		(-0.28, 0.04)
p-value		0.142
Corrected Hedges g [3]		-0.31
95% CI		(-0.73, 0.10)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Physical Symptom Subscale Score
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	45	42
LS Mean (SE)	0.71 (0.069)	0.60 (0.071)
LS Mean Change (SE)	-0.20 (0.069)	-0.31 (0.071)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.11
95% CI		(-0.31, 0.09)
p-value		0.263
Corrected Hedges g [3]		-0.24
95% CI		(-0.66, 0.18)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Physical Symptom Subscale Score
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	41	42
LS Mean (SE)	0.77 (0.073)	0.57 (0.074)
LS Mean Change (SE)	-0.14 (0.073)	-0.34 (0.074)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.20
95% CI		(-0.41, 0.01)
p-value		0.057
Corrected Hedges g [3]		-0.42
95% CI		(-0.86, 0.02)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Psychological Symptom Subscale Score
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	51	51
LS Mean (SE)	1.14 (0.094)	1.03 (0.094)
LS Mean Change (SE)	-0.21 (0.094)	-0.32 (0.094)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.11
95% CI		(-0.38, 0.15)
p-value		0.410
Corrected Hedges g [3]		-0.16
95% CI		(-0.55, 0.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Psychological Symptom Subscale Score
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	49	47
LS Mean (SE)	1.09 (0.098)	1.09 (0.101)
LS Mean Change (SE)	-0.26 (0.098)	-0.26 (0.101)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.00
95% CI		(-0.29, 0.28)
p-value		0.977
Corrected Hedges g [3]		-0.01
95% CI		(-0.41, 0.39)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Psychological Symptom Subscale Score
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	46	44
LS Mean (SE)	1.05 (0.102)	1.00 (0.105)
LS Mean Change (SE)	-0.29 (0.102)	-0.34 (0.105)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.05
95% CI		(-0.34, 0.24)
p-value		0.733
Corrected Hedges g [3]		-0.07
95% CI		(-0.49, 0.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Psychological Symptom Subscale Score
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	45	42
LS Mean (SE)	1.15 (0.115)	0.97 (0.119)
LS Mean Change (SE)	-0.19 (0.115)	-0.38 (0.119)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.18
95% CI		(-0.51, 0.15)
p-value		0.277
Corrected Hedges g [3]		-0.23
95% CI		(-0.66, 0.19)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.76
Analysis of Change from Baseline in MSAS-SF Total and Subscale Scores
(Mixed Model Repeated Measures)

Endpoint: Psychological Symptom Subscale Score
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	41	42
LS Mean (SE)	1.06 (0.119)	0.96 (0.120)
LS Mean Change (SE)	-0.29 (0.119)	-0.38 (0.120)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.10
95% CI		(-0.43, 0.24)
p-value		0.570
Corrected Hedges g [3]		-0.12
95% CI		(-0.56, 0.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 2.53
Summary of PROMIS Physical Function Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Physical Function Score	n	54	54
		Mean	3.59	3.49
		SD	1.018	1.124
		Median	3.79	3.42
		Min.	1.4	1.3
		Max.	5.0	5.0
Week 4	Physical Function Score	n	51	51
		Mean	3.74	3.90
		SD	1.047	1.009
		Median	3.92	4.08
		Min.	1.4	1.3
		Max.	5.0	5.0
	Change from Baseline	n	51	51
		Mean	0.17	0.39
		SD	0.564	0.685
		Median	0.00	0.25
		Min.	-1.2	-0.8
		Max.	1.9	2.3

Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 2.53
Summary of PROMIS Physical Function Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Physical Function Score	n	49	47
		Mean	3.83	4.02
		SD	1.071	1.077
		Median	4.08	4.42
		Min.	1.4	1.3
		Max.	5.0	5.0
	Change from Baseline	n	49	47
		Mean	0.28	0.47
		SD	0.501	0.850
		Median	0.17	0.25
		Min.	-0.8	-2.1
		Max.	1.6	2.4
Week 16	Physical Function Score	n	44	44
		Mean	3.91	4.10
		SD	0.959	1.038
		Median	3.92	4.42
		Min.	1.4	1.3
		Max.	5.0	5.0
	Change from Baseline	n	44	44
		Mean	0.45	0.50
		SD	0.606	0.748
		Median	0.33	0.42
		Min.	-1.2	-1.2
		Max.	1.8	2.8

Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 2.53
Summary of PROMIS Physical Function Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Physical Function Score	n	43	42
		Mean	3.75	4.06
		SD	1.087	1.055
		Median	3.75	4.46
		Min.	1.3	1.4
		Max.	5.0	5.0
	Change from Baseline	n	43	42
		Mean	0.30	0.51
		SD	0.742	0.700
		Median	0.17	0.33
		Min.	-1.1	-1.0
		Max.	2.8	2.5
Week 32	Physical Function Score	n	41	42
		Mean	3.78	4.11
		SD	1.091	1.008
		Median	4.00	4.50
		Min.	1.3	1.3
		Max.	5.0	5.0
	Change from Baseline	n	41	42
		Mean	0.36	0.49
		SD	0.653	0.785
		Median	0.17	0.29
		Min.	-0.8	-0.9
		Max.	2.7	3.3

Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.84
Analysis of Change from Baseline in PROMIS Physical Function Score
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	51	51
LS Mean (SE)	3.70 (0.083)	3.92 (0.083)
LS Mean Change (SE)	0.17 (0.083)	0.39 (0.083)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.22
95% CI		(-0.01, 0.45)
p-value		0.065
Corrected Hedges g [3]		0.37
95% CI		(-0.02, 0.76)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Population: Intent-to-Treat

Table 90.84
Analysis of Change from Baseline in PROMIS Physical Function Score
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	49	47
LS Mean (SE)	3.80 (0.091)	4.03 (0.093)
LS Mean Change (SE)	0.27 (0.091)	0.50 (0.093)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.23
95% CI		(-0.03, 0.49)
p-value		0.085
Corrected Hedges g [3]		0.35
95% CI		(-0.05, 0.76)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Population: Intent-to-Treat

Table 90.84
Analysis of Change from Baseline in PROMIS Physical Function Score
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	44	44
LS Mean (SE)	3.95 (0.089)	4.06 (0.089)
LS Mean Change (SE)	0.42 (0.089)	0.53 (0.089)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.10
95% CI		(-0.15, 0.36)
p-value		0.416
Corrected Hedges g [3]		0.17
95% CI		(-0.25, 0.59)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Population: Intent-to-Treat

Table 90.84
Analysis of Change from Baseline in PROMIS Physical Function Score
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	43	42
LS Mean (SE)	3.82 (0.100)	4.03 (0.101)
LS Mean Change (SE)	0.29 (0.100)	0.50 (0.101)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.21
95% CI		(-0.08, 0.49)
p-value		0.147
Corrected Hedges g [3]		0.32
95% CI		(-0.11, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.84
Analysis of Change from Baseline in PROMIS Physical Function Score
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	41	42
LS Mean (SE)	3.86 (0.101)	4.01 (0.101)
LS Mean Change (SE)	0.33 (0.101)	0.48 (0.101)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.15
95% CI		(-0.13, 0.44)
p-value		0.287
Corrected Hedges g [3]		0.23
95% CI		(-0.20, 0.67)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 2.56
Summary of PROMIS Sleep Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Sleep Score	n	54	54
		Mean	2.61	2.44
		SD	1.376	1.097
		Median	2.50	2.00
		Min.	1.0	1.0
		Max.	5.0	5.0
Week 4	Sleep Score	n	51	51
		Mean	2.41	2.37
		SD	1.219	1.104
		Median	2.00	2.00
		Min.	1.0	1.0
		Max.	5.0	5.0
	Change from Baseline	n	51	51
		Mean	-0.15	-0.05
		SD	0.783	0.923
		Median	0.00	0.00
		Min.	-2.5	-2.0
		Max.	1.5	2.5

Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to
5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 2.56
Summary of PROMIS Sleep Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Sleep Score	n	49	47
		Mean	2.46	2.27
		SD	1.294	0.972
		Median	2.50	2.00
		Min.	1.0	1.0
		Max.	5.0	4.5
	Change from Baseline	n	49	47
		Mean	-0.07	-0.17
		SD	0.952	0.892
		Median	0.00	0.00
		Min.	-2.0	-2.0
		Max.	3.0	2.0
Week 16	Sleep Score	n	44	44
		Mean	2.38	2.35
		SD	1.317	1.097
		Median	2.00	2.00
		Min.	1.0	1.0
		Max.	5.0	5.0
	Change from Baseline	n	44	44
		Mean	-0.22	-0.07
		SD	1.020	1.038
		Median	0.00	0.00
		Min.	-2.5	-2.0
		Max.	2.0	3.0

Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to
5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 2.56
Summary of PROMIS Sleep Score

Visit	Endpoint		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Sleep Score	n	43	42
		Mean	2.41	2.30
		SD	1.297	1.153
		Median	2.00	2.00
		Min.	1.0	1.0
		Max.	5.0	5.0
	Change from Baseline	n	43	42
		Mean	-0.19	-0.11
		SD	1.296	1.107
		Median	0.00	0.00
		Min.	-3.5	-3.0
		Max.	3.0	2.5
Week 32	Sleep Score	n	41	42
		Mean	2.62	2.11
		SD	1.144	0.880
		Median	2.50	2.00
		Min.	1.0	1.0
		Max.	5.0	5.0
	Change from Baseline	n	41	42
		Mean	-0.05	-0.23
		SD	0.907	0.864
		Median	0.00	0.00
		Min.	-1.5	-2.5
		Max.	2.0	1.5

Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to
5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.92
Analysis of Change from Baseline in PROMIS Sleep Score
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	51	51
LS Mean (SE)	2.37 (0.108)	2.43 (0.108)
LS Mean Change (SE)	-0.13 (0.108)	-0.06 (0.108)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.07
95% CI		(-0.24, 0.37)
p-value		0.667
Corrected Hedges g [3]		0.09
95% CI		(-0.30, 0.47)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.92
Analysis of Change from Baseline in PROMIS Sleep Score
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	49	47
LS Mean (SE)	2.44 (0.120)	2.26 (0.122)
LS Mean Change (SE)	-0.06 (0.120)	-0.23 (0.122)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.17
95% CI		(-0.52, 0.17)
p-value		0.315
Corrected Hedges g [3]		-0.21
95% CI		(-0.61, 0.20)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Population: Intent-to-Treat

Table 90.92
Analysis of Change from Baseline in PROMIS Sleep Score
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	44	44
LS Mean (SE)	2.29 (0.139)	2.36 (0.139)
LS Mean Change (SE)	-0.20 (0.139)	-0.13 (0.139)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.07
95% CI		(-0.32, 0.46)
p-value		0.734
Corrected Hedges g [3]		0.07
95% CI		(-0.35, 0.49)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Population: Intent-to-Treat

Table 90.92
Analysis of Change from Baseline in PROMIS Sleep Score
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	43	42
LS Mean (SE)	2.32 (0.156)	2.28 (0.158)
LS Mean Change (SE)	-0.18 (0.156)	-0.22 (0.158)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.04
95% CI		(-0.48, 0.40)
p-value		0.864
Corrected Hedges g [3]		-0.04
95% CI		(-0.46, 0.39)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Population: Intent-to-Treat

Table 90.92
Analysis of Change from Baseline in PROMIS Sleep Score
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	51	51
n [2]	41	42
LS Mean (SE)	2.47 (0.111)	2.17 (0.110)
LS Mean Change (SE)	-0.02 (0.111)	-0.33 (0.110)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.30
95% CI		(-0.62, 0.01)
p-value		0.058
Corrected Hedges g [3]		-0.42
95% CI		(-0.86, 0.01)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Physical Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	40.42	39.87
		SD	9.824	10.338
		Median	40.25	38.99
		Min.	19.4	17.2
		Max.	60.5	58.1
Week 4	Score	n	54	54
		Mean	43.18	43.73
		SD	9.136	9.263
		Median	44.49	43.42
		Min.	20.4	21.5
		Max.	60.4	59.8
	Change from Baseline	n	54	54
		Mean	2.75	3.85
		SD	5.832	7.234
		Median	1.83	2.03
		Min.	-8.9	-8.4
		Max.	18.8	31.1

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Physical Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	43.47	45.32
		SD	10.249	10.225
		Median	44.63	45.87
		Min.	23.7	23.9
		Max.	60.6	61.0
	Change from Baseline	n	53	54
		Mean	3.27	5.44
		SD	5.756	9.251
		Median	2.17	4.63
		Min.	-9.3	-19.9
		Max.	17.6	35.4
Week 12	Score	n	53	53
		Mean	43.39	45.43
		SD	8.450	9.816
		Median	43.27	45.45
		Min.	23.0	21.6
		Max.	61.1	63.1
	Change from Baseline	n	53	53
		Mean	3.19	5.46
		SD	5.681	8.890
		Median	3.60	3.40
		Min.	-10.6	-14.4
		Max.	13.0	38.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Physical Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	44.61	44.79
		SD	9.391	10.123
		Median	47.73	45.94
		Min.	23.4	20.0
		Max.	61.2	62.9
	Change from Baseline	n	53	53
		Mean	4.41	4.82
		SD	5.723	9.348
		Median	4.22	3.05
		Min.	-10.0	-12.1
		Max.	15.0	35.7
Week 20	Score	n	52	52
		Mean	43.66	45.59
		SD	9.872	9.589
		Median	44.82	45.50
		Min.	15.3	22.6
		Max.	60.0	63.7
	Change from Baseline	n	52	52
		Mean	3.55	5.96
		SD	6.047	8.561
		Median	3.86	3.96
		Min.	-11.0	-7.3
		Max.	18.3	33.7

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Physical Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	44.22	45.85
		SD	9.784	10.155
		Median	44.69	47.91
		Min.	18.6	22.1
		Max.	60.3	63.0
	Change from Baseline	n	52	51
		Mean	4.11	6.04
		SD	6.738	8.853
		Median	4.08	3.63
		Min.	-8.8	-8.8
		Max.	19.4	35.1
Week 28	Score	n	51	51
		Mean	44.47	45.19
		SD	9.169	9.188
		Median	45.15	47.24
		Min.	24.3	20.4
		Max.	61.5	62.1
	Change from Baseline	n	51	51
		Mean	4.35	5.33
		SD	6.015	8.546
		Median	4.94	3.83
		Min.	-14.9	-6.5
		Max.	22.3	35.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Physical Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	44.10	46.11
		SD	9.996	8.901
		Median	44.40	45.52
		Min.	20.9	22.7
		Max.	61.6	62.7
	Change from Baseline	n	50	50
		Mean	3.81	6.33
		SD	5.745	9.466
		Median	3.88	3.87
		Min.	-6.0	-10.1
		Max.	25.2	37.7

PPD

Population: Intent-to-Treat

Table 90.100
Analysis of Change from Baseline in SF-36 Physical Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	42.77 (0.800)	43.93 (0.800)
LS Mean Change (SE)	2.75 (0.800)	3.90 (0.800)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.16
95% CI		(-1.10, 3.41)
p-value		0.311
Corrected Hedges g [3]		0.20
95% CI		(-0.18, 0.57)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.100
Analysis of Change from Baseline in SF-36 Physical Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	43.11 (0.979)	45.52 (0.973)
LS Mean Change (SE)	3.09 (0.979)	5.50 (0.973)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.41
95% CI		(-0.34, 5.16)
p-value		0.085
Corrected Hedges g [3]		0.34
95% CI		(-0.05, 0.72)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.100
Analysis of Change from Baseline in SF-36 Physical Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	43.05 (0.911)	45.38 (0.909)
LS Mean Change (SE)	3.03 (0.911)	5.35 (0.909)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.33
95% CI		(-0.24, 4.89)
p-value		0.075
Corrected Hedges g [3]		0.35
95% CI		(-0.03, 0.73)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.100
Analysis of Change from Baseline in SF-36 Physical Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	44.27 (0.958)	44.74 (0.956)
LS Mean Change (SE)	4.24 (0.958)	4.71 (0.956)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.47
95% CI		(-2.23, 3.16)
p-value		0.731
Corrected Hedges g [3]		0.07
95% CI		(-0.31, 0.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.100
Analysis of Change from Baseline in SF-36 Physical Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	43.31 (0.935)	45.65 (0.933)
LS Mean Change (SE)	3.28 (0.935)	5.62 (0.933)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.34
95% CI		(-0.29, 4.98)
p-value		0.080
Corrected Hedges g [3]		0.35
95% CI		(-0.04, 0.73)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.100
Analysis of Change from Baseline in SF-36 Physical Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	43.88 (1.013)	45.57 (1.015)
LS Mean Change (SE)	3.86 (1.013)	5.54 (1.015)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.68
95% CI		(-1.17, 4.54)
p-value		0.245
Corrected Hedges g [3]		0.23
95% CI		(-0.16, 0.62)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.100
Analysis of Change from Baseline in SF-36 Physical Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	44.24 (0.907)	45.09 (0.906)
LS Mean Change (SE)	4.21 (0.907)	5.06 (0.906)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.85
95% CI		(-1.71, 3.40)
p-value		0.513
Corrected Hedges g [3]		0.13
95% CI		(-0.26, 0.52)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.100
Analysis of Change from Baseline in SF-36 Physical Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	43.77 (0.955)	46.11 (0.954)
LS Mean Change (SE)	3.74 (0.955)	6.08 (0.954)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.34
95% CI		(-0.35, 5.03)
p-value		0.088
Corrected Hedges g [3]		0.34
95% CI		(-0.05, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Mental Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	44.78	43.52
		SD	10.885	11.077
		Median	47.68	46.23
		Min.	19.3	18.8
		Max.	66.8	61.7
Week 4	Score	n	54	54
		Mean	44.76	46.26
		SD	11.345	10.605
		Median	47.58	49.33
		Min.	19.3	20.8
		Max.	64.2	65.3
	Change from Baseline	n	54	54
		Mean	-0.02	2.73
		SD	6.048	8.282
		Median	-0.33	3.01
		Min.	-14.6	-15.7
		Max.	16.8	26.6

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Mental Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	47.19	45.83
		SD	10.134	10.382
		Median	49.08	47.96
		Min.	24.3	20.0
		Max.	63.0	60.5
	Change from Baseline	n	53	54
		Mean	2.13	2.31
		SD	7.949	7.936
		Median	1.06	1.25
		Min.	-13.8	-14.3
		Max.	32.1	26.8
Week 12	Score	n	53	53
		Mean	45.40	43.72
		SD	11.323	10.261
		Median	47.47	46.35
		Min.	16.7	22.3
		Max.	63.3	59.8
	Change from Baseline	n	53	53
		Mean	0.35	0.23
		SD	9.957	8.517
		Median	-0.73	-0.04
		Min.	-20.6	-19.2
		Max.	40.9	21.2

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Mental Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	46.14	45.84
		SD	11.340	9.733
		Median	48.54	47.28
		Min.	17.2	24.0
		Max.	62.1	60.2
	Change from Baseline	n	53	53
		Mean	1.09	2.35
		SD	9.643	7.632
		Median	1.25	1.19
		Min.	-17.4	-13.2
		Max.	27.4	16.9
Week 20	Score	n	52	52
		Mean	46.38	45.59
		SD	11.168	10.414
		Median	50.05	47.81
		Min.	19.1	25.8
		Max.	60.1	61.6
	Change from Baseline	n	52	52
		Mean	1.39	1.65
		SD	8.659	8.902
		Median	1.20	0.66
		Min.	-16.9	-23.9
		Max.	28.4	17.7

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Mental Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	46.09	46.85
		SD	11.145	10.374
		Median	46.76	48.14
		Min.	17.3	21.0
		Max.	63.3	61.7
	Change from Baseline	n	52	51
		Mean	1.09	3.04
		SD	10.162	8.626
		Median	2.29	2.28
		Min.	-30.6	-15.8
		Max.	31.4	23.6
Week 28	Score	n	51	51
		Mean	45.49	45.73
		SD	11.740	11.254
		Median	45.56	47.30
		Min.	13.8	16.9
		Max.	63.7	62.9
	Change from Baseline	n	51	51
		Mean	0.64	1.92
		SD	8.938	10.396
		Median	0.59	1.48
		Min.	-22.2	-17.6
		Max.	25.3	24.5

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.2
Summary of SF-36 Health Survey Component Summary Scores

Component: SF363-Mental Component Score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	45.94	47.67
		SD	12.777	10.098
		Median	47.97	49.18
		Min.	17.5	22.4
		Max.	63.8	64.7
	Change from Baseline	n	50	50
		Mean	1.46	3.55
		SD	8.765	9.030
		Median	0.96	4.95
		Min.	-25.9	-14.3
		Max.	27.5	20.4

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.109
Analysis of Change from Baseline in SF-36 Mental Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	44.49 (0.938)	46.74 (0.939)
LS Mean Change (SE)	0.18 (0.938)	2.43 (0.939)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.25
95% CI		(-0.39, 4.90)
p-value		0.094
Corrected Hedges g [3]		0.32
95% CI		(-0.06, 0.70)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.109
Analysis of Change from Baseline in SF-36 Mental Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	46.65 (1.008)	46.24 (1.002)
LS Mean Change (SE)	2.34 (1.008)	1.93 (1.002)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.41
95% CI		(-3.24, 2.42)
p-value		0.776
Corrected Hedges g [3]		-0.06
95% CI		(-0.43, 0.32)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.109
Analysis of Change from Baseline in SF-36 Mental Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	44.93 (1.164)	43.92 (1.160)
LS Mean Change (SE)	0.62 (1.164)	-0.39 (1.160)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.01
95% CI		(-4.29, 2.26)
p-value		0.540
Corrected Hedges g [3]		-0.12
95% CI		(-0.50, 0.26)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.109
Analysis of Change from Baseline in SF-36 Mental Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	45.67 (1.087)	46.11 (1.084)
LS Mean Change (SE)	1.36 (1.087)	1.79 (1.084)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.43
95% CI		(-2.62, 3.49)
p-value		0.779
Corrected Hedges g [3]		0.05
95% CI		(-0.33, 0.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.109
Analysis of Change from Baseline in SF-36 Mental Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	45.91 (1.107)	45.55 (1.105)
LS Mean Change (SE)	1.60 (1.107)	1.24 (1.105)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.36
95% CI		(-3.47, 2.75)
p-value		0.818
Corrected Hedges g [3]		-0.04
95% CI		(-0.43, 0.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.109
Analysis of Change from Baseline in SF-36 Mental Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	45.63 (1.195)	46.64 (1.197)
LS Mean Change (SE)	1.32 (1.195)	2.33 (1.197)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.01
95% CI		(-2.36, 4.38)
p-value		0.553
Corrected Hedges g [3]		0.12
95% CI		(-0.27, 0.50)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.109
Analysis of Change from Baseline in SF-36 Mental Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	44.94 (1.238)	45.84 (1.236)
LS Mean Change (SE)	0.63 (1.238)	1.53 (1.236)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.90
95% CI		(-2.58, 4.38)
p-value		0.610
Corrected Hedges g [3]		0.10
95% CI		(-0.29, 0.49)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.109
Analysis of Change from Baseline in SF-36 Mental Component Summary Score
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	45.78 (1.176)	47.56 (1.175)
LS Mean Change (SE)	1.46 (1.176)	3.25 (1.175)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.78
95% CI		(-1.52, 5.09)
p-value		0.287
Corrected Hedges g [3]		0.21
95% CI		(-0.18, 0.61)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	52.22	50.56
		SD	28.199	24.605
		Median	51.00	46.50
		Min.	0.0	0.0
		Max.	100.0	100.0
Week 4	Score	n	54	54
		Mean	59.19	60.61
		SD	25.657	25.140
		Median	62.00	61.50
		Min.	0.0	10.0
		Max.	100.0	100.0
	Change from Baseline	n	54	54
		Mean	6.96	10.06
		SD	18.414	20.100
		Median	9.00	4.50
		Min.	-38.0	-22.0
		Max.	58.0	69.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	59.49	67.52
		SD	30.710	28.554
		Median	62.00	74.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	53	54
		Mean	8.17	16.96
		SD	21.072	27.863
		Median	9.00	14.00
		Min.	-40.0	-44.0
		Max.	62.0	90.0
Week 12	Score	n	53	53
		Mean	58.08	60.21
		SD	25.131	26.281
		Median	61.00	62.00
		Min.	10.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	6.75	10.09
		SD	20.571	26.272
		Median	9.00	10.00
		Min.	-40.0	-52.0
		Max.	41.0	68.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	63.25	58.89
		SD	26.114	26.273
		Median	62.00	62.00
		Min.	10.0	10.0
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	11.92	8.77
		SD	19.550	24.566
		Median	16.00	0.00
		Min.	-31.0	-40.0
		Max.	69.0	59.0
Week 20	Score	n	52	52
		Mean	62.81	62.21
		SD	27.467	23.804
		Median	63.00	62.00
		Min.	0.0	22.0
		Max.	100.0	100.0
	Change from Baseline	n	52	52
		Mean	11.48	12.56
		SD	21.128	22.560
		Median	12.00	10.00
		Min.	-52.0	-29.0
		Max.	53.0	78.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	61.79	66.41
		SD	27.619	26.204
		Median	62.00	74.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	52	51
		Mean	10.46	16.22
		SD	21.640	26.090
		Median	9.50	16.00
		Min.	-49.0	-38.0
		Max.	69.0	78.0
Week 28	Score	n	51	51
		Mean	62.80	63.59
		SD	27.767	26.225
		Median	62.00	62.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	51	51
		Mean	11.27	13.39
		SD	21.630	24.997
		Median	10.00	10.00
		Min.	-40.0	-31.0
		Max.	69.0	78.0

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	62.78	66.70
		SD	28.490	28.134
		Median	62.00	72.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	50	50
		Mean	11.08	17.36
		SD	19.013	27.360
		Median	5.00	16.00
		Min.	-33.0	-41.0
		Max.	49.0	78.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	42.73	42.06
		SD	11.370	9.920
		Median	42.24	40.43
		Min.	21.7	21.7
		Max.	62.0	62.0
Week 4	Score	n	54	54
		Mean	45.54	46.12
		SD	10.345	10.137
		Median	46.68	46.48
		Min.	21.7	25.7
		Max.	62.0	62.0
	Change from Baseline	n	54	54
		Mean	2.81	4.05
		SD	7.424	8.104
		Median	3.63	1.82
		Min.	-15.3	-8.9
		Max.	23.4	27.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	45.67	48.90
		SD	12.383	11.514
		Median	46.68	51.51
		Min.	21.7	21.7
		Max.	62.0	62.0
	Change from Baseline	n	53	54
		Mean	3.29	6.84
		SD	8.496	11.234
		Median	3.63	5.64
		Min.	-16.1	-17.7
		Max.	25.0	36.3
Week 12	Score	n	53	53
		Mean	45.09	45.95
		SD	10.133	10.597
		Median	46.27	46.68
		Min.	25.7	21.7
		Max.	62.0	62.0
	Change from Baseline	n	53	53
		Mean	2.72	4.07
		SD	8.295	10.593
		Median	3.63	4.03
		Min.	-16.1	-21.0
		Max.	16.5	27.4

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	47.18	45.42
		SD	10.529	10.594
		Median	46.68	46.68
		Min.	25.7	25.7
		Max.	62.0	62.0
	Change from Baseline	n	53	53
		Mean	4.81	3.54
		SD	7.883	9.905
		Median	6.45	0.00
		Min.	-12.5	-16.1
		Max.	27.8	23.8
Week 20	Score	n	52	52
		Mean	47.00	46.76
		SD	11.075	9.598
		Median	47.08	46.68
		Min.	21.7	30.6
		Max.	62.0	62.0
	Change from Baseline	n	52	52
		Mean	4.63	5.06
		SD	8.519	9.097
		Median	4.83	4.03
		Min.	-21.0	-11.7
		Max.	21.4	31.5

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	46.59	48.46
		SD	11.136	10.566
		Median	46.68	51.51
		Min.	21.7	21.7
		Max.	62.0	62.0
	Change from Baseline	n	52	51
		Mean	4.22	6.54
		SD	8.726	10.518
		Median	3.84	6.45
		Min.	-19.8	-15.3
		Max.	27.8	31.5
Week 28	Score	n	51	51
		Mean	47.00	47.32
		SD	11.196	10.574
		Median	46.68	46.68
		Min.	21.7	21.7
		Max.	62.0	62.0
	Change from Baseline	n	51	51
		Mean	4.55	5.40
		SD	8.721	10.078
		Median	4.04	4.03
		Min.	-16.1	-12.5
		Max.	27.8	31.5

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Bodily Pain: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	46.99	48.57
		SD	11.487	11.344
		Median	46.68	50.71
		Min.	21.7	21.7
		Max.	62.0	62.0
	Change from Baseline	n	50	50
		Mean	4.47	7.00
		SD	7.666	11.032
		Median	2.01	6.45
		Min.	-13.3	-16.5
		Max.	19.8	31.5

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	41.19	36.52
		SD	20.851	19.566
		Median	38.50	33.50
		Min.	10.0	5.0
		Max.	87.0	87.0
Week 4	Score	n	54	54
		Mean	45.22	43.63
		SD	21.802	18.587
		Median	41.00	40.00
		Min.	10.0	10.0
		Max.	87.0	87.0
	Change from Baseline	n	54	54
		Mean	4.04	7.11
		SD	12.977	15.029
		Median	0.00	5.00
		Min.	-25.0	-25.0
		Max.	50.0	42.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	48.25	44.89
		SD	21.517	20.405
		Median	47.00	43.50
		Min.	10.0	5.0
		Max.	92.0	87.0
	Change from Baseline	n	53	54
		Mean	6.75	8.37
		SD	15.024	16.265
		Median	5.00	10.00
		Min.	-35.0	-25.0
		Max.	55.0	60.0
Week 12	Score	n	53	53
		Mean	46.17	47.47
		SD	20.386	20.570
		Median	45.00	47.00
		Min.	10.0	10.0
		Max.	92.0	87.0
	Change from Baseline	n	53	53
		Mean	4.68	10.55
		SD	14.172	19.244
		Median	5.00	10.00
		Min.	-35.0	-32.0
		Max.	37.0	62.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	44.98	47.85
		SD	21.032	22.372
		Median	42.00	42.00
		Min.	5.0	5.0
		Max.	97.0	100.0
	Change from Baseline	n	53	53
		Mean	3.49	10.92
		SD	15.611	20.856
		Median	0.00	5.00
		Min.	-35.0	-32.0
		Max.	42.0	72.0
Week 20	Score	n	52	52
		Mean	45.19	46.63
		SD	20.726	21.858
		Median	45.00	40.00
		Min.	5.0	0.0
		Max.	92.0	100.0
	Change from Baseline	n	52	52
		Mean	3.81	10.00
		SD	14.871	21.775
		Median	5.00	5.00
		Min.	-35.0	-40.0
		Max.	55.0	72.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	44.79	48.31
		SD	22.492	23.040
		Median	40.00	42.00
		Min.	5.0	0.0
		Max.	97.0	95.0
	Change from Baseline	n	52	51
		Mean	3.40	11.35
		SD	15.506	21.208
		Median	0.00	10.00
		Min.	-35.0	-25.0
		Max.	50.0	72.0
Week 28	Score	n	51	51
		Mean	44.47	45.80
		SD	21.742	23.543
		Median	40.00	45.00
		Min.	5.0	5.0
		Max.	97.0	95.0
	Change from Baseline	n	51	51
		Mean	2.86	8.65
		SD	16.588	23.760
		Median	0.00	5.00
		Min.	-35.0	-47.0
		Max.	62.0	67.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	44.58	47.98
		SD	22.385	21.646
		Median	41.00	43.50
		Min.	5.0	10.0
		Max.	97.0	100.0
	Change from Baseline	n	50	50
		Mean	4.02	11.12
		SD	17.881	21.098
		Median	0.00	5.00
		Min.	-35.0	-32.0
		Max.	67.0	72.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	38.54	36.32
		SD	9.915	9.304
		Median	37.26	34.88
		Min.	23.7	21.3
		Max.	60.3	60.3
Week 4	Score	n	54	54
		Mean	40.45	39.70
		SD	10.367	8.838
		Median	38.45	37.97
		Min.	23.7	23.7
		Max.	60.3	60.3
	Change from Baseline	n	54	54
		Mean	1.92	3.38
		SD	6.171	7.146
		Median	0.00	2.38
		Min.	-11.9	-11.9
		Max.	23.8	20.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	41.89	40.30
		SD	10.231	9.702
		Median	41.30	39.64
		Min.	23.7	21.3
		Max.	62.7	60.3
	Change from Baseline	n	53	54
		Mean	3.21	3.98
		SD	7.143	7.733
		Median	2.38	4.75
		Min.	-16.6	-11.9
		Max.	26.2	28.5
Week 12	Score	n	53	53
		Mean	40.91	41.52
		SD	9.693	9.781
		Median	40.35	41.30
		Min.	23.7	23.7
		Max.	62.7	60.3
	Change from Baseline	n	53	53
		Mean	2.22	5.02
		SD	6.738	9.150
		Median	2.37	4.75
		Min.	-16.6	-15.2
		Max.	17.6	29.5

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	40.34	41.70
		SD	10.000	10.638
		Median	38.92	38.92
		Min.	21.3	21.3
		Max.	65.1	66.5
	Change from Baseline	n	53	53
		Mean	1.66	5.19
		SD	7.423	9.917
		Median	0.00	2.38
		Min.	-16.6	-15.2
		Max.	20.0	34.2
Week 20	Score	n	52	52
		Mean	40.44	41.12
		SD	9.854	10.393
		Median	40.35	37.97
		Min.	21.3	19.0
		Max.	62.7	66.5
	Change from Baseline	n	52	52
		Mean	1.81	4.75
		SD	7.070	10.354
		Median	2.38	2.38
		Min.	-16.6	-19.0
		Max.	26.2	34.2

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	40.25	41.92
		SD	10.695	10.955
		Median	37.97	38.92
		Min.	21.3	19.0
		Max.	65.1	64.1
	Change from Baseline	n	52	51
		Mean	1.62	5.40
		SD	7.373	10.084
		Median	0.00	4.75
		Min.	-16.6	-11.9
		Max.	23.8	34.2
Week 28	Score	n	51	51
		Mean	40.10	40.73
		SD	10.338	11.194
		Median	37.97	40.35
		Min.	21.3	21.3
		Max.	65.1	64.1
	Change from Baseline	n	51	51
		Mean	1.36	4.11
		SD	7.888	11.297
		Median	0.00	2.38
		Min.	-16.6	-22.3
		Max.	29.5	31.9

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-General Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	40.15	41.76
		SD	10.644	10.292
		Median	38.45	39.64
		Min.	21.3	23.7
		Max.	65.1	66.5
	Change from Baseline	n	50	50
		Mean	1.91	5.29
		SD	8.502	10.032
		Median	0.00	2.38
		Min.	-16.6	-15.2
		Max.	31.9	34.2

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Health Utility Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	0.63	0.61
		SD	0.113	0.101
		Median	0.62	0.62
		Min.	0.4	0.4
		Max.	0.9	0.8
Week 4	Score	n	54	54
		Mean	0.65	0.67
		SD	0.123	0.116
		Median	0.64	0.64
		Min.	0.3	0.5
		Max.	1.0	0.9
	Change from Baseline	n	54	54
		Mean	0.02	0.05
		SD	0.061	0.091
		Median	0.00	0.04
		Min.	-0.1	-0.1
		Max.	0.2	0.3

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Health Utility Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	0.67	0.67
		SD	0.140	0.116
		Median	0.64	0.64
		Min.	0.4	0.5
		Max.	1.0	0.9
	Change from Baseline	n	53	54
		Mean	0.03	0.06
		SD	0.075	0.087
		Median	0.02	0.06
		Min.	-0.1	-0.1
		Max.	0.3	0.3
Week 12	Score	n	53	53
		Mean	0.66	0.65
		SD	0.122	0.123
		Median	0.63	0.62
		Min.	0.4	0.4
		Max.	0.9	1.0
	Change from Baseline	n	53	53
		Mean	0.03	0.03
		SD	0.084	0.104
		Median	0.02	0.04
		Min.	-0.1	-0.2
		Max.	0.4	0.3

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Health Utility Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	0.68	0.66
		SD	0.125	0.122
		Median	0.65	0.64
		Min.	0.4	0.4
		Max.	1.0	0.9
	Change from Baseline	n	53	53
		Mean	0.05	0.05
		SD	0.083	0.087
		Median	0.05	0.04
		Min.	-0.1	-0.1
		Max.	0.3	0.3
Week 20	Score	n	52	52
		Mean	0.67	0.67
		SD	0.142	0.110
		Median	0.64	0.65
		Min.	0.4	0.4
		Max.	1.0	0.9
	Change from Baseline	n	52	52
		Mean	0.04	0.06
		SD	0.090	0.097
		Median	0.02	0.05
		Min.	-0.1	-0.2
		Max.	0.3	0.3

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Health Utility Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	0.67	0.68
		SD	0.146	0.122
		Median	0.65	0.64
		Min.	0.3	0.4
		Max.	1.0	0.9
	Change from Baseline	n	52	51
		Mean	0.04	0.07
		SD	0.094	0.094
		Median	0.04	0.06
		Min.	-0.2	-0.1
		Max.	0.3	0.3
Week 28	Score	n	51	51
		Mean	0.67	0.68
		SD	0.144	0.132
		Median	0.64	0.64
		Min.	0.4	0.3
		Max.	0.9	1.0
	Change from Baseline	n	51	51
		Mean	0.04	0.07
		SD	0.085	0.098
		Median	0.04	0.06
		Min.	-0.1	-0.1
		Max.	0.2	0.4

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Health Utility Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	0.68	0.70
		SD	0.135	0.120
		Median	0.65	0.69
		Min.	0.4	0.4
		Max.	0.9	0.9
	Change from Baseline	n	50	50
		Mean	0.04	0.08
		SD	0.084	0.099
		Median	0.04	0.08
		Min.	-0.2	-0.1
		Max.	0.3	0.4

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	62.41	59.72
		SD	18.902	20.591
		Median	62.50	65.00
		Min.	20.0	15.0
		Max.	95.0	90.0
Week 4	Score	n	54	54
		Mean	62.13	65.00
		SD	19.753	21.191
		Median	65.00	70.00
		Min.	25.0	10.0
		Max.	95.0	100.0
	Change from Baseline	n	54	54
		Mean	-0.28	5.28
		SD	11.672	15.091
		Median	0.00	5.00
		Min.	-25.0	-25.0
		Max.	40.0	40.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	66.70	66.11
		SD	18.835	21.050
		Median	70.00	70.00
		Min.	25.0	15.0
		Max.	100.0	100.0
	Change from Baseline	n	53	54
		Mean	3.87	6.39
		SD	14.827	16.323
		Median	5.00	5.00
		Min.	-25.0	-25.0
		Max.	65.0	45.0
Week 12	Score	n	53	53
		Mean	63.30	62.08
		SD	20.638	20.391
		Median	65.00	65.00
		Min.	5.0	20.0
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	0.47	2.26
		SD	15.910	15.980
		Median	0.00	0.00
		Min.	-35.0	-30.0
		Max.	70.0	50.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	65.38	64.81
		SD	18.883	19.264
		Median	65.00	65.00
		Min.	20.0	25.0
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	2.55	5.00
		SD	15.981	16.984
		Median	0.00	5.00
		Min.	-30.0	-30.0
		Max.	50.0	50.0
Week 20	Score	n	52	52
		Mean	63.94	64.90
		SD	20.468	20.687
		Median	67.50	65.00
		Min.	20.0	15.0
		Max.	100.0	100.0
	Change from Baseline	n	52	52
		Mean	1.15	4.42
		SD	17.110	18.005
		Median	0.00	2.50
		Min.	-45.0	-35.0
		Max.	45.0	45.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	65.10	66.96
		SD	21.636	20.859
		Median	65.00	70.00
		Min.	20.0	15.0
		Max.	100.0	100.0
	Change from Baseline	n	52	51
		Mean	2.31	6.96
		SD	18.108	17.552
		Median	0.00	5.00
		Min.	-35.0	-40.0
		Max.	55.0	50.0
Week 28	Score	n	51	51
		Mean	63.14	65.39
		SD	21.702	22.178
		Median	70.00	70.00
		Min.	10.0	15.0
		Max.	100.0	100.0
	Change from Baseline	n	51	51
		Mean	0.59	5.00
		SD	16.871	20.857
		Median	0.00	5.00
		Min.	-35.0	-40.0
		Max.	40.0	60.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	64.80	68.20
		SD	22.268	19.840
		Median	67.50	72.50
		Min.	15.0	25.0
		Max.	100.0	100.0
	Change from Baseline	n	50	50
		Mean	2.90	7.20
		SD	16.416	17.704
		Median	2.50	10.00
		Min.	-35.0	-30.0
		Max.	40.0	50.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	44.28	42.88
		SD	9.889	10.773
		Median	44.33	45.64
		Min.	22.1	19.5
		Max.	61.3	58.7
Week 4	Score	n	54	54
		Mean	44.13	45.64
		SD	10.335	11.087
		Median	45.64	48.25
		Min.	24.7	16.9
		Max.	61.3	64.0
	Change from Baseline	n	54	54
		Mean	-0.14	2.76
		SD	6.107	7.896
		Median	0.00	2.61
		Min.	-13.1	-13.1
		Max.	20.9	20.9

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	46.52	46.22
		SD	9.855	11.013
		Median	48.25	48.25
		Min.	24.7	19.5
		Max.	64.0	64.0
	Change from Baseline	n	53	54
		Mean	2.02	3.34
		SD	7.758	8.539
		Median	2.61	2.61
		Min.	-13.1	-13.1
		Max.	34.0	23.5
Week 12	Score	n	53	53
		Mean	44.75	44.11
		SD	10.798	10.669
		Median	45.64	45.64
		Min.	14.2	22.1
		Max.	64.0	64.0
	Change from Baseline	n	53	53
		Mean	0.25	1.18
		SD	8.325	8.361
		Median	0.00	0.00
		Min.	-18.3	-15.7
		Max.	36.6	26.2

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	45.83	45.54
		SD	9.880	10.079
		Median	45.64	45.64
		Min.	22.1	24.7
		Max.	64.0	64.0
	Change from Baseline	n	53	53
		Mean	1.33	2.62
		SD	8.361	8.886
		Median	0.00	2.61
		Min.	-15.7	-15.7
		Max.	26.2	26.2
Week 20	Score	n	52	52
		Mean	45.08	45.59
		SD	10.709	10.823
		Median	46.95	45.64
		Min.	22.1	19.5
		Max.	64.0	64.0
	Change from Baseline	n	52	52
		Mean	0.60	2.31
		SD	8.952	9.420
		Median	0.00	1.30
		Min.	-23.5	-18.3
		Max.	23.5	23.5

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	45.69	46.66
		SD	11.320	10.914
		Median	45.64	48.25
		Min.	22.1	19.5
		Max.	64.0	64.0
	Change from Baseline	n	52	51
		Mean	1.21	3.64
		SD	9.475	9.184
		Median	0.00	2.62
		Min.	-18.3	-20.9
		Max.	28.8	26.2
Week 28	Score	n	51	51
		Mean	44.66	45.84
		SD	11.354	11.604
		Median	48.25	48.25
		Min.	16.9	19.5
		Max.	64.0	64.0
	Change from Baseline	n	51	51
		Mean	0.31	2.62
		SD	8.828	10.912
		Median	0.00	2.61
		Min.	-18.3	-20.9
		Max.	20.9	31.4

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Mental Health: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	45.53	47.31
		SD	11.651	10.381
		Median	46.95	49.56
		Min.	19.5	24.7
		Max.	64.0	64.0
	Change from Baseline	n	50	50
		Mean	1.52	3.77
		SD	8.589	9.263
		Median	1.30	5.23
		Min.	-18.3	-15.7
		Max.	20.9	26.2

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	63.06	62.50
		SD	26.977	29.231
		Median	62.51	70.00
		Min.	10.0	0.0
		Max.	100.0	100.0
Week 4	Score	n	54	54
		Mean	66.67	72.87
		SD	24.514	25.077
		Median	70.00	70.00
		Min.	10.0	5.0
		Max.	100.0	100.0
	Change from Baseline	n	54	54
		Mean	3.61	10.37
		SD	15.029	19.470
		Median	2.49	5.00
		Min.	-45.0	-35.0
		Max.	40.0	60.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	70.28	72.78
		SD	25.522	27.311
		Median	75.00	79.99
		Min.	5.0	5.0
		Max.	100.0	100.0
	Change from Baseline	n	53	54
		Mean	7.64	10.28
		SD	16.542	20.954
		Median	5.00	5.00
		Min.	-40.0	-50.0
		Max.	55.0	65.0
Week 12	Score	n	53	53
		Mean	69.53	73.40
		SD	23.944	27.557
		Median	70.00	79.99
		Min.	10.0	5.0
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	6.89	10.47
		SD	13.202	19.982
		Median	5.00	5.00
		Min.	-30.0	-20.0
		Max.	45.0	65.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	73.21	75.47
		SD	24.001	25.062
		Median	79.99	79.99
		Min.	10.0	5.0
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	10.57	12.55
		SD	19.057	20.976
		Median	5.01	10.00
		Min.	-55.0	-45.0
		Max.	60.0	65.0
Week 20	Score	n	52	52
		Mean	69.62	76.25
		SD	26.250	26.621
		Median	72.50	79.99
		Min.	0.0	5.0
		Max.	100.0	100.0
	Change from Baseline	n	52	52
		Mean	7.40	14.04
		SD	18.511	20.652
		Median	5.00	7.49
		Min.	-45.0	-15.0
		Max.	65.0	65.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	71.64	73.92
		SD	26.359	25.794
		Median	79.99	79.99
		Min.	5.0	10.0
		Max.	100.0	100.0
	Change from Baseline	n	52	51
		Mean	9.42	11.96
		SD	21.274	20.834
		Median	10.00	5.00
		Min.	-70.0	-15.0
		Max.	70.0	65.0
Week 28	Score	n	51	51
		Mean	69.71	75.29
		SD	25.483	25.247
		Median	70.00	79.99
		Min.	10.0	5.0
		Max.	100.0	100.0
	Change from Baseline	n	51	51
		Mean	8.24	12.55
		SD	18.543	19.605
		Median	5.00	5.00
		Min.	-65.0	-10.0
		Max.	60.0	65.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	70.80	78.00
		SD	25.642	23.776
		Median	77.50	85.00
		Min.	15.0	5.0
		Max.	100.0	100.0
	Change from Baseline	n	50	50
		Mean	8.20	14.50
		SD	20.070	21.123
		Median	5.00	5.00
		Min.	-60.0	-30.0
		Max.	65.0	70.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	43.40	43.19
		SD	10.326	11.189
		Median	43.19	46.06
		Min.	23.1	19.3
		Max.	57.5	57.5
Week 4	Score	n	54	54
		Mean	44.78	47.16
		SD	9.383	9.598
		Median	46.06	46.06
		Min.	23.1	21.2
		Max.	57.5	57.5
	Change from Baseline	n	54	54
		Mean	1.38	3.97
		SD	5.752	7.452
		Median	0.95	1.92
		Min.	-17.2	-13.4
		Max.	15.3	23.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	46.17	47.12
		SD	9.768	10.454
		Median	47.97	49.88
		Min.	21.2	21.2
		Max.	57.5	57.5
	Change from Baseline	n	53	54
		Mean	2.92	3.93
		SD	6.332	8.020
		Median	1.91	1.92
		Min.	-15.3	-19.1
		Max.	21.1	24.9
Week 12	Score	n	53	53
		Mean	45.88	47.36
		SD	9.165	10.548
		Median	46.06	49.88
		Min.	23.1	21.2
		Max.	57.5	57.5
	Change from Baseline	n	53	53
		Mean	2.64	4.01
		SD	5.053	7.648
		Median	1.91	1.91
		Min.	-11.5	-7.7
		Max.	17.2	24.9

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	47.29	48.15
		SD	9.187	9.593
		Median	49.88	49.88
		Min.	23.1	21.2
		Max.	57.5	57.5
	Change from Baseline	n	53	53
		Mean	4.04	4.80
		SD	7.295	8.028
		Median	1.92	3.83
		Min.	-21.1	-17.2
		Max.	23.0	24.9
Week 20	Score	n	52	52
		Mean	45.91	48.45
		SD	10.047	10.190
		Median	47.02	49.88
		Min.	19.3	21.2
		Max.	57.5	57.5
	Change from Baseline	n	52	52
		Mean	2.83	5.37
		SD	7.086	7.904
		Median	1.91	2.87
		Min.	-17.2	-5.7
		Max.	24.9	24.9

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	46.68	47.56
		SD	10.089	9.873
		Median	49.88	49.88
		Min.	21.2	23.1
		Max.	57.5	57.5
	Change from Baseline	n	52	51
		Mean	3.61	4.58
		SD	8.143	7.974
		Median	3.83	1.91
		Min.	-26.8	-5.7
		Max.	26.8	24.9
Week 28	Score	n	51	51
		Mean	45.95	48.08
		SD	9.754	9.663
		Median	46.06	49.88
		Min.	23.1	21.2
		Max.	57.5	57.5
	Change from Baseline	n	51	51
		Mean	3.15	4.80
		SD	7.098	7.503
		Median	1.92	1.91
		Min.	-24.9	-3.8
		Max.	23.0	24.9

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Physical Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	46.36	49.12
		SD	9.815	9.100
		Median	48.93	51.80
		Min.	25.0	21.2
		Max.	57.5	57.5
	Change from Baseline	n	50	50
		Mean	3.14	5.55
		SD	7.682	8.085
		Median	1.91	1.92
		Min.	-23.0	-11.5
		Max.	24.9	26.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Response Consistency Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	0.15	0.04
		SD	0.563	0.191
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	3.0	1.0
Week 4	Score	n	54	54
		Mean	0.13	0.06
		SD	0.516	0.302
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	3.0	2.0
	Change from Baseline	n	54	54
		Mean	-0.02	0.02
		SD	0.629	0.363
		Median	0.00	0.00
		Min.	-3.0	-1.0
		Max.	3.0	2.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Response Consistency Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	0.00	0.06
		SD	0.000	0.302
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	0.0	2.0
	Change from Baseline	n	53	54
		Mean	-0.15	0.02
		SD	0.568	0.363
		Median	0.00	0.00
		Min.	-3.0	-1.0
		Max.	0.0	2.0
Week 12	Score	n	53	53
		Mean	0.02	0.15
		SD	0.137	0.632
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	1.0	4.0
	Change from Baseline	n	53	53
		Mean	-0.13	0.11
		SD	0.590	0.640
		Median	0.00	0.00
		Min.	-3.0	-1.0
		Max.	1.0	4.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Response Consistency Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	0.13	0.11
		SD	0.621	0.577
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	4.0	4.0
	Change from Baseline	n	53	53
		Mean	-0.02	0.08
		SD	0.747	0.583
		Median	0.00	0.00
		Min.	-3.0	-1.0
		Max.	4.0	4.0
Week 20	Score	n	52	52
		Mean	0.02	0.06
		SD	0.139	0.235
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	1.0	1.0
	Change from Baseline	n	52	52
		Mean	-0.13	0.02
		SD	0.595	0.242
		Median	0.00	0.00
		Min.	-3.0	-1.0
		Max.	1.0	1.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Response Consistency Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	0.04	0.16
		SD	0.194	0.758
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	1.0	5.0
	Change from Baseline	n	52	51
		Mean	-0.12	0.12
		SD	0.548	0.791
		Median	0.00	0.00
		Min.	-3.0	-1.0
		Max.	1.0	5.0
Week 28	Score	n	51	51
		Mean	0.06	0.06
		SD	0.311	0.238
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	2.0	1.0
	Change from Baseline	n	51	51
		Mean	-0.10	0.02
		SD	0.539	0.316
		Median	0.00	0.00
		Min.	-3.0	-1.0
		Max.	1.0	1.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Response Consistency Index

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	0.06	0.16
		SD	0.314	0.738
		Median	0.00	0.00
		Min.	0.0	0.0
		Max.	2.0	5.0
	Change from Baseline	n	50	50
		Mean	-0.06	0.12
		SD	0.470	0.773
		Median	0.00	0.00
		Min.	-3.0	-1.0
		Max.	1.0	5.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	74.07	71.30
		SD	28.533	27.694
		Median	83.33	75.00
		Min.	0.0	0.0
		Max.	100.0	100.0
Week 4	Score	n	54	54
		Mean	74.23	81.02
		SD	27.342	21.983
		Median	79.17	91.67
		Min.	0.0	16.7
		Max.	100.0	100.0
	Change from Baseline	n	54	54
		Mean	0.15	9.72
		SD	20.509	22.358
		Median	0.00	0.00
		Min.	-66.7	-41.7
		Max.	41.7	75.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	77.99	76.39
		SD	26.000	24.960
		Median	83.33	83.33
		Min.	16.7	25.0
		Max.	100.0	100.0
	Change from Baseline	n	53	54
		Mean	3.46	5.09
		SD	24.593	23.202
		Median	0.00	0.00
		Min.	-75.0	-58.3
		Max.	66.7	66.7
Week 12	Score	n	53	53
		Mean	74.69	71.86
		SD	26.602	24.473
		Median	75.00	75.00
		Min.	16.7	8.3
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	0.16	0.47
		SD	25.866	22.846
		Median	0.00	0.00
		Min.	-83.3	-58.3
		Max.	75.0	66.7

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	77.20	78.46
		SD	27.403	23.595
		Median	83.33	83.33
		Min.	8.3	8.3
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	2.67	7.08
		SD	26.443	22.253
		Median	0.00	0.00
		Min.	-75.0	-33.3
		Max.	66.7	66.7
Week 20	Score	n	52	52
		Mean	77.88	76.60
		SD	27.805	25.407
		Median	91.67	83.33
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	52	52
		Mean	3.85	4.65
		SD	25.269	20.104
		Median	0.00	0.00
		Min.	-75.0	-33.3
		Max.	66.7	50.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	75.32	79.41
		SD	27.064	24.173
		Median	79.17	83.33
		Min.	16.7	16.7
		Max.	100.0	100.0
	Change from Baseline	n	52	51
		Mean	1.28	8.01
		SD	26.217	24.264
		Median	0.00	0.00
		Min.	-75.0	-50.0
		Max.	66.7	58.3
Week 28	Score	n	51	51
		Mean	74.51	76.80
		SD	28.646	23.882
		Median	83.33	83.33
		Min.	0.0	25.0
		Max.	100.0	100.0
	Change from Baseline	n	51	51
		Mean	0.98	5.07
		SD	24.981	23.039
		Median	0.00	0.00
		Min.	-100.0	-33.3
		Max.	66.7	58.3

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	75.67	83.00
		SD	28.315	21.558
		Median	87.50	91.67
		Min.	8.3	16.7
		Max.	100.0	100.0
	Change from Baseline	n	50	50
		Mean	2.50	10.17
		SD	22.977	22.543
		Median	0.00	8.33
		Min.	-58.3	-33.3
		Max.	66.7	75.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	45.34	44.18
		SD	11.922	11.571
		Median	49.20	45.72
		Min.	14.4	14.4
		Max.	56.2	56.2
Week 4	Score	n	54	54
		Mean	45.40	48.24
		SD	11.424	9.185
		Median	47.46	52.69
		Min.	14.4	21.4
		Max.	56.2	56.2
	Change from Baseline	n	54	54
		Mean	0.06	4.06
		SD	8.569	9.341
		Median	0.00	0.00
		Min.	-27.9	-17.4
		Max.	17.4	31.3

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	46.97	46.30
		SD	10.864	10.429
		Median	49.20	49.20
		Min.	21.4	24.8
		Max.	56.2	56.2
	Change from Baseline	n	53	54
		Mean	1.45	2.13
		SD	10.276	9.694
		Median	0.00	0.00
		Min.	-31.3	-24.4
		Max.	27.9	27.9
Week 12	Score	n	53	53
		Mean	45.59	44.41
		SD	11.115	10.225
		Median	45.72	45.72
		Min.	21.4	17.9
		Max.	56.2	56.2
	Change from Baseline	n	53	53
		Mean	0.07	0.20
		SD	10.808	9.545
		Median	0.00	0.00
		Min.	-34.8	-24.4
		Max.	31.3	27.9

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	46.64	47.17
		SD	11.450	9.859
		Median	49.20	49.20
		Min.	17.9	17.9
		Max.	56.2	56.2
	Change from Baseline	n	53	53
		Mean	1.12	2.96
		SD	11.048	9.298
		Median	0.00	0.00
		Min.	-31.3	-13.9
		Max.	27.9	27.9
Week 20	Score	n	52	52
		Mean	46.93	46.39
		SD	11.618	10.616
		Median	52.69	49.20
		Min.	14.4	14.4
		Max.	56.2	56.2
	Change from Baseline	n	52	52
		Mean	1.61	1.94
		SD	10.559	8.400
		Median	0.00	0.00
		Min.	-31.3	-13.9
		Max.	27.9	20.9

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	45.86	47.57
		SD	11.309	10.101
		Median	47.46	49.20
		Min.	21.4	21.4
		Max.	56.2	56.2
	Change from Baseline	n	52	51
		Mean	0.54	3.35
		SD	10.955	10.138
		Median	0.00	0.00
		Min.	-31.3	-20.9
		Max.	27.9	24.4
Week 28	Score	n	51	51
		Mean	45.52	46.47
		SD	11.969	9.979
		Median	49.20	49.20
		Min.	14.4	24.8
		Max.	56.2	56.2
	Change from Baseline	n	51	51
		Mean	0.41	2.12
		SD	10.438	9.626
		Median	0.00	0.00
		Min.	-41.8	-13.9
		Max.	27.9	24.4

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Emotional: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	46.00	49.07
		SD	11.831	9.008
		Median	50.95	52.69
		Min.	17.9	21.4
		Max.	56.2	56.2
	Change from Baseline	n	50	50
		Mean	1.05	4.25
		SD	9.601	9.420
		Median	0.00	3.48
		Min.	-24.4	-13.9
		Max.	27.9	31.3

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	51.74	49.77
		SD	29.326	28.291
		Median	50.00	50.00
		Min.	0.0	0.0
		Max.	100.0	100.0
Week 4	Score	n	54	54
		Mean	57.41	60.65
		SD	28.579	27.756
		Median	62.50	62.50
		Min.	0.0	6.3
		Max.	100.0	100.0
	Change from Baseline	n	54	54
		Mean	5.67	10.88
		SD	17.563	23.233
		Median	6.25	3.13
		Min.	-25.0	-25.0
		Max.	43.8	81.3

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	58.25	63.19
		SD	29.335	27.570
		Median	62.50	65.63
		Min.	0.0	6.3
		Max.	100.0	100.0
	Change from Baseline	n	53	54
		Mean	6.49	13.43
		SD	19.839	25.450
		Median	6.25	9.38
		Min.	-31.3	-37.5
		Max.	68.8	93.8
Week 12	Score	n	53	53
		Mean	56.96	61.67
		SD	28.527	27.244
		Median	56.25	62.50
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	5.19	11.56
		SD	20.019	25.162
		Median	6.25	6.25
		Min.	-43.8	-37.5
		Max.	56.3	93.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	61.20	61.79
		SD	29.503	26.620
		Median	62.50	68.75
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	9.43	11.67
		SD	19.249	23.769
		Median	6.25	6.25
		Min.	-31.3	-31.3
		Max.	62.5	93.8
Week 20	Score	n	52	52
		Mean	57.45	63.70
		SD	29.211	27.842
		Median	50.00	75.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	52	52
		Mean	6.13	13.58
		SD	19.744	23.507
		Median	6.25	6.25
		Min.	-37.5	-25.0
		Max.	62.5	93.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	60.10	66.30
		SD	28.417	30.261
		Median	62.50	75.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	52	51
		Mean	8.77	16.18
		SD	19.697	26.815
		Median	6.25	12.50
		Min.	-37.5	-31.3
		Max.	75.0	93.8
Week 28	Score	n	51	51
		Mean	61.52	61.64
		SD	28.267	28.423
		Median	56.25	68.75
		Min.	6.3	0.0
		Max.	100.0	100.0
	Change from Baseline	n	51	51
		Mean	10.17	11.64
		SD	23.683	26.605
		Median	6.25	6.25
		Min.	-37.5	-50.0
		Max.	81.3	93.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	59.63	66.38
		SD	29.645	27.108
		Median	59.38	71.88
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	50	50
		Mean	8.25	15.63
		SD	21.630	27.177
		Median	6.25	12.50
		Min.	-37.5	-25.0
		Max.	81.3	93.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	39.82	39.11
		SD	10.536	10.164
		Median	39.19	39.19
		Min.	21.2	21.2
		Max.	57.2	57.2
Week 4	Score	n	54	54
		Mean	41.85	43.02
		SD	10.268	9.973
		Median	43.68	43.68
		Min.	21.2	23.5
		Max.	57.2	57.2
	Change from Baseline	n	54	54
		Mean	2.04	3.91
		SD	6.310	8.347
		Median	2.24	1.12
		Min.	-9.0	-9.0
		Max.	15.7	29.2

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	42.16	43.93
		SD	10.540	9.906
		Median	43.68	44.81
		Min.	21.2	23.5
		Max.	57.2	57.2
	Change from Baseline	n	53	54
		Mean	2.33	4.82
		SD	7.128	9.144
		Median	2.24	3.37
		Min.	-11.2	-13.5
		Max.	24.7	33.7
Week 12	Score	n	53	53
		Mean	41.69	43.39
		SD	10.250	9.788
		Median	41.44	43.68
		Min.	21.2	21.2
		Max.	57.2	57.2
	Change from Baseline	n	53	53
		Mean	1.86	4.15
		SD	7.193	9.040
		Median	2.25	2.25
		Min.	-15.7	-13.5
		Max.	20.2	33.7

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	43.22	43.43
		SD	10.600	9.564
		Median	43.68	45.93
		Min.	21.2	21.2
		Max.	57.2	57.2
	Change from Baseline	n	53	53
		Mean	3.39	4.19
		SD	6.916	8.540
		Median	2.24	2.25
		Min.	-11.2	-11.2
		Max.	22.5	33.7
Week 20	Score	n	52	52
		Mean	41.87	44.11
		SD	10.496	10.003
		Median	39.19	48.17
		Min.	21.2	21.2
		Max.	57.2	57.2
	Change from Baseline	n	52	52
		Mean	2.20	4.88
		SD	7.094	8.446
		Median	2.24	2.25
		Min.	-13.5	-9.0
		Max.	22.5	33.7

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	42.82	45.05
		SD	10.210	10.873
		Median	43.68	48.17
		Min.	21.2	21.2
		Max.	57.2	57.2
	Change from Baseline	n	52	51
		Mean	3.15	5.81
		SD	7.077	9.635
		Median	2.25	4.49
		Min.	-13.5	-11.2
		Max.	27.0	33.7
Week 28	Score	n	51	51
		Mean	43.33	43.37
		SD	10.156	10.212
		Median	41.44	45.93
		Min.	23.5	21.2
		Max.	57.2	57.2
	Change from Baseline	n	51	51
		Mean	3.65	4.18
		SD	8.509	9.558
		Median	2.25	2.24
		Min.	-13.5	-18.0
		Max.	29.2	33.7

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Role Physical: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	42.65	45.08
		SD	10.651	9.739
		Median	42.56	47.05
		Min.	21.2	21.2
		Max.	57.2	57.2
	Change from Baseline	n	50	50
		Mean	2.96	5.61
		SD	7.771	9.764
		Median	2.25	4.49
		Min.	-13.5	-9.0
		Max.	29.2	33.7

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	62.73	59.03
		SD	29.087	26.756
		Median	75.00	62.50
		Min.	0.0	0.0
		Max.	100.0	100.0
Week 4	Score	n	54	54
		Mean	65.74	66.67
		SD	30.733	26.377
		Median	75.00	62.50
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	54	54
		Mean	3.01	7.64
		SD	19.567	20.520
		Median	0.00	0.00
		Min.	-37.5	-50.0
		Max.	37.5	50.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	71.23	70.14
		SD	28.121	23.843
		Median	75.00	75.00
		Min.	0.0	25.0
		Max.	100.0	100.0
	Change from Baseline	n	53	54
		Mean	8.49	11.11
		SD	23.612	20.841
		Median	0.00	12.50
		Min.	-50.0	-50.0
		Max.	62.5	62.5
Week 12	Score	n	53	53
		Mean	68.63	66.04
		SD	28.125	26.332
		Median	75.00	62.50
		Min.	0.0	12.5
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	5.90	7.55
		SD	21.734	22.779
		Median	0.00	0.00
		Min.	-37.5	-37.5
		Max.	75.0	75.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	71.70	70.05
		SD	27.859	24.921
		Median	75.00	75.00
		Min.	0.0	12.5
		Max.	100.0	100.0
	Change from Baseline	n	53	53
		Mean	8.96	11.56
		SD	22.784	18.645
		Median	0.00	12.50
		Min.	-25.0	-50.0
		Max.	62.5	50.0
Week 20	Score	n	52	52
		Mean	69.95	71.39
		SD	30.544	24.795
		Median	75.00	75.00
		Min.	0.0	25.0
		Max.	100.0	100.0
	Change from Baseline	n	52	52
		Mean	7.69	12.26
		SD	23.891	21.364
		Median	0.00	12.50
		Min.	-50.0	-37.5
		Max.	75.0	62.5

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	70.43	71.57
		SD	28.335	27.395
		Median	75.00	75.00
		Min.	0.0	12.5
		Max.	100.0	100.0
	Change from Baseline	n	52	51
		Mean	8.17	12.25
		SD	21.277	22.007
		Median	0.00	12.50
		Min.	-37.5	-37.5
		Max.	62.5	62.5
Week 28	Score	n	51	51
		Mean	70.59	69.85
		SD	29.136	28.414
		Median	75.00	75.00
		Min.	0.0	0.0
		Max.	100.0	100.0
	Change from Baseline	n	51	51
		Mean	8.82	10.54
		SD	21.549	26.501
		Median	0.00	12.50
		Min.	-37.5	-50.0
		Max.	62.5	62.5

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	71.00	72.00
		SD	29.390	26.069
		Median	75.00	75.00
		Min.	0.0	12.5
		Max.	100.0	100.0
	Change from Baseline	n	50	50
		Mean	9.00	13.00
		SD	23.151	22.863
		Median	12.50	12.50
		Min.	-50.0	-50.0
		Max.	62.5	50.0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	42.39	40.91
		SD	11.666	10.731
		Median	47.31	42.30
		Min.	17.2	17.2
		Max.	57.3	57.3
Week 4	Score	n	54	54
		Mean	43.60	43.97
		SD	12.326	10.579
		Median	47.31	42.30
		Min.	17.2	17.2
		Max.	57.3	57.3
	Change from Baseline	n	54	54
		Mean	1.21	3.06
		SD	7.848	8.230
		Median	0.00	0.00
		Min.	-15.0	-20.1
		Max.	15.0	20.1

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	45.80	45.36
		SD	11.278	9.563
		Median	47.31	47.31
		Min.	17.2	27.3
		Max.	57.3	57.3
	Change from Baseline	n	53	54
		Mean	3.41	4.46
		SD	9.470	8.359
		Median	0.00	5.01
		Min.	-20.1	-20.1
		Max.	25.1	25.1
Week 12	Score	n	53	53
		Mean	44.76	43.72
		SD	11.280	10.561
		Median	47.31	42.30
		Min.	17.2	22.3
		Max.	57.3	57.3
	Change from Baseline	n	53	53
		Mean	2.36	3.03
		SD	8.717	9.136
		Median	0.00	0.00
		Min.	-15.0	-15.0
		Max.	30.1	30.1

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	45.99	45.33
		SD	11.174	9.995
		Median	47.31	47.31
		Min.	17.2	22.3
		Max.	57.3	57.3
	Change from Baseline	n	53	53
		Mean	3.59	4.64
		SD	9.138	7.478
		Median	0.00	5.01
		Min.	-10.0	-20.1
		Max.	25.1	20.1
Week 20	Score	n	52	52
		Mean	45.29	45.87
		SD	12.251	9.945
		Median	47.31	47.31
		Min.	17.2	27.3
		Max.	57.3	57.3
	Change from Baseline	n	52	52
		Mean	3.09	4.92
		SD	9.582	8.569
		Median	0.00	5.01
		Min.	-20.1	-15.0
		Max.	30.1	25.1

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	45.48	45.94
		SD	11.365	10.987
		Median	47.31	47.31
		Min.	17.2	22.3
		Max.	57.3	57.3
	Change from Baseline	n	52	51
		Mean	3.28	4.92
		SD	8.534	8.826
		Median	0.00	5.01
		Min.	-15.0	-15.0
		Max.	25.1	25.1
Week 28	Score	n	51	51
		Mean	45.54	45.25
		SD	11.685	11.397
		Median	47.31	47.31
		Min.	17.2	17.2
		Max.	57.3	57.3
	Change from Baseline	n	51	51
		Mean	3.54	4.23
		SD	8.642	10.630
		Median	0.00	5.01
		Min.	-15.0	-20.1
		Max.	25.1	25.1

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Social Functioning: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	45.71	46.11
		SD	11.787	10.455
		Median	47.31	47.31
		Min.	17.2	22.3
		Max.	57.3	57.3
	Change from Baseline	n	50	50
		Mean	3.61	5.21
		SD	9.286	9.169
		Median	5.01	5.01
		Min.	-20.1	-20.1
		Max.	25.1	20.1

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	38.89	39.70
		SD	21.122	22.751
		Median	37.50	40.63
		Min.	0.0	0.0
		Max.	87.5	87.5
Week 4	Score	n	54	54
		Mean	43.98	45.49
		SD	21.272	22.857
		Median	43.75	43.75
		Min.	0.0	6.3
		Max.	100.0	87.5
	Change from Baseline	n	54	54
		Mean	5.09	5.79
		SD	12.266	16.860
		Median	6.25	0.00
		Min.	-18.8	-37.5
		Max.	25.0	43.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	47.41	46.76
		SD	23.718	20.914
		Median	43.75	43.75
		Min.	0.0	6.3
		Max.	93.8	87.5
	Change from Baseline	n	53	54
		Mean	8.37	7.06
		SD	16.212	20.570
		Median	6.25	6.25
		Min.	-12.5	-43.8
		Max.	56.3	56.3
Week 12	Score	n	53	53
		Mean	45.28	45.87
		SD	21.403	19.648
		Median	50.00	43.75
		Min.	0.0	0.0
		Max.	87.5	87.5
	Change from Baseline	n	53	53
		Mean	6.25	5.90
		SD	15.649	20.960
		Median	6.25	0.00
		Min.	-18.8	-43.8
		Max.	68.8	56.3

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	46.46	45.28
		SD	22.585	20.762
		Median	50.00	43.75
		Min.	6.3	6.3
		Max.	93.8	81.3
	Change from Baseline	n	53	53
		Mean	7.43	5.31
		SD	16.764	20.304
		Median	6.25	6.25
		Min.	-25.0	-37.5
		Max.	50.0	56.3
Week 20	Score	n	52	52
		Mean	47.96	47.00
		SD	22.234	20.580
		Median	46.88	43.75
		Min.	0.0	0.0
		Max.	93.8	81.3
	Change from Baseline	n	52	52
		Mean	8.65	6.85
		SD	16.932	20.609
		Median	6.25	6.25
		Min.	-25.0	-43.8
		Max.	68.8	43.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	48.68	49.63
		SD	22.799	21.773
		Median	50.00	50.00
		Min.	0.0	0.0
		Max.	100.0	81.3
	Change from Baseline	n	52	51
		Mean	9.38	8.82
		SD	18.913	20.432
		Median	6.25	6.25
		Min.	-37.5	-25.0
		Max.	75.0	62.5
Week 28	Score	n	51	51
		Mean	48.28	47.18
		SD	23.455	24.119
		Median	50.00	50.00
		Min.	0.0	0.0
		Max.	93.8	93.8
	Change from Baseline	n	51	51
		Mean	8.95	7.23
		SD	19.655	20.516
		Median	6.25	6.25
		Min.	-37.5	-31.3
		Max.	62.5	68.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: 0-100 score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	46.38	51.25
		SD	24.617	21.724
		Median	46.88	50.00
		Min.	0.0	0.0
		Max.	93.8	93.8
	Change from Baseline	n	50	50
		Mean	7.63	10.75
		SD	19.856	19.358
		Median	6.25	6.25
		Min.	-37.5	-25.0
		Max.	68.8	56.3

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Baseline	Score	n	54	54
		Mean	41.38	41.76
		SD	10.041	10.816
		Median	40.72	42.21
		Min.	22.9	22.9
		Max.	64.5	64.5
Week 4	Score	n	54	54
		Mean	43.80	44.51
		SD	10.112	10.865
		Median	43.69	43.69
		Min.	22.9	25.9
		Max.	70.4	64.5
	Change from Baseline	n	54	54
		Mean	2.42	2.75
		SD	5.832	8.016
		Median	2.97	0.00
		Min.	-8.9	-17.8
		Max.	11.9	20.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 8	Score	n	53	54
		Mean	45.42	45.12
		SD	11.275	9.942
		Median	43.69	43.69
		Min.	22.9	25.9
		Max.	67.5	64.5
	Change from Baseline	n	53	54
		Mean	3.98	3.36
		SD	7.707	9.779
		Median	2.97	2.97
		Min.	-5.9	-20.8
		Max.	26.7	26.7
Week 12	Score	n	53	53
		Mean	44.42	44.69
		SD	10.174	9.341
		Median	46.66	43.69
		Min.	22.9	22.9
		Max.	64.5	64.5
	Change from Baseline	n	53	53
		Mean	2.97	2.80
		SD	7.439	9.965
		Median	2.97	0.00
		Min.	-8.9	-20.8
		Max.	32.7	26.7

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 16	Score	n	53	53
		Mean	44.98	44.41
		SD	10.736	9.870
		Median	46.66	43.69
		Min.	25.9	25.9
		Max.	67.5	61.5
	Change from Baseline	n	53	53
		Mean	3.53	2.52
		SD	7.969	9.653
		Median	2.97	2.97
		Min.	-11.9	-17.8
		Max.	23.8	26.7
Week 20	Score	n	52	52
		Mean	45.69	45.23
		SD	10.569	9.783
		Median	45.18	43.69
		Min.	22.9	22.9
		Max.	67.5	61.5
	Change from Baseline	n	52	52
		Mean	4.11	3.26
		SD	8.049	9.798
		Median	2.97	2.97
		Min.	-11.9	-20.8
		Max.	32.7	20.8

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 24	Score	n	52	51
		Mean	46.03	46.48
		SD	10.838	10.350
		Median	46.66	46.66
		Min.	22.9	22.9
		Max.	70.4	61.5
	Change from Baseline	n	52	51
		Mean	4.46	4.19
		SD	8.990	9.713
		Median	2.97	2.97
		Min.	-17.8	-11.9
		Max.	35.7	29.7
Week 28	Score	n	51	51
		Mean	45.84	45.32
		SD	11.149	11.465
		Median	46.66	46.66
		Min.	22.9	22.9
		Max.	67.5	67.5
	Change from Baseline	n	51	51
		Mean	4.25	3.44
		SD	9.343	9.753
		Median	2.97	2.97
		Min.	-17.8	-14.9
		Max.	29.7	32.7

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.1
Summary of SF-36 Health Survey Domain Scores

Domain: SF363-Vitality: norm-based score

Analysis Time Point			Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Week 32	Score	n	50	50
		Mean	44.93	47.25
		SD	11.702	10.327
		Median	45.18	46.66
		Min.	22.9	22.9
		Max.	67.5	67.5
	Change from Baseline	n	50	50
		Mean	3.62	5.11
		SD	9.439	9.203
		Median	2.97	2.97
		Min.	-17.8	-11.9
		Max.	32.7	26.7

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.118
Analysis of Change from Baseline in SF-36 Domain Score:
Physical Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	66.02 (2.089)	73.22 (2.091)
LS Mean Change (SE)	3.47 (2.089)	10.68 (2.091)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		7.21
95% CI		(1.32, 13.10)
p-value		0.017
Corrected Hedges g [3]		0.47
95% CI		(0.08, 0.85)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.118
Analysis of Change from Baseline in SF-36 Domain Score:
Physical Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	69.61 (2.341)	73.13 (2.330)
LS Mean Change (SE)	7.06 (2.341)	10.58 (2.330)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		3.52
95% CI		(-3.06, 10.10)
p-value		0.291
Corrected Hedges g [3]		0.20
95% CI		(-0.18, 0.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.118
Analysis of Change from Baseline in SF-36 Domain Score:
Physical Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	68.90 (2.137)	72.92 (2.134)
LS Mean Change (SE)	6.35 (2.137)	10.37 (2.134)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		4.02
95% CI		(-2.00, 10.04)
p-value		0.188
Corrected Hedges g [3]		0.26
95% CI		(-0.13, 0.64)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.118
Analysis of Change from Baseline in SF-36 Domain Score:
Physical Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	72.53 (2.372)	74.95 (2.369)
LS Mean Change (SE)	9.99 (2.372)	12.40 (2.369)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.41
95% CI		(-4.26, 9.09)
p-value		0.475
Corrected Hedges g [3]		0.14
95% CI		(-0.24, 0.52)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Protocol: 200622
Population: Intent-to-Treat

Table 90.118
Analysis of Change from Baseline in SF-36 Domain Score:
Physical Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	69.25 (2.484)	75.77 (2.480)
LS Mean Change (SE)	6.70 (2.484)	13.22 (2.480)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.52
95% CI		(-0.48, 13.52)
p-value		0.067
Corrected Hedges g [3]		0.36
95% CI		(-0.03, 0.75)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.118
Analysis of Change from Baseline in SF-36 Domain Score:
Physical Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	71.26 (2.606)	73.46 (2.609)
LS Mean Change (SE)	8.71 (2.606)	10.91 (2.609)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.20
95% CI		(-5.14, 9.54)
p-value		0.553
Corrected Hedges g [3]		0.12
95% CI		(-0.27, 0.50)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.118
Analysis of Change from Baseline in SF-36 Domain Score:
Physical Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	69.83 (2.369)	74.38 (2.367)
LS Mean Change (SE)	7.29 (2.369)	11.84 (2.367)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		4.55
95% CI		(-2.12, 11.22)
p-value		0.179
Corrected Hedges g [3]		0.27
95% CI		(-0.12, 0.66)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.118
Analysis of Change from Baseline in SF-36 Domain Score:
Physical Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	70.16 (2.480)	76.22 (2.477)
LS Mean Change (SE)	7.61 (2.480)	13.67 (2.477)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.06
95% CI		(-0.92, 13.04)
p-value		0.088
Corrected Hedges g [3]		0.34
95% CI		(-0.05, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.119
Analysis of Change from Baseline in SF-36 Domain Score:
Role Physical (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	56.40 (2.609)	61.72 (2.611)
LS Mean Change (SE)	5.58 (2.609)	10.89 (2.611)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		5.31
95% CI		(-2.04, 12.67)
p-value		0.155
Corrected Hedges g [3]		0.28
95% CI		(-0.10, 0.65)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Protocol: 200622
Population: Intent-to-Treat

Table 90.119
Analysis of Change from Baseline in SF-36 Domain Score:
Role Physical (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	56.96 (2.844)	64.21 (2.824)
LS Mean Change (SE)	6.14 (2.844)	13.39 (2.824)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		7.25
95% CI		(-0.74, 15.23)
p-value		0.075
Corrected Hedges g [3]		0.35
95% CI		(-0.03, 0.73)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Protocol: 200622
Population: Intent-to-Treat

Table 90.119
Analysis of Change from Baseline in SF-36 Domain Score:
Role Physical (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	55.66 (2.838)	61.99 (2.829)
LS Mean Change (SE)	4.83 (2.838)	11.17 (2.829)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.34
95% CI		(-1.64, 14.32)
p-value		0.118
Corrected Hedges g [3]		0.31
95% CI		(-0.08, 0.69)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.119
Analysis of Change from Baseline in SF-36 Domain Score:
Role Physical (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	59.89 (2.728)	62.18 (2.721)
LS Mean Change (SE)	9.07 (2.728)	11.35 (2.721)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.29
95% CI		(-5.39, 9.96)
p-value		0.556
Corrected Hedges g [3]		0.11
95% CI		(-0.27, 0.50)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.119
Analysis of Change from Baseline in SF-36 Domain Score:
Role Physical (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	56.43 (2.797)	63.68 (2.790)
LS Mean Change (SE)	5.61 (2.797)	12.85 (2.790)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		7.24
95% CI		(-0.63, 15.11)
p-value		0.071
Corrected Hedges g [3]		0.36
95% CI		(-0.03, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.119
Analysis of Change from Baseline in SF-36 Domain Score:
Role Physical (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	59.06 (3.021)	65.81 (3.026)
LS Mean Change (SE)	8.24 (3.021)	14.99 (3.026)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.75
95% CI		(-1.76, 15.26)
p-value		0.119
Corrected Hedges g [3]		0.31
95% CI		(-0.08, 0.70)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.119
Analysis of Change from Baseline in SF-36 Domain Score:
Role Physical (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	60.61 (3.099)	61.61 (3.094)
LS Mean Change (SE)	9.79 (3.099)	10.79 (3.094)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.00
95% CI		(-7.71, 9.72)
p-value		0.820
Corrected Hedges g [3]		0.04
95% CI		(-0.34, 0.43)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.119
Analysis of Change from Baseline in SF-36 Domain Score:
Role Physical (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	59.36 (3.051)	65.67 (3.045)
LS Mean Change (SE)	8.54 (3.051)	14.85 (3.045)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.31
95% CI		(-2.27, 14.89)
p-value		0.148
Corrected Hedges g [3]		0.29
95% CI		(-0.10, 0.68)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.120
Analysis of Change from Baseline in SF-36 Domain Score:
Bodily Pain (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	58.14 (2.407)	60.77 (2.407)
LS Mean Change (SE)	7.34 (2.407)	9.96 (2.407)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.63
95% CI		(-4.15, 9.40)
p-value		0.443
Corrected Hedges g [3]		0.15
95% CI		(-0.23, 0.53)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.120
Analysis of Change from Baseline in SF-36 Domain Score:
Bodily Pain (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	58.78 (3.275)	67.67 (3.249)
LS Mean Change (SE)	7.97 (3.275)	16.87 (3.249)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		8.90
95% CI		(-0.27, 18.07)
p-value		0.057
Corrected Hedges g [3]		0.37
95% CI		(-0.01, 0.75)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Population: Intent-to-Treat

Table 90.120
Analysis of Change from Baseline in SF-36 Domain Score:
Bodily Pain (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	57.45 (2.948)	60.12 (2.941)
LS Mean Change (SE)	6.65 (2.948)	9.32 (2.941)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.67
95% CI		(-5.62, 10.95)
p-value		0.524
Corrected Hedges g [3]		0.12
95% CI		(-0.26, 0.50)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.120
Analysis of Change from Baseline in SF-36 Domain Score:
Bodily Pain (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	62.68 (2.813)	58.91 (2.807)
LS Mean Change (SE)	11.88 (2.813)	8.11 (2.807)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.77
95% CI		(-11.68, 4.13)
p-value		0.346
Corrected Hedges g [3]		-0.18
95% CI		(-0.56, 0.20)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Population: Intent-to-Treat

Table 90.120
Analysis of Change from Baseline in SF-36 Domain Score:
Bodily Pain (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	61.83 (2.763)	62.48 (2.759)
LS Mean Change (SE)	11.03 (2.763)	11.67 (2.759)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.65
95% CI		(-7.13, 8.42)
p-value		0.869
Corrected Hedges g [3]		0.03
95% CI		(-0.35, 0.42)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Population: Intent-to-Treat

Table 90.120
Analysis of Change from Baseline in SF-36 Domain Score:
Bodily Pain (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	60.78 (3.026)	66.04 (3.037)
LS Mean Change (SE)	9.98 (3.026)	15.23 (3.037)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		5.26
95% CI		(-3.27, 13.78)
p-value		0.224
Corrected Hedges g [3]		0.24
95% CI		(-0.15, 0.63)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.120
Analysis of Change from Baseline in SF-36 Domain Score:
Bodily Pain (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	61.91 (2.976)	63.35 (2.970)
LS Mean Change (SE)	11.11 (2.976)	12.55 (2.970)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.44
95% CI		(-6.92, 9.81)
p-value		0.733
Corrected Hedges g [3]		0.07
95% CI		(-0.32, 0.46)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.120
Analysis of Change from Baseline in SF-36 Domain Score:
Bodily Pain (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	61.43 (3.131)	67.65 (3.128)
LS Mean Change (SE)	10.63 (3.131)	16.85 (3.128)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.22
95% CI		(-2.58, 15.03)
p-value		0.164
Corrected Hedges g [3]		0.28
95% CI		(-0.11, 0.67)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.121
Analysis of Change from Baseline in SF-36 Domain Score:
General Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	43.46 (1.823)	45.62 (1.826)
LS Mean Change (SE)	4.39 (1.823)	6.55 (1.826)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.16
95% CI		(-3.00, 7.32)
p-value		0.408
Corrected Hedges g [3]		0.16
95% CI		(-0.22, 0.54)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.121
Analysis of Change from Baseline in SF-36 Domain Score:
General Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	46.11 (2.027)	46.83 (2.020)
LS Mean Change (SE)	7.04 (2.027)	7.76 (2.020)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.72
95% CI		(-5.00, 6.44)
p-value		0.804
Corrected Hedges g [3]		0.05
95% CI		(-0.33, 0.43)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.121
Analysis of Change from Baseline in SF-36 Domain Score:
General Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	44.19 (2.142)	48.65 (2.139)
LS Mean Change (SE)	5.12 (2.142)	9.59 (2.139)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		4.46
95% CI		(-1.58, 10.51)
p-value		0.146
Corrected Hedges g [3]		0.28
95% CI		(-0.10, 0.67)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.121
Analysis of Change from Baseline in SF-36 Domain Score:
General Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	42.99 (2.340)	49.02 (2.337)
LS Mean Change (SE)	3.92 (2.340)	9.95 (2.337)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.03
95% CI		(-0.58, 12.63)
p-value		0.073
Corrected Hedges g [3]		0.35
95% CI		(-0.03, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.121
Analysis of Change from Baseline in SF-36 Domain Score:
General Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	43.13 (2.331)	47.63 (2.328)
LS Mean Change (SE)	4.06 (2.331)	8.56 (2.328)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		4.50
95% CI		(-2.07, 11.08)
p-value		0.177
Corrected Hedges g [3]		0.27
95% CI		(-0.12, 0.65)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.121
Analysis of Change from Baseline in SF-36 Domain Score:
General Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	42.50 (2.440)	48.83 (2.442)
LS Mean Change (SE)	3.43 (2.440)	9.77 (2.442)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.34
95% CI		(-0.55, 13.23)
p-value		0.071
Corrected Hedges g [3]		0.36
95% CI		(-0.03, 0.75)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.121
Analysis of Change from Baseline in SF-36 Domain Score:
General Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	42.19 (2.609)	46.52 (2.607)
LS Mean Change (SE)	3.13 (2.609)	7.45 (2.607)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		4.33
95% CI		(-3.03, 11.68)
p-value		0.246
Corrected Hedges g [3]		0.23
95% CI		(-0.16, 0.62)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.121
Analysis of Change from Baseline in SF-36 Domain Score:
General Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	43.23 (2.438)	48.65 (2.434)
LS Mean Change (SE)	4.16 (2.438)	9.58 (2.434)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		5.42
95% CI		(-1.46, 12.29)
p-value		0.121
Corrected Hedges g [3]		0.31
95% CI		(-0.08, 0.71)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.122
Analysis of Change from Baseline in SF-36 Domain Score:
Vitality (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	44.52 (1.919)	45.30 (1.920)
LS Mean Change (SE)	4.93 (1.919)	5.72 (1.920)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.78
95% CI		(-4.63, 6.19)
p-value		0.774
Corrected Hedges g [3]		0.06
95% CI		(-0.32, 0.43)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.122
Analysis of Change from Baseline in SF-36 Domain Score:
Vitality (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	47.68 (2.345)	46.59 (2.328)
LS Mean Change (SE)	8.10 (2.345)	7.00 (2.328)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.09
95% CI		(-7.68, 5.49)
p-value		0.742
Corrected Hedges g [3]		-0.06
95% CI		(-0.44, 0.32)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.122
Analysis of Change from Baseline in SF-36 Domain Score:
Vitality (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	45.53 (2.247)	45.14 (2.240)
LS Mean Change (SE)	5.94 (2.247)	5.55 (2.240)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.39
95% CI		(-6.71, 5.93)
p-value		0.903
Corrected Hedges g [3]		-0.02
95% CI		(-0.40, 0.36)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.122
Analysis of Change from Baseline in SF-36 Domain Score:
Vitality (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	46.72 (2.340)	44.56 (2.337)
LS Mean Change (SE)	7.13 (2.340)	4.98 (2.337)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.15
95% CI		(-8.74, 4.43)
p-value		0.518
Corrected Hedges g [3]		-0.13
95% CI		(-0.51, 0.26)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.122
Analysis of Change from Baseline in SF-36 Domain Score:
Vitality (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	47.82 (2.302)	45.99 (2.299)
LS Mean Change (SE)	8.23 (2.302)	6.41 (2.299)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.82
95% CI		(-8.30, 4.66)
p-value		0.578
Corrected Hedges g [3]		-0.11
95% CI		(-0.49, 0.28)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.122
Analysis of Change from Baseline in SF-36 Domain Score:
Vitality (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	48.58 (2.503)	47.75 (2.510)
LS Mean Change (SE)	8.99 (2.503)	8.17 (2.510)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.83
95% CI		(-7.88, 6.23)
p-value		0.816
Corrected Hedges g [3]		-0.05
95% CI		(-0.43, 0.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.122
Analysis of Change from Baseline in SF-36 Domain Score:
Vitality (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	48.05 (2.571)	46.00 (2.567)
LS Mean Change (SE)	8.46 (2.571)	6.41 (2.567)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.05
95% CI		(-9.28, 5.18)
p-value		0.575
Corrected Hedges g [3]		-0.11
95% CI		(-0.50, 0.28)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.122
Analysis of Change from Baseline in SF-36 Domain Score:
Vitality (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	47.01 (2.532)	50.43 (2.528)
LS Mean Change (SE)	7.43 (2.532)	10.85 (2.528)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		3.42
95% CI		(-3.70, 10.54)
p-value		0.343
Corrected Hedges g [3]		0.19
95% CI		(-0.20, 0.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.123
Analysis of Change from Baseline in SF-36 Domain Score:
Social Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	64.01 (2.652)	68.07 (2.652)
LS Mean Change (SE)	3.32 (2.652)	7.38 (2.652)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		4.06
95% CI		(-3.41, 11.53)
p-value		0.283
Corrected Hedges g [3]		0.21
95% CI		(-0.17, 0.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.123
Analysis of Change from Baseline in SF-36 Domain Score:
Social Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	69.47 (2.665)	71.29 (2.644)
LS Mean Change (SE)	8.78 (2.665)	10.60 (2.644)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.81
95% CI		(-5.66, 9.29)
p-value		0.631
Corrected Hedges g [3]		0.09
95% CI		(-0.29, 0.47)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.123
Analysis of Change from Baseline in SF-36 Domain Score:
Social Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	66.89 (2.776)	67.25 (2.769)
LS Mean Change (SE)	6.20 (2.776)	6.55 (2.769)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.36
95% CI		(-7.45, 8.16)
p-value		0.928
Corrected Hedges g [3]		0.02
95% CI		(-0.36, 0.40)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.123
Analysis of Change from Baseline in SF-36 Domain Score:
Social Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	70.04 (2.540)	71.44 (2.534)
LS Mean Change (SE)	9.35 (2.540)	10.75 (2.534)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.40
95% CI		(-5.75, 8.55)
p-value		0.699
Corrected Hedges g [3]		0.08
95% CI		(-0.31, 0.46)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.123
Analysis of Change from Baseline in SF-36 Domain Score:
Social Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	68.30 (2.898)	71.84 (2.895)
LS Mean Change (SE)	7.61 (2.898)	11.15 (2.895)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		3.54
95% CI		(-4.61, 11.70)
p-value		0.391
Corrected Hedges g [3]		0.17
95% CI		(-0.22, 0.55)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.123
Analysis of Change from Baseline in SF-36 Domain Score:
Social Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	68.81 (2.772)	71.33 (2.777)
LS Mean Change (SE)	8.12 (2.772)	10.64 (2.777)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.52
95% CI		(-5.29, 10.34)
p-value		0.523
Corrected Hedges g [3]		0.13
95% CI		(-0.26, 0.51)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.123
Analysis of Change from Baseline in SF-36 Domain Score:
Social Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	68.91 (3.103)	70.62 (3.099)
LS Mean Change (SE)	8.22 (3.103)	9.93 (3.099)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.71
95% CI		(-7.02, 10.43)
p-value		0.698
Corrected Hedges g [3]		0.08
95% CI		(-0.31, 0.46)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.123
Analysis of Change from Baseline in SF-36 Domain Score:
Social Functioning (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	70.13 (2.896)	72.95 (2.894)
LS Mean Change (SE)	9.44 (2.896)	12.26 (2.894)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.82
95% CI		(-5.32, 10.97)
p-value		0.493
Corrected Hedges g [3]		0.14
95% CI		(-0.26, 0.53)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.124
Analysis of Change from Baseline in SF-36 Domain Score:
Role Emotional (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	73.60 (2.530)	81.80 (2.532)
LS Mean Change (SE)	0.74 (2.530)	8.95 (2.532)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		8.21
95% CI		(1.08, 15.33)
p-value		0.024
Corrected Hedges g [3]		0.44
95% CI		(0.06, 0.82)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.124
Analysis of Change from Baseline in SF-36 Domain Score:
Role Emotional (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	76.72 (2.842)	77.11 (2.825)
LS Mean Change (SE)	3.86 (2.842)	4.25 (2.825)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.39
95% CI		(-7.59, 8.37)
p-value		0.923
Corrected Hedges g [3]		0.02
95% CI		(-0.36, 0.40)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.124
Analysis of Change from Baseline in SF-36 Domain Score:
Role Emotional (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	73.52 (2.875)	72.14 (2.868)
LS Mean Change (SE)	0.66 (2.875)	-0.72 (2.868)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.38
95% CI		(-9.46, 6.70)
p-value		0.735
Corrected Hedges g [3]		-0.07
95% CI		(-0.45, 0.32)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.124
Analysis of Change from Baseline in SF-36 Domain Score:
Role Emotional (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	76.05 (2.883)	78.78 (2.877)
LS Mean Change (SE)	3.19 (2.883)	5.93 (2.877)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.74
95% CI		(-5.37, 10.84)
p-value		0.505
Corrected Hedges g [3]		0.13
95% CI		(-0.25, 0.51)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Protocol: 200622
Population: Intent-to-Treat

Table 90.124
Analysis of Change from Baseline in SF-36 Domain Score:
Role Emotional (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	76.90 (2.810)	76.33 (2.804)
LS Mean Change (SE)	4.04 (2.810)	3.47 (2.804)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.57
95% CI		(-8.47, 7.33)
p-value		0.886
Corrected Hedges g [3]		-0.03
95% CI		(-0.41, 0.36)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.124
Analysis of Change from Baseline in SF-36 Domain Score:
Role Emotional (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	74.40 (2.980)	79.16 (2.988)
LS Mean Change (SE)	1.54 (2.980)	6.31 (2.988)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		4.77
95% CI		(-3.63, 13.17)
p-value		0.263
Corrected Hedges g [3]		0.22
95% CI		(-0.17, 0.61)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.124
Analysis of Change from Baseline in SF-36 Domain Score:
Role Emotional (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	73.60 (2.900)	76.83 (2.897)
LS Mean Change (SE)	0.74 (2.900)	3.97 (2.897)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		3.23
95% CI		(-4.93, 11.38)
p-value		0.434
Corrected Hedges g [3]		0.15
95% CI		(-0.23, 0.54)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.124
Analysis of Change from Baseline in SF-36 Domain Score:
Role Emotional (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	75.00 (2.769)	81.85 (2.766)
LS Mean Change (SE)	2.15 (2.769)	8.99 (2.766)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.84
95% CI		(-0.95, 14.64)
p-value		0.085
Corrected Hedges g [3]		0.35
95% CI		(-0.05, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.125
Analysis of Change from Baseline in SF-36 Domain Score:
Mental Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	54	54
LS Mean (SE)	61.41 (1.769)	66.13 (1.772)
LS Mean Change (SE)	0.05 (1.769)	4.77 (1.772)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		4.72
95% CI		(-0.27, 9.71)
p-value		0.064
Corrected Hedges g [3]		0.36
95% CI		(-0.02, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.125
Analysis of Change from Baseline in SF-36 Domain Score:
Mental Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	54
LS Mean (SE)	65.54 (2.030)	67.08 (2.019)
LS Mean Change (SE)	4.18 (2.030)	5.72 (2.019)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.54
95% CI		(-4.17, 7.24)
p-value		0.594
Corrected Hedges g [3]		0.10
95% CI		(-0.28, 0.48)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.125
Analysis of Change from Baseline in SF-36 Domain Score:
Mental Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	62.18 (2.090)	62.64 (2.084)
LS Mean Change (SE)	0.82 (2.090)	1.28 (2.084)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.46
95% CI		(-5.42, 6.34)
p-value		0.877
Corrected Hedges g [3]		0.03
95% CI		(-0.35, 0.41)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.125
Analysis of Change from Baseline in SF-36 Domain Score:
Mental Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	53	53
LS Mean (SE)	64.41 (2.047)	65.29 (2.043)
LS Mean Change (SE)	3.04 (2.047)	3.92 (2.043)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.88
95% CI		(-4.88, 6.64)
p-value		0.762
Corrected Hedges g [3]		0.06
95% CI		(-0.32, 0.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.125
Analysis of Change from Baseline in SF-36 Domain Score:
Mental Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	52
LS Mean (SE)	62.85 (2.237)	64.92 (2.233)
LS Mean Change (SE)	1.48 (2.237)	3.56 (2.233)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.07
95% CI		(-4.22, 8.37)
p-value		0.515
Corrected Hedges g [3]		0.13
95% CI		(-0.26, 0.51)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.125
Analysis of Change from Baseline in SF-36 Domain Score:
Mental Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	52	51
LS Mean (SE)	63.96 (2.347)	66.91 (2.353)
LS Mean Change (SE)	2.60 (2.347)	5.54 (2.353)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		2.95
95% CI		(-3.67, 9.56)
p-value		0.379
Corrected Hedges g [3]		0.17
95% CI		(-0.21, 0.56)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.125
Analysis of Change from Baseline in SF-36 Domain Score:
Mental Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	51	51
LS Mean (SE)	61.96 (2.449)	65.50 (2.446)
LS Mean Change (SE)	0.60 (2.449)	4.14 (2.446)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		3.54
95% CI		(-3.34, 10.43)
p-value		0.310
Corrected Hedges g [3]		0.20
95% CI		(-0.19, 0.59)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.125
Analysis of Change from Baseline in SF-36 Domain Score:
Mental Health (0-100 score)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	54	54
n [2]	50	50
LS Mean (SE)	64.15 (2.212)	67.79 (2.211)
LS Mean Change (SE)	2.79 (2.212)	6.43 (2.211)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		3.64
95% CI		(-2.58, 9.87)
p-value		0.249
Corrected Hedges g [3]		0.23
95% CI		(-0.16, 0.62)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 0

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Work time missed due to health (%)	n	31	30
	Mean	20.8	20.8
	SD	32.92	34.04
	Median	0.0	0.0
	Min.	0	0
	Max.	100	100
Impairment while working due to health (%)	n	29	27
	Mean	30.7	42.2
	SD	27.51	25.32
	Median	30.0	40.0
	Min.	0	0
	Max.	100	80
Overall work impairment due to health (%)	n	31	30
	Mean	40.9	53.1
	SD	35.34	31.46
	Median	30.0	55.0
	Min.	0	0
	Max.	100	100
Activity impairment due to health (%)	n	54	54
	Mean	40.4	46.3
	SD	28.61	30.49
	Median	40.0	50.0
	Min.	0	0
	Max.	100	100

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 4

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Work time missed due to health (%)	n	27	26
	Mean	21.2	18.0
	SD	34.11	33.06
	Median	0.0	0.0
	Min.	0	0
	Max.	100	100
Work time missed due to health change from baseline (%)	n	26	23
	Mean	-1.7	1.2
	SD	37.20	36.58
	Median	0.0	0.0
	Min.	-100	-100
	Max.	100	88
Impairment while working due to health (%)	n	25	24
	Mean	31.2	24.6
	SD	29.20	23.95
	Median	30.0	20.0
	Min.	0	0
	Max.	90	80
Impairment while working due to health change from baseline (%)	n	22	19
	Mean	-1.8	-18.4
	SD	13.32	23.16
	Median	0.0	-10.0
	Min.	-30	-70
	Max.	20	20

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 4

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Overall work impairment due to health (%)	n	27	26
	Mean	41.7	34.6
	SD	37.21	34.35
	Median	31.4	20.0
	Min.	0	0
	Max.	100	100
Overall work impairment due to health change from baseline (%)	n	26	23
	Mean	-2.1	-15.6
	SD	24.68	34.37
	Median	0.0	-10.0
	Min.	-50	-100
	Max.	70	62
Activity impairment due to health (%)	n	51	51
	Mean	36.3	31.6
	SD	28.84	28.03
	Median	30.0	20.0
	Min.	0	0
	Max.	100	90
Activity impairment due to health change from baseline (%)	n	51	51
	Mean	-3.7	-13.7
	SD	17.66	25.77
	Median	0.0	-10.0
	Min.	-40	-80
	Max.	40	30

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 8

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Work time missed due to health (%)	n	27	26
	Mean	15.8	16.5
	SD	23.45	29.45
	Median	0.0	0.0
	Min.	0	0
	Max.	87	100
Work time missed due to health change from baseline (%)	n	25	23
	Mean	-2.5	-3.9
	SD	32.73	34.20
	Median	0.0	0.0
	Min.	-100	-100
	Max.	60	88
Impairment while working due to health (%)	n	27	25
	Mean	25.9	32.8
	SD	27.49	30.21
	Median	30.0	30.0
	Min.	0	0
	Max.	80	100
Impairment while working due to health change from baseline (%)	n	23	20
	Mean	-3.5	-13.5
	SD	16.13	26.21
	Median	0.0	-10.0
	Min.	-30	-70
	Max.	20	30

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 8

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Overall work impairment due to health (%)	n	27	26
	Mean	33.2	39.2
	SD	33.30	34.69
	Median	30.0	30.0
	Min.	0	0
	Max.	97	100
Overall work impairment due to health change from baseline (%)	n	25	23
	Mean	-5.3	-13.9
	SD	25.97	37.03
	Median	-0.7	-10.0
	Min.	-80	-100
	Max.	50	62
Activity impairment due to health (%)	n	49	47
	Mean	31.8	32.6
	SD	27.13	28.70
	Median	30.0	30.0
	Min.	0	0
	Max.	90	100
Activity impairment due to health change from baseline (%)	n	49	47
	Mean	-8.6	-12.8
	SD	21.21	31.19
	Median	-10.0	-10.0
	Min.	-70	-80
	Max.	40	100

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 12

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Work time missed due to health (%)	n	26	23
	Mean	19.5	24.6
	SD	35.42	36.70
	Median	0.0	0.0
	Min.	0	0
	Max.	100	100
Work time missed due to health change from baseline (%)	n	23	21
	Mean	-1.7	3.5
	SD	37.77	34.63
	Median	0.0	0.0
	Min.	-71	-70
	Max.	100	77
Impairment while working due to health (%)	n	23	20
	Mean	29.6	29.5
	SD	29.00	26.85
	Median	20.0	20.0
	Min.	0	0
	Max.	90	80
Impairment while working due to health change from baseline (%)	n	19	18
	Mean	-5.8	-11.7
	SD	24.11	22.29
	Median	0.0	-5.0
	Min.	-70	-60
	Max.	30	20

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 12

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Overall work impairment due to health (%)	n	26	23
	Mean	40.2	44.5
	SD	37.36	37.23
	Median	30.0	50.0
	Min.	0	0
	Max.	100	100
Overall work impairment due to health change from baseline (%)	n	23	21
	Mean	-4.6	-8.2
	SD	33.20	30.19
	Median	0.0	-5.6
	Min.	-91	-69
	Max.	80	50
Activity impairment due to health (%)	n	46	45
	Mean	36.3	35.1
	SD	28.00	29.74
	Median	40.0	30.0
	Min.	0	0
	Max.	100	100
Activity impairment due to health change from baseline (%)	n	46	45
	Mean	-3.7	-9.3
	SD	21.54	27.75
	Median	0.0	-10.0
	Min.	-50	-80
	Max.	50	100

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 16

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Work time missed due to health (%)	n	23	19
	Mean	13.9	10.8
	SD	29.08	20.35
	Median	0.0	0.0
	Min.	0	0
	Max.	100	62
Work time missed due to health change from baseline (%)	n	21	19
	Mean	-5.7	-9.3
	SD	39.30	39.38
	Median	0.0	0.0
	Min.	-100	-100
	Max.	100	54
Impairment while working due to health (%)	n	21	19
	Mean	31.9	23.2
	SD	29.60	22.37
	Median	30.0	20.0
	Min.	0	0
	Max.	80	80
Impairment while working due to health change from baseline (%)	n	18	17
	Mean	2.8	-14.7
	SD	28.03	25.52
	Median	0.0	-10.0
	Min.	-40	-70
	Max.	80	20

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 16

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Overall work impairment due to health (%)	n	23	19
	Mean	40.2	29.6
	SD	34.66	28.24
	Median	48.0	20.0
	Min.	0	0
	Max.	100	87
Overall work impairment due to health change from baseline (%)	n	21	19
	Mean	1.8	-21.9
	SD	36.37	43.00
	Median	0.0	-10.0
	Min.	-41	-100
	Max.	90	63
Activity impairment due to health (%)	n	45	44
	Mean	33.6	30.0
	SD	27.81	26.33
	Median	40.0	30.0
	Min.	0	0
	Max.	100	100
Activity impairment due to health change from baseline (%)	n	45	44
	Mean	-7.3	-14.1
	SD	19.70	28.64
	Median	0.0	-10.0
	Min.	-60	-80
	Max.	40	50

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 20

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Work time missed due to health (%)	n	21	20
	Mean	20.3	15.3
	SD	35.87	27.49
	Median	0.0	0.0
	Min.	0	0
	Max.	100	100
Work time missed due to health change from baseline (%)	n	19	19
	Mean	5.5	-2.8
	SD	37.63	30.61
	Median	0.0	0.0
	Min.	-70	-100
	Max.	100	50
Impairment while working due to health (%)	n	19	19
	Mean	32.6	23.2
	SD	33.47	19.74
	Median	30.0	20.0
	Min.	0	0
	Max.	100	70
Impairment while working due to health change from baseline (%)	n	16	16
	Mean	1.3	-16.9
	SD	32.22	23.87
	Median	0.0	-10.0
	Min.	-40	-70
	Max.	100	20

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 20

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Overall work impairment due to health (%)	n	21	20
	Mean	40.7	34.7
	SD	38.44	28.05
	Median	32.3	33.1
	Min.	0	0
	Max.	100	100
Overall work impairment due to health change from baseline (%)	n	19	19
	Mean	3.9	-16.2
	SD	39.33	34.76
	Median	0.0	-10.0
	Min.	-61	-100
	Max.	100	50
Activity impairment due to health (%)	n	46	42
	Mean	37.8	32.4
	SD	29.73	29.78
	Median	35.0	20.0
	Min.	0	0
	Max.	100	100
Activity impairment due to health change from baseline (%)	n	46	42
	Mean	-1.7	-11.9
	SD	24.97	29.40
	Median	0.0	-10.0
	Min.	-50	-80
	Max.	70	100

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 24

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Work time missed due to health (%)	n	20	20
	Mean	11.1	14.7
	SD	24.44	32.08
	Median	0.0	0.0
	Min.	0	0
	Max.	89	100
Work time missed due to health change from baseline (%)	n	18	19
	Mean	-5.9	-3.0
	SD	26.68	49.60
	Median	0.0	0.0
	Min.	-65	-100
	Max.	68	100
Impairment while working due to health (%)	n	20	19
	Mean	35.0	18.4
	SD	33.32	23.40
	Median	30.0	10.0
	Min.	0	0
	Max.	90	80
Impairment while working due to health change from baseline (%)	n	17	16
	Mean	4.7	-17.5
	SD	26.95	29.78
	Median	0.0	-10.0
	Min.	-40	-60
	Max.	60	40

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 24

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Overall work impairment due to health (%)	n	20	20
	Mean	37.7	26.2
	SD	36.04	33.62
	Median	30.0	10.0
	Min.	0	0
	Max.	99	100
Overall work impairment due to health change from baseline (%)	n	18	19
	Mean	0.5	-23.3
	SD	31.40	39.44
	Median	0.0	-10.0
	Min.	-57	-100
	Max.	71	51
Activity impairment due to health (%)	n	43	42
	Mean	35.8	25.7
	SD	30.26	28.21
	Median	30.0	15.0
	Min.	0	0
	Max.	90	100
Activity impairment due to health change from baseline (%)	n	43	42
	Mean	-4.7	-17.9
	SD	22.50	29.26
	Median	0.0	-10.0
	Min.	-70	-80
	Max.	30	40

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 28

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Work time missed due to health (%)	n	22	23
	Mean	11.2	12.8
	SD	22.74	25.69
	Median	0.0	0.0
	Min.	0	0
	Max.	80	100
Work time missed due to health change from baseline (%)	n	20	21
	Mean	-4.4	-5.8
	SD	22.89	39.60
	Median	0.0	0.0
	Min.	-70	-100
	Max.	50	93
Impairment while working due to health (%)	n	22	22
	Mean	29.1	20.0
	SD	31.61	19.02
	Median	25.0	15.0
	Min.	0	0
	Max.	90	60
Impairment while working due to health change from baseline (%)	n	19	18
	Mean	-1.6	-19.4
	SD	19.79	23.13
	Median	0.0	-10.0
	Min.	-40	-70
	Max.	40	0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 28

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Overall work impairment due to health (%)	n	22	23
	Mean	32.4	30.3
	SD	35.13	27.39
	Median	25.0	20.0
	Min.	0	0
	Max.	98	100
Overall work impairment due to health change from baseline (%)	n	20	21
	Mean	-4.2	-20.6
	SD	23.02	38.93
	Median	0.0	-10.0
	Min.	-61	-100
	Max.	40	65
Activity impairment due to health (%)	n	43	43
	Mean	35.1	26.0
	SD	28.32	24.89
	Median	30.0	20.0
	Min.	0	0
	Max.	90	90
Activity impairment due to health change from baseline (%)	n	43	43
	Mean	-5.3	-17.2
	SD	20.86	29.87
	Median	0.0	-10.0
	Min.	-70	-80
	Max.	40	50

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 32

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Work time missed due to health (%)	n	21	20
	Mean	6.6	15.2
	SD	19.66	32.46
	Median	0.0	0.0
	Min.	0	0
	Max.	88	100
Work time missed due to health change from baseline (%)	n	18	19
	Mean	-7.5	2.4
	SD	19.75	37.93
	Median	0.0	0.0
	Min.	-70	-100
	Max.	12	93
Impairment while working due to health (%)	n	21	18
	Mean	29.0	18.3
	SD	27.55	19.48
	Median	30.0	10.0
	Min.	0	0
	Max.	90	60
Impairment while working due to health change from baseline (%)	n	17	16
	Mean	-2.4	-20.6
	SD	21.66	22.94
	Median	0.0	-10.0
	Min.	-50	-70
	Max.	40	0

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 3.4
Summary of Work Productivity and Activity Impairment

Visit: Week 32

		Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Overall work impairment due to health (%)	n	21	20
	Mean	30.8	30.9
	SD	29.30	32.00
	Median	30.0	20.0
	Min.	0	0
	Max.	99	100
Overall work impairment due to health change from baseline (%)	n	18	19
	Mean	-5.4	-17.0
	SD	25.46	39.63
	Median	0.0	-10.0
	Min.	-71	-100
	Max.	40	65
Activity impairment due to health (%)	n	41	42
	Mean	36.1	22.9
	SD	29.49	25.88
	Median	30.0	10.0
	Min.	0	0
	Max.	90	90
Activity impairment due to health change from baseline (%)	n	41	42
	Mean	-3.7	-19.0
	SD	24.98	27.66
	Median	0.0	-10.0
	Min.	-70	-80
	Max.	40	40

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.126
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Work Time Missed Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	26	23
LS Mean (SE)	18.53 (6.007)	18.50 (6.261)
LS Mean Change (SE)	0.55 (6.007)	0.52 (6.261)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.03
95% CI		(-17.47, 17.41)
p-value		0.997
Corrected Hedges g [3]		0.00
95% CI		(-0.56, 0.56)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.126
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Work Time Missed Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	25	23
LS Mean (SE)	17.60 (5.056)	11.72 (5.194)
LS Mean Change (SE)	-0.38 (5.056)	-6.26 (5.194)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.88
95% CI		(-20.50, 8.74)
p-value		0.421
Corrected Hedges g [3]		-0.23
95% CI		(-0.80, 0.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.126
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Work Time Missed Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	23	21
LS Mean (SE)	18.68 (7.168)	15.19 (7.353)
LS Mean Change (SE)	0.70 (7.168)	-2.79 (7.353)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.49
95% CI		(-24.27, 17.29)
p-value		0.736
Corrected Hedges g [3]		-0.10
95% CI		(-0.69, 0.49)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.126
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Work Time Missed Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	21	19
LS Mean (SE)	16.55 (6.319)	15.58 (6.538)
LS Mean Change (SE)	-1.43 (6.319)	-2.40 (6.538)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.97
95% CI		(-19.55, 17.61)
p-value		0.916
Corrected Hedges g [3]		-0.03
95% CI		(-0.65, 0.59)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.126
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Work Time Missed Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	19	19
LS Mean (SE)	24.77 (7.379)	18.60 (7.357)
LS Mean Change (SE)	6.79 (7.379)	0.62 (7.357)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-6.17
95% CI		(-27.48, 15.13)
p-value		0.558
Corrected Hedges g [3]		-0.19
95% CI		(-0.83, 0.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.126
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Work Time Missed Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	18	19
LS Mean (SE)	13.14 (7.715)	20.53 (7.443)
LS Mean Change (SE)	-4.84 (7.715)	2.56 (7.443)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		7.40
95% CI		(-14.90, 29.70)
p-value		0.498
Corrected Hedges g [3]		0.22
95% CI		(-0.42, 0.87)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.126
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Work Time Missed Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	20	21
LS Mean (SE)	15.10 (5.552)	13.68 (5.429)
LS Mean Change (SE)	-2.88 (5.552)	-4.30 (5.429)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.42
95% CI		(-17.30, 14.45)
p-value		0.856
Corrected Hedges g [3]		-0.06
95% CI		(-0.67, 0.56)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Population: Intent-to-Treat

Table 90.126
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Work Time Missed Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	18	19
LS Mean (SE)	12.65 (6.395)	20.32 (6.293)
LS Mean Change (SE)	-5.33 (6.395)	2.34 (6.293)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		7.67
95% CI		(-10.71, 26.05)
p-value		0.399
Corrected Hedges g [3]		0.28
95% CI		(-0.37, 0.92)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.133
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Impairment While Working Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	25	25
n [2]	22	19
LS Mean (SE)	30.62 (3.329)	18.31 (3.528)
LS Mean Change (SE)	-3.34 (3.329)	-15.64 (3.528)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-12.31
95% CI		(-22.27, -2.34)
p-value		0.017
Corrected Hedges g [3]		-0.78
95% CI		(-1.41, -0.14)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.133
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Impairment While Working Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	25	25
n [2]	23	20
LS Mean (SE)	26.89 (4.056)	24.19 (4.251)
LS Mean Change (SE)	-7.06 (4.056)	-9.76 (4.251)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-2.70
95% CI		(-14.81, 9.42)
p-value		0.655
Corrected Hedges g [3]		-0.14
95% CI		(-0.74, 0.46)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.133
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Impairment While Working Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	25	25
n [2]	19	18
LS Mean (SE)	31.87 (5.251)	27.28 (5.431)
LS Mean Change (SE)	-2.09 (5.251)	-6.67 (5.431)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.58
95% CI		(-20.16, 10.99)
p-value		0.553
Corrected Hedges g [3]		-0.20
95% CI		(-0.84, 0.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.133
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Impairment While Working Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	25	25
n [2]	18	17
LS Mean (SE)	29.64 (5.713)	21.10 (5.812)
LS Mean Change (SE)	-4.31 (5.713)	-12.86 (5.812)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.55
95% CI		(-25.37, 8.27)
p-value		0.309
Corrected Hedges g [3]		-0.35
95% CI		(-1.01, 0.32)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.133
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Impairment While Working Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	25	25
n [2]	16	16
LS Mean (SE)	31.45 (5.917)	24.50 (5.903)
LS Mean Change (SE)	-2.50 (5.917)	-9.45 (5.903)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-6.95
95% CI		(-24.34, 10.44)
p-value		0.420
Corrected Hedges g [3]		-0.29
95% CI		(-0.98, 0.41)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.133
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Impairment While Working Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	25	25
n [2]	17	16
LS Mean (SE)	35.49 (6.220)	23.23 (6.452)
LS Mean Change (SE)	1.54 (6.220)	-10.72 (6.452)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-12.26
95% CI		(-30.79, 6.28)
p-value		0.187
Corrected Hedges g [3]		-0.46
95% CI		(-1.16, 0.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.133
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Impairment While Working Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	25	25
n [2]	19	18
LS Mean (SE)	30.57 (4.449)	19.51 (4.606)
LS Mean Change (SE)	-3.39 (4.449)	-14.44 (4.606)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.05
95% CI		(-24.26, 2.15)
p-value		0.098
Corrected Hedges g [3]		-0.56
95% CI		(-1.21, 0.10)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.133
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Impairment While Working Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	25	25
n [2]	17	16
LS Mean (SE)	28.19 (4.616)	20.34 (4.698)
LS Mean Change (SE)	-5.76 (4.616)	-13.61 (4.698)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.86
95% CI		(-21.56, 5.85)
p-value		0.251
Corrected Hedges g [3]		-0.41
95% CI		(-1.09, 0.28)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.140
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Overall Work Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	26	23
LS Mean (SE)	40.50 (5.316)	31.10 (5.577)
LS Mean Change (SE)	-4.03 (5.316)	-13.44 (5.577)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-9.41
95% CI		(-24.95, 6.14)
p-value		0.230
Corrected Hedges g [3]		-0.34
95% CI		(-0.91, 0.22)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.140
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Overall Work Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	25	23
LS Mean (SE)	37.24 (5.607)	31.99 (5.776)
LS Mean Change (SE)	-7.29 (5.607)	-12.54 (5.776)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.24
95% CI		(-21.60, 11.12)
p-value		0.522
Corrected Hedges g [3]		-0.18
95% CI		(-0.75, 0.38)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.140
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Overall Work Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	23	21
LS Mean (SE)	41.83 (6.722)	41.37 (7.022)
LS Mean Change (SE)	-2.70 (6.722)	-3.17 (7.022)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.47
95% CI		(-20.24, 19.30)
p-value		0.962
Corrected Hedges g [3]		-0.01
95% CI		(-0.61, 0.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.140
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Overall Work Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	21	19
LS Mean (SE)	43.83 (6.945)	27.63 (7.218)
LS Mean Change (SE)	-0.70 (6.945)	-16.90 (7.218)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-16.20
95% CI		(-36.60, 4.19)
p-value		0.116
Corrected Hedges g [3]		-0.50
95% CI		(-1.13, 0.13)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.140
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Overall Work Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	19	19
LS Mean (SE)	47.80 (7.500)	36.10 (7.543)
LS Mean Change (SE)	3.27 (7.500)	-8.43 (7.543)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.70
95% CI		(-33.53, 10.13)
p-value		0.284
Corrected Hedges g [3]		-0.35
95% CI		(-0.99, 0.29)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.140
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Overall Work Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	18	19
LS Mean (SE)	43.49 (7.518)	31.89 (7.461)
LS Mean Change (SE)	-1.04 (7.518)	-12.64 (7.461)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.60
95% CI		(-33.26, 10.06)
p-value		0.285
Corrected Hedges g [3]		-0.35
95% CI		(-1.00, 0.30)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.140
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Overall Work Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	20	21
LS Mean (SE)	39.78 (6.190)	30.13 (6.204)
LS Mean Change (SE)	-4.75 (6.190)	-14.40 (6.204)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-9.64
95% CI		(-27.49, 8.20)
p-value		0.282
Corrected Hedges g [3]		-0.34
95% CI		(-0.95, 0.28)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.140
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Overall Work Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	29	28
n [2]	18	19
LS Mean (SE)	38.66 (6.743)	31.15 (6.659)
LS Mean Change (SE)	-5.87 (6.743)	-13.38 (6.659)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.51
95% CI		(-26.90, 11.89)
p-value		0.438
Corrected Hedges g [3]		-0.25
95% CI		(-0.90, 0.39)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.147
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Activity Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	51	51
LS Mean (SE)	37.87 (2.814)	29.40 (2.822)
LS Mean Change (SE)	-4.24 (2.814)	-12.71 (2.822)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.47
95% CI		(-16.42, -0.53)
p-value		0.037
Corrected Hedges g [3]		-0.42
95% CI		(-0.81, -0.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.147
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Activity Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	49	47
LS Mean (SE)	33.37 (3.232)	30.20 (3.299)
LS Mean Change (SE)	-8.74 (3.232)	-11.91 (3.299)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-3.17
95% CI		(-12.38, 6.04)
p-value		0.496
Corrected Hedges g [3]		-0.14
95% CI		(-0.54, 0.26)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.147
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Activity Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	46	45
LS Mean (SE)	37.83 (3.169)	33.14 (3.225)
LS Mean Change (SE)	-4.29 (3.169)	-8.97 (3.225)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-4.68
95% CI		(-13.71, 4.35)
p-value		0.306
Corrected Hedges g [3]		-0.22
95% CI		(-0.63, 0.20)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.147
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Activity Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	45	44
LS Mean (SE)	35.03 (2.953)	27.91 (2.997)
LS Mean Change (SE)	-7.08 (2.953)	-14.20 (2.997)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.12
95% CI		(-15.52, 1.28)
p-value		0.095
Corrected Hedges g [3]		-0.36
95% CI		(-0.77, 0.06)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.147
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Activity Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	46	42
LS Mean (SE)	40.02 (3.464)	30.45 (3.591)
LS Mean Change (SE)	-2.09 (3.464)	-11.66 (3.591)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-9.57
95% CI		(-19.52, 0.38)
p-value		0.059
Corrected Hedges g [3]		-0.41
95% CI		(-0.83, 0.02)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.147
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Activity Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	43	42
LS Mean (SE)	37.82 (3.411)	25.17 (3.447)
LS Mean Change (SE)	-4.29 (3.411)	-16.94 (3.447)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-12.65
95% CI		(-22.32, -2.97)
p-value		0.011
Corrected Hedges g [3]		-0.56
95% CI		(-0.99, -0.13)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.147
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Activity Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	43	43
LS Mean (SE)	37.04 (3.175)	24.96 (3.204)
LS Mean Change (SE)	-5.07 (3.175)	-17.15 (3.204)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-12.08
95% CI		(-21.09, -3.07)
p-value		0.009
Corrected Hedges g [3]		-0.57
95% CI		(-1.00, -0.14)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.147
Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI): Activity Impairment Due to Health (%)
(Mixed Model Repeated Measures)

Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n [1]	52	51
n [2]	41	42
LS Mean (SE)	38.50 (3.461)	21.91 (3.473)
LS Mean Change (SE)	-3.61 (3.461)	-20.20 (3.473)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-16.59
95% CI		(-26.39, -6.80)
p-value		0.001
Corrected Hedges g [3]		-0.74
95% CI		(-1.18, -0.29)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed using mixed model repeated measures with covariates of baseline, baseline OCS dose region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.3
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Age (Treatment Policy Estimand)

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Subjects with >=1 HES flare or who withdraw from study	2 (67%)	0
Subjects with >=1 HES flare	2 (67%)	0
Subjects with no HES flare who withdraw from study	0	0
Subjects with no HES flare who complete study	1 (33%)	1 (100%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		Non-estimable
Logistic regression [3]		
Odds ratio (95% CI)		Non-estimable
p-value		Non-estimable
Unadjusted odds ratio (95% CI) [4]		1.00 (<0.01,19.00)
Relative risk (95% CI) [5]		0.00 (0.00,4.24)
Risk difference (95% CI) [5]		-0.67 (-0.99,0.59)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Population: Intent-to-Treat

Table 90.3
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Age (Treatment Policy Estimand)

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Subjects with >=1 HES flare or who withdraw from study	23 (56%)	13 (27%)
Subjects with >=1 HES flare	21 (51%)	12 (24%)
Subjects with no HES flare who withdraw from study	2 (5%)	1 (2%)
Subjects with no HES flare who complete study	18 (44%)	36 (73%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.002
Logistic regression [3]		
Odds ratio (95% CI)		0.26 (0.11,0.65)
p-value		0.004
Unadjusted odds ratio (95% CI) [4]		0.29 (0.11,0.75)
Relative risk (95% CI) [5]		0.47 (0.25,0.85)
Risk difference (95% CI) [5]		-0.30 (-0.48,-0.07)
Fisher's Exact p-value (2-sided)		0.005

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Population: Intent-to-Treat

Table 90.3
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Age (Treatment Policy Estimand)

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Subjects with >=1 HES flare or who withdraw from study	5 (50%)	2 (50%)
Subjects with >=1 HES flare	5 (50%)	2 (50%)
Subjects with no HES flare who withdraw from study	0	0
Subjects with no HES flare who complete study	5 (50%)	2 (50%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.679
Logistic regression [3]		
Odds ratio (95% CI)		3.05 (0.05,205.71)
p-value		0.603
Unadjusted odds ratio (95% CI) [4]		1.00 (0.05,19.26)
Relative risk (95% CI) [5]		1.00 (0.17,3.18)
Risk difference (95% CI) [5]		0.00 (-0.55,0.55)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.4
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Gender (Treatment Policy Estimand)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Subjects with >=1 HES flare or who withdraw from study	17 (63%)	6 (20%)
Subjects with >=1 HES flare	16 (59%)	6 (20%)
Subjects with no HES flare who withdraw from study	1 (4%)	0
Subjects with no HES flare who complete study	10 (37%)	24 (80%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		<0.001
Logistic regression [3]		
Odds ratio (95% CI)		0.10 (0.02,0.41)
p-value		0.001
Unadjusted odds ratio (95% CI) [4]		0.15 (0.04,0.55)
Relative risk (95% CI) [5]		0.32 (0.09,0.69)
Risk difference (95% CI) [5]		-0.43 (-0.65,-0.16)
Fisher's Exact p-value (2-sided)		0.001

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score. statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.4
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Gender (Treatment Policy Estimand)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Subjects with >=1 HES flare or who withdraw from study	13 (48%)	9 (38%)
Subjects with >=1 HES flare	12 (44%)	8 (33%)
Subjects with no HES flare who withdraw from study	1 (4%)	1 (4%)
Subjects with no HES flare who complete study	14 (52%)	15 (63%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.484
Logistic regression [3]		
Odds ratio (95% CI)		0.64 (0.20,2.09)
p-value		0.461
Unadjusted odds ratio (95% CI) [4]		0.65 (0.18,2.27)
Relative risk (95% CI) [5]		0.78 (0.36,1.52)
Risk difference (95% CI) [5]		-0.11 (-0.38,0.17)
Fisher's Exact p-value (2-sided)		0.573

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score. statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.5
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Region (Treatment Policy Estimand)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Subjects with >=1 HES flare or who withdraw from study	18 (55%)	10 (32%)
Subjects with >=1 HES flare	16 (48%)	10 (32%)
Subjects with no HES flare who withdraw from study	2 (6%)	0
Subjects with no HES flare who complete study	15 (45%)	21 (68%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.116
Logistic regression [3]		
Odds ratio (95% CI)		0.40 (0.14,1.12)
p-value		0.080
Unadjusted odds ratio (95% CI) [4]		0.40 (0.13,1.23)
Relative risk (95% CI) [5]		0.59 (0.30,1.06)
Risk difference (95% CI) [5]		-0.22 (-0.46,0.03)
Fisher's Exact p-value (2-sided)		0.084

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent).
[3] Logistic regression analysis adjusted for baseline OCS dose.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Table 90.5
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Region (Treatment Policy Estimand)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Subjects with >=1 HES flare or who withdraw from study	12 (57%)	5 (22%)
Subjects with >=1 HES flare	12 (57%)	4 (17%)
Subjects with no HES flare who withdraw from study	0	1 (4%)
Subjects with no HES flare who complete study	9 (43%)	18 (78%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.007
Logistic regression [3]		
Odds ratio (95% CI)		0.10 (0.02,0.51)
p-value		0.006
Unadjusted odds ratio (95% CI) [4]		0.22 (0.04,0.91)
Relative risk (95% CI) [5]		0.38 (0.10,0.89)
Risk difference (95% CI) [5]		-0.35 (-0.61,-0.05)
Fisher's Exact p-value (2-sided)		0.029

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent).
[3] Logistic regression analysis adjusted for baseline OCS dose.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.6
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Duration of Disease (Treatment Policy Estimand)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Subjects with >=1 HES flare or who withdraw from study	16 (50%)	8 (36%)
Subjects with >=1 HES flare	15 (47%)	7 (32%)
Subjects with no HES flare who withdraw from study	1 (3%)	1 (5%)
Subjects with no HES flare who complete study	16 (50%)	14 (64%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.172
Logistic regression [3]		
Odds ratio (95% CI)		0.44 (0.13,1.46)
p-value		0.182
Unadjusted odds ratio (95% CI) [4]		0.58 (0.16,1.98)
Relative risk (95% CI) [5]		0.73 (0.34,1.37)
Risk difference (95% CI) [5]		-0.14 (-0.39,0.14)
Fisher's Exact p-value (2-sided)		0.407

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.6
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Duration of Disease (Treatment Policy Estimand)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Subjects with >=1 HES flare or who withdraw from study	14 (64%)	7 (22%)
Subjects with >=1 HES flare	13 (59%)	7 (22%)
Subjects with no HES flare who withdraw from study	1 (5%)	0
Subjects with no HES flare who complete study	8 (36%)	25 (78%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.004
Logistic regression [3]		
Odds ratio (95% CI)		0.15 (0.04,0.52)
p-value		0.003
Unadjusted odds ratio (95% CI) [4]		0.17 (0.04,0.62)
Relative risk (95% CI) [5]		0.34 (0.14,0.74)
Risk difference (95% CI) [5]		-0.42 (-0.64,-0.10)
Fisher's Exact p-value (2-sided)		0.004

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.7
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Baseline Blood Eosinophils (Treatment Policy Estimand)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Subjects with >=1 HES flare or who withdraw from study	16 (53%)	10 (38%)
Subjects with >=1 HES flare	16 (53%)	9 (35%)
Subjects with no HES flare who withdraw from study	0	1 (4%)
Subjects with no HES flare who complete study	14 (47%)	16 (62%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.192
Logistic regression [3]		
Odds ratio (95% CI)		0.37 (0.11,1.24)
p-value		0.107
Unadjusted odds ratio (95% CI) [4]		0.55 (0.16,1.80)
Relative risk (95% CI) [5]		0.72 (0.36,1.30)
Risk difference (95% CI) [5]		-0.15 (-0.40,0.12)
Fisher's Exact p-value (2-sided)		0.295

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Population: Intent-to-Treat

Table 90.7
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During the 32-Week Treatment Period by Baseline Blood Eosinophils (Treatment Policy Estimand)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Subjects with >=1 HES flare or who withdraw from study	14 (58%)	5 (18%)
Subjects with >=1 HES flare	12 (50%)	5 (18%)
Subjects with no HES flare who withdraw from study	2 (8%)	0
Subjects with no HES flare who complete study	10 (42%)	23 (82%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.007
Logistic regression [3]		
Odds ratio (95% CI)		0.14 (0.03,0.53)
p-value		0.004
Unadjusted odds ratio (95% CI) [4]		0.16 (0.04,0.63)
Relative risk (95% CI) [5]		0.31 (0.06,0.76)
Risk difference (95% CI) [5]		-0.40 (-0.63,-0.12)
Fisher's Exact p-value (2-sided)		0.004

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.19
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Age (Treatment Policy Estimand)

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Subjects with >=1 HES flare or who withdraw from study	2 (67%)	0
Subjects with >=1 HES flare	2 (67%)	0
Subjects with no HES flare who withdraw from study	0	0
Subjects with no HES flare who complete study	1 (33%)	1 (100%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		Non-estimable
Logistic regression [3]		
Odds ratio (95% CI)		Non-estimable
p-value		Non-estimable
Unadjusted odds ratio (95% CI) [4]		1.00 (<0.01,19.00)
Relative risk (95% CI) [5]		0.00 (0.00,4.24)
Risk difference (95% CI) [5]		-0.67 (-0.99,0.59)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Population: Intent-to-Treat

Table 90.19
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Age (Treatment Policy Estimand)

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Subjects with >=1 HES flare or who withdraw from study	15 (37%)	7 (14%)
Subjects with >=1 HES flare	13 (32%)	6 (12%)
Subjects with no HES flare who withdraw from study	2 (5%)	1 (2%)
Subjects with no HES flare who complete study	26 (63%)	42 (86%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.013
Logistic regression [3]		
Odds ratio (95% CI)		0.28 (0.10,0.79)
p-value		0.016
Unadjusted odds ratio (95% CI) [4]		0.29 (0.09,0.89)
Relative risk (95% CI) [5]		0.39 (0.14,0.90)
Risk difference (95% CI) [5]		-0.22 (-0.40,-0.03)
Fisher's Exact p-value (2-sided)		0.025

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.19
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Age (Treatment Policy Estimand)

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Subjects with >=1 HES flare or who withdraw from study	2 (20%)	2 (50%)
Subjects with >=1 HES flare	2 (20%)	1 (25%)
Subjects with no HES flare who withdraw from study	0	1 (25%)
Subjects with no HES flare who complete study	8 (80%)	2 (50%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.258
Logistic regression [3]		
Odds ratio (95% CI)		292.21 (0.02,>999.99)
p-value		0.244
Unadjusted odds ratio (95% CI) [4]		3.56 (0.16,85.59)
Relative risk (95% CI) [5]		2.50 (0.18,25.54)
Risk difference (95% CI) [5]		0.30 (-0.25,0.81)
Fisher's Exact p-value (2-sided)		0.520

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.20
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Gender (Treatment Policy Estimand)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Subjects with >=1 HES flare or who withdraw from study	9 (33%)	4 (13%)
Subjects with >=1 HES flare	8 (30%)	4 (13%)
Subjects with no HES flare who withdraw from study	1 (4%)	0
Subjects with no HES flare who complete study	18 (67%)	26 (87%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.096
Logistic regression [3]		
Odds ratio (95% CI)		0.27 (0.06,1.15)
p-value		0.077
Unadjusted odds ratio (95% CI) [4]		0.31 (0.06,1.34)
Relative risk (95% CI) [5]		0.40 (0.06,1.12)
Risk difference (95% CI) [5]		-0.20 (-0.42,0.02)
Fisher's Exact p-value (2-sided)		0.114

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.20
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Gender (Treatment Policy Estimand)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Subjects with >=1 HES flare or who withdraw from study	10 (37%)	5 (21%)
Subjects with >=1 HES flare	9 (33%)	3 (13%)
Subjects with no HES flare who withdraw from study	1 (4%)	2 (8%)
Subjects with no HES flare who complete study	17 (63%)	19 (79%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.362
Logistic regression [3]		
Odds ratio (95% CI)		0.51 (0.13,1.95)
p-value		0.328
Unadjusted odds ratio (95% CI) [4]		0.45 (0.10,1.82)
Relative risk (95% CI) [5]		0.56 (0.17,1.44)
Risk difference (95% CI) [5]		-0.16 (-0.41,0.10)
Fisher's Exact p-value (2-sided)		0.235

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.21
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Region (Treatment Policy Estimand)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Subjects with >=1 HES flare or who withdraw from study	12 (36%)	5 (16%)
Subjects with >=1 HES flare	10 (30%)	5 (16%)
Subjects with no HES flare who withdraw from study	2 (6%)	0
Subjects with no HES flare who complete study	21 (64%)	26 (84%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.095
Logistic regression [3]		
Odds ratio (95% CI)		0.34 (0.10,1.12)
p-value		0.075
Unadjusted odds ratio (95% CI) [4]		0.34 (0.08,1.25)
Relative risk (95% CI) [5]		0.44 (0.10,1.09)
Risk difference (95% CI) [5]		-0.20 (-0.41,0.02)
Fisher's Exact p-value (2-sided)		0.091

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent).
[3] Logistic regression analysis adjusted for baseline OCS dose.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.21
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Region (Treatment Policy Estimand)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Subjects with >=1 HES flare or who withdraw from study	7 (33%)	4 (17%)
Subjects with >=1 HES flare	7 (33%)	2 (9%)
Subjects with no HES flare who withdraw from study	0	2 (9%)
Subjects with no HES flare who complete study	14 (67%)	19 (83%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.161
Logistic regression [3]		
Odds ratio (95% CI)		0.31 (0.07,1.45)
p-value		0.137
Unadjusted odds ratio (95% CI) [4]		0.43 (0.08,2.09)
Relative risk (95% CI) [5]		0.52 (0.12,1.56)
Risk difference (95% CI) [5]		-0.16 (-0.42,0.11)
Fisher's Exact p-value (2-sided)		0.303

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent).
[3] Logistic regression analysis adjusted for baseline OCS dose.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.22
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Duration of Disease (Treatment Policy Estimand)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Subjects with >=1 HES flare or who withdraw from study	9 (28%)	4 (18%)
Subjects with >=1 HES flare	8 (25%)	2 (9%)
Subjects with no HES flare who withdraw from study	1 (3%)	2 (9%)
Subjects with no HES flare who complete study	23 (72%)	18 (82%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.273
Logistic regression [3]		
Odds ratio (95% CI)		0.40 (0.09,1.83)
p-value		0.240
Unadjusted odds ratio (95% CI) [4]		0.57 (0.11,2.49)
Relative risk (95% CI) [5]		0.65 (0.10,1.78)
Risk difference (95% CI) [5]		-0.10 (-0.32,0.16)
Fisher's Exact p-value (2-sided)		0.523

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.22
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Duration of Disease (Treatment Policy Estimand)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Subjects with >=1 HES flare or who withdraw from study	10 (45%)	5 (16%)
Subjects with >=1 HES flare	9 (41%)	5 (16%)
Subjects with no HES flare who withdraw from study	1 (5%)	0
Subjects with no HES flare who complete study	12 (55%)	27 (84%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.023
Logistic regression [3]		
Odds ratio (95% CI)		0.21 (0.06,0.77)
p-value		0.019
Unadjusted odds ratio (95% CI) [4]		0.23 (0.05,0.93)
Relative risk (95% CI) [5]		0.34 (0.10,0.88)
Risk difference (95% CI) [5]		-0.30 (-0.54,-0.03)
Fisher's Exact p-value (2-sided)		0.029

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.23
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Baseline Blood Eosinophils (Treatment Policy Estimand)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Subjects with >=1 HES flare or who withdraw from study	12 (40%)	6 (23%)
Subjects with >=1 HES flare	12 (40%)	4 (15%)
Subjects with no HES flare who withdraw from study	0	2 (8%)
Subjects with no HES flare who complete study	18 (60%)	20 (77%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.201
Logistic regression [3]		
Odds ratio (95% CI)		0.33 (0.09,1.20)
p-value		0.092
Unadjusted odds ratio (95% CI) [4]		0.46 (0.11,1.65)
Relative risk (95% CI) [5]		0.58 (0.20,1.30)
Risk difference (95% CI) [5]		-0.17 (-0.41,0.08)
Fisher's Exact p-value (2-sided)		0.253

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.23
Subgroup Analysis of Proportion of Subjects Who Experience a HES Flare
During Week 20 Through Week 32 by Baseline Blood Eosinophils (Treatment Policy Estimand)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Subjects with >=1 HES flare or who withdraw from study	7 (29%)	3 (11%)
Subjects with >=1 HES flare	5 (21%)	3 (11%)
Subjects with no HES flare who withdraw from study	2 (8%)	0
Subjects with no HES flare who complete study	17 (71%)	25 (89%)
Comparison Mepolizumab 300mg vs Placebo [1]		
CMH p-value [2]		0.098
Logistic regression [3]		
Odds ratio (95% CI)		0.22 (0.04,1.13)
p-value		0.070
Unadjusted odds ratio (95% CI) [4]		0.30 (0.04,1.54)
Relative risk (95% CI) [5]		0.37 (0.06,1.26)
Risk difference (95% CI) [5]		-0.18 (-0.42,0.04)
Fisher's Exact p-value (2-sided)		0.157

[1] Analysis compares the number of subjects who experience >=1 HES flare and/or withdraw from the study prematurely.
[2] Cochran-Mantel-Haenszel (CMH) test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[3] Logistic regression analysis adjusted for baseline OCS dose and region.
Note: Odds ratio and relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.
[4] Exact method.
[5] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.

PPD

Population: Intent-to-Treat

Table 90.11
Subgroup Analysis of Time to First HES Flare by Age

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
Flare by week 4		
Probability of a flare [1]	0.0%	0.0%
95% CI	(0.0, 0.0)	(0.0, 0.0)
Flare by week 8		
Probability of a flare [1]	33.3%	0.0%
95% CI	(5.5, 94.6)	(0.0, 0.0)
Flare by week 12		
Probability of a flare [1]	66.7%	0.0%
95% CI	(22.6, 99.1)	(0.0, 0.0)
Flare by week 16		
Probability of a flare [1]	66.7%	0.0%
95% CI	(22.6, 99.1)	(0.0, 0.0)
Flare by week 20		
Probability of a flare [1]	66.7%	0.0%
95% CI	(22.6, 99.1)	(0.0, 0.0)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.
PPD

Population: Intent-to-Treat

Table 90.11
Subgroup Analysis of Time to First HES Flare by Age

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 24		
Probability of a flare [1]	66.7%	0.0%
95% CI	(22.6, 99.1)	(0.0, 0.0)
Flare by week 28		
Probability of a flare [1]	66.7%	0.0%
95% CI	(22.6, 99.1)	(0.0, 0.0)
Flare by week 32		
Probability of a flare [1]	66.7%	0.0%
95% CI	(22.6, 99.1)	(0.0, 0.0)
n	3	1
HES flare	2 (67%)	0
Withdrawn - censored	0	0
Completed - censored	1 (33%)	1 (100%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		Non-estimable
Cox regression [2]		
Hazard ratio		Non-estimable
95% CI for hazard ratio		Non-estimable
Wald Chi-Square p-value		Non-estimable

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.
PPD

Population: Intent-to-Treat

Table 90.11
Subgroup Analysis of Time to First HES Flare by Age

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
Flare by week 4		
Probability of a flare [1]	4.9%	6.1%
95% CI	(1.2, 18.1)	(2.0, 17.8)
Flare by week 8		
Probability of a flare [1]	12.3%	6.1%
95% CI	(5.3, 27.0)	(2.0, 17.8)
Flare by week 12		
Probability of a flare [1]	19.8%	8.2%
95% CI	(10.4, 35.7)	(3.1, 20.3)
Flare by week 16		
Probability of a flare [1]	29.8%	12.2%
95% CI	(18.2, 46.5)	(5.7, 25.2)
Flare by week 20		
Probability of a flare [1]	37.3%	12.2%
95% CI	(24.4, 54.1)	(5.7, 25.2)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.11
Subgroup Analysis of Time to First HES Flare by Age

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 24		
Probability of a flare [1]	47.4%	14.3%
95% CI	(33.4, 63.7)	(7.1, 27.6)
Flare by week 28		
Probability of a flare [1]	49.9%	18.5%
95% CI	(35.7, 66.0)	(10.1, 32.5)
Flare by week 32		
Probability of a flare [1]	52.4%	24.9%
95% CI	(38.0, 68.3)	(14.9, 39.6)
n	41	49
HES flare	21 (51%)	12 (24%)
Withdrawn - censored	2 (5%)	1 (2%)
Completed - censored	18 (44%)	36 (73%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		0.002
Cox regression [2]		
Hazard ratio		0.32
95% CI for hazard ratio		(0.15, 0.66)
Wald Chi-Square p-value		0.002

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.
PPD

Population: Intent-to-Treat

Table 90.11
Subgroup Analysis of Time to First HES Flare by Age

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
Flare by week 4		
Probability of a flare [1]	20.0%	0.0%
95% CI	(5.4, 59.1)	(0.0, 0.0)
Flare by week 8		
Probability of a flare [1]	20.0%	25.0%
95% CI	(5.4, 59.1)	(3.9, 87.2)
Flare by week 12		
Probability of a flare [1]	40.0%	25.0%
95% CI	(17.3, 74.7)	(3.9, 87.2)
Flare by week 16		
Probability of a flare [1]	40.0%	25.0%
95% CI	(17.3, 74.7)	(3.9, 87.2)
Flare by week 20		
Probability of a flare [1]	50.0%	25.0%
95% CI	(24.7, 81.6)	(3.9, 87.2)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.11
Subgroup Analysis of Time to First HES Flare by Age

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 24		
Probability of a flare [1]	50.0%	25.0%
95% CI	(24.7, 81.6)	(3.9, 87.2)
Flare by week 28		
Probability of a flare [1]	50.0%	50.0%
95% CI	(24.7, 81.6)	(15.5, 94.2)
Flare by week 32		
Probability of a flare [1]	50.0%	50.0%
95% CI	(24.7, 81.6)	(15.5, 94.2)
n	10	4
HES flare	5 (50%)	2 (50%)
Withdrawn - censored	0	0
Completed - censored	5 (50%)	2 (50%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		0.929
Cox regression [2]		
Hazard ratio		1.74
95% CI for hazard ratio		(0.10, 29.97)
Wald Chi-Square p-value		0.703

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.
PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.12
Subgroup Analysis of Time to First HES Flare by Gender

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
Flare by week 4		
Probability of a flare [1]	11.1%	3.3%
95% CI	(3.7, 30.6)	(0.5, 21.4)
Flare by week 8		
Probability of a flare [1]	22.4%	3.3%
95% CI	(10.7, 43.2)	(0.5, 21.4)
Flare by week 12		
Probability of a flare [1]	37.9%	3.3%
95% CI	(22.5, 59.1)	(0.5, 21.4)
Flare by week 16		
Probability of a flare [1]	49.6%	6.7%
95% CI	(32.5, 69.7)	(1.7, 24.1)
Flare by week 20		
Probability of a flare [1]	57.3%	6.7%
95% CI	(39.6, 76.2)	(1.7, 24.1)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Population: Intent-to-Treat

Table 90.12
Subgroup Analysis of Time to First HES Flare by Gender

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 24		
Probability of a flare [1]	61.2%	10.0%
95% CI	(43.3, 79.3)	(3.3, 27.9)
Flare by week 28		
Probability of a flare [1]	61.2%	16.7%
95% CI	(43.3, 79.3)	(7.3, 35.5)
Flare by week 32		
Probability of a flare [1]	61.2%	20.3%
95% CI	(43.3, 79.3)	(9.7, 39.7)
n	27	30
HES flare	16 (59%)	6 (20%)
Withdrawn - censored	1 (4%)	0
Completed - censored	10 (37%)	24 (80%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		<0.001
Cox regression [2]		
Hazard ratio		0.13
95% CI for hazard ratio		(0.04, 0.40)
Wald Chi-Square p-value		<0.001

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Population: Intent-to-Treat

Table 90.12
Subgroup Analysis of Time to First HES Flare by Gender

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
Flare by week 4		
Probability of a flare [1]	3.7%	8.3%
95% CI	(0.5, 23.5)	(2.2, 29.4)
Flare by week 8		
Probability of a flare [1]	7.4%	12.5%
95% CI	(1.9, 26.5)	(4.2, 33.9)
Flare by week 12		
Probability of a flare [1]	14.8%	16.7%
95% CI	(5.8, 34.8)	(6.6, 38.5)
Flare by week 16		
Probability of a flare [1]	18.5%	20.8%
95% CI	(8.2, 38.9)	(9.2, 43.0)
Flare by week 20		
Probability of a flare [1]	25.9%	20.8%
95% CI	(13.3, 46.8)	(9.2, 43.0)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Table 90.12
Subgroup Analysis of Time to First HES Flare by Gender

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 24		
Probability of a flare [1]	37.0%	20.8%
95% CI	(21.9, 57.9)	(9.2, 43.0)
Flare by week 28		
Probability of a flare [1]	40.7%	25.2%
95% CI	(25.0, 61.4)	(12.2, 47.8)
Flare by week 32		
Probability of a flare [1]	44.4%	34.0%
95% CI	(28.2, 64.8)	(18.7, 56.7)
n	27	24
HES flare	12 (44%)	8 (33%)
Withdrawn - censored	1 (4%)	1 (4%)
Completed - censored	14 (52%)	15 (63%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		0.488
Cox regression [2]		
Hazard ratio		0.74
95% CI for hazard ratio		(0.29, 1.87)
Wald Chi-Square p-value		0.522

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.13
Subgroup Analysis of Time to First HES Flare by Region

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
Flare by week 4		
Probability of a flare [1]	6.1%	6.5%
95% CI	(1.6, 22.1)	(1.7, 23.4)
Flare by week 8		
Probability of a flare [1]	12.1%	6.5%
95% CI	(4.7, 29.1)	(1.7, 23.4)
Flare by week 12		
Probability of a flare [1]	21.5%	9.7%
95% CI	(10.9, 40.0)	(3.2, 27.1)
Flare by week 16		
Probability of a flare [1]	31.0%	16.1%
95% CI	(18.0, 49.9)	(7.1, 34.5)
Flare by week 20		
Probability of a flare [1]	40.4%	16.1%
95% CI	(25.8, 59.2)	(7.1, 34.5)
Flare by week 24		
Probability of a flare [1]	43.5%	19.4%
95% CI	(28.5, 62.2)	(9.2, 38.1)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent).
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.13
Subgroup Analysis of Time to First HES Flare by Region

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 28		
Probability of a flare [1]	46.6%	25.8%
95% CI	(31.3, 65.1)	(13.8, 45.0)
Flare by week 32		
Probability of a flare [1]	49.8%	32.3%
95% CI	(34.1, 67.9)	(18.8, 51.6)
n	33	31
HES flare	16 (48%)	10 (32%)
Withdrawn - censored	2 (6%)	0
Completed - censored	15 (45%)	21 (68%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		0.169
Cox regression [2]		
Hazard ratio		0.54
95% CI for hazard ratio		(0.24, 1.21)
Wald Chi-Square p-value		0.134

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent).
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.13
Subgroup Analysis of Time to First HES Flare by Region

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
Flare by week 4		
Probability of a flare [1]	9.5%	4.3%
95% CI	(2.5, 33.0)	(0.6, 27.1)
Flare by week 8		
Probability of a flare [1]	19.0%	8.7%
95% CI	(7.6, 43.1)	(2.2, 30.5)
Flare by week 12		
Probability of a flare [1]	33.3%	8.7%
95% CI	(17.5, 57.5)	(2.2, 30.5)
Flare by week 16		
Probability of a flare [1]	38.1%	8.7%
95% CI	(21.2, 61.9)	(2.2, 30.5)
Flare by week 20		
Probability of a flare [1]	42.9%	8.7%
95% CI	(25.1, 66.2)	(2.2, 30.5)
Flare by week 24		
Probability of a flare [1]	57.1%	8.7%
95% CI	(37.7, 78.1)	(2.2, 30.5)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent).
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.13
Subgroup Analysis of Time to First HES Flare by Region

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 28		
Probability of a flare [1]	57.1%	13.3%
95% CI	(37.7, 78.1)	(4.5, 35.7)
Flare by week 32		
Probability of a flare [1]	57.1%	18.4%
95% CI	(37.7, 78.1)	(7.3, 42.0)
n	21	23
HES flare	12 (57%)	4 (17%)
Withdrawn - censored	0	1 (4%)
Completed - censored	9 (43%)	18 (78%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		0.002
Cox regression [2]		
Hazard ratio		0.13
95% CI for hazard ratio		(0.04, 0.50)
Wald Chi-Square p-value		0.003

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent).
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.14
Subgroup Analysis of Time to First HES Flare by Duration of Disease

Duration of Disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
Flare by week 4		
Probability of a flare [1]	3.1%	13.6%
95% CI	(0.4, 20.2)	(4.6, 36.6)
Flare by week 8		
Probability of a flare [1]	12.6%	18.2%
95% CI	(4.9, 30.2)	(7.2, 41.5)
Flare by week 12		
Probability of a flare [1]	25.6%	22.7%
95% CI	(13.7, 44.7)	(10.2, 46.3)
Flare by week 16		
Probability of a flare [1]	32.0%	22.7%
95% CI	(18.7, 51.4)	(10.2, 46.3)
Flare by week 20		
Probability of a flare [1]	35.3%	22.7%
95% CI	(21.3, 54.6)	(10.2, 46.3)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.
PPD

Table 90.14
Subgroup Analysis of Time to First HES Flare by Duration of Disease

Duration of Disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 24		
Probability of a flare [1]	45.0%	22.7%
95% CI	(29.6, 63.8)	(10.2, 46.3)
Flare by week 28		
Probability of a flare [1]	45.0%	27.6%
95% CI	(29.6, 63.8)	(13.4, 51.4)
Flare by week 32		
Probability of a flare [1]	48.2%	32.4%
95% CI	(32.5, 66.8)	(16.9, 56.3)
n	32	22
HES flare	15 (47%)	7 (32%)
Withdrawn - censored	1 (3%)	1 (5%)
Completed - censored	16 (50%)	14 (64%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		0.130
Cox regression [2]		
Hazard ratio		0.50
95% CI for hazard ratio		(0.19, 1.30)
Wald Chi-Square p-value		0.156

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.14
Subgroup Analysis of Time to First HES Flare by Duration of Disease

Duration of Disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
Flare by week 4		
Probability of a flare [1]	13.6%	0.0%
95% CI	(4.6, 36.6)	(0.0, 0.0)
Flare by week 8		
Probability of a flare [1]	18.2%	0.0%
95% CI	(7.2, 41.5)	(0.0, 0.0)
Flare by week 12		
Probability of a flare [1]	27.3%	0.0%
95% CI	(13.3, 50.9)	(0.0, 0.0)
Flare by week 16		
Probability of a flare [1]	36.4%	6.3%
95% CI	(20.1, 59.7)	(1.6, 22.7)
Flare by week 20		
Probability of a flare [1]	50.0%	6.3%
95% CI	(31.6, 71.8)	(1.6, 22.7)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.
PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.14
Subgroup Analysis of Time to First HES Flare by Duration of Disease

Duration of Disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 24		
Probability of a flare [1]	54.5%	9.4%
95% CI	(35.7, 75.6)	(3.1, 26.3)
Flare by week 28		
Probability of a flare [1]	59.1%	15.6%
95% CI	(39.9, 79.1)	(6.8, 33.5)
Flare by week 32		
Probability of a flare [1]	59.1%	21.9%
95% CI	(39.9, 79.1)	(11.1, 40.5)
n	22	32
HES flare	13 (59%)	7 (22%)
Withdrawn - censored	1 (5%)	0
Completed - censored	8 (36%)	25 (78%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		0.003
Cox regression [2]		
Hazard ratio		0.23
95% CI for hazard ratio		(0.09, 0.60)
Wald Chi-Square p-value		0.002

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.15
Subgroup Analysis of Time to First HES Flare by Baseline Blood Eosinophils

Baseline Blood Eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
Flare by week 4		
Probability of a flare [1]	6.7%	3.8%
95% CI	(1.7, 24.1)	(0.6, 24.3)
Flare by week 8		
Probability of a flare [1]	13.3%	7.7%
95% CI	(5.2, 31.7)	(2.0, 27.4)
Flare by week 12		
Probability of a flare [1]	23.3%	11.5%
95% CI	(11.9, 42.8)	(3.9, 31.6)
Flare by week 16		
Probability of a flare [1]	33.3%	19.2%
95% CI	(19.5, 53.1)	(8.5, 40.2)
Flare by week 20		
Probability of a flare [1]	36.7%	19.2%
95% CI	(22.2, 56.4)	(8.5, 40.2)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.
PPD

Population: Intent-to-Treat

Table 90.15
Subgroup Analysis of Time to First HES Flare by Baseline Blood Eosinophils

Baseline Blood Eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 24		
Probability of a flare [1]	46.7%	19.2%
95% CI	(30.9, 65.7)	(8.5, 40.2)
Flare by week 28		
Probability of a flare [1]	50.0%	27.3%
95% CI	(33.9, 68.7)	(14.0, 48.9)
Flare by week 32		
Probability of a flare [1]	53.3%	35.4%
95% CI	(37.0, 71.6)	(20.2, 57.1)
n	30	26
HES flare	16 (53%)	9 (35%)
Withdrawn - censored	0	1 (4%)
Completed - censored	14 (47%)	16 (62%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		0.058
Cox regression [2]		
Hazard ratio		0.37
95% CI for hazard ratio		(0.16, 0.90)
Wald Chi-Square p-value		0.028

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Population: Intent-to-Treat

Table 90.15
Subgroup Analysis of Time to First HES Flare by Baseline Blood Eosinophils

Baseline Blood Eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
Flare by week 4		
Probability of a flare [1]	8.3%	7.1%
95% CI	(2.2, 29.4)	(1.8, 25.7)
Flare by week 8		
Probability of a flare [1]	16.9%	7.1%
95% CI	(6.7, 39.0)	(1.8, 25.7)
Flare by week 12		
Probability of a flare [1]	30.0%	7.1%
95% CI	(15.6, 52.9)	(1.8, 25.7)
Flare by week 16		
Probability of a flare [1]	34.4%	7.1%
95% CI	(18.9, 57.2)	(1.8, 25.7)
Flare by week 20		
Probability of a flare [1]	47.5%	7.1%
95% CI	(29.7, 69.2)	(1.8, 25.7)

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.15
Subgroup Analysis of Time to First HES Flare by Baseline Blood Eosinophils

Baseline Blood Eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Flare by week 24		
Probability of a flare [1]	51.9%	10.7%
95% CI	(33.6, 72.9)	(3.6, 29.6)
Flare by week 28		
Probability of a flare [1]	51.9%	14.3%
95% CI	(33.6, 72.9)	(5.6, 33.7)
Flare by week 32		
Probability of a flare [1]	51.9%	17.9%
95% CI	(33.6, 72.9)	(7.9, 37.7)
n	24	28
HES flare	12 (50%)	5 (18%)
Withdrawn - censored	2 (8%)	0
Completed - censored	10 (42%)	23 (82%)
Comparison Mepolizumab 300mg vs Placebo		
Stratified Log-Rank p-value [1]		0.020
Cox regression [2]		
Hazard ratio		0.27
95% CI for hazard ratio		(0.09, 0.77)
Wald Chi-Square p-value		0.015

Note: Subjects withdrawing from the study prematurely prior to reporting a HES flare are censored at the date of study withdrawal.
[1] Log-Rank test stratified by baseline OCS (0-<=20mg/day and >20mg/day prednisone or equivalent) and region.
[2] Cox proportional hazards regression analysis adjusted for baseline OCS dose and region.
Hazard ratio <1 indicates a lower risk of HES flare with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.26
Subgroup Analysis of Rate of HES Flares by Age

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	3	1
0	1 (33%)	1 (100%)
1	0	0
2	1 (33%)	0
3	1 (33%)	0
4	0	0
Adjusted mean rate/year [1]	Non-estimable	Non-estimable
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		Non-estimable
Negative binomial model [1]		
Rate ratio		Non-estimable
95% CI for rate ratio		Non-estimable
p-value		Non-estimable

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, region, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent) and region.

PPD

Table 90.26
Subgroup Analysis of Rate of HES Flares by Age

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	41	49
0	20 (49%)	37 (76%)
1	12 (29%)	10 (20%)
2	5 (12%)	2 (4%)
3	3 (7%)	0
4	1 (2%)	0
Adjusted mean rate/year [1]	1.38	0.45
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.003
Negative binomial model [1]		
Rate ratio		0.32
95% CI for rate ratio		(0.17,0.63)
p-value		<0.001

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, region, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent) and region.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.26
Subgroup Analysis of Rate of HES Flares by Age

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	10	4
0	5 (50%)	2 (50%)
1	3 (30%)	1 (25%)
2	1 (10%)	1 (25%)
3	1 (10%)	0
4	0	0
Adjusted mean rate/year [1]	0.93	2.02
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.879
Negative binomial model [1]		
Rate ratio		2.17
95% CI for rate ratio		(0.18,26.55)
p-value		0.545

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, region, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent) and region.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.27
Subgroup Analysis of Rate of HES Flares by Gender

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	27	30
0	11 (41%)	24 (80%)
1	7 (26%)	4 (13%)
2	5 (19%)	2 (7%)
3	3 (11%)	0
4	1 (4%)	0
Adjusted mean rate/year [1]	1.63	0.37
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.002
Negative binomial model [1]		
Rate ratio		0.23
95% CI for rate ratio		(0.10,0.53)
p-value		<0.001

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, region, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent) and region.

PPD

Table 90.27
Subgroup Analysis of Rate of HES Flares by Gender

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	27	24
0	15 (56%)	16 (67%)
1	8 (30%)	7 (29%)
2	2 (7%)	1 (4%)
3	2 (7%)	0
4	0	0
Adjusted mean rate/year [1]	0.85	0.66
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.385
Negative binomial model [1]		
Rate ratio		0.77
95% CI for rate ratio		(0.33,1.81)
p-value		0.549

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, region, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent) and region.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.28
Subgroup Analysis of Rate of HES Flares by Region

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	33	31
0	17 (52%)	21 (68%)
1	8 (24%)	8 (26%)
2	4 (12%)	2 (6%)
3	3 (9%)	0
4	1 (3%)	0
Adjusted mean rate/year [1]	1.44	0.62
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.131
Negative binomial model [1]		
Rate ratio		0.43
95% CI for rate ratio		(0.20,0.92)
p-value		0.029

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent)

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.28
Subgroup Analysis of Rate of HES Flares by Region

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	21	23
0	9 (43%)	19 (83%)
1	7 (33%)	3 (13%)
2	3 (14%)	1 (4%)
3	2 (10%)	0
4	0	0
Adjusted mean rate/year [1]	1.53	0.30
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.003
Negative binomial model [1]		
Rate ratio		0.19
95% CI for rate ratio		(0.06,0.59)
p-value		0.004

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent)

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.29
Subgroup Analysis of Rate of HES Flares by Duration of Disease

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	32	22
0	17 (53%)	15 (68%)
1	10 (31%)	6 (27%)
2	4 (13%)	1 (5%)
3	1 (3%)	0
4	0	0
Adjusted mean rate/year [1]	1.11	0.55
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.092
Negative binomial model [1]		
Rate ratio		0.50
95% CI for rate ratio		(0.21,1.18)
p-value		0.112

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, region, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent) and region.

PPD

Population: Intent-to-Treat

Table 90.29
Subgroup Analysis of Rate of HES Flares by Duration of Disease

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	22	32
0	9 (41%)	25 (78%)
1	5 (23%)	5 (16%)
2	3 (14%)	2 (6%)
3	4 (18%)	0
4	1 (5%)	0
Adjusted mean rate/year [1]	1.95	0.45
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.008
Negative binomial model [1]		
Rate ratio		0.23
95% CI for rate ratio		(0.10,0.54)
p-value		<0.001

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, region, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent) and region.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.30
Subgroup Analysis of Rate of HES Flares by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	30	26
0	14 (47%)	17 (65%)
1	8 (27%)	7 (27%)
2	5 (17%)	2 (8%)
3	3 (10%)	0
4	0	0
Adjusted mean rate/year [1]	1.48	0.61
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.049
Negative binomial model [1]		
Rate ratio		0.42
95% CI for rate ratio		(0.19,0.89)
p-value		0.023

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, region, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent) and region.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.30
Subgroup Analysis of Rate of HES Flares by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
All HES flare		
n	24	28
0	12 (50%)	23 (82%)
1	7 (29%)	4 (14%)
2	2 (8%)	1 (4%)
3	2 (8%)	0
4	1 (4%)	0
Adjusted mean rate/year [1]	1.40	0.32
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [2]		0.029
Negative binomial model [1]		
Rate ratio		0.23
95% CI for rate ratio		(0.08,0.65)
p-value		0.005

Note: For subjects withdrawing prematurely from the study during the 32-week treatment period, all data up to the time of study withdrawal is used to calculate the rate of HES flares.
[1] Negative binomial generalised linear model including baseline OCS dose, region, treatment and observed time (offset variable). Rate ratio <1 indicates a lower flare rate with Mepolizumab compared with Placebo.
[2] Wilcoxon test stratified by baseline OCS (0-<=20mg/day, >20mg/day prednisone or equivalent) and region.

PPD

Population: Intent-to-Treat

Table 90.50
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	2	1
n [2]	2	1
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Population: Intent-to-Treat

Table 90.50
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	37	45
n [2]	28	33
LS Mean (SE)	3.45 (0.323)	2.56 (0.294)
LS Mean Change (SE)	-0.33 (0.323)	-1.22 (0.294)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.89
95% CI		(-1.76, -0.02)
p-value		0.045
Corrected Hedges g [3]		-0.52
95% CI		(-1.03, 0.00)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.50
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	10	4
n [2]	6	2
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.51
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	27	27
n [2]	22	19
LS Mean (SE)	3.48 (0.421)	3.22 (0.432)
LS Mean Change (SE)	-0.79 (0.421)	-1.05 (0.432)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.26
95% CI		(-1.48, 0.96)
p-value		0.667
Corrected Hedges g [3]		-0.13
95% CI		(-0.75, 0.48)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Population: Intent-to-Treat

Table 90.51
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	22	23
n [2]	14	17
LS Mean (SE)	3.12 (0.369)	2.04 (0.347)
LS Mean Change (SE)	-0.43 (0.369)	-1.51 (0.347)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.08
95% CI		(-2.14, -0.02)
p-value		0.047
Corrected Hedges g [3]		-0.74
95% CI		(-1.47, -0.01)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.52
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	31	30
n [2]	23	25
LS Mean (SE)	3.01 (0.456)	2.66 (0.456)
LS Mean Change (SE)	-0.85 (0.363)	-1.58 (0.360)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.74
95% CI		(-1.76, 0.29)
p-value		0.155
Corrected Hedges g [3]		-0.41
95% CI		(-0.98, 0.16)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment and visit, plus interaction terms for visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Population: Intent-to-Treat

Table 90.52
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	18	20
n [2]	13	11
LS Mean (SE)	3.44 (0.710)	3.85 (0.693)
LS Mean Change (SE)	-0.58 (0.533)	-0.61 (0.528)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.04
95% CI		(-1.57, 1.50)
p-value		0.960
Corrected Hedges g [3]		-0.02
95% CI		(-0.82, 0.78)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment and visit, plus interaction terms for visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Population: Intent-to-Treat

Table 90.53
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32 by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	31	22
n [2]	22	15
LS Mean (SE)	3.11 (0.394)	3.13 (0.484)
LS Mean Change (SE)	-0.79 (0.394)	-0.77 (0.484)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.02
95% CI		(-1.24, 1.28)
p-value		0.975
Corrected Hedges g [3]		0.01
95% CI		(-0.65, 0.67)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Population: Intent-to-Treat

Table 90.53
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32 by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	18	28
n [2]	14	21
LS Mean (SE)	3.90 (0.450)	2.48 (0.364)
LS Mean Change (SE)	-0.09 (0.450)	-1.51 (0.364)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.42
95% CI		(-2.60, -0.23)
p-value		0.020
Corrected Hedges g [3]		-0.83
95% CI		(-1.53, -0.12)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

Protocol: 200622
Population: Intent-to-Treat

Table 90.54
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32
by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	28	26
n [2]	25	19
LS Mean (SE)	3.09 (0.493)	3.51 (0.527)
LS Mean Change (SE)	-0.73 (0.404)	-0.88 (0.439)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.15
95% CI		(-1.35, 1.05)
p-value		0.805
Corrected Hedges g [3]		-0.07
95% CI		(-0.67, 0.52)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment and visit, plus an interaction term for visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.54
Subgroup Analysis of Change from Baseline in Total BFI Score at Week 32
by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	21	24
n [2]	11	17
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment and visit, plus an interaction term for visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue/Does not interfere to 10 = As bad as you can imagine/Completely interferes.

PPD

Population: Intent-to-Treat

Table 90.33
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Age (Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	3	1
n [2]	3	1
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Table 90.33
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	41	49
n [2]	35	46
LS Mean (SE)	4.16 (0.337)	3.29 (0.297)
LS Mean Change (SE)	-0.16 (0.337)	-1.03 (0.297)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.87
95% CI		(-1.76, 0.02)
p-value		0.057
Corrected Hedges g [3]		-0.43
95% CI		(-0.87, 0.02)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.33
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Age (Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	10	4
n [2]	9	3
LS Mean (SE)	5.19 (0.780)	4.63 (1.465)
LS Mean Change (SE)	-0.04 (0.780)	-0.60 (1.465)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.56
95% CI		(-4.45, 3.32)
p-value		0.752
Corrected Hedges g [3]		-0.22
95% CI		(-1.53, 1.09)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.34
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	27	30
n [2]	25	28
LS Mean (SE)	4.46 (0.429)	3.72 (0.402)
LS Mean Change (SE)	-0.19 (0.429)	-0.93 (0.402)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.74
95% CI		(-1.94, 0.46)
p-value		0.219
Corrected Hedges g [3]		-0.34
95% CI		(-0.88, 0.20)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.34
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	27	24
n [2]	22	22
LS Mean (SE)	3.78 (0.404)	3.31 (0.413)
LS Mean Change (SE)	-0.56 (0.404)	-1.03 (0.413)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.47
95% CI		(-1.66, 0.72)
p-value		0.432
Corrected Hedges g [3]		-0.24
95% CI		(-0.83, 0.35)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.35
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	33	31
n [2]	29	29
LS Mean (SE)	4.17 (0.379)	3.52 (0.378)
LS Mean Change (SE)	-0.39 (0.379)	-1.05 (0.378)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.65
95% CI		(-1.73, 0.42)
p-value		0.231
Corrected Hedges g [3]		-0.32
95% CI		(-0.83, 0.20)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.35
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Region (Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	21	23
n [2]	18	21
LS Mean (SE)	4.28 (0.471)	3.32 (0.451)
LS Mean Change (SE)	-0.13 (0.471)	-1.08 (0.451)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.95
95% CI		(-2.28, 0.38)
p-value		0.155
Corrected Hedges g [3]		-0.46
95% CI		(-1.10, 0.18)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.36
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	32	22
n [2]	29	20
LS Mean (SE)	3.79 (0.360)	3.41 (0.440)
LS Mean Change (SE)	-0.55 (0.360)	-0.93 (0.440)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.38
95% CI		(-1.53, 0.77)
p-value		0.509
Corrected Hedges g [3]		-0.19
95% CI		(-0.76, 0.38)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.36
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	22	32
n [2]	18	30
LS Mean (SE)	4.77 (0.472)	3.55 (0.371)
LS Mean Change (SE)	0.10 (0.472)	-1.11 (0.371)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.22
95% CI		(-2.43, -0.01)
p-value		0.048
Corrected Hedges g [3]		-0.59
95% CI		(-1.19, 0.00)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.37
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Baseline Blood Eosinophils (Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	30	26
n [2]	29	24
LS Mean (SE)	4.14 (0.384)	3.71 (0.421)
LS Mean Change (SE)	-0.49 (0.384)	-0.91 (0.421)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.42
95% CI		(-1.58, 0.73)
p-value		0.463
Corrected Hedges g [3]		-0.20
95% CI		(-0.74, 0.34)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.37
Subgroup Analysis of Change from Baseline in Mean Daily Fatigue Severity - Worst Level of Fatigue in Past 24 Hours (BFI Item 3) at Week 32 by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	24	28
n [2]	18	26
LS Mean (SE)	4.44 (0.437)	3.19 (0.386)
LS Mean Change (SE)	0.07 (0.437)	-1.17 (0.386)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.24
95% CI		(-2.42, -0.06)
p-value		0.039
Corrected Hedges g [3]		-0.64
95% CI		(-1.25, -0.02)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = No fatigue to 10 = As bad as you can imagine.

Population: Intent-to-Treat

Table 90.41
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	3	1
n [2]	3	1
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.41
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	41	49
n [2]	35	46
LS Mean (SE)	3.33 (0.307)	2.61 (0.272)
LS Mean Change (SE)	-0.99 (0.307)	-1.71 (0.272)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.72
95% CI		(-1.53, 0.10)
p-value		0.084
Corrected Hedges g [3]		-0.39
95% CI		(-0.83, 0.06)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.41
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	10	4
n [2]	9	3
LS Mean (SE)	3.92 (0.588)	2.16 (1.071)
LS Mean Change (SE)	-0.52 (0.589)	-2.28 (1.071)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.76
95% CI		(-4.59, 1.07)
p-value		0.197
Corrected Hedges g [3]		-0.91
95% CI		(-2.27, 0.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.42
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	27	30
n [2]	25	28
LS Mean (SE)	3.83 (0.399)	2.86 (0.375)
LS Mean Change (SE)	-0.64 (0.399)	-1.61 (0.375)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.97
95% CI		(-2.08, 0.14)
p-value		0.086
Corrected Hedges g [3]		-0.48
95% CI		(-1.03, 0.07)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.42
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	27	24
n [2]	22	22
LS Mean (SE)	2.78 (0.334)	2.53 (0.341)
LS Mean Change (SE)	-1.48 (0.334)	-1.73 (0.341)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.25
95% CI		(-1.23, 0.73)
p-value		0.608
Corrected Hedges g [3]		-0.15
95% CI		(-0.75, 0.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.43
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	33	31
n [2]	29	29
LS Mean (SE)	3.20 (0.336)	2.62 (0.337)
LS Mean Change (SE)	-1.14 (0.336)	-1.72 (0.337)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.58
95% CI		(-1.53, 0.38)
p-value		0.231
Corrected Hedges g [3]		-0.31
95% CI		(-0.83, 0.20)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.43
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	21	23
n [2]	18	21
LS Mean (SE)	3.72 (0.423)	2.74 (0.407)
LS Mean Change (SE)	-0.70 (0.423)	-1.68 (0.407)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.98
95% CI		(-2.18, 0.22)
p-value		0.108
Corrected Hedges g [3]		-0.52
95% CI		(-1.16, 0.12)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.44
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	32	22
n [2]	29	20
LS Mean (SE)	3.09 (0.340)	3.03 (0.414)
LS Mean Change (SE)	-1.08 (0.340)	-1.14 (0.414)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.06
95% CI		(-1.15, 1.03)
p-value		0.914
Corrected Hedges g [3]		-0.03
95% CI		(-0.60, 0.54)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.44
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	22	32
n [2]	18	30
LS Mean (SE)	3.82 (0.402)	2.50 (0.314)
LS Mean Change (SE)	-0.76 (0.402)	-2.08 (0.314)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.32
95% CI		(-2.35, -0.29)
p-value		0.013
Corrected Hedges g [3]		-0.76
95% CI		(-1.36, -0.15)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.45
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	30	26
n [2]	29	24
LS Mean (SE)	3.24 (0.302)	3.08 (0.331)
LS Mean Change (SE)	-1.21 (0.302)	-1.37 (0.331)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.16
95% CI		(-1.07, 0.74)
p-value		0.722
Corrected Hedges g [3]		-0.10
95% CI		(-0.64, 0.44)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

PPD

Population: Intent-to-Treat

Table 90.45
Subgroup Analysis of Change from Baseline in Most Bothersome HES Symptom Severity Score (HES-DS) at Week 32 by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	24	28
n [2]	18	26
LS Mean (SE)	3.62 (0.431)	2.25 (0.381)
LS Mean Change (SE)	-0.67 (0.431)	-2.04 (0.381)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-1.37
95% CI		(-2.54, -0.21)
p-value		0.022
Corrected Hedges g [3]		-0.71
95% CI		(-1.33, -0.09)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = None to 10 = As bad as you can imagine.

Protocol: 200622
Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	1 (33%)	0
Mildly improved (3)	0	0
No change (4)	2 (67%)	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	0	1 (100%)
Median response	4.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	1 (33%)	0
Moderately improved (2)	1 (33%)	0
Mildly improved (3)	0	0
No change (4)	1 (33%)	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	0	1 (100%)
Median response	2.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	2 (67%)	0
Mildly improved (3)	0	0
No change (4)	0	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	2.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	0	0
Mildly improved (3)	1 (33%)	0
No change (4)	0	0
Mildly worse (5)	1 (33%)	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	5.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	0	0
Mildly improved (3)	2 (67%)	0
No change (4)	0	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	3.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	0	0
Mildly improved (3)	1 (33%)	0
No change (4)	1 (33%)	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	4.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	0	0
Mildly improved (3)	1 (33%)	0
No change (4)	0	0
Mildly worse (5)	1 (33%)	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	5.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	0	0
Mildly improved (3)	1 (33%)	0
No change (4)	1 (33%)	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	4.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	2 (5%)	9 (18%)
Moderately improved (2)	6 (15%)	8 (16%)
Mildly improved (3)	7 (17%)	10 (20%)
No change (4)	19 (46%)	17 (35%)
Mildly worse (5)	3 (7%)	1 (2%)
Moderately worse (6)	1 (2%)	2 (4%)
Significantly worse (7)	3 (7%)	2 (4%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.032
Logistic regression [2]		
Inverse odds ratio		0.43
95% CI for inverse odds ratio		(0.20,0.94)
p-value		0.034

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	4 (10%)	12 (24%)
Moderately improved (2)	5 (12%)	4 (8%)
Mildly improved (3)	9 (22%)	6 (12%)
No change (4)	15 (37%)	17 (35%)
Mildly worse (5)	2 (5%)	3 (6%)
Moderately worse (6)	2 (5%)	0
Significantly worse (7)	4 (10%)	7 (14%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.574
Logistic regression [2]		
Inverse odds ratio		0.80
95% CI for inverse odds ratio		(0.38,1.69)
p-value		0.561

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	5 (12%)	11 (22%)
Moderately improved (2)	7 (17%)	6 (12%)
Mildly improved (3)	5 (12%)	10 (20%)
No change (4)	12 (29%)	11 (22%)
Mildly worse (5)	4 (10%)	4 (8%)
Moderately worse (6)	2 (5%)	0
Significantly worse (7)	6 (15%)	7 (14%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.210
Logistic regression [2]		
Inverse odds ratio		0.67
95% CI for inverse odds ratio		(0.32,1.40)
p-value		0.282

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	5 (12%)	14 (29%)
Moderately improved (2)	3 (7%)	6 (12%)
Mildly improved (3)	7 (17%)	10 (20%)
No change (4)	13 (32%)	7 (14%)
Mildly worse (5)	3 (7%)	3 (6%)
Moderately worse (6)	3 (7%)	0
Significantly worse (7)	7 (17%)	9 (18%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.031
Logistic regression [2]		
Inverse odds ratio		0.45
95% CI for inverse odds ratio		(0.21,0.95)
p-value		0.037

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	5 (12%)	11 (22%)
Moderately improved (2)	3 (7%)	9 (18%)
Mildly improved (3)	5 (12%)	8 (16%)
No change (4)	13 (32%)	9 (18%)
Mildly worse (5)	5 (12%)	2 (4%)
Moderately worse (6)	1 (2%)	0
Significantly worse (7)	9 (22%)	10 (20%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.049
Logistic regression [2]		
Inverse odds ratio		0.48
95% CI for inverse odds ratio		(0.23,1.03)
p-value		0.059

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	3 (7%)	11 (22%)
Moderately improved (2)	7 (17%)	7 (14%)
Mildly improved (3)	5 (12%)	8 (16%)
No change (4)	11 (27%)	9 (18%)
Mildly worse (5)	4 (10%)	3 (6%)
Moderately worse (6)	2 (5%)	0
Significantly worse (7)	9 (22%)	11 (22%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.099
Logistic regression [2]		
Inverse odds ratio		0.60
95% CI for inverse odds ratio		(0.29,1.26)
p-value		0.178

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	6 (15%)	14 (29%)
Moderately improved (2)	3 (7%)	8 (16%)
Mildly improved (3)	5 (12%)	4 (8%)
No change (4)	14 (34%)	8 (16%)
Mildly worse (5)	3 (7%)	3 (6%)
Moderately worse (6)	1 (2%)	3 (6%)
Significantly worse (7)	9 (22%)	9 (18%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.134
Logistic regression [2]		
Inverse odds ratio		0.58
95% CI for inverse odds ratio		(0.27,1.22)
p-value		0.152

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	3 (7%)	16 (33%)
Moderately improved (2)	6 (15%)	3 (6%)
Mildly improved (3)	9 (22%)	7 (14%)
No change (4)	9 (22%)	6 (12%)
Mildly worse (5)	4 (10%)	3 (6%)
Moderately worse (6)	0	3 (6%)
Significantly worse (7)	10 (24%)	11 (22%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.163
Logistic regression [2]		
Inverse odds ratio		0.61
95% CI for inverse odds ratio		(0.29,1.28)
p-value		0.187

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	1 (25%)
Moderately improved (2)	1 (10%)	1 (25%)
Mildly improved (3)	1 (10%)	0
No change (4)	5 (50%)	1 (25%)
Mildly worse (5)	2 (20%)	0
Moderately worse (6)	1 (10%)	0
Significantly worse (7)	0	1 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.709
Logistic regression [2]		
Inverse odds ratio		2.43
95% CI for inverse odds ratio		(0.06,100.02)
p-value		0.640

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	1 (10%)	0
Moderately improved (2)	0	2 (50%)
Mildly improved (3)	1 (10%)	1 (25%)
No change (4)	4 (40%)	0
Mildly worse (5)	2 (20%)	0
Moderately worse (6)	1 (10%)	1 (25%)
Significantly worse (7)	1 (10%)	0
Median response	4.0	2.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.334
Logistic regression [2]		
Inverse odds ratio		0.16
95% CI for inverse odds ratio		(<0.01,6.51)
p-value		0.331

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	2 (50%)
Moderately improved (2)	0	0
Mildly improved (3)	1 (10%)	1 (25%)
No change (4)	5 (50%)	0
Mildly worse (5)	3 (30%)	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (10%)	1 (25%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.327
Logistic regression [2]		
Inverse odds ratio		0.08
95% CI for inverse odds ratio		(<0.01,4.18)
p-value		0.212

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	1 (25%)
Moderately improved (2)	1 (10%)	1 (25%)
Mildly improved (3)	3 (30%)	1 (25%)
No change (4)	2 (20%)	0
Mildly worse (5)	1 (10%)	0
Moderately worse (6)	1 (10%)	0
Significantly worse (7)	2 (20%)	1 (25%)
Median response	4.0	2.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.349
Logistic regression [2]		
Inverse odds ratio		0.45
95% CI for inverse odds ratio		(0.01,21.31)
p-value		0.683

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	1 (25%)
Moderately improved (2)	2 (20%)	1 (25%)
Mildly improved (3)	1 (10%)	0
No change (4)	3 (30%)	0
Mildly worse (5)	0	1 (25%)
Moderately worse (6)	1 (10%)	0
Significantly worse (7)	3 (30%)	1 (25%)
Median response	4.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.681
Logistic regression [2]		
Inverse odds ratio		4.31
95% CI for inverse odds ratio		(0.09,201.88)
p-value		0.456

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	2 (50%)
Moderately improved (2)	4 (40%)	0
Mildly improved (3)	0	0
No change (4)	2 (20%)	0
Mildly worse (5)	2 (20%)	1 (25%)
Moderately worse (6)	0	0
Significantly worse (7)	2 (20%)	1 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.827
Logistic regression [2]		
Inverse odds ratio		1.70
95% CI for inverse odds ratio		(0.04,66.72)
p-value		0.776

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	2 (20%)	2 (50%)
Moderately improved (2)	1 (10%)	0
Mildly improved (3)	2 (20%)	1 (25%)
No change (4)	3 (30%)	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	2 (20%)	1 (25%)
Median response	3.5	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.613
Logistic regression [2]		
Inverse odds ratio		0.48
95% CI for inverse odds ratio		(0.01,18.79)
p-value		0.696

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.57
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	2 (50%)
Moderately improved (2)	2 (20%)	0
Mildly improved (3)	1 (10%)	0
No change (4)	2 (20%)	1 (25%)
Mildly worse (5)	2 (20%)	0
Moderately worse (6)	0	0
Significantly worse (7)	3 (30%)	1 (25%)
Median response	4.5	2.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.386
Logistic regression [2]		
Inverse odds ratio		0.70
95% CI for inverse odds ratio		(0.02,27.31)
p-value		0.847

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	2 (7%)	7 (23%)
Moderately improved (2)	5 (19%)	5 (17%)
Mildly improved (3)	2 (7%)	5 (17%)
No change (4)	12 (44%)	8 (27%)
Mildly worse (5)	5 (19%)	0
Moderately worse (6)	1 (4%)	2 (7%)
Significantly worse (7)	0	3 (10%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.039
Logistic regression [2]		
Inverse odds ratio		0.39
95% CI for inverse odds ratio		(0.15,1.05)
p-value		0.062

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	4 (15%)	8 (27%)
Moderately improved (2)	1 (4%)	2 (7%)
Mildly improved (3)	2 (7%)	2 (7%)
No change (4)	11 (41%)	10 (33%)
Mildly worse (5)	4 (15%)	2 (7%)
Moderately worse (6)	3 (11%)	0
Significantly worse (7)	2 (7%)	6 (20%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.189
Logistic regression [2]		
Inverse odds ratio		0.52
95% CI for inverse odds ratio		(0.19,1.40)
p-value		0.196

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	2 (7%)	8 (27%)
Moderately improved (2)	5 (19%)	3 (10%)
Mildly improved (3)	3 (11%)	5 (17%)
No change (4)	11 (41%)	5 (17%)
Mildly worse (5)	3 (11%)	2 (7%)
Moderately worse (6)	0	0
Significantly worse (7)	3 (11%)	7 (23%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.122
Logistic regression [2]		
Inverse odds ratio		0.55
95% CI for inverse odds ratio		(0.21,1.45)
p-value		0.228

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	2 (7%)	7 (23%)
Moderately improved (2)	1 (4%)	5 (17%)
Mildly improved (3)	6 (22%)	6 (20%)
No change (4)	8 (30%)	2 (7%)
Mildly worse (5)	4 (15%)	3 (10%)
Moderately worse (6)	2 (7%)	0
Significantly worse (7)	4 (15%)	7 (23%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.029
Logistic regression [2]		
Inverse odds ratio		0.35
95% CI for inverse odds ratio		(0.13,0.94)
p-value		0.036

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	2 (7%)	5 (17%)
Moderately improved (2)	1 (4%)	4 (13%)
Mildly improved (3)	5 (19%)	7 (23%)
No change (4)	9 (33%)	5 (17%)
Mildly worse (5)	4 (15%)	1 (3%)
Moderately worse (6)	2 (7%)	0
Significantly worse (7)	4 (15%)	8 (27%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.073
Logistic regression [2]		
Inverse odds ratio		0.44
95% CI for inverse odds ratio		(0.17,1.16)
p-value		0.097

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	2 (7%)	6 (20%)
Moderately improved (2)	5 (19%)	4 (13%)
Mildly improved (3)	1 (4%)	5 (17%)
No change (4)	10 (37%)	4 (13%)
Mildly worse (5)	4 (15%)	3 (10%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	4 (15%)	8 (27%)
Median response	4.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.229
Logistic regression [2]		
Inverse odds ratio		0.67
95% CI for inverse odds ratio		(0.26,1.73)
p-value		0.404

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	5 (19%)	6 (20%)
Moderately improved (2)	0	6 (20%)
Mildly improved (3)	3 (11%)	2 (7%)
No change (4)	11 (41%)	5 (17%)
Mildly worse (5)	2 (7%)	2 (7%)
Moderately worse (6)	1 (4%)	2 (7%)
Significantly worse (7)	5 (19%)	7 (23%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.208
Logistic regression [2]		
Inverse odds ratio		0.53
95% CI for inverse odds ratio		(0.20,1.43)
p-value		0.210

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	2 (7%)	8 (27%)
Moderately improved (2)	3 (11%)	2 (7%)
Mildly improved (3)	5 (19%)	5 (17%)
No change (4)	7 (26%)	4 (13%)
Mildly worse (5)	4 (15%)	2 (7%)
Moderately worse (6)	0	2 (7%)
Significantly worse (7)	6 (22%)	7 (23%)
Median response	4.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.118
Logistic regression [2]		
Inverse odds ratio		0.44
95% CI for inverse odds ratio		(0.16,1.16)
p-value		0.097

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	0	3 (13%)
Moderately improved (2)	3 (11%)	4 (17%)
Mildly improved (3)	6 (22%)	5 (21%)
No change (4)	14 (52%)	10 (42%)
Mildly worse (5)	0	1 (4%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	3 (11%)	1 (4%)
Median response	4.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.282
Logistic regression [2]		
Inverse odds ratio		0.49
95% CI for inverse odds ratio		(0.17,1.43)
p-value		0.192

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	2 (7%)	4 (17%)
Moderately improved (2)	5 (19%)	4 (17%)
Mildly improved (3)	8 (30%)	5 (21%)
No change (4)	9 (33%)	7 (29%)
Mildly worse (5)	0	1 (4%)
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	3 (11%)	2 (8%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.757
Logistic regression [2]		
Inverse odds ratio		1.08
95% CI for inverse odds ratio		(0.39,2.96)
p-value		0.885

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	3 (11%)	5 (21%)
Moderately improved (2)	4 (15%)	3 (13%)
Mildly improved (3)	3 (11%)	6 (25%)
No change (4)	6 (22%)	6 (25%)
Mildly worse (5)	4 (15%)	2 (8%)
Moderately worse (6)	2 (7%)	0
Significantly worse (7)	5 (19%)	2 (8%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.368
Logistic regression [2]		
Inverse odds ratio		0.53
95% CI for inverse odds ratio		(0.19,1.47)
p-value		0.224

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	3 (11%)	8 (33%)
Moderately improved (2)	3 (11%)	2 (8%)
Mildly improved (3)	5 (19%)	5 (21%)
No change (4)	7 (26%)	5 (21%)
Mildly worse (5)	1 (4%)	0
Moderately worse (6)	2 (7%)	0
Significantly worse (7)	6 (22%)	4 (17%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.210
Logistic regression [2]		
Inverse odds ratio		0.44
95% CI for inverse odds ratio		(0.16,1.21)
p-value		0.110

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	3 (11%)	7 (29%)
Moderately improved (2)	4 (15%)	6 (25%)
Mildly improved (3)	3 (11%)	1 (4%)
No change (4)	7 (26%)	4 (17%)
Mildly worse (5)	1 (4%)	2 (8%)
Moderately worse (6)	0	0
Significantly worse (7)	9 (33%)	4 (17%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.238
Logistic regression [2]		
Inverse odds ratio		0.46
95% CI for inverse odds ratio		(0.17,1.28)
p-value		0.136

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	1 (4%)	7 (29%)
Moderately improved (2)	6 (22%)	3 (13%)
Mildly improved (3)	5 (19%)	3 (13%)
No change (4)	4 (15%)	5 (21%)
Mildly worse (5)	2 (7%)	1 (4%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	8 (30%)	5 (21%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.313
Logistic regression [2]		
Inverse odds ratio		0.54
95% CI for inverse odds ratio		(0.20,1.48)
p-value		0.230

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	3 (11%)	10 (42%)
Moderately improved (2)	4 (15%)	2 (8%)
Mildly improved (3)	5 (19%)	3 (13%)
No change (4)	6 (22%)	3 (13%)
Mildly worse (5)	2 (7%)	1 (4%)
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	7 (26%)	4 (17%)
Median response	4.0	2.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.250
Logistic regression [2]		
Inverse odds ratio		0.45
95% CI for inverse odds ratio		(0.16,1.26)
p-value		0.128

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.58
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	1 (4%)	10 (42%)
Moderately improved (2)	5 (19%)	1 (4%)
Mildly improved (3)	6 (22%)	2 (8%)
No change (4)	5 (19%)	3 (13%)
Mildly worse (5)	2 (7%)	1 (4%)
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	8 (30%)	6 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.195
Logistic regression [2]		
Inverse odds ratio		0.49
95% CI for inverse odds ratio		(0.18,1.35)
p-value		0.169

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	1 (3%)	6 (19%)
Moderately improved (2)	4 (12%)	5 (16%)
Mildly improved (3)	6 (18%)	5 (16%)
No change (4)	17 (52%)	13 (42%)
Mildly worse (5)	4 (12%)	1 (3%)
Moderately worse (6)	0	1 (3%)
Significantly worse (7)	1 (3%)	0
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.095
Logistic regression [2]		
Inverse odds ratio		0.42
95% CI for inverse odds ratio		(0.17,1.07)
p-value		0.071

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	5 (15%)	8 (26%)
Moderately improved (2)	2 (6%)	5 (16%)
Mildly improved (3)	6 (18%)	4 (13%)
No change (4)	14 (42%)	11 (35%)
Mildly worse (5)	1 (3%)	2 (6%)
Moderately worse (6)	2 (6%)	0
Significantly worse (7)	3 (9%)	1 (3%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.167
Logistic regression [2]		
Inverse odds ratio		0.49
95% CI for inverse odds ratio		(0.20,1.20)
p-value		0.117

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	5 (15%)	10 (32%)
Moderately improved (2)	7 (21%)	3 (10%)
Mildly improved (3)	3 (9%)	7 (23%)
No change (4)	9 (27%)	7 (23%)
Mildly worse (5)	2 (6%)	3 (10%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	6 (18%)	1 (3%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.139
Logistic regression [2]		
Inverse odds ratio		0.46
95% CI for inverse odds ratio		(0.19,1.12)
p-value		0.087

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	5 (15%)	11 (35%)
Moderately improved (2)	2 (6%)	2 (6%)
Mildly improved (3)	5 (15%)	10 (32%)
No change (4)	9 (27%)	5 (16%)
Mildly worse (5)	4 (12%)	1 (3%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	7 (21%)	2 (6%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.007
Logistic regression [2]		
Inverse odds ratio		0.25
95% CI for inverse odds ratio		(0.10,0.63)
p-value		0.003

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	4 (12%)	12 (39%)
Moderately improved (2)	3 (9%)	5 (16%)	
Mildly improved (3)	3 (9%)	5 (16%)
No change (4)	8 (24%)	6 (19%)
Mildly worse (5)	4 (12%)	2 (6%)
Moderately worse (6)	2 (6%)	0
Significantly worse (7)	9 (27%)	1 (3%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		<0.001
Logistic regression [2]		
Inverse odds ratio		0.17
95% CI for inverse odds ratio		(0.07,0.45)
p-value		<0.001

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	3 (9%)	11 (35%)
Moderately improved (2)	4 (12%)	3 (10%)
Mildly improved (3)	1 (3%)	6 (19%)
No change (4)	10 (30%)	8 (26%)
Mildly worse (5)	6 (18%)	2 (6%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	8 (24%)	1 (3%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		<0.001
Logistic regression [2]		
Inverse odds ratio		0.18
95% CI for inverse odds ratio		(0.07,0.46)
p-value		<0.001

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	6 (18%)	12 (39%)
Moderately improved (2)	1 (3%)	6 (19%)
Mildly improved (3)	4 (12%)	4 (13%)
No change (4)	12 (36%)	6 (19%)
Mildly worse (5)	1 (3%)	0
Moderately worse (6)	1 (3%)	2 (6%)
Significantly worse (7)	8 (24%)	1 (3%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.004
Logistic regression [2]		
Inverse odds ratio		0.24
95% CI for inverse odds ratio		(0.09,0.60)
p-value		0.002

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	3 (9%)	14 (45%)
Moderately improved (2)	4 (12%)	3 (10%)
Mildly improved (3)	4 (12%)	4 (13%)
No change (4)	9 (27%)	6 (19%)
Mildly worse (5)	4 (12%)	1 (3%)
Moderately worse (6)	0	1 (3%)
Significantly worse (7)	9 (27%)	2 (6%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.001
Logistic regression [2]		
Inverse odds ratio		0.20
95% CI for inverse odds ratio		(0.08,0.52)
p-value		<0.001

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	1 (5%)	4 (17%)
Moderately improved (2)	4 (19%)	4 (17%)
Mildly improved (3)	2 (10%)	5 (22%)
No change (4)	9 (43%)	5 (22%)
Mildly worse (5)	1 (5%)	0
Moderately worse (6)	2 (10%)	1 (4%)
Significantly worse (7)	2 (10%)	4 (17%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.151
Logistic regression [2]		
Inverse odds ratio		0.37
95% CI for inverse odds ratio		(0.12,1.12)
p-value		0.078

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	1 (5%)	4 (17%)
Moderately improved (2)	4 (19%)	1 (4%)
Mildly improved (3)	4 (19%)	3 (13%)
No change (4)	6 (29%)	6 (26%)
Mildly worse (5)	3 (14%)	1 (4%)
Moderately worse (6)	1 (5%)	1 (4%)
Significantly worse (7)	2 (10%)	7 (30%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.633
Logistic regression [2]		
Inverse odds ratio		1.05
95% CI for inverse odds ratio		(0.36,3.07)
p-value		0.928

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	0	3 (13%)
Moderately improved (2)	2 (10%)	3 (13%)
Mildly improved (3)	3 (14%)	4 (17%)
No change (4)	8 (38%)	4 (17%)
Mildly worse (5)	5 (24%)	1 (4%)
Moderately worse (6)	1 (5%)	0
Significantly worse (7)	2 (10%)	8 (35%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.458
Logistic regression [2]		
Inverse odds ratio		0.64
95% CI for inverse odds ratio		(0.22,1.89)
p-value		0.422

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	0	4 (17%)
Moderately improved (2)	2 (10%)	5 (22%)
Mildly improved (3)	6 (29%)	1 (4%)
No change (4)	6 (29%)	2 (9%)
Mildly worse (5)	1 (5%)	2 (9%)
Moderately worse (6)	3 (14%)	0
Significantly worse (7)	3 (14%)	9 (39%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.580
Logistic regression [2]		
Inverse odds ratio		0.69
95% CI for inverse odds ratio		(0.23,2.02)
p-value		0.497

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	1 (5%)	0
Moderately improved (2)	2 (10%)	5 (22%)
Mildly improved (3)	5 (24%)	3 (13%)
No change (4)	8 (38%)	3 (13%)
Mildly worse (5)	1 (5%)	1 (4%)
Moderately worse (6)	0	0
Significantly worse (7)	4 (19%)	11 (48%)
Median response	4.0	5.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.459
Logistic regression [2]		
Inverse odds ratio		1.69
95% CI for inverse odds ratio		(0.57,5.06)
p-value		0.345

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	0	2 (9%)
Moderately improved (2)	7 (33%)	4 (17%)
Mildly improved (3)	5 (24%)	2 (9%)
No change (4)	4 (19%)	1 (4%)
Mildly worse (5)	0	2 (9%)
Moderately worse (6)	1 (5%)	0
Significantly worse (7)	4 (19%)	12 (52%)
Median response	3.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.247
Logistic regression [2]		
Inverse odds ratio		2.34
95% CI for inverse odds ratio		(0.77,7.10)
p-value		0.133

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	2 (10%)	4 (17%)
Moderately improved (2)	3 (14%)	2 (9%)
Mildly improved (3)	4 (19%)	1 (4%)
No change (4)	5 (24%)	2 (9%)
Mildly worse (5)	3 (14%)	3 (13%)
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	4 (19%)	10 (43%)
Median response	4.0	5.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.337
Logistic regression [2]		
Inverse odds ratio		1.89
95% CI for inverse odds ratio		(0.64,5.60)
p-value		0.250

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.59
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	0	4 (17%)
Moderately improved (2)	4 (19%)	0
Mildly improved (3)	7 (33%)	3 (13%)
No change (4)	3 (14%)	1 (4%)
Mildly worse (5)	2 (10%)	2 (9%)
Moderately worse (6)	0	2 (9%)
Significantly worse (7)	5 (24%)	11 (48%)
Median response	3.0	6.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.263
Logistic regression [2]		
Inverse odds ratio		2.09
95% CI for inverse odds ratio		(0.70,6.30)
p-value		0.188

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	1 (3%)	5 (23%)
Moderately improved (2)	5 (16%)	3 (14%)
Mildly improved (3)	7 (22%)	3 (14%)
No change (4)	14 (44%)	7 (32%)
Mildly worse (5)	2 (6%)	1 (5%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	2 (6%)	3 (14%)
Median response	4.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.169
Logistic regression [2]		
Inverse odds ratio		0.56
95% CI for inverse odds ratio		(0.20,1.52)
p-value		0.252

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	6 (19%)	4 (18%)
Moderately improved (2)	1 (3%)	4 (18%)
Mildly improved (3)	9 (28%)	2 (9%)
No change (4)	7 (22%)	6 (27%)
Mildly worse (5)	3 (9%)	2 (9%)
Moderately worse (6)	2 (6%)	1 (5%)
Significantly worse (7)	4 (13%)	3 (14%)
Median response	3.5	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.760
Logistic regression [2]		
Inverse odds ratio		0.84
95% CI for inverse odds ratio		(0.31,2.25)
p-value		0.730

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	4 (13%)	5 (23%)
Moderately improved (2)	7 (22%)	3 (14%)
Mildly improved (3)	2 (6%)	3 (14%)
No change (4)	9 (28%)	5 (23%)
Mildly worse (5)	4 (13%)	3 (14%)
Moderately worse (6)	0	0
Significantly worse (7)	6 (19%)	3 (14%)
Median response	4.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.354
Logistic regression [2]		
Inverse odds ratio		0.67
95% CI for inverse odds ratio		(0.25,1.79)
p-value		0.421

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	5 (16%)	7 (32%)
Moderately improved (2)	2 (6%)	3 (14%)
Mildly improved (3)	7 (22%)	4 (18%)
No change (4)	5 (16%)	4 (18%)
Mildly worse (5)	4 (13%)	0
Moderately worse (6)	2 (6%)	0
Significantly worse (7)	7 (22%)	4 (18%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.091
Logistic regression [2]		
Inverse odds ratio		0.41
95% CI for inverse odds ratio		(0.15,1.13)
p-value		0.085

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	4 (13%)	6 (27%)
Moderately improved (2)	3 (9%)	4 (18%)
Mildly improved (3)	6 (19%)	3 (14%)
No change (4)	6 (19%)	4 (18%)
Mildly worse (5)	2 (6%)	1 (5%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	10 (31%)	4 (18%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.095
Logistic regression [2]		
Inverse odds ratio		0.42
95% CI for inverse odds ratio		(0.15,1.16)
p-value		0.093

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	3 (9%)	6 (27%)
Moderately improved (2)	10 (31%)	3 (14%)
Mildly improved (3)	3 (9%)	2 (9%)
No change (4)	5 (16%)	5 (23%)
Mildly worse (5)	4 (13%)	1 (5%)
Moderately worse (6)	0	0
Significantly worse (7)	7 (22%)	5 (23%)
Median response	3.5	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.321
Logistic regression [2]		
Inverse odds ratio		0.77
95% CI for inverse odds ratio		(0.28,2.06)
p-value		0.595

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	8 (25%)	7 (32%)
Moderately improved (2)	3 (9%)	4 (18%)
Mildly improved (3)	7 (22%)	1 (5%)
No change (4)	3 (9%)	5 (23%)
Mildly worse (5)	3 (9%)	1 (5%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	7 (22%)	4 (18%)
Median response	3.0	2.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.491
Logistic regression [2]		
Inverse odds ratio		0.77
95% CI for inverse odds ratio		(0.28,2.07)
p-value		0.599

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	3 (9%)	6 (27%)
Moderately improved (2)	7 (22%)	3 (14%)
Mildly improved (3)	6 (19%)	3 (14%)
No change (4)	5 (16%)	4 (18%)
Mildly worse (5)	3 (9%)	1 (5%)
Moderately worse (6)	0	0
Significantly worse (7)	8 (25%)	5 (23%)
Median response	3.5	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.315
Logistic regression [2]		
Inverse odds ratio		0.66
95% CI for inverse odds ratio		(0.25,1.79)
p-value		0.416

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	1 (5%)	5 (16%)
Moderately improved (2)	3 (14%)	6 (19%)
Mildly improved (3)	1 (5%)	7 (22%)
No change (4)	12 (55%)	11 (34%)
Mildly worse (5)	3 (14%)	0
Moderately worse (6)	1 (5%)	2 (6%)
Significantly worse (7)	1 (5%)	1 (3%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.047
Logistic regression [2]		
Inverse odds ratio		0.32
95% CI for inverse odds ratio		(0.11,0.91)
p-value		0.033

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	8 (25%)
Moderately improved (2)	5 (23%)	2 (6%)
Mildly improved (3)	1 (5%)	5 (16%)
No change (4)	13 (59%)	11 (34%)
Mildly worse (5)	1 (5%)	1 (3%)
Moderately worse (6)	1 (5%)	0
Significantly worse (7)	1 (5%)	5 (16%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.317
Logistic regression [2]		
Inverse odds ratio		0.62
95% CI for inverse odds ratio		(0.23,1.69)
p-value		0.349

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	1 (5%)	8 (25%)
Moderately improved (2)	2 (9%)	3 (9%)
Mildly improved (3)	4 (18%)	8 (25%)
No change (4)	8 (36%)	6 (19%)
Mildly worse (5)	3 (14%)	1 (3%)
Moderately worse (6)	2 (9%)	0
Significantly worse (7)	2 (9%)	6 (19%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.200
Logistic regression [2]		
Inverse odds ratio		0.48
95% CI for inverse odds ratio		(0.18,1.30)
p-value		0.152

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	8 (25%)
Moderately improved (2)	2 (9%)	4 (13%)
Mildly improved (3)	4 (18%)	7 (22%)
No change (4)	10 (45%)	3 (9%)
Mildly worse (5)	1 (5%)	3 (9%)
Moderately worse (6)	2 (9%)	0
Significantly worse (7)	3 (14%)	7 (22%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.056
Logistic regression [2]		
Inverse odds ratio		0.41
95% CI for inverse odds ratio		(0.15,1.10)
p-value		0.078

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	1 (5%)	6 (19%)
Moderately improved (2)	2 (9%)	6 (19%)
Mildly improved (3)	2 (9%)	5 (16%)
No change (4)	10 (45%)	5 (16%)
Mildly worse (5)	3 (14%)	2 (6%)
Moderately worse (6)	1 (5%)	0
Significantly worse (7)	3 (14%)	8 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.169
Logistic regression [2]		
Inverse odds ratio		0.53
95% CI for inverse odds ratio		(0.20,1.41)
p-value		0.205

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	7 (22%)
Moderately improved (2)	1 (5%)	4 (13%)
Mildly improved (3)	3 (14%)	6 (19%)
No change (4)	9 (41%)	4 (13%)
Mildly worse (5)	2 (9%)	3 (9%)
Moderately worse (6)	2 (9%)	0
Significantly worse (7)	5 (23%)	8 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.080
Logistic regression [2]		
Inverse odds ratio		0.41
95% CI for inverse odds ratio		(0.15,1.11)
p-value		0.081

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	9 (28%)
Moderately improved (2)	1 (5%)	4 (13%)
Mildly improved (3)	1 (5%)	4 (13%)
No change (4)	14 (64%)	3 (9%)
Mildly worse (5)	1 (5%)	2 (6%)
Moderately worse (6)	0	3 (9%)
Significantly worse (7)	5 (23%)	7 (22%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.066
Logistic regression [2]		
Inverse odds ratio		0.38
95% CI for inverse odds ratio		(0.14,1.04)
p-value		0.059

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.60
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	12 (38%)
Moderately improved (2)	1 (5%)	0
Mildly improved (3)	5 (23%)	4 (13%)
No change (4)	7 (32%)	3 (9%)
Mildly worse (5)	3 (14%)	2 (6%)
Moderately worse (6)	0	3 (9%)
Significantly worse (7)	6 (27%)	8 (25%)
Median response	4.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.110
Logistic regression [2]		
Inverse odds ratio		0.44
95% CI for inverse odds ratio		(0.16,1.19)
p-value		0.107

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	0	4 (15%)
Moderately improved (2)	4 (13%)	2 (8%)
Mildly improved (3)	3 (10%)	5 (19%)
No change (4)	15 (50%)	10 (38%)
Mildly worse (5)	4 (13%)	1 (4%)
Moderately worse (6)	2 (7%)	1 (4%)
Significantly worse (7)	2 (7%)	3 (12%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.123
Logistic regression [2]		
Inverse odds ratio		0.41
95% CI for inverse odds ratio		(0.15,1.12)
p-value		0.083

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	2 (7%)	3 (12%)
Moderately improved (2)	3 (10%)	2 (8%)
Mildly improved (3)	7 (23%)	5 (19%)
No change (4)	13 (43%)	9 (35%)
Mildly worse (5)	2 (7%)	1 (4%)
Moderately worse (6)	1 (3%)	1 (4%)
Significantly worse (7)	2 (7%)	5 (19%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.829
Logistic regression [2]		
Inverse odds ratio		1.11
95% CI for inverse odds ratio		(0.43,2.92)
p-value		0.826

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	2 (7%)	3 (12%)
Moderately improved (2)	4 (13%)	2 (8%)
Mildly improved (3)	5 (17%)	8 (31%)
No change (4)	13 (43%)	4 (15%)
Mildly worse (5)	2 (7%)	4 (15%)
Moderately worse (6)	2 (7%)	0
Significantly worse (7)	2 (7%)	5 (19%)
Median response	4.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.951
Logistic regression [2]		
Inverse odds ratio		0.89
95% CI for inverse odds ratio		(0.34,2.30)
p-value		0.807

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	1 (3%)	4 (15%)
Moderately improved (2)	2 (7%)	3 (12%)
Mildly improved (3)	7 (23%)	8 (31%)
No change (4)	14 (47%)	4 (15%)
Mildly worse (5)	3 (10%)	1 (4%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	2 (7%)	6 (23%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.184
Logistic regression [2]		
Inverse odds ratio		0.46
95% CI for inverse odds ratio		(0.17,1.22)
p-value		0.117

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	2 (7%)	5 (19%)
Moderately improved (2)	3 (10%)	2 (8%)
Mildly improved (3)	4 (13%)	5 (19%)
No change (4)	14 (47%)	6 (23%)
Mildly worse (5)	3 (10%)	2 (8%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	3 (10%)	6 (23%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.615
Logistic regression [2]		
Inverse odds ratio		0.80
95% CI for inverse odds ratio		(0.31,2.10)
p-value		0.656

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	1 (3%)	4 (15%)
Moderately improved (2)	6 (20%)	3 (12%)
Mildly improved (3)	4 (13%)	5 (19%)
No change (4)	10 (33%)	5 (19%)
Mildly worse (5)	5 (17%)	2 (8%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	3 (10%)	7 (27%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.637
Logistic regression [2]		
Inverse odds ratio		0.89
95% CI for inverse odds ratio		(0.34,2.29)
p-value		0.802

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	4 (13%)	5 (19%)
Moderately improved (2)	2 (7%)	5 (19%)
Mildly improved (3)	6 (20%)	2 (8%)
No change (4)	12 (40%)	6 (23%)
Mildly worse (5)	2 (7%)	2 (8%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	3 (10%)	6 (23%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.882
Logistic regression [2]		
Inverse odds ratio		0.91
95% CI for inverse odds ratio		(0.35,2.38)
p-value		0.848

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	1 (3%)	5 (19%)
Moderately improved (2)	4 (13%)	2 (8%)
Mildly improved (3)	10 (33%)	3 (12%)
No change (4)	8 (27%)	5 (19%)
Mildly worse (5)	3 (10%)	2 (8%)
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	4 (13%)	8 (31%)
Median response	3.5	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.561
Logistic regression [2]		
Inverse odds ratio		1.35
95% CI for inverse odds ratio		(0.52,3.48)
p-value		0.537

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	2 (8%)	6 (21%)
Moderately improved (2)	4 (17%)	7 (25%)
Mildly improved (3)	5 (21%)	5 (18%)
No change (4)	11 (46%)	8 (29%)
Mildly worse (5)	1 (4%)	0
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	1 (4%)	1 (4%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.094
Logistic regression [2]		
Inverse odds ratio		0.45
95% CI for inverse odds ratio		(0.16,1.25)
p-value		0.127

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	4 (17%)	9 (32%)
Moderately improved (2)	3 (13%)	4 (14%)
Mildly improved (3)	3 (13%)	2 (7%)
No change (4)	7 (29%)	8 (29%)
Mildly worse (5)	2 (8%)	2 (7%)
Moderately worse (6)	2 (8%)	0
Significantly worse (7)	3 (13%)	3 (11%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.282
Logistic regression [2]		
Inverse odds ratio		0.55
95% CI for inverse odds ratio		(0.20,1.47)
p-value		0.231

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	3 (13%)	10 (36%)
Moderately improved (2)	5 (21%)	4 (14%)
Mildly improved (3)	1 (4%)	3 (11%)
No change (4)	4 (17%)	7 (25%)
Mildly worse (5)	5 (21%)	0
Moderately worse (6)	0	0
Significantly worse (7)	6 (25%)	4 (14%)
Median response	4.0	2.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.090
Logistic regression [2]		
Inverse odds ratio		0.36
95% CI for inverse odds ratio		(0.13,1.00)
p-value		0.049

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	4 (17%)	11 (39%)
Moderately improved (2)	2 (8%)	4 (14%)
Mildly improved (3)	4 (17%)	3 (11%)
No change (4)	1 (4%)	3 (11%)
Mildly worse (5)	2 (8%)	2 (7%)
Moderately worse (6)	3 (13%)	0
Significantly worse (7)	8 (33%)	5 (18%)
Median response	5.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.070
Logistic regression [2]		
Inverse odds ratio		0.34
95% CI for inverse odds ratio		(0.12,0.93)
p-value		0.036

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	3 (13%)	7 (25%)
Moderately improved (2)	2 (8%)	8 (29%)
Mildly improved (3)	4 (17%)	3 (11%)
No change (4)	2 (8%)	3 (11%)
Mildly worse (5)	2 (8%)	1 (4%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	10 (42%)	6 (21%)
Median response	5.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.042
Logistic regression [2]		
Inverse odds ratio		0.32
95% CI for inverse odds ratio		(0.11,0.89)
p-value		0.029

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	2 (8%)	9 (32%)
Moderately improved (2)	5 (21%)	4 (14%)
Mildly improved (3)	2 (8%)	3 (11%)
No change (4)	4 (17%)	4 (14%)
Mildly worse (5)	1 (4%)	2 (7%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	9 (38%)	6 (21%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.088
Logistic regression [2]		
Inverse odds ratio		0.40
95% CI for inverse odds ratio		(0.15,1.09)
p-value		0.073

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	4 (17%)	11 (39%)
Moderately improved (2)	2 (8%)	3 (11%)
Mildly improved (3)	2 (8%)	3 (11%)
No change (4)	5 (21%)	2 (7%)
Mildly worse (5)	2 (8%)	1 (4%)
Moderately worse (6)	0	3 (11%)
Significantly worse (7)	9 (38%)	5 (18%)
Median response	4.0	2.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.061
Logistic regression [2]		
Inverse odds ratio		0.37
95% CI for inverse odds ratio		(0.13,1.02)
p-value		0.054

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.61
Subgroup Analysis of Clinician-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	2 (8%)	13 (46%)
Moderately improved (2)	4 (17%)	1 (4%)
Mildly improved (3)	1 (4%)	4 (14%)
No change (4)	4 (17%)	2 (7%)
Mildly worse (5)	3 (13%)	1 (4%)
Moderately worse (6)	0	2 (7%)
Significantly worse (7)	10 (42%)	5 (18%)
Median response	5.0	2.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.004
Logistic regression [2]		
Inverse odds ratio		0.21
95% CI for inverse odds ratio		(0.07,0.62)
p-value		0.005

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	2 (67%)	0
Mildly improved (3)	1 (33%)	0
No change (4)	0	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	0	1 (100%)
Median response	2.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	1 (33%)	0
Moderately improved (2)	1 (33%)	0
Mildly improved (3)	1 (33%)	0
No change (4)	0	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	0	1 (100%)
Median response	2.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	1 (33%)	0
Moderately improved (2)	1 (33%)	0
Mildly improved (3)	0	0
No change (4)	0	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	2.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	1 (33%)	0
Mildly improved (3)	0	0
No change (4)	1 (33%)	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	4.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	1 (33%)	0
Mildly improved (3)	1 (33%)	0
No change (4)	0	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	3.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	1 (33%)	0
Mildly improved (3)	1 (33%)	0
No change (4)	0	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	3.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	0	0
Mildly improved (3)	1 (33%)	0
No change (4)	1 (33%)	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	4.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 12-<18 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Significantly improved (1)	0	0
Moderately improved (2)	1 (33%)	0
Mildly improved (3)	1 (33%)	0
No change (4)	0	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	1 (33%)	1 (100%)
Median response	3.0	7.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	2 (5%)	12 (24%)
Moderately improved (2)	6 (15%)	4 (8%)
Mildly improved (3)	13 (32%)	9 (18%)
No change (4)	14 (34%)	17 (35%)
Mildly worse (5)	0	4 (8%)
Moderately worse (6)	1 (2%)	1 (2%)
Significantly worse (7)	5 (12%)	2 (4%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.204
Logistic regression [2]		
Inverse odds ratio		0.67
95% CI for inverse odds ratio		(0.32,1.41)
p-value		0.288

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	5 (12%)	13 (27%)
Moderately improved (2)	7 (17%)	6 (12%)
Mildly improved (3)	6 (15%)	7 (14%)
No change (4)	16 (39%)	15 (31%)
Mildly worse (5)	2 (5%)	1 (2%)
Moderately worse (6)	1 (2%)	0
Significantly worse (7)	4 (10%)	7 (14%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.276
Logistic regression [2]		
Inverse odds ratio		0.68
95% CI for inverse odds ratio		(0.32,1.44)
p-value		0.318

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	5 (12%)	12 (24%)
Moderately improved (2)	3 (7%)	7 (14%)
Mildly improved (3)	10 (24%)	7 (14%)
No change (4)	13 (32%)	13 (27%)
Mildly worse (5)	3 (7%)	1 (2%)
Moderately worse (6)	1 (2%)	1 (2%)
Significantly worse (7)	6 (15%)	8 (16%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.120
Logistic regression [2]		
Inverse odds ratio		0.62
95% CI for inverse odds ratio		(0.29,1.30)
p-value		0.202

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	5 (12%)	12 (24%)
Moderately improved (2)	9 (22%)	4 (8%)
Mildly improved (3)	4 (10%)	14 (29%)
No change (4)	15 (37%)	9 (18%)
Mildly worse (5)	1 (2%)	2 (4%)
Moderately worse (6)	0	0
Significantly worse (7)	7 (17%)	8 (16%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.219
Logistic regression [2]		
Inverse odds ratio		0.67
95% CI for inverse odds ratio		(0.32,1.40)
p-value		0.286

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	4 (10%)	13 (27%)
Moderately improved (2)	7 (17%)	4 (8%)
Mildly improved (3)	9 (22%)	13 (27%)
No change (4)	11 (27%)	7 (14%)
Mildly worse (5)	1 (2%)	2 (4%)
Moderately worse (6)	2 (5%)	0
Significantly worse (7)	7 (17%)	10 (20%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.155
Logistic regression [2]		
Inverse odds ratio		0.66
95% CI for inverse odds ratio		(0.31,1.38)
p-value		0.265

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	4 (10%)	15 (31%)
Moderately improved (2)	8 (20%)	5 (10%)
Mildly improved (3)	5 (12%)	7 (14%)
No change (4)	12 (29%)	11 (22%)
Mildly worse (5)	2 (5%)	1 (2%)
Moderately worse (6)	2 (5%)	0
Significantly worse (7)	8 (20%)	10 (20%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.107
Logistic regression [2]		
Inverse odds ratio		0.57
95% CI for inverse odds ratio		(0.27,1.21)
p-value		0.142

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	3 (7%)	12 (24%)
Moderately improved (2)	7 (17%)	10 (20%)
Mildly improved (3)	7 (17%)	7 (14%)
No change (4)	13 (32%)	8 (16%)
Mildly worse (5)	1 (2%)	1 (2%)
Moderately worse (6)	2 (5%)	1 (2%)
Significantly worse (7)	8 (20%)	10 (20%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.040
Logistic regression [2]		
Inverse odds ratio		0.52
95% CI for inverse odds ratio		(0.24,1.09)
p-value		0.082

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: 18-64 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Significantly improved (1)	7 (17%)	11 (22%)
Moderately improved (2)	6 (15%)	9 (18%)
Mildly improved (3)	4 (10%)	10 (20%)
No change (4)	10 (24%)	8 (16%)
Mildly worse (5)	4 (10%)	1 (2%)
Moderately worse (6)	1 (2%)	0
Significantly worse (7)	9 (22%)	10 (20%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.106
Logistic regression [2]		
Inverse odds ratio		0.60
95% CI for inverse odds ratio		(0.29,1.26)
p-value		0.177

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	0
Moderately improved (2)	1 (10%)	1 (25%)
Mildly improved (3)	2 (20%)	2 (50%)
No change (4)	4 (40%)	0
Mildly worse (5)	3 (30%)	0
Moderately worse (6)	0	1 (25%)
Significantly worse (7)	0	0
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.416
Logistic regression [2]		
Inverse odds ratio		1.18
95% CI for inverse odds ratio		(0.03,48.68)
p-value		0.931

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	0
Moderately improved (2)	1 (10%)	0
Mildly improved (3)	1 (10%)	1 (25%)
No change (4)	6 (60%)	2 (50%)
Mildly worse (5)	1 (10%)	0
Moderately worse (6)	0	1 (25%)
Significantly worse (7)	1 (10%)	0
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.683
Logistic regression [2]		
Inverse odds ratio		2.99
95% CI for inverse odds ratio		(0.05,177.50)
p-value		0.599

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	1 (10%)	1 (25%)
Moderately improved (2)	1 (10%)	0
Mildly improved (3)	2 (20%)	1 (25%)
No change (4)	3 (30%)	0
Mildly worse (5)	1 (10%)	1 (25%)
Moderately worse (6)	0	0
Significantly worse (7)	2 (20%)	1 (25%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.614
Logistic regression [2]		
Inverse odds ratio		3.05
95% CI for inverse odds ratio		(0.08,112.63)
p-value		0.545

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	0
Moderately improved (2)	3 (30%)	1 (25%)
Mildly improved (3)	2 (20%)	2 (50%)
No change (4)	3 (30%)	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	2 (20%)	1 (25%)
Median response	3.5	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.942
Logistic regression [2]		
Inverse odds ratio		0.39
95% CI for inverse odds ratio		(0.01,15.47)
p-value		0.612

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	1 (10%)	0
Moderately improved (2)	2 (20%)	2 (50%)
Mildly improved (3)	2 (20%)	0
No change (4)	3 (30%)	1 (25%)
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	2 (20%)	1 (25%)
Median response	3.5	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.940
Logistic regression [2]		
Inverse odds ratio		1.63
95% CI for inverse odds ratio		(0.04,60.87)
p-value		0.790

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	1 (10%)	0
Moderately improved (2)	2 (20%)	2 (50%)
Mildly improved (3)	1 (10%)	0
No change (4)	4 (40%)	1 (25%)
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	2 (20%)	1 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.709
Logistic regression [2]		
Inverse odds ratio		2.01
95% CI for inverse odds ratio		(0.05,79.85)
p-value		0.709

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	1 (25%)
Moderately improved (2)	1 (10%)	1 (25%)
Mildly improved (3)	1 (10%)	0
No change (4)	6 (60%)	1 (25%)
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	2 (20%)	1 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.698
Logistic regression [2]		
Inverse odds ratio		1.87
95% CI for inverse odds ratio		(0.04,90.11)
p-value		0.752

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.64
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Age

Age: >=65 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Significantly improved (1)	0	1 (25%)
Moderately improved (2)	0	0
Mildly improved (3)	4 (40%)	2 (50%)
No change (4)	3 (30%)	0
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	3 (30%)	1 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.369
Logistic regression [2]		
Inverse odds ratio		0.67
95% CI for inverse odds ratio		(0.01,42.15)
p-value		0.852

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	1 (4%)	11 (37%)
Moderately improved (2)	2 (7%)	2 (7%)
Mildly improved (3)	7 (26%)	3 (10%)
No change (4)	11 (41%)	9 (30%)
Mildly worse (5)	3 (11%)	2 (7%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	2 (7%)	3 (10%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.017
Logistic regression [2]		
Inverse odds ratio		0.31
95% CI for inverse odds ratio		(0.12,0.85)
p-value		0.023

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	3 (11%)	8 (27%)
Moderately improved (2)	5 (19%)	1 (3%)
Mildly improved (3)	3 (11%)	3 (10%)
No change (4)	11 (41%)	11 (37%)
Mildly worse (5)	2 (7%)	0
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	2 (7%)	7 (23%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.704
Logistic regression [2]		
Inverse odds ratio		0.83
95% CI for inverse odds ratio		(0.32,2.19)
p-value		0.711

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	3 (11%)	7 (23%)
Moderately improved (2)	3 (11%)	2 (7%)
Mildly improved (3)	3 (11%)	4 (13%)
No change (4)	11 (41%)	8 (27%)
Mildly worse (5)	2 (7%)	1 (3%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	4 (15%)	8 (27%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.354
Logistic regression [2]		
Inverse odds ratio		0.68
95% CI for inverse odds ratio		(0.26,1.77)
p-value		0.425

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	3 (11%)	8 (27%)
Moderately improved (2)	5 (19%)	2 (7%)
Mildly improved (3)	3 (11%)	7 (23%)
No change (4)	12 (44%)	4 (13%)
Mildly worse (5)	0	2 (7%)
Moderately worse (6)	0	0
Significantly worse (7)	4 (15%)	7 (23%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.205
Logistic regression [2]		
Inverse odds ratio		0.59
95% CI for inverse odds ratio		(0.22,1.54)
p-value		0.279

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	2 (7%)	7 (23%)
Moderately improved (2)	5 (19%)	3 (10%)
Mildly improved (3)	3 (11%)	7 (23%)
No change (4)	10 (37%)	4 (13%)
Mildly worse (5)	1 (4%)	1 (3%)
Moderately worse (6)	2 (7%)	0
Significantly worse (7)	4 (15%)	8 (27%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.115
Logistic regression [2]		
Inverse odds ratio		0.53
95% CI for inverse odds ratio		(0.20,1.40)
p-value		0.200

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	2 (7%)	8 (27%)
Moderately improved (2)	6 (22%)	3 (10%)
Mildly improved (3)	3 (11%)	4 (13%)
No change (4)	9 (33%)	7 (23%)
Mildly worse (5)	1 (4%)	0
Moderately worse (6)	2 (7%)	0
Significantly worse (7)	4 (15%)	8 (27%)
Median response	4.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.241
Logistic regression [2]		
Inverse odds ratio		0.62
95% CI for inverse odds ratio		(0.24,1.62)
p-value		0.330

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	1 (4%)	7 (23%)
Moderately improved (2)	4 (15%)	6 (20%)
Mildly improved (3)	4 (15%)	3 (10%)
No change (4)	11 (41%)	5 (17%)
Mildly worse (5)	1 (4%)	1 (3%)
Moderately worse (6)	2 (7%)	0
Significantly worse (7)	4 (15%)	8 (27%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.046
Logistic regression [2]		
Inverse odds ratio		0.43
95% CI for inverse odds ratio		(0.16,1.13)
p-value		0.086

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Female
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Significantly improved (1)	2 (7%)	7 (23%)
Moderately improved (2)	3 (11%)	3 (10%)
Mildly improved (3)	4 (15%)	8 (27%)
No change (4)	8 (30%)	4 (13%)
Mildly worse (5)	4 (15%)	1 (3%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	5 (19%)	7 (23%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.016
Logistic regression [2]		
Inverse odds ratio		0.34
95% CI for inverse odds ratio		(0.13,0.92)
p-value		0.034

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	1 (4%)	1 (4%)
Moderately improved (2)	7 (26%)	3 (13%)
Mildly improved (3)	9 (33%)	8 (33%)
No change (4)	7 (26%)	8 (33%)
Mildly worse (5)	0	2 (8%)
Moderately worse (6)	0	2 (8%)
Significantly worse (7)	3 (11%)	0
Median response	3.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.355
Logistic regression [2]		
Inverse odds ratio		1.67
95% CI for inverse odds ratio		(0.60,4.66)
p-value		0.327

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	3 (11%)	5 (21%)
Moderately improved (2)	4 (15%)	5 (21%)
Mildly improved (3)	5 (19%)	5 (21%)
No change (4)	11 (41%)	6 (25%)
Mildly worse (5)	1 (4%)	1 (4%)
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	3 (11%)	1 (4%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.302
Logistic regression [2]		
Inverse odds ratio		0.52
95% CI for inverse odds ratio		(0.19,1.43)
p-value		0.204

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	4 (15%)	6 (25%)
Moderately improved (2)	2 (7%)	5 (21%)
Mildly improved (3)	9 (33%)	4 (17%)
No change (4)	5 (19%)	5 (21%)
Mildly worse (5)	2 (7%)	1 (4%)
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	5 (19%)	2 (8%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.338
Logistic regression [2]		
Inverse odds ratio		0.59
95% CI for inverse odds ratio		(0.21,1.61)
p-value		0.300

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	2 (7%)	4 (17%)
Moderately improved (2)	8 (30%)	3 (13%)
Mildly improved (3)	3 (11%)	9 (38%)
No change (4)	7 (26%)	5 (21%)
Mildly worse (5)	1 (4%)	0
Moderately worse (6)	0	0
Significantly worse (7)	6 (22%)	3 (13%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.481
Logistic regression [2]		
Inverse odds ratio		0.64
95% CI for inverse odds ratio		(0.23,1.76)
p-value		0.388

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	3 (11%)	6 (25%)
Moderately improved (2)	5 (19%)	3 (13%)
Mildly improved (3)	9 (33%)	6 (25%)
No change (4)	4 (15%)	4 (17%)
Mildly worse (5)	0	1 (4%)
Moderately worse (6)	0	0
Significantly worse (7)	6 (22%)	4 (17%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.579
Logistic regression [2]		
Inverse odds ratio		0.79
95% CI for inverse odds ratio		(0.29,2.16)
p-value		0.648

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	3 (11%)	7 (29%)
Moderately improved (2)	5 (19%)	4 (17%)
Mildly improved (3)	4 (15%)	3 (13%)
No change (4)	7 (26%)	5 (21%)
Mildly worse (5)	1 (4%)	1 (4%)
Moderately worse (6)	0	0
Significantly worse (7)	7 (26%)	4 (17%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.586
Logistic regression [2]		
Inverse odds ratio		0.60
95% CI for inverse odds ratio		(0.22,1.64)
p-value		0.320

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	2 (7%)	6 (25%)
Moderately improved (2)	4 (15%)	5 (21%)
Mildly improved (3)	5 (19%)	4 (17%)
No change (4)	9 (33%)	4 (17%)
Mildly worse (5)	0	0
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	7 (26%)	4 (17%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.283
Logistic regression [2]		
Inverse odds ratio		0.49
95% CI for inverse odds ratio		(0.18,1.35)
p-value		0.167

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.65
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Gender

Gender: Male
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Significantly improved (1)	5 (19%)	5 (21%)
Moderately improved (2)	4 (15%)	6 (25%)
Mildly improved (3)	5 (19%)	4 (17%)
No change (4)	5 (19%)	4 (17%)
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	8 (30%)	5 (21%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.733
Logistic regression [2]		
Inverse odds ratio		0.74
95% CI for inverse odds ratio		(0.27,2.03)
p-value		0.564

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	1 (3%)	7 (23%)
Moderately improved (2)	4 (12%)	3 (10%)
Mildly improved (3)	9 (27%)	7 (23%)
No change (4)	14 (42%)	10 (32%)
Mildly worse (5)	1 (3%)	3 (10%)
Moderately worse (6)	1 (3%)	1 (3%)
Significantly worse (7)	3 (9%)	0
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.237
Logistic regression [2]		
Inverse odds ratio		0.53
95% CI for inverse odds ratio		(0.22,1.31)
p-value		0.168

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	5 (15%)	9 (29%)
Moderately improved (2)	3 (9%)	5 (16%)
Mildly improved (3)	5 (15%)	5 (16%)
No change (4)	14 (42%)	10 (32%)
Mildly worse (5)	2 (6%)	1 (3%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	3 (9%)	1 (3%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.060
Logistic regression [2]		
Inverse odds ratio		0.39
95% CI for inverse odds ratio		(0.16,0.96)
p-value		0.041

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	7 (21%)	10 (32%)
Moderately improved (2)	1 (3%)	4 (13%)
Mildly improved (3)	5 (15%)	6 (19%)
No change (4)	12 (36%)	9 (29%)
Mildly worse (5)	1 (3%)	1 (3%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	6 (18%)	1 (3%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.049
Logistic regression [2]		
Inverse odds ratio		0.37
95% CI for inverse odds ratio		(0.15,0.91)
p-value		0.030

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	5 (15%)	8 (26%)
Moderately improved (2)	8 (24%)	2 (6%)
Mildly improved (3)	2 (6%)	14 (45%)
No change (4)	10 (30%)	6 (19%)
Mildly worse (5)	1 (3%)	0
Moderately worse (6)	0	0
Significantly worse (7)	7 (21%)	1 (3%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.076
Logistic regression [2]		
Inverse odds ratio		0.41
95% CI for inverse odds ratio		(0.17,1.01)
p-value		0.052

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	5 (15%)	10 (32%)
Moderately improved (2)	2 (6%)	2 (6%)
Mildly improved (3)	7 (21%)	12 (39%)
No change (4)	10 (30%)	5 (16%)
Mildly worse (5)	0	1 (3%)
Moderately worse (6)	2 (6%)	0
Significantly worse (7)	7 (21%)	1 (3%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.008
Logistic regression [2]		
Inverse odds ratio		0.26
95% CI for inverse odds ratio		(0.10,0.66)
p-value		0.005

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	5 (15%)	10 (32%)
Moderately improved (2)	4 (12%)	6 (19%)
Mildly improved (3)	4 (12%)	6 (19%)
No change (4)	9 (27%)	8 (26%)
Mildly worse (5)	2 (6%)	0
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	8 (24%)	1 (3%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.006
Logistic regression [2]		
Inverse odds ratio		0.25
95% CI for inverse odds ratio		(0.10,0.64)
p-value		0.004

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	2 (6%)	11 (35%)
Moderately improved (2)	5 (15%)	6 (19%)
Mildly improved (3)	4 (12%)	6 (19%)
No change (4)	12 (36%)	7 (23%)
Mildly worse (5)	1 (3%)	0
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	8 (24%)	1 (3%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		<0.001
Logistic regression [2]		
Inverse odds ratio		0.16
95% CI for inverse odds ratio		(0.06,0.43)
p-value		<0.001

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Europe
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Significantly improved (1)	6 (18%)	8 (26%)
Moderately improved (2)	2 (6%)	8 (26%)
Mildly improved (3)	4 (12%)	8 (26%)
No change (4)	9 (27%)	5 (16%)
Mildly worse (5)	3 (9%)	0
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	8 (24%)	2 (6%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.006
Logistic regression [2]		
Inverse odds ratio		0.25
95% CI for inverse odds ratio		(0.10,0.63)
p-value		0.003

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	1 (5%)	5 (22%)
Moderately improved (2)	5 (24%)	2 (9%)
Mildly improved (3)	7 (33%)	4 (17%)
No change (4)	4 (19%)	7 (30%)
Mildly worse (5)	2 (10%)	1 (4%)
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	2 (10%)	3 (13%)
Median response	3.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.794
Logistic regression [2]		
Inverse odds ratio		0.79
95% CI for inverse odds ratio		(0.27,2.32)
p-value		0.670

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	1 (5%)	4 (17%)
Moderately improved (2)	6 (29%)	1 (4%)
Mildly improved (3)	3 (14%)	3 (13%)
No change (4)	8 (38%)	7 (30%)
Mildly worse (5)	1 (5%)	0
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	2 (10%)	7 (30%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.346
Logistic regression [2]		
Inverse odds ratio		1.42
95% CI for inverse odds ratio		(0.48,4.22)
p-value		0.527

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	0	3 (13%)
Moderately improved (2)	4 (19%)	3 (13%)
Mildly improved (3)	7 (33%)	2 (9%)
No change (4)	4 (19%)	4 (17%)
Mildly worse (5)	3 (14%)	1 (4%)
Moderately worse (6)	0	1 (4%)
Significantly worse (7)	3 (14%)	9 (39%)
Median response	3.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.496
Logistic regression [2]		
Inverse odds ratio		1.27
95% CI for inverse odds ratio		(0.43,3.72)
p-value		0.665

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	0	4 (17%)
Moderately improved (2)	5 (24%)	3 (13%)
Mildly improved (3)	4 (19%)	2 (9%)
No change (4)	9 (43%)	3 (13%)
Mildly worse (5)	0	2 (9%)
Moderately worse (6)	0	0
Significantly worse (7)	3 (14%)	9 (39%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.781
Logistic regression [2]		
Inverse odds ratio		1.23
95% CI for inverse odds ratio		(0.42,3.61)
p-value		0.712

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	0	3 (13%)
Moderately improved (2)	8 (38%)	4 (17%)
Mildly improved (3)	5 (24%)	1 (4%)
No change (4)	4 (19%)	3 (13%)
Mildly worse (5)	1 (5%)	1 (4%)
Moderately worse (6)	0	0
Significantly worse (7)	3 (14%)	11 (48%)
Median response	3.0	5.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.299
Logistic regression [2]		
Inverse odds ratio		2.00
95% CI for inverse odds ratio		(0.67,5.98)
p-value		0.217

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	0	5 (22%)
Moderately improved (2)	7 (33%)	1 (4%)
Mildly improved (3)	3 (14%)	1 (4%)
No change (4)	7 (33%)	4 (17%)
Mildly worse (5)	0	1 (4%)
Moderately worse (6)	1 (5%)	0
Significantly worse (7)	3 (14%)	11 (48%)
Median response	4.0	5.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.307
Logistic regression [2]		
Inverse odds ratio		2.00
95% CI for inverse odds ratio		(0.67,5.98)
p-value		0.217

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	1 (5%)	2 (9%)
Moderately improved (2)	3 (14%)	5 (22%)
Mildly improved (3)	5 (24%)	1 (4%)
No change (4)	8 (38%)	2 (9%)
Mildly worse (5)	0	1 (4%)
Moderately worse (6)	1 (5%)	1 (4%)
Significantly worse (7)	3 (14%)	11 (48%)
Median response	4.0	6.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.384
Logistic regression [2]		
Inverse odds ratio		1.87
95% CI for inverse odds ratio		(0.63,5.58)
p-value		0.260

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.66
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Region

Region: Rest of World
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Significantly improved (1)	1 (5%)	4 (17%)
Moderately improved (2)	5 (24%)	1 (4%)
Mildly improved (3)	5 (24%)	4 (17%)
No change (4)	4 (19%)	3 (13%)
Mildly worse (5)	1 (5%)	1 (4%)
Moderately worse (6)	0	0
Significantly worse (7)	5 (24%)	10 (43%)
Median response	3.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.602
Logistic regression [2]		
Inverse odds ratio		1.38
95% CI for inverse odds ratio		(0.47,4.07)
p-value		0.562

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	2 (6%)	3 (14%)
Moderately improved (2)	5 (16%)	2 (9%)
Mildly improved (3)	10 (31%)	6 (27%)
No change (4)	8 (25%)	5 (23%)
Mildly worse (5)	3 (9%)	3 (14%)
Moderately worse (6)	0	1 (5%)
Significantly worse (7)	4 (13%)	2 (9%)
Median response	3.0	3.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.657
Logistic regression [2]		
Inverse odds ratio		0.94
95% CI for inverse odds ratio		(0.35,2.51)
p-value		0.897

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	4 (13%)	5 (23%)
Moderately improved (2)	8 (25%)	4 (18%)	
Mildly improved (3)	6 (19%)	3 (14%)
No change (4)	8 (25%)	5 (23%)
Mildly worse (5)	2 (6%)	1 (5%)
Moderately worse (6)	0	1 (5%)
Significantly worse (7)	4 (13%)	3 (14%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.615
Logistic regression [2]		
Inverse odds ratio		0.68
95% CI for inverse odds ratio		(0.25,1.83)
p-value		0.448

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	5 (16%)	5 (23%)
Moderately improved (2)	4 (13%)	4 (18%)
Mildly improved (3)	7 (22%)	1 (5%)
No change (4)	6 (19%)	6 (27%)
Mildly worse (5)	2 (6%)	2 (9%)
Moderately worse (6)	1 (3%)	1 (5%)
Significantly worse (7)	7 (22%)	3 (14%)
Median response	3.5	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.576
Logistic regression [2]		
Inverse odds ratio		0.69
95% CI for inverse odds ratio		(0.26,1.86)
p-value		0.463

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	4 (13%)	2 (9%)
Moderately improved (2)	9 (28%)	5 (23%)
Mildly improved (3)	4 (13%)	8 (36%)
No change (4)	8 (25%)	3 (14%)
Mildly worse (5)	0	1 (5%)
Moderately worse (6)	0	0
Significantly worse (7)	7 (22%)	3 (14%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.564
Logistic regression [2]		
Inverse odds ratio		0.77
95% CI for inverse odds ratio		(0.29,2.08)
p-value		0.610

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	5 (16%)	5 (23%)
Moderately improved (2)	6 (19%)	5 (23%)
Mildly improved (3)	7 (22%)	5 (23%)
No change (4)	5 (16%)	3 (14%)
Mildly worse (5)	0	0
Moderately worse (6)	2 (6%)	0
Significantly worse (7)	7 (22%)	4 (18%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.189
Logistic regression [2]		
Inverse odds ratio		0.60
95% CI for inverse odds ratio		(0.22,1.63)
p-value		0.318

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	5 (16%)	6 (27%)
Moderately improved (2)	8 (25%)	3 (14%)
Mildly improved (3)	4 (13%)	3 (14%)
No change (4)	7 (22%)	5 (23%)
Mildly worse (5)	0	1 (5%)
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	7 (22%)	4 (18%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.658
Logistic regression [2]		
Inverse odds ratio		0.77
95% CI for inverse odds ratio		(0.29,2.08)
p-value		0.610

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	3 (9%)	5 (23%)
Moderately improved (2)	7 (22%)	7 (32%)
Mildly improved (3)	4 (13%)	2 (9%)
No change (4)	10 (31%)	3 (14%)
Mildly worse (5)	0	0
Moderately worse (6)	1 (3%)	1 (5%)
Significantly worse (7)	7 (22%)	4 (18%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.122
Logistic regression [2]		
Inverse odds ratio		0.46
95% CI for inverse odds ratio		(0.17,1.26)
p-value		0.131

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: <2.76 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Significantly improved (1)	7 (22%)	5 (23%)
Moderately improved (2)	3 (9%)	5 (23%)
Mildly improved (3)	7 (22%)	5 (23%)
No change (4)	6 (19%)	3 (14%)
Mildly worse (5)	1 (3%)	0
Moderately worse (6)	0	0
Significantly worse (7)	8 (25%)	4 (18%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.290
Logistic regression [2]		
Inverse odds ratio		0.60
95% CI for inverse odds ratio		(0.22,1.64)
p-value		0.324

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	9 (28%)
Moderately improved (2)	4 (18%)	3 (9%)
Mildly improved (3)	6 (27%)	5 (16%)
No change (4)	10 (45%)	12 (38%)
Mildly worse (5)	0	1 (3%)
Moderately worse (6)	1 (5%)	1 (3%)
Significantly worse (7)	1 (5%)	1 (3%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.209
Logistic regression [2]		
Inverse odds ratio		0.49
95% CI for inverse odds ratio		(0.18,1.34)
p-value		0.166

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	2 (9%)	8 (25%)
Moderately improved (2)	1 (5%)	2 (6%)
Mildly improved (3)	2 (9%)	5 (16%)
No change (4)	14 (64%)	12 (38%)
Mildly worse (5)	1 (5%)	0
Moderately worse (6)	1 (5%)	0
Significantly worse (7)	1 (5%)	5 (16%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.206
Logistic regression [2]		
Inverse odds ratio		0.55
95% CI for inverse odds ratio		(0.20,1.55)
p-value		0.257

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	2 (9%)	8 (25%)
Moderately improved (2)	1 (5%)	3 (9%)
Mildly improved (3)	5 (23%)	7 (22%)
No change (4)	10 (45%)	7 (22%)
Mildly worse (5)	2 (9%)	0
Moderately worse (6)	0	0
Significantly worse (7)	2 (9%)	7 (22%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.267
Logistic regression [2]		
Inverse odds ratio		0.60
95% CI for inverse odds ratio		(0.22,1.60)
p-value		0.308

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	1 (5%)	10 (31%)
Moderately improved (2)	4 (18%)	0
Mildly improved (3)	2 (9%)	8 (25%)
No change (4)	11 (50%)	6 (19%)
Mildly worse (5)	1 (5%)	1 (3%)
Moderately worse (6)	0	0
Significantly worse (7)	3 (14%)	7 (22%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.361
Logistic regression [2]		
Inverse odds ratio		0.57
95% CI for inverse odds ratio		(0.21,1.52)
p-value		0.259

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	8 (25%)
Moderately improved (2)	4 (18%)	1 (3%)
Mildly improved (3)	5 (23%)	8 (25%)
No change (4)	9 (41%)	5 (16%)
Mildly worse (5)	1 (5%)	2 (6%)
Moderately worse (6)	0	0
Significantly worse (7)	3 (14%)	8 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.442
Logistic regression [2]		
Inverse odds ratio		0.75
95% CI for inverse odds ratio		(0.28,1.99)
p-value		0.565

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	9 (28%)
Moderately improved (2)	3 (14%)	4 (13%)
Mildly improved (3)	3 (14%)	4 (13%)
No change (4)	9 (41%)	7 (22%)
Mildly worse (5)	2 (9%)	0
Moderately worse (6)	1 (5%)	0
Significantly worse (7)	4 (18%)	8 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.111
Logistic regression [2]		
Inverse odds ratio		0.44
95% CI for inverse odds ratio		(0.16,1.18)
p-value		0.102

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	8 (25%)
Moderately improved (2)	1 (5%)	4 (13%)
Mildly improved (3)	5 (23%)	5 (16%)
No change (4)	10 (45%)	6 (19%)
Mildly worse (5)	1 (5%)	1 (3%)
Moderately worse (6)	1 (5%)	0
Significantly worse (7)	4 (18%)	8 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.084
Logistic regression [2]		
Inverse odds ratio		0.45
95% CI for inverse odds ratio		(0.17,1.21)
p-value		0.115

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.67
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Duration of Disease

Duration of disease: >=2.76 Years
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Significantly improved (1)	0	7 (22%)
Moderately improved (2)	4 (18%)	4 (13%)
Mildly improved (3)	2 (9%)	7 (22%)
No change (4)	7 (32%)	5 (16%)
Mildly worse (5)	3 (14%)	1 (3%)
Moderately worse (6)	1 (5%)	0
Significantly worse (7)	5 (23%)	8 (25%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.058
Logistic regression [2]		
Inverse odds ratio		0.44
95% CI for inverse odds ratio		(0.16,1.18)
p-value		0.102

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	0	5 (19%)
Moderately improved (2)	3 (10%)	1 (4%)
Mildly improved (3)	11 (37%)	4 (15%)
No change (4)	10 (33%)	11 (42%)
Mildly worse (5)	2 (7%)	1 (4%)
Moderately worse (6)	1 (3%)	2 (8%)
Significantly worse (7)	3 (10%)	2 (8%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.532
Logistic regression [2]		
Inverse odds ratio		0.69
95% CI for inverse odds ratio		(0.26,1.80)
p-value		0.445

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	2 (7%)	4 (15%)
Moderately improved (2)	6 (20%)	5 (19%)
Mildly improved (3)	6 (20%)	2 (8%)
No change (4)	12 (40%)	9 (35%)
Mildly worse (5)	1 (3%)	0
Moderately worse (6)	1 (3%)	1 (4%)
Significantly worse (7)	2 (7%)	5 (19%)
Median response	4.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.913
Logistic regression [2]		
Inverse odds ratio		0.89
95% CI for inverse odds ratio		(0.34,2.32)
p-value		0.813

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	3 (10%)	4 (15%)
Moderately improved (2)	4 (13%)	4 (15%)
Mildly improved (3)	9 (30%)	3 (12%)
No change (4)	10 (33%)	7 (27%)
Mildly worse (5)	1 (3%)	1 (4%)
Moderately worse (6)	1 (3%)	1 (4%)
Significantly worse (7)	2 (7%)	6 (23%)
Median response	3.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.573
Logistic regression [2]		
Inverse odds ratio		1.27
95% CI for inverse odds ratio		(0.49,3.30)
p-value		0.620

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	1 (3%)	4 (15%)
Moderately improved (2)	10 (33%)	3 (12%)
Mildly improved (3)	5 (17%)	7 (27%)
No change (4)	11 (37%)	5 (19%)
Mildly worse (5)	1 (3%)	2 (8%)
Moderately worse (6)	0	0
Significantly worse (7)	2 (7%)	5 (19%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.788
Logistic regression [2]		
Inverse odds ratio		1.10
95% CI for inverse odds ratio		(0.42,2.85)
p-value		0.849

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	2 (7%)	6 (23%)
Moderately improved (2)	8 (27%)	2 (8%)
Mildly improved (3)	5 (17%)	6 (23%)
No change (4)	12 (40%)	6 (23%)
Mildly worse (5)	0	0
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	2 (7%)	6 (23%)
Median response	3.5	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.838
Logistic regression [2]		
Inverse odds ratio		0.98
95% CI for inverse odds ratio		(0.38,2.55)
p-value		0.968

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	2 (7%)	7 (27%)
Moderately improved (2)	9 (30%)	3 (12%)
Mildly improved (3)	5 (17%)	2 (8%)
No change (4)	10 (33%)	7 (27%)
Mildly worse (5)	1 (3%)	0
Moderately worse (6)	1 (3%)	0
Significantly worse (7)	2 (7%)	7 (27%)
Median response	3.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.939
Logistic regression [2]		
Inverse odds ratio		1.00
95% CI for inverse odds ratio		(0.39,2.60)
p-value		0.997

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	2 (7%)	5 (19%)
Moderately improved (2)	4 (13%)	4 (15%)
Mildly improved (3)	9 (30%)	3 (12%)
No change (4)	12 (40%)	6 (23%)
Mildly worse (5)	0	0
Moderately worse (6)	1 (3%)	1 (4%)
Significantly worse (7)	2 (7%)	7 (27%)
Median response	3.5	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.986
Logistic regression [2]		
Inverse odds ratio		1.12
95% CI for inverse odds ratio		(0.43,2.89)
p-value		0.822

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Significantly improved (1)	2 (7%)	3 (12%)
Moderately improved (2)	7 (23%)	5 (19%)
Mildly improved (3)	7 (23%)	6 (23%)
No change (4)	8 (27%)	5 (19%)
Mildly worse (5)	3 (10%)	0
Moderately worse (6)	0	0
Significantly worse (7)	3 (10%)	7 (27%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.910
Logistic regression [2]		
Inverse odds ratio		0.97
95% CI for inverse odds ratio		(0.38,2.50)
p-value		0.946

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 4

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	2 (8%)	7 (25%)
Moderately improved (2)	6 (25%)	4 (14%)
Mildly improved (3)	5 (21%)	7 (25%)
No change (4)	8 (33%)	6 (21%)
Mildly worse (5)	1 (4%)	3 (11%)
Moderately worse (6)	0	0
Significantly worse (7)	2 (8%)	1 (4%)
Median response	3.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.341
Logistic regression [2]		
Inverse odds ratio		0.67
95% CI for inverse odds ratio		(0.25,1.78)
p-value		0.420

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 8

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	4 (17%)	9 (32%)
Moderately improved (2)	3 (13%)	1 (4%)
Mildly improved (3)	2 (8%)	6 (21%)
No change (4)	10 (42%)	8 (29%)
Mildly worse (5)	2 (8%)	1 (4%)
Moderately worse (6)	0	0
Significantly worse (7)	3 (13%)	3 (11%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.304
Logistic regression [2]		
Inverse odds ratio		0.56
95% CI for inverse odds ratio		(0.21,1.52)
p-value		0.254

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 12

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	4 (17%)	9 (32%)
Moderately improved (2)	1 (4%)	3 (11%)
Mildly improved (3)	3 (13%)	5 (18%)
No change (4)	6 (25%)	6 (21%)
Mildly worse (5)	3 (13%)	1 (4%)
Moderately worse (6)	0	0
Significantly worse (7)	7 (29%)	4 (14%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.066
Logistic regression [2]		
Inverse odds ratio		0.36
95% CI for inverse odds ratio		(0.13,0.99)
p-value		0.048

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 16

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	4 (17%)	8 (29%)
Moderately improved (2)	3 (13%)	2 (7%)
Mildly improved (3)	1 (4%)	9 (32%)
No change (4)	8 (33%)	4 (14%)
Mildly worse (5)	0	0
Moderately worse (6)	0	0
Significantly worse (7)	8 (33%)	5 (18%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.135
Logistic regression [2]		
Inverse odds ratio		0.39
95% CI for inverse odds ratio		(0.14,1.06)
p-value		0.066

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 20

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	3 (13%)	7 (25%)
Moderately improved (2)	2 (8%)	4 (14%)
Mildly improved (3)	7 (29%)	7 (25%)
No change (4)	2 (8%)	2 (7%)
Mildly worse (5)	1 (4%)	2 (7%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	8 (33%)	6 (21%)
Median response	3.5	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.111
Logistic regression [2]		
Inverse odds ratio		0.46
95% CI for inverse odds ratio		(0.17,1.24)
p-value		0.126

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 24

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	3 (13%)	8 (29%)
Moderately improved (2)	2 (8%)	4 (14%)
Mildly improved (3)	2 (8%)	5 (18%)
No change (4)	6 (25%)	5 (18%)
Mildly worse (5)	1 (4%)	1 (4%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	9 (38%)	5 (18%)
Median response	4.0	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.062
Logistic regression [2]		
Inverse odds ratio		0.33
95% CI for inverse odds ratio		(0.12,0.91)
p-value		0.032

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 28

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	1 (4%)	8 (29%)
Moderately improved (2)	4 (17%)	7 (25%)
Mildly improved (3)	0	4 (14%)
No change (4)	8 (33%)	3 (11%)
Mildly worse (5)	1 (4%)	1 (4%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	9 (38%)	5 (18%)
Median response	4.0	2.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.004
Logistic regression [2]		
Inverse odds ratio		0.22
95% CI for inverse odds ratio		(0.08,0.63)
p-value		0.005

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.68
Subgroup Analysis of Subject-Rated Overall Response to Therapy by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L
Visit: Week 32

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Significantly improved (1)	5 (21%)	9 (32%)
Moderately improved (2)	0	4 (14%)
Mildly improved (3)	2 (8%)	6 (21%)
No change (4)	5 (21%)	3 (11%)
Mildly worse (5)	1 (4%)	1 (4%)
Moderately worse (6)	1 (4%)	0
Significantly worse (7)	10 (42%)	5 (18%)
Median response	4.5	3.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.021
Logistic regression [2]		
Inverse odds ratio		0.28
95% CI for inverse odds ratio		(0.10,0.80)
p-value		0.017

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.70
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Age

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
4 point improvement (-4)	0	0
3 point improvement (-3)	0	0
2 point improvement (-2)	1 (33%)	0
1 point improvement (-1)	0	0
No change (0)	1 (33%)	0
1 point worsening (1)	0	0
2 point worsening (2)	0	0
3 point worsening (3)	0	0
4 point worsening (4)	1 (33%)	1 (100%)
Median response	0.0	4.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		Non-estimable
Logistic regression [2]		
Inverse odds ratio		Non-estimable
95% CI for inverse odds ratio		Non-estimable
p-value		Non-estimable

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.70
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Age

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
4 point improvement (-4)	0	0
3 point improvement (-3)	1 (2%)	7 (14%)
2 point improvement (-2)	3 (7%)	1 (2%)
1 point improvement (-1)	13 (32%)	13 (27%)
No change (0)	9 (22%)	8 (16%)
1 point worsening (1)	4 (10%)	9 (18%)
2 point worsening (2)	2 (5%)	1 (2%)
3 point worsening (3)	0	0
4 point worsening (4)	9 (22%)	10 (20%)
Median response	0.0	0.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.667
Logistic regression [2]		
Inverse odds ratio		0.86
95% CI for inverse odds ratio		(0.41,1.80)
p-value		0.683

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.70
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Age

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
4 point improvement (-4)	0	0
3 point improvement (-3)	0	0
2 point improvement (-2)	1 (10%)	0
1 point improvement (-1)	3 (30%)	1 (25%)
No change (0)	3 (30%)	2 (50%)
1 point worsening (1)	0	0
2 point worsening (2)	0	0
3 point worsening (3)	0	0
4 point worsening (4)	3 (30%)	1 (25%)
Median response	0.0	0.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.850
Logistic regression [2]		
Inverse odds ratio		0.33
95% CI for inverse odds ratio		(0.01,15.08)
p-value		0.568

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.71
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Gender

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
4 point improvement (-4)	0	0
3 point improvement (-3)	1 (4%)	5 (17%)
2 point improvement (-2)	3 (11%)	0
1 point improvement (-1)	7 (26%)	5 (17%)
No change (0)	6 (22%)	8 (27%)
1 point worsening (1)	4 (15%)	4 (13%)
2 point worsening (2)	1 (4%)	1 (3%)
3 point worsening (3)	0	0
4 point worsening (4)	5 (19%)	7 (23%)
Median response	0.0	0.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.828
Logistic regression [2]		
Inverse odds ratio		0.90
95% CI for inverse odds ratio		(0.35,2.34)
p-value		0.833

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.71
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Gender

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
4 point improvement (-4)	0	0
3 point improvement (-3)	0	2 (8%)
2 point improvement (-2)	2 (7%)	1 (4%)
1 point improvement (-1)	9 (33%)	9 (38%)
No change (0)	7 (26%)	2 (8%)
1 point worsening (1)	0	5 (21%)
2 point worsening (2)	1 (4%)	0
3 point worsening (3)	0	0
4 point worsening (4)	8 (30%)	5 (21%)
Median response	0.0	-0.5
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.464
Logistic regression [2]		
Inverse odds ratio		0.77
95% CI for inverse odds ratio		(0.28,2.12)
p-value		0.608

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.72
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Region

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
4 point improvement (-4)	0	0
3 point improvement (-3)	1 (3%)	6 (19%)
2 point improvement (-2)	3 (9%)	1 (3%)
1 point improvement (-1)	8 (24%)	11 (35%)
No change (0)	8 (24%)	5 (16%)
1 point worsening (1)	3 (9%)	6 (19%)
2 point worsening (2)	2 (6%)	0
3 point worsening (3)	0	0
4 point worsening (4)	8 (24%)	2 (6%)
Median response	0.0	-1.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.031
Logistic regression [2]		
Inverse odds ratio		0.36
95% CI for inverse odds ratio		(0.15,0.90)
p-value		0.028

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Population: Intent-To-Treat

Table 90.72
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Region

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
4 point improvement (-4)	0	0
3 point improvement (-3)	0	1 (4%)
2 point improvement (-2)	2 (10%)	0
1 point improvement (-1)	8 (38%)	3 (13%)
No change (0)	5 (24%)	5 (22%)
1 point worsening (1)	1 (5%)	3 (13%)
2 point worsening (2)	0	1 (4%)
3 point worsening (3)	0	0
4 point worsening (4)	5 (24%)	10 (43%)
Median response	0.0	1.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.050
Logistic regression [2]		
Inverse odds ratio		3.17
95% CI for inverse odds ratio		(1.02,9.82)
p-value		0.045

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent.
[2] Ordinal logistic regression analysis adjusted for baseline OCS. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.73
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Duration of Disease

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
4 point improvement (-4)	0	0
3 point improvement (-3)	1 (3%)	3 (14%)
2 point improvement (-2)	3 (9%)	0
1 point improvement (-1)	10 (31%)	5 (23%)
No change (0)	8 (25%)	5 (23%)
1 point worsening (1)	2 (6%)	5 (23%)
2 point worsening (2)	0	0
3 point worsening (3)	0	0
4 point worsening (4)	8 (25%)	4 (18%)
Median response	0.0	0.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.938
Logistic regression [2]		
Inverse odds ratio		1.01
95% CI for inverse odds ratio		(0.38,2.74)
p-value		0.979

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.73
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Duration of Disease

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
4 point improvement (-4)	0	0
3 point improvement (-3)	0	4 (13%)
2 point improvement (-2)	2 (9%)	1 (3%)
1 point improvement (-1)	6 (27%)	9 (28%)
No change (0)	5 (23%)	5 (16%)
1 point worsening (1)	2 (9%)	4 (13%)
2 point worsening (2)	2 (9%)	1 (3%)
3 point worsening (3)	0	0
4 point worsening (4)	5 (23%)	8 (25%)
Median response	0.0	0.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.664
Logistic regression [2]		
Inverse odds ratio		0.76
95% CI for inverse odds ratio		(0.29,2.02)
p-value		0.589

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.74
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
4 point improvement (-4)	0	0
3 point improvement (-3)	0	3 (12%)
2 point improvement (-2)	5 (17%)	1 (4%)
1 point improvement (-1)	9 (30%)	6 (23%)
No change (0)	9 (30%)	4 (15%)
1 point worsening (1)	3 (10%)	4 (15%)
2 point worsening (2)	1 (3%)	1 (4%)
3 point worsening (3)	0	0
4 point worsening (4)	3 (10%)	7 (27%)
Median response	0.0	0.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.331
Logistic regression [2]		
Inverse odds ratio		1.67
95% CI for inverse odds ratio		(0.64,4.35)
p-value		0.291

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-To-Treat

Table 90.74
Subgroup Analysis of Subject-Rated Symptom Severity at Week 32 by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
4 point improvement (-4)	0	0
3 point improvement (-3)	1 (4%)	4 (14%)
2 point improvement (-2)	0	0
1 point improvement (-1)	7 (29%)	8 (29%)
No change (0)	4 (17%)	6 (21%)
1 point worsening (1)	1 (4%)	5 (18%)
2 point worsening (2)	1 (4%)	0
3 point worsening (3)	0	0
4 point worsening (4)	10 (42%)	5 (18%)
Median response	0.5	0.0
Comparison Mepolizumab 300mg vs Placebo		
Wilcoxon Rank Sum Test p-value [1]		0.107
Logistic regression [2]		
Inverse odds ratio		0.41
95% CI for inverse odds ratio		(0.15,1.13)
p-value		0.084

Note: Subjects with missing response at Week 32 are included with the largest (i.e., worst) change observed for any subject.
[1] Wilcoxon Rank Sum test stratified by baseline OCS (0-<=20mg/day and >20mg/day) prednisone or equivalent and region.
[2] Ordinal logistic regression analysis adjusted for baseline OCS and region. Inverse odds ratio <1 indicates higher odds of a lower score (more favourable response) with Mepolizumab compared with Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.77
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	3	0
n [2]	2	0
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.77
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	39	47
n [2]	32	39
LS Mean (SE)	0.84 (0.077)	0.58 (0.070)
LS Mean Change (SE)	-0.13 (0.077)	-0.39 (0.070)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.25
95% CI		(-0.46, -0.05)
p-value		0.017
Corrected Hedges g [3]		-0.58
95% CI		(-1.05, -0.10)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.77
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	10	4
n [2]	7	3
LS Mean (SE)	0.55 (0.159)	1.17 (0.279)
LS Mean Change (SE)	-0.42 (0.159)	0.20 (0.279)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.62
95% CI		(-0.14, 1.39)
p-value		0.103
Corrected Hedges g [3]		1.29
95% CI		(-0.18, 2.76)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.78
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	27	27
n [2]	22	23
LS Mean (SE)	0.95 (0.101)	0.79 (0.101)
LS Mean Change (SE)	-0.16 (0.101)	-0.31 (0.101)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.15
95% CI		(-0.44, 0.14)
p-value		0.297
Corrected Hedges g [3]		-0.31
95% CI		(-0.90, 0.28)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.78
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	25	24
n [2]	19	19
LS Mean (SE)	0.56 (0.096)	0.54 (0.097)
LS Mean Change (SE)	-0.27 (0.096)	-0.30 (0.097)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.02
95% CI		(-0.31, 0.26)
p-value		0.870
Corrected Hedges g [3]		-0.05
95% CI		(-0.69, 0.58)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.79
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	32	31
n [2]	25	29
LS Mean (SE)	0.90 (0.092)	0.60 (0.089)
LS Mean Change (SE)	-0.09 (0.092)	-0.39 (0.089)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.30
95% CI		(-0.56, -0.04)
p-value		0.024
Corrected Hedges g [3]		-0.62
95% CI		(-1.17, -0.08)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.79
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	20	20
n [2]	16	13
LS Mean (SE)	0.67 (0.107)	0.72 (0.116)
LS Mean Change (SE)	-0.30 (0.107)	-0.25 (0.116)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.05
95% CI		(-0.27, 0.37)
p-value		0.750
Corrected Hedges g [3]		0.12
95% CI		(-0.62, 0.85)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.80
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32 by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	31	20
n [2]	24	18
LS Mean (SE)	0.71 (0.080)	0.60 (0.096)
LS Mean Change (SE)	-0.19 (0.080)	-0.29 (0.096)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.11
95% CI		(-0.36, 0.15)
p-value		0.403
Corrected Hedges g [3]		-0.26
95% CI		(-0.87, 0.35)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.80
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32 by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	21	31
n [2]	17	24
LS Mean (SE)	0.94 (0.125)	0.68 (0.106)
LS Mean Change (SE)	-0.12 (0.125)	-0.38 (0.106)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.26
95% CI		(-0.59, 0.08)
p-value		0.128
Corrected Hedges g [3]		-0.48
95% CI		(-1.11, 0.15)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.81
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32
by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	29	24
n [2]	27	19
LS Mean (SE)	0.79 (0.093)	0.69 (0.108)
LS Mean Change (SE)	-0.17 (0.093)	-0.27 (0.108)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.10
95% CI		(-0.39, 0.19)
p-value		0.490
Corrected Hedges g [3]		-0.20
95% CI		(-0.79, 0.38)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

Protocol: 200622
Population: Intent-to-Treat

Table 90.81
Subgroup Analysis of Change from Baseline in MSAS-SF Total Score at Week 32
by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	23	27
n [2]	14	23
LS Mean (SE)	0.75 (0.101)	0.63 (0.085)
LS Mean Change (SE)	-0.24 (0.101)	-0.36 (0.085)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.12
95% CI		(-0.39, 0.15)
p-value		0.385
Corrected Hedges g [3]		-0.29
95% CI		(-0.95, 0.38)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 0 = Not at all distressed or bothered/No symptoms to 4 = Very much distressed or bothered/Almost constant symptoms.

PPD

Population: Intent-to-Treat

Table 90.85
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	3	0
n [2]	2	0
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Population: Intent-to-Treat

Table 90.85
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	38	47
n [2]	32	39
LS Mean (SE)	3.93 (0.111)	4.10 (0.100)
LS Mean Change (SE)	0.35 (0.111)	0.52 (0.100)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.17
95% CI		(-0.13, 0.47)
p-value		0.263
Corrected Hedges g [3]		0.27
95% CI		(-0.20, 0.74)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Population: Intent-to-Treat

Table 90.85
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	10	4
n [2]	7	3
LS Mean (SE)	3.34 (0.358)	2.70 (0.688)
LS Mean Change (SE)	0.27 (0.358)	-0.37 (0.688)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.64
95% CI		(-2.61, 1.33)
p-value		0.495
Corrected Hedges g [3]		-0.57
95% CI		(-1.95, 0.80)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.86
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	27	27
n [2]	22	23
LS Mean (SE)	3.51 (0.166)	3.87 (0.166)
LS Mean Change (SE)	0.26 (0.166)	0.63 (0.166)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.36
95% CI		(-0.11, 0.84)
p-value		0.128
Corrected Hedges g [3]		0.46
95% CI		(-0.14, 1.05)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Population: Intent-to-Treat

Table 90.86
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	24	24
n [2]	19	19
LS Mean (SE)	4.27 (0.117)	4.15 (0.117)
LS Mean Change (SE)	0.42 (0.117)	0.30 (0.117)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.12
95% CI		(-0.46, 0.22)
p-value		0.496
Corrected Hedges g [3]		-0.22
95% CI		(-0.86, 0.42)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Population: Intent-to-Treat

Table 90.87
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	32	31
n [2]	25	29
LS Mean (SE)	3.81 (0.131)	4.19 (0.128)
LS Mean Change (SE)	0.21 (0.131)	0.59 (0.128)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.38
95% CI		(0.02, 0.75)
p-value		0.040
Corrected Hedges g [3]		0.56
95% CI		(0.02, 1.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.87
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	19	20
n [2]	16	13
LS Mean (SE)	3.93 (0.128)	3.77 (0.135)
LS Mean Change (SE)	0.52 (0.128)	0.35 (0.135)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.17
95% CI		(-0.55, 0.22)
p-value		0.380
Corrected Hedges g [3]		-0.33
95% CI		(-1.06, 0.41)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.88
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32
by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	30	20
n [2]	24	18
LS Mean (SE)	3.97 (0.128)	3.95 (0.151)
LS Mean Change (SE)	0.41 (0.128)	0.39 (0.151)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.02
95% CI		(-0.42, 0.39)
p-value		0.936
Corrected Hedges g [3]		-0.03
95% CI		(-0.64, 0.59)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.88
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32
by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	21	31
n [2]	17	24
LS Mean (SE)	3.71 (0.171)	4.05 (0.142)
LS Mean Change (SE)	0.21 (0.171)	0.56 (0.142)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.35
95% CI		(-0.11, 0.80)
p-value		0.130
Corrected Hedges g [3]		0.48
95% CI		(-0.15, 1.11)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.89
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32
by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	28	24
n [2]	27	19
LS Mean (SE)	3.84 (0.135)	3.94 (0.153)
LS Mean Change (SE)	0.32 (0.135)	0.41 (0.153)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.10
95% CI		(-0.32, 0.51)
p-value		0.640
Corrected Hedges g [3]		0.14
95% CI		(-0.45, 0.73)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Population: Intent-to-Treat

Table 90.89
Subgroup Analysis of Change from Baseline in PROMIS Physical Function Score at Week 32
by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	23	27
n [2]	14	23
LS Mean (SE)	3.90 (0.156)	4.10 (0.136)
LS Mean Change (SE)	0.37 (0.156)	0.56 (0.136)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		0.19
95% CI		(-0.23, 0.61)
p-value		0.360
Corrected Hedges g [3]		0.30
95% CI		(-0.37, 0.97)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Cannot do/unable to do to 5 = Not at all/Without any difficulty.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.93
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	3	0
n [2]	2	0
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Population: Intent-to-Treat

Table 90.93
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	38	47
n [2]	32	39
LS Mean (SE)	2.46 (0.129)	2.18 (0.118)
LS Mean Change (SE)	-0.04 (0.129)	-0.32 (0.118)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.28
95% CI		(-0.63, 0.07)
p-value		0.120
Corrected Hedges g [3]		-0.37
95% CI		(-0.85, 0.10)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Population: Intent-to-Treat

Table 90.93
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32 by Age
(Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	10	4
n [2]	7	3
LS Mean (SE)	2.10 (0.328)	3.58 (0.551)
LS Mean Change (SE)	-0.55 (0.328)	0.92 (0.551)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		1.47
95% CI		(-0.01, 2.96)
p-value		0.052
Corrected Hedges g [3]		1.49
95% CI		(-0.01, 2.99)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

Protocol: 200622
Population: Intent-to-Treat

Table 90.94
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	27	27
n [2]	22	23
LS Mean (SE)	2.75 (0.171)	2.37 (0.168)
LS Mean Change (SE)	0.15 (0.171)	-0.24 (0.168)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.38
95% CI		(-0.88, 0.11)
p-value		0.127
Corrected Hedges g [3]		-0.47
95% CI		(-1.06, 0.12)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Population: Intent-to-Treat

Table 90.94
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32 by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	24	24
n [2]	19	19
LS Mean (SE)	2.11 (0.126)	2.03 (0.127)
LS Mean Change (SE)	-0.27 (0.126)	-0.35 (0.127)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.07
95% CI		(-0.44, 0.29)
p-value		0.689
Corrected Hedges g [3]		-0.13
95% CI		(-0.77, 0.51)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

Protocol: 200622
Population: Intent-to-Treat

Table 90.95
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	32	31
n [2]	25	29
LS Mean (SE)	2.59 (0.154)	2.19 (0.148)
LS Mean Change (SE)	0.04 (0.154)	-0.36 (0.148)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.41
95% CI		(-0.84, 0.03)
p-value		0.065
Corrected Hedges g [3]		-0.51
95% CI		(-1.05, 0.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.95
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32 by Region
(Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	19	20
n [2]	16	13
LS Mean (SE)	2.26 (0.135)	2.20 (0.151)
LS Mean Change (SE)	-0.14 (0.135)	-0.21 (0.151)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.06
95% CI		(-0.48, 0.35)
p-value		0.760
Corrected Hedges g [3]		-0.11
95% CI		(-0.85, 0.62)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.96
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32
by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	30	20
n [2]	24	18
LS Mean (SE)	2.42 (0.141)	2.14 (0.164)
LS Mean Change (SE)	0.04 (0.141)	-0.23 (0.164)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.27
95% CI		(-0.72, 0.17)
p-value		0.218
Corrected Hedges g [3]		-0.39
95% CI		(-1.00, 0.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

Population: Intent-to-Treat

Table 90.96
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32
by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	21	31
n [2]	17	24
LS Mean (SE)	2.55 (0.175)	2.19 (0.148)
LS Mean Change (SE)	-0.06 (0.175)	-0.42 (0.148)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.36
95% CI		(-0.83, 0.11)
p-value		0.131
Corrected Hedges g [3]		-0.49
95% CI		(-1.12, 0.14)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

Protocol: 200622
Population: Intent-to-Treat

Table 90.97
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32
by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	28	24
n [2]	27	19
LS Mean (SE)	2.59 (0.150)	2.15 (0.176)
LS Mean Change (SE)	0.00 (0.150)	-0.44 (0.176)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.44
95% CI		(-0.92, 0.03)
p-value		0.064
Corrected Hedges g [3]		-0.56
95% CI		(-1.16, 0.04)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

Population: Intent-to-Treat

Table 90.97
Subgroup Analysis of Change from Baseline in PROMIS Sleep Score at Week 32
by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	23	27
n [2]	14	23
LS Mean (SE)	2.33 (0.175)	2.17 (0.141)
LS Mean Change (SE)	-0.06 (0.175)	-0.22 (0.141)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.16
95% CI		(-0.62, 0.30)
p-value		0.493
Corrected Hedges g [3]		-0.23
95% CI		(-0.90, 0.43)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group. LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.
Scale 1 = Not at all difficulty in falling asleep/Never trouble staying asleep to 5 = Very much difficulty in falling asleep/Always trouble staying asleep.

PPD

Population: Intent-to-Treat

Table 90.102
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Physical Component Summary Score at Week 32 by Age

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Responder	2 (67%)	0
Non-Responder	1 (33%)	1 (100%)
Missing response	0	1 (100%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		Non-estimable
p-value		Non-estimable
Inverse unadjusted odds ratio (95% CI) [3]		1.00 (0.05,>999.99)
Inverse relative risk (95% CI) [4]		>999.99 (0.24,>999.99)
Risk difference (95% CI) [4]		0.67 (-0.59,0.99)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Table 90.102
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Physical Component Summary Score at Week 32 by Age

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Responder	15 (37%)	22 (45%)
Non-Responder	26 (63%)	27 (55%)
Missing response	3 (7%)	2 (4%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.70 (0.27,1.81)
p-value		0.461
Inverse unadjusted odds ratio (95% CI) [3]		0.71 (0.28,1.79)
Inverse relative risk (95% CI) [4]		0.81 (0.45,1.36)
Risk difference (95% CI) [4]		-0.08 (-0.28,0.12)
Fisher's Exact p-value (2-sided)		0.520

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 90.102
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Physical Component Summary Score at Week 32 by Age

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Responder	3 (30%)	1 (25%)
Non-Responder	7 (70%)	3 (75%)
Missing response	1 (10%)	1 (25%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.19 (<0.01,100.89)
p-value		0.607
Inverse unadjusted odds ratio (95% CI) [3]		1.26 (0.06,89.70)
Inverse relative risk (95% CI) [4]		1.20 (0.18,31.21)
Risk difference (95% CI) [4]		0.05 (-0.56,0.51)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.103
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in Physical Component Summary Score at Week 32 by Gender

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Responder	13 (48%)	16 (53%)
Non-Responder	14 (52%)	14 (47%)
Missing response	2 (7%)	1 (3%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.94 (0.31,2.89)
p-value		0.913
Inverse unadjusted odds ratio (95% CI) [3]		0.82 (0.25,2.60)
Inverse relative risk (95% CI) [4]		0.90 (0.50,1.58)
Risk difference (95% CI) [4]		-0.05 (-0.31,0.21)
Fisher's Exact p-value (2-sided)		0.793

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.103
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in Physical Component Summary Score at Week 32 by Gender

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Responder	7 (26%)	7 (29%)
Non-Responder	20 (74%)	17 (71%)
Missing response	2 (7%)	3 (13%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.66 (0.13,3.42)
p-value		0.624
Inverse unadjusted odds ratio (95% CI) [3]		0.85 (0.21,3.50)
Inverse relative risk (95% CI) [4]		0.89 (0.32,2.47)
Risk difference (95% CI) [4]		-0.03 (-0.29,0.22)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.104
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Physical Component Summary Score at Week 32 by Region

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Responder	12 (36%)	14 (45%)
Non-Responder	21 (64%)	17 (55%)
Missing response	2 (6%)	1 (3%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.68 (0.23,1.98)
p-value		0.481
Inverse unadjusted odds ratio (95% CI) [3]		0.70 (0.23,2.12)
Inverse relative risk (95% CI) [4]		0.81 (0.41,1.49)
Risk difference (95% CI) [4]		-0.09 (-0.33,0.16)
Fisher's Exact p-value (2-sided)		0.611

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Table 90.104
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Physical Component Summary Score at Week 32 by Region

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	21	23
Responder	8 (38%)	9 (39%)
Non-Responder	13 (62%)	14 (61%)
Missing response	2 (10%)	3 (13%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		1.31 (0.28,6.05)
p-value		0.729
Inverse unadjusted odds ratio (95% CI) [3]		0.96 (0.24,3.80)
Inverse relative risk (95% CI) [4]		0.97 (0.41,2.16)
Risk difference (95% CI) [4]		-0.01 (-0.31,0.28)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.105
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Physical Component Summary Score at Week 32 by Duration of Disease

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Responder	12 (38%)	7 (32%)
Non-Responder	20 (63%)	15 (68%)
Missing response	2 (6%)	3 (14%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.99 (0.25,3.97)
p-value		0.990
Inverse unadjusted odds ratio (95% CI) [3]		1.28 (0.36,4.84)
Inverse relative risk (95% CI) [4]		1.18 (0.55,2.85)
Risk difference (95% CI) [4]		0.06 (-0.21,0.31)
Fisher's Exact p-value (2-sided)		0.775

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.105
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Physical Component Summary Score at Week 32 by Duration of Disease

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Responder	8 (36%)	16 (50%)
Non-Responder	14 (64%)	16 (50%)
Missing response	2 (9%)	1 (3%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.73 (0.22,2.46)
p-value		0.617
Inverse unadjusted odds ratio (95% CI) [3]		0.58 (0.16,1.98)
Inverse relative risk (95% CI) [4]		0.73 (0.34,1.37)
Risk difference (95% CI) [4]		-0.14 (-0.39,0.14)
Fisher's Exact p-value (2-sided)		0.407

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.106
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Physical Component Summary Score at Week 32 by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Responder	13 (43%)	11 (42%)
Non-Responder	17 (57%)	15 (58%)
Missing response	1 (3%)	4 (15%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.84 (0.25,2.88)
p-value		0.785
Inverse unadjusted odds ratio (95% CI) [3]		1.04 (0.32,3.44)
Inverse relative risk (95% CI) [4]		1.02 (0.54,2.08)
Risk difference (95% CI) [4]		0.01 (-0.25,0.27)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.106
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Physical Component Summary Score at Week 32 by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	
n	24	28	
Responder	7 (29%)	12 (43%)	
Non-Responder	17 (71%)	16 (57%)	
Missing response	3 (13%)	0	
Comparison Mepolizumab 300mg vs Placebo [1]			
Logistic regression [2]			
Inverse odds ratio (95% CI)		0.61	(0.17,2.28)
p-value		0.466	
Inverse unadjusted odds ratio (95% CI) [3]		0.56	(0.15,2.00)
Inverse relative risk (95% CI) [4]		0.68	(0.28,1.45)
Risk difference (95% CI) [4]		-0.14	(-0.40,0.15)
Fisher's Exact p-value (2-sided)		0.391	

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 90.111
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Age

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	3	1
Responder	1 (33%)	0
Non-Responder	2 (67%)	1 (100%)
Missing response	0	1 (100%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		Non-estimable
p-value		Non-estimable
Inverse unadjusted odds ratio (95% CI) [3]		0.33 (0.02,>999.99)
Inverse relative risk (95% CI) [4]		>999.99 (0.03,>999.99)
Risk difference (95% CI) [4]		0.33 (-0.81,0.91)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Table 90.111
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Age

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	41	49
Responder	12 (29%)	23 (47%)
Non-Responder	29 (71%)	26 (53%)
Missing response	3 (7%)	2 (4%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.36 (0.13,1.01)
p-value		0.051
Inverse unadjusted odds ratio (95% CI) [3]		0.47 (0.18,1.22)
Inverse relative risk (95% CI) [4]		0.62 (0.33,1.09)
Risk difference (95% CI) [4]		-0.18 (-0.37,0.04)
Fisher's Exact p-value (2-sided)		0.128

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 90.111
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Age

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	10	4
Responder	4 (40%)	2 (50%)
Non-Responder	6 (60%)	2 (50%)
Missing response	1 (10%)	1 (25%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		11.29 (0.02,>999.99)
p-value		0.472
Inverse unadjusted odds ratio (95% CI) [3]		0.69 (0.03,13.30)
Inverse relative risk (95% CI) [4]		0.80 (0.22,5.70)
Risk difference (95% CI) [4]		-0.10 (-0.64,0.45)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.112
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Gender

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	30
Responder	10 (37%)	12 (40%)
Non-Responder	17 (63%)	18 (60%)
Missing response	2 (7%)	1 (3%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		1.26 (0.38,4.19)
p-value		0.709
Inverse unadjusted odds ratio (95% CI) [3]		0.88 (0.26,2.92)
Inverse relative risk (95% CI) [4]		0.93 (0.42,1.85)
Risk difference (95% CI) [4]		-0.03 (-0.29,0.23)
Fisher's Exact p-value (2-sided)		1.000

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 90.112
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Gender

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	27	24
Responder	7 (26%)	13 (54%)
Non-Responder	20 (74%)	11 (46%)
Missing response	2 (7%)	3 (13%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.08 (0.01,0.51)
p-value		0.007
Inverse unadjusted odds ratio (95% CI) [3]		0.30 (0.08,1.11)
Inverse relative risk (95% CI) [4]		0.48 (0.21,1.01)
Risk difference (95% CI) [4]		-0.28 (-0.53,0.00)
Fisher's Exact p-value (2-sided)		0.049

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.113
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Region

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	33	31
Responder	8 (24%)	16 (52%)
Non-Responder	25 (76%)	15 (48%)
Missing response	2 (6%)	1 (3%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.29 (0.09,0.90)
p-value		0.032
Inverse unadjusted odds ratio (95% CI) [3]		0.31 (0.09,0.97)
Inverse relative risk (95% CI) [4]		0.47 (0.21,0.93)
Risk difference (95% CI) [4]		-0.27 (-0.49,-0.03)
Fisher's Exact p-value (2-sided)		0.038

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Population: Intent-to-Treat

Table 90.113
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Region

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	
n	21	23	
Responder	9 (43%)	9 (39%)	
Non-Responder	12 (57%)	14 (61%)	
Missing response	2 (10%)	3 (13%)	
Comparison Mepolizumab 300mg vs Placebo [1]			
Logistic regression [2]			
Inverse odds ratio (95% CI)			1.31 (0.32,5.39)
p-value			0.704
Inverse unadjusted odds ratio (95% CI) [3]			1.16 (0.30,4.58)
Inverse relative risk (95% CI) [4]			1.10 (0.50,2.39)
Risk difference (95% CI) [4]			0.04 (-0.27,0.33)
Fisher's Exact p-value (2-sided)			1.000

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.114
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Duration of Disease

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	32	22
Responder	13 (41%)	11 (50%)
Non-Responder	19 (59%)	11 (50%)
Missing response	2 (6%)	3 (14%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.33 (0.07,1.59)
p-value		0.168
Inverse unadjusted odds ratio (95% CI) [3]		0.69 (0.20,2.34)
Inverse relative risk (95% CI) [4]		0.81 (0.44,1.63)
Risk difference (95% CI) [4]		-0.09 (-0.36,0.18)
Fisher's Exact p-value (2-sided)		0.582

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.114
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Duration of Disease

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	22	32
Responder	4 (18%)	14 (44%)
Non-Responder	18 (82%)	18 (56%)
Missing response	2 (9%)	1 (3%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.31 (0.08,1.18)
p-value		0.085
Inverse unadjusted odds ratio (95% CI) [3]		0.29 (0.06,1.17)
Inverse relative risk (95% CI) [4]		0.42 (0.10,1.06)
Risk difference (95% CI) [4]		-0.26 (-0.48,0.01)
Fisher's Exact p-value (2-sided)		0.078

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.115
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Baseline Blood Eosinophils

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	30	26
Responder	10 (33%)	10 (38%)
Non-Responder	20 (67%)	16 (62%)
Missing response	1 (3%)	4 (15%)
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.79 (0.20,3.15)
p-value		0.742
Inverse unadjusted odds ratio (95% CI) [3]		0.80 (0.23,2.75)
Inverse relative risk (95% CI) [4]		0.87 (0.41,1.84)
Risk difference (95% CI) [4]		-0.05 (-0.32,0.21)
Fisher's Exact p-value (2-sided)		0.783

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.115
Subgroup Analysis of Proportion of Subjects with an Improvement of >=5 in SF-36 Mental Component Summary Score at Week 32 by Baseline Blood Eosinophils

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
n	24	28
Responder	7 (29%)	15 (54%)
Non-Responder	17 (71%)	13 (46%)
Missing response	3 (13%)	0
Comparison Mepolizumab 300mg vs Placebo [1]		
Logistic regression [2]		
Inverse odds ratio (95% CI)		0.44 (0.12,1.58)
p-value		0.206
Inverse unadjusted odds ratio (95% CI) [3]		0.36 (0.09,1.29)
Inverse relative risk (95% CI) [4]		0.54 (0.22,1.08)
Risk difference (95% CI) [4]		-0.24 (-0.49,0.03)
Fisher's Exact p-value (2-sided)		0.096

[1] Analysis compares the number of responders. Subjects with missing response are categorised as non-responders.
[2] Logistic regression analysis adjusted for baseline OCS dose, region and baseline score.
[3] Exact method.
[4] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
Note: Inverse odds ratio and inverse relative risk <1 and risk difference <0 indicate benefit for Mepolizumab over Placebo.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.127
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	0	0
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.127
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	25	28
n [2]	17	19
LS Mean (SE)	12.46 (6.676)	19.79 (6.348)
LS Mean Change (SE)	-6.04 (6.676)	1.28 (6.348)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		7.33
95% CI		(-11.56, 26.21)
p-value		0.432
Corrected Hedges g [3]		0.26
95% CI		(-0.40, 0.92)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.127
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	4	0
n [2]	1	0
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.128
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	14	14
n [2]	8	10
LS Mean (SE)	14.64 (11.442)	22.79 (11.284)
LS Mean Change (SE)	-11.44 (11.442)	-3.28 (11.284)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		8.15
95% CI		(-25.96, 42.26)
p-value		0.619
Corrected Hedges g [3]		0.23
95% CI		(-0.71, 1.16)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.128
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	15	14
n [2]	10	9
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.129
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	17	17
n [2]	11	13
LS Mean (SE)	8.92 (6.787)	8.72 (6.360)
LS Mean Change (SE)	-10.19 (6.787)	-10.39 (6.360)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-0.20
95% CI		(-19.82, 19.41)
p-value		0.983
Corrected Hedges g [3]		-0.01
95% CI		(-0.81, 0.79)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.129
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Region
(Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	12	11
n [2]	7	6
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.130
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	16	11
n [2]	9	9
LS Mean (SE)	12.55 (22.491)	-0.13 (25.684)
LS Mean Change (SE)	-3.30 (22.454)	-15.99 (25.680)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-12.68
95% CI		(-90.07, 64.71)
p-value		0.719
Corrected Hedges g [3]		-0.17
95% CI		(-1.09, 0.76)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.130
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	13	17
n [2]	9	10
LS Mean (SE)	10.16 (8.503)	17.01 (7.841)
LS Mean Change (SE)	-9.80 (8.503)	-2.95 (7.848)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		6.85
95% CI		(-17.68, 31.38)
p-value		0.564
Corrected Hedges g [3]		0.26
95% CI		(-0.64, 1.16)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.131
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	16	14
n [2]	14	10
LS Mean (SE)	-6.09 (13.983)	43.34 (15.532)
LS Mean Change (SE)	-20.95 (14.006)	28.49 (15.537)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		49.44
95% CI		(4.72, 94.16)
p-value		0.033
Corrected Hedges g [3]		0.93
95% CI		(0.08, 1.79)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.131
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Work Time Missed Due to Health (%) by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	13	14
n [2]	4	9
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.134
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	0	0
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Protocol: 200622
Population: Intent-to-Treat

Table 90.134
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	21	25
n [2]	16	16
LS Mean (SE)	29.42 (4.517)	20.53 (4.314)
LS Mean Change (SE)	-5.64 (4.517)	-14.53 (4.314)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.89
95% CI		(-21.79, 4.01)
p-value		0.170
Corrected Hedges g [3]		-0.49
95% CI		(-1.19, 0.21)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.134
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	4	0
n [2]	1	0
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.135
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	11	12
n [2]	7	7
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment and visit, plus interaction terms for visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.135
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	14	13
n [2]	10	9
LS Mean (SE)	19.09 (5.651)	17.96 (5.832)
LS Mean Change (SE)	1.14 (5.051)	-10.87 (5.317)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-12.02
95% CI		(-27.37, 3.34)
p-value		0.118
Corrected Hedges g [3]		-0.72
95% CI		(-1.65, 0.21)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment and visit, plus interaction terms for visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.136
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	14	14
n [2]	10	12
LS Mean (SE)	27.21 (4.566)	15.32 (4.271)
LS Mean Change (SE)	-4.43 (4.566)	-16.32 (4.271)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.89
95% CI		(-24.95, 1.16)
p-value		0.072
Corrected Hedges g [3]		-0.78
95% CI		(-1.65, 0.09)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.136
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Region
(Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	11	11
n [2]	7	4
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.137
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Duration of Disease (Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	13	10
n [2]	8	8
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.137
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Duration of Disease (Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	12	15
n [2]	9	8
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.138
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	16	12
n [2]	14	8
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.138
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Impairment While Working Due to Health (%) by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	9	13
n [2]	3	8
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.141
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	0	0
n [2]	0	0

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.141
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	25	28
n [2]	17	19
LS Mean (SE)	39.37 (6.960)	31.79 (6.577)
LS Mean Change (SE)	-6.63 (6.960)	-14.21 (6.577)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-7.58
95% CI		(-27.15, 11.98)
p-value		0.436
Corrected Hedges g [3]		-0.26
95% CI		(-0.92, 0.40)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Protocol: 200622
Population: Intent-to-Treat

Table 90.141
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	4	0
n [2]	1	0
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.142
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	14	14
n [2]	8	10
LS Mean (SE)	45.33 (11.773)	36.66 (11.028)
LS Mean Change (SE)	-14.23 (11.773)	-22.90 (11.028)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-8.67
95% CI		(-42.98, 25.64)
p-value		0.603
Corrected Hedges g [3]		-0.24
95% CI		(-1.17, 0.69)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.142
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	15	14
n [2]	10	9
LS Mean (SE)	32.33 (10.092)	11.74 (10.328)
LS Mean Change (SE)	0.81 (10.092)	-19.78 (10.328)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-20.59
95% CI		(-54.38, 13.20)
p-value		0.196
Corrected Hedges g [3]		-0.62
95% CI		(-1.55, 0.30)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.143
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	17	17
n [2]	11	13
LS Mean (SE)	39.55 (8.038)	21.29 (7.356)
LS Mean Change (SE)	-4.13 (8.038)	-22.40 (7.356)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-18.27
95% CI		(-41.40, 4.86)
p-value		0.114
Corrected Hedges g [3]		-0.66
95% CI		(-1.49, 0.16)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.143
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Region
(Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	12	11
n [2]	7	6
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.144
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Duration of Disease (Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	16	11
n [2]	9	9
LS Mean (SE)	28.08 (10.615)	47.91 (11.465)
LS Mean Change (SE)	-10.50 (10.163)	-5.64 (10.745)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		4.86
95% CI		(-26.39, 36.11)
p-value		0.747
Corrected Hedges g [3]		0.15
95% CI		(-0.78, 1.07)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment and visit, plus interaction terms for visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.144
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Duration of Disease (Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	13	17
n [2]	9	10
LS Mean (SE)	42.75 (8.834)	22.25 (8.176)
LS Mean Change (SE)	3.56 (10.691)	-25.63 (9.908)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-29.18
95% CI		(-59.50, 1.13)
p-value		0.058
Corrected Hedges g [3]		-0.88
95% CI		(-1.82, 0.06)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of treatment and visit, plus interaction terms for visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.145
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	16	14
n [2]	14	10
LS Mean (SE)	30.23 (7.385)	47.82 (8.640)
LS Mean Change (SE)	-14.22 (7.385)	3.37 (8.640)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		17.59
95% CI		(-6.68, 41.86)
p-value		0.145
Corrected Hedges g [3]		0.62
95% CI		(-0.21, 1.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.145
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Overall Work Impairment Due to Health (%) by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	13	14
n [2]	4	9
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.148
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	3	1
n [1]	3	0
n [2]	2	0
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.148
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	41	49
n [1]	39	47
n [2]	32	39
LS Mean (SE)	39.21 (4.042)	20.77 (3.693)
LS Mean Change (SE)	-2.94 (4.042)	-21.39 (3.693)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-18.44
95% CI		(-29.40, -7.49)
p-value		0.001
Corrected Hedges g [3]		-0.79
95% CI		(-1.28, -0.31)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

Population: Intent-to-Treat

Table 90.148
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Age
(Mixed Model Repeated Measures)

Age (years): >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	10	4
n [1]	10	4
n [2]	7	3
LS Mean (SE)	Non-estimable	Non-estimable
LS Mean Change (SE)	Non-estimable	Non-estimable

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.149
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Gender
(Mixed Model Repeated Measures)

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	30
n [1]	27	27
n [2]	22	23
LS Mean (SE)	42.21 (5.394)	30.28 (5.387)
LS Mean Change (SE)	-7.87 (5.394)	-19.80 (5.387)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-11.93
95% CI		(-27.32, 3.46)
p-value		0.126
Corrected Hedges g [3]		-0.46
95% CI		(-1.05, 0.13)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.149
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Gender
(Mixed Model Repeated Measures)

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	27	24
n [1]	25	24
n [2]	19	19
LS Mean (SE)	32.24 (4.287)	12.76 (4.248)
LS Mean Change (SE)	-1.07 (4.287)	-20.54 (4.248)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-19.47
95% CI		(-31.87, -7.07)
p-value		0.003
Corrected Hedges g [3]		-1.02
95% CI		(-1.70, -0.35)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.150
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Region
(Mixed Model Repeated Measures)

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	33	31
n [1]	32	31
n [2]	25	29
LS Mean (SE)	39.11 (4.680)	20.24 (4.444)
LS Mean Change (SE)	-3.01 (4.680)	-21.88 (4.444)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-18.87
95% CI		(-31.85, -5.89)
p-value		0.005
Corrected Hedges g [3]		-0.78
95% CI		(-1.34, -0.23)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.150
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Region
(Mixed Model Repeated Measures)

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	21	23
n [1]	20	20
n [2]	16	13
LS Mean (SE)	38.97 (5.196)	25.32 (5.846)
LS Mean Change (SE)	-3.13 (5.196)	-16.78 (5.846)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-13.65
95% CI		(-29.69, 2.39)
p-value		0.092
Corrected Hedges g [3]		-0.63
95% CI		(-1.38, 0.12)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.151
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	32	22
n [1]	31	20
n [2]	24	18
LS Mean (SE)	29.00 (4.223)	23.99 (5.061)
LS Mean Change (SE)	-8.08 (4.223)	-13.09 (5.061)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-5.01
95% CI		(-18.37, 8.34)
p-value		0.454
Corrected Hedges g [3]		-0.23
95% CI		(-0.85, 0.38)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.151
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Duration of Disease
(Mixed Model Repeated Measures)

Duration of disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	22	32
n [1]	21	31
n [2]	17	24
LS Mean (SE)	49.72 (5.865)	22.02 (4.963)
LS Mean Change (SE)	2.58 (5.865)	-25.12 (4.963)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-27.70
95% CI		(-43.40, -12.01)
p-value		<0.001
Corrected Hedges g [3]		-1.12
95% CI		(-1.79, -0.45)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Intent-to-Treat

Table 90.152
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	30	26
n [1]	29	24
n [2]	27	19
LS Mean (SE)	35.74 (4.469)	20.81 (5.289)
LS Mean Change (SE)	-5.64 (4.469)	-20.57 (5.289)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-14.93
95% CI		(-29.00, -0.86)
p-value		0.038
Corrected Hedges g [3]		-0.63
95% CI		(-1.23, -0.03)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Population: Intent-to-Treat

Table 90.152
Subgroup Analysis of Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Week 32: Activity Impairment Due to Health (%) by Baseline Blood Eosinophils
(Mixed Model Repeated Measures)

Baseline blood eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)
Number of subjects in subgroup	24	28
n [1]	23	27
n [2]	14	23
LS Mean (SE)	42.21 (5.668)	23.61 (4.793)
LS Mean Change (SE)	-0.76 (5.668)	-19.36 (4.793)
Mepolizumab 300mg SC vs Placebo		
Difference (Mepo - Placebo)		-18.59
95% CI		(-33.65, -3.53)
p-value		0.017
Corrected Hedges g [3]		-0.81
95% CI		(-1.50, -0.12)

[1] Number of subjects with analysable data for one or more time points.
[2] Number of subjects with analysable data at the given time point.
[3] Derived from LS means and associated SE.
Note: Analysis performed separately for each subgroup using mixed model repeated measures with covariates of baseline, baseline OCS dose, region, treatment and visit, plus interaction terms for visit-by-baseline and visit-by-treatment group.
LS mean estimates are weighted according to the observed proportion of each categorical covariate in the study data.

PPD

Protocol: 200622
Population: Safety

Table 100.1
Summary and Analysis of Proportion of Subjects with On-Treatment Adverse Events Overall and by Subgroup

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
All Subjects	47 (87%)	48 (89%)	1.19 (0.32,4.63)	1.02 (0.87,1.20)	0.02 (-0.11,0.15)	>0.999
Subgroups						
Age (Years)						
12-<18	2/3 (67%)	0/1	0.00 (0.00,19.00)	0.00 (0.00,4.24)	-0.67 (-0.99,0.59)	>0.999
18-64	36/41 (88%)	44/49 (90%)	1.22 (0.26,5.75)	1.02 (0.87,1.24)	0.02 (-0.12,0.17)	>0.999
>=65	9/10 (90%)	4/4 (>99%)	Inf (0.02,Inf)	1.11 (0.41,1.80)	0.10 (-0.47,0.47)	>0.999
Gender						
Male	23/27 (85%)	21/24 (88%)	1.22 (0.18,9.27)	1.03 (0.77,1.34)	0.02 (-0.20,0.24)	>0.999
Female	24/27 (89%)	27/30 (90%)	1.13 (0.14,9.20)	1.01 (0.81,1.30)	0.01 (-0.17,0.20)	>0.999
Region						
Europe	29/33 (88%)	28/31 (90%)	1.29 (0.20,9.55)	1.03 (0.83,1.27)	0.02 (-0.15,0.20)	>0.999
Rest of World	18/21 (86%)	20/23 (87%)	1.11 (0.13,9.37)	1.01 (0.76,1.38)	0.01 (-0.23,0.25)	>0.999
Duration of Disease (Years)						
<2.76	26/32 (81%)	19/22 (86%)	1.46 (0.27,10.11)	1.06 (0.76,1.39)	0.05 (-0.19,0.26)	0.723
>=2.76	21/22 (95%)	29/32 (91%)	0.46 (0.01,6.28)	0.95 (0.78,1.19)	-0.05 (-0.21,0.16)	0.638
Baseline Blood Eosinophils						
<1.5 10^9/L	25/30 (83%)	22/26 (85%)	1.10 (0.21,6.27)	1.02 (0.76,1.34)	0.01 (-0.21,0.22)	>0.999
>=1.5 10^9/L	22/24 (92%)	26/28 (93%)	1.18 (0.08,17.50)	1.01 (0.82,1.29)	0.01 (-0.16,0.21)	>0.999

Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher's Exact p-value.

PPD

Protocol: 200622
Population: Safety

Table 100.8
Summary and Analysis of Proportion of Subjects with On-Treatment Non-Fatal Serious Adverse Events
Overall and by Subgroup

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [1]	Risk Difference (Exact 95% CI) [1]	p-value [2]
All Subjects	8 (15%)	9 (17%)	1.15 (0.36,3.76)	1.13 (0.45,3.22)	0.02 (-0.13,0.16)	>0.999
Subgroups						
Age (Years)						
12-<18	2/3 (67%)	0/1	0.00 (0.00,19.00)	0.00 (0.00,4.24)	-0.67 (-0.99,0.59)	>0.999
18-64	5/41 (12%)	8/49 (16%)	1.40 (0.36,5.95)	1.34 (0.47,4.57)	0.04 (-0.12,0.19)	0.765
>=65	1/10 (10%)	1/4 (25%)	3.00 (0.03,261.12)	2.50 (0.08,78.55)	0.15 (-0.30,0.69)	0.505
Gender						
Male	2/27 (7%)	4/24 (17%)	2.50 (0.31,29.77)	2.25 (0.42,16.63)	0.09 (-0.10,0.31)	0.402
Female	6/27 (22%)	5/30 (17%)	0.70 (0.15,3.22)	0.75 (0.23,2.42)	-0.06 (-0.28,0.16)	0.740
Region						
Europe	5/33 (15%)	5/31 (16%)	1.08 (0.22,5.27)	1.06 (0.31,3.68)	0.01 (-0.18,0.20)	>0.999
Rest of World	3/21 (14%)	4/23 (17%)	1.26 (0.18,9.80)	1.22 (0.28,7.62)	0.03 (-0.23,0.27)	>0.999
Duration of Disease (Years)						
<2.76	6/32 (19%)	6/22 (27%)	1.63 (0.36,7.22)	1.45 (0.46,4.55)	0.09 (-0.15,0.33)	0.517
>=2.76	2/22 (9%)	3/32 (9%)	1.03 (0.11,13.43)	1.03 (0.18,10.20)	0.00 (-0.20,0.18)	>0.999
Baseline Blood Eosinophils						
<1.5 10^9/L	3/30 (10%)	5/26 (19%)	2.14 (0.36,15.18)	1.92 (0.47,16.67)	0.09 (-0.11,0.31)	0.451
>=1.5 10^9/L	5/24 (21%)	4/28 (14%)	0.63 (0.11,3.43)	0.69 (0.18,2.69)	-0.07 (-0.29,0.15)	0.716

Note: Information presented as number of subjects with event / number subjects in the subgroup.
[1] Exact unconditional CI calculated by inverting two separate one-sided tests based on the score statistic.
[2] 2-sided Fisher's Exact p-value.

PPD

Protocol: 200622 Page 1 of 9
Population: Safety

Table 100.14
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	3	1				
Risks						
Serious Adverse Events	2 (67%)	0	0.00 (0.00,19.00)	0.00 (0.00,4.24)	-0.67 (-0.99,0.59)	>0.999
Systemic Reactions [1]	0	0				
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.14
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	0				
Local Injection Site Reactions [3]	0	0				
All Infections [4]	0	0				
Serious Infections	0	0				
Potential Opportunistic Infections [5]	0	0				
Neoplasms [4]	0	0				
Malignancies [6]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.14
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age: 12-<18 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	0	0				
Serious Cardiac Disorders	0	0				
Serious CVT Events [6]	0	0				
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.14
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	41	49				
Risks						
Serious Adverse Events	5 (12%)	8 (16%)	1.40 (0.36,5.95)	1.34 (0.47,4.57)	0.04 (-0.12,0.19)	0.765
Systemic Reactions [1]	0	1 (2%)	Inf (0.04,Inf)	Inf (0.06,Inf)	0.02 (-0.07,0.11)	>0.999
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.14
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	1 (2%)	Inf (0.04,Inf)	Inf (0.06,Inf)	0.02 (-0.07,0.11)	>0.999
Local Injection Site Reactions [3]	1 (2%)	4 (8%)	3.56 (0.33,179.40)	3.35 (0.47,84.62)	0.06 (-0.06,0.18)	0.371
All Infections [4]	23 (56%)	35 (71%)	1.96 (0.75,5.15)	1.27 (0.92,1.87)	0.15 (-0.05,0.35)	0.185
Serious Infections	0	5 (10%)	Inf (1.07,Inf)	Inf (1.01,Inf)	0.10 (0.01,0.22)	0.060
Potential Opportunistic Infections [5]	3 (7%)	2 (4%)	0.54 (0.04,4.99)	0.56 (0.06,3.36)	-0.03 (-0.17,0.08)	0.656
Neoplasms [4]	2 (5%)	0	0.00 (0.00,2.88)	0.00 (0.00,2.23)	-0.05 (-0.17,0.03)	0.205
Malignancies [6]	1 (2%)	0	0.00 (0.00,15.90)	0.00 (0.00,12.19)	-0.02 (-0.13,0.06)	0.456

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.14
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age: 18-64 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	1 (2%)	4 (8%)	3.56 (0.33,179.40)	3.35 (0.47,84.62)	0.06 (-0.06,0.18)	0.371
Serious Cardiac Disorders	0	1 (2%)	Inf (0.04,Inf)	Inf (0.06,Inf)	0.02 (-0.07,0.11)	>0.999
Serious CVT Events [6]	1 (2%)	2 (4%)	1.70 (0.09,102.89)	1.67 (0.15,45.44)	0.02 (-0.09,0.12)	>0.999
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.14
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	10	4				
Risks						
Serious Adverse Events	1 (10%)	2 (50%)	9.00 (0.27,587.99)	5.00 (0.52,136.38)	0.40 (-0.13,0.85)	0.176
Systemic Reactions [1]	0	0				
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.14
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	0				
Local Injection Site Reactions [3]	1 (10%)	0	0.00 (0.00,47.50)	0.00 (0.00,33.15)	-0.10 (-0.47,0.47)	>0.999
All Infections [4]	5 (50%)	2 (50%)	1.00 (0.05,19.26)	1.00 (0.17,3.18)	0.00 (-0.55,0.55)	>0.999
Serious Infections	0	2 (50%)	Inf (0.83,Inf)	Inf (0.96,Inf)	0.50 (-0.01,0.93)	0.066
Potential Opportunistic Infections [5]	1 (10%)	1 (25%)	3.00 (0.03,261.12)	2.50 (0.08,78.55)	0.15 (-0.30,0.69)	0.505
Neoplasms [4]	0	0				
Malignancies [6]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.14
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Age

Age: >=65 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	1 (10%)	0	0.00 (0.00,47.50)	0.00 (0.00,33.15)	-0.10 (-0.47,0.47)	>0.999
Serious Cardiac Disorders	1 (10%)	0	0.00 (0.00,47.50)	0.00 (0.00,33.15)	-0.10 (-0.47,0.47)	>0.999
Serious CVT Events [6]	1 (10%)	0	0.00 (0.00,47.50)	0.00 (0.00,33.15)	-0.10 (-0.47,0.47)	>0.999
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	27	24				
Risks						
Serious Adverse Events	2 (7%)	5 (21%)	3.29 (0.46,37.24)	2.81 (0.59,20.77)	0.13 (-0.07,0.35)	0.232
Systemic Reactions [1]	0	1 (4%)	Inf (0.06,Inf)	Inf (0.08,Inf)	0.04 (-0.09,0.21)	0.471
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	1 (4%)	Inf (0.06,Inf)	Inf (0.08,Inf)	0.04 (-0.09,0.21)	0.471
Local Injection Site Reactions [3]	0	1 (4%)	Inf (0.06,Inf)	Inf (0.08,Inf)	0.04 (-0.09,0.21)	0.471
All Infections [4]	12 (44%)	17 (71%)	3.04 (0.83,11.54)	1.59 (0.97,2.97)	0.26 (-0.02,0.52)	0.089
Serious Infections	0	4 (17%)	Inf (1.08,Inf)	Inf (1.11,Inf)	0.17 (0.02,0.37)	0.043
Potential Opportunistic Infections [5]	2 (7%)	1 (4%)	0.54 (0.01,11.23)	0.56 (0.02,6.01)	-0.03 (-0.21,0.15)	>0.999
Neoplasms [4]	0	0				
Malignancies [6]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Male

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	0	2 (8%)	Inf (0.33,Inf)	Inf (0.43,Inf)	0.08 (-0.05,0.27)	0.216
Serious Cardiac Disorders	0	1 (4%)	Inf (0.06,Inf)	Inf (0.08,Inf)	0.04 (-0.09,0.21)	0.471
Serious CVT Events [6]	0	1 (4%)	Inf (0.06,Inf)	Inf (0.08,Inf)	0.04 (-0.09,0.21)	0.471
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	27	30				
Risks						
Serious Adverse Events	6 (22%)	5 (17%)	0.70 (0.15,3.22)	0.75 (0.23,2.42)	-0.06 (-0.28,0.16)	0.740
Systemic Reactions [1]	0	0				
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	0				
Local Injection Site Reactions [3]	2 (7%)	3 (10%)	1.39 (0.15,17.82)	1.35 (0.23,13.34)	0.03 (-0.16,0.20)	>0.999
All Infections [4]	16 (59%)	20 (67%)	1.38 (0.41,4.64)	1.13 (0.74,1.78)	0.07 (-0.19,0.33)	0.594
Serious Infections	0	3 (10%)	Inf (0.54,Inf)	Inf (0.63,Inf)	0.10 (-0.03,0.27)	0.239
Potential Opportunistic Infections [5]	2 (7%)	2 (7%)	0.89 (0.06,13.20)	0.90 (0.06,13.26)	-0.01 (-0.19,0.16)	>0.999
Neoplasms [4]	2 (7%)	0	0.00 (0.00,3.09)	0.00 (0.00,2.36)	-0.07 (-0.24,0.05)	0.220
Malignancies [6]	1 (4%)	0	0.00 (0.00,17.10)	0.00 (0.00,13.03)	-0.04 (-0.19,0.09)	0.474

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.15
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Gender

Gender: Female

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	2 (7%)	2 (7%)	0.89 (0.06,13.20)	0.90 (0.06,13.26)	-0.01 (-0.19,0.16)	>0.999
Serious Cardiac Disorders	1 (4%)	0	0.00 (0.00,17.10)	0.00 (0.00,13.03)	-0.04 (-0.19,0.09)	0.474
Serious CVT Events [6]	2 (7%)	1 (3%)	0.43 (0.01,8.87)	0.45 (0.02,4.84)	-0.04 (-0.21,0.11)	0.599
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Protocol: 200622
Population: Safety

Table 100.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	33	31				
Risks						
Serious Adverse Events	5 (15%)	5 (16%)	1.08 (0.22,5.27)	1.06 (0.31,3.68)	0.01 (-0.18,0.20)	>0.999
Systemic Reactions [1]	0	1 (3%)	Inf (0.06,Inf)	Inf (0.07,Inf)	0.03 (-0.08,0.17)	0.484
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	1 (3%)	Inf (0.06,Inf)	Inf (0.07,Inf)	0.03 (-0.08,0.17)	0.484
Local Injection Site Reactions [3]	1 (3%)	2 (6%)	2.21 (0.11,134.20)	2.13 (0.20,57.73)	0.03 (-0.11,0.19)	0.607
All Infections [4]	18 (55%)	22 (71%)	2.04 (0.65,6.58)	1.30 (0.88,2.08)	0.16 (-0.08,0.40)	0.205
Serious Infections	0	4 (13%)	Inf (1.00,Inf)	Inf (1.06,Inf)	0.13 (0.01,0.30)	0.050
Potential Opportunistic Infections [5]	3 (9%)	1 (3%)	0.33 (0.01,4.49)	0.35 (0.01,3.36)	-0.06 (-0.22,0.09)	0.614
Neoplasms [4]	2 (6%)	0	0.00 (0.00,3.67)	0.00 (0.00,2.81)	-0.06 (-0.20,0.06)	0.493
Malignancies [6]	1 (3%)	0	0.00 (0.00,20.23)	0.00 (0.00,15.42)	-0.03 (-0.16,0.08)	>0.999

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Europe

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	2 (6%)	3 (10%)	1.66 (0.18,21.08)	1.60 (0.27,15.79)	0.04 (-0.12,0.20)	0.667
Serious Cardiac Disorders	1 (3%)	1 (3%)	1.07 (0.01,86.31)	1.06 (0.03,35.34)	0.00 (-0.14,0.14)	>0.999
Serious CVT Events [6]	1 (3%)	1 (3%)	1.07 (0.01,86.31)	1.06 (0.03,35.34)	0.00 (-0.14,0.14)	>0.999
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	21	23				
Risks						
Serious Adverse Events	3 (14%)	5 (22%)	1.67 (0.27,12.22)	1.52 (0.39,13.16)	0.07 (-0.18,0.31)	0.701
Systemic Reactions [1]	0	0				
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	0				
Local Injection Site Reactions [3]	1 (5%)	2 (9%)	1.90 (0.09,117.90)	1.83 (0.17,49.46)	0.04 (-0.16,0.24)	>0.999
All Infections [4]	10 (48%)	15 (65%)	2.06 (0.52,8.24)	1.37 (0.80,2.83)	0.18 (-0.14,0.46)	0.361
Serious Infections	0	3 (13%)	Inf (0.55,Inf)	Inf (0.64,Inf)	0.13 (-0.05,0.34)	0.234
Potential Opportunistic Infections [5]	1 (5%)	2 (9%)	1.90 (0.09,117.90)	1.83 (0.17,49.46)	0.04 (-0.16,0.24)	>0.999
Neoplasms [4]	0	0				
Malignancies [6]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.16
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Region

Region: Rest of World

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	0	1 (4%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.04 (-0.13,0.23)	>0.999
Serious Cardiac Disorders	0	0				
Serious CVT Events [6]	1 (5%)	1 (4%)	0.91 (0.01,74.89)	0.91 (0.03,30.20)	0.00 (-0.20,0.18)	>0.999
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Protocol: 200622
Population: Safety

Table 100.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Duration of Disease

Duration of Disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	32	22				
Risks						
Serious Adverse Events	6 (19%)	7 (32%)	2.02 (0.47,8.71)	1.70 (0.58,4.74)	0.13 (-0.11,0.38)	0.338
Systemic Reactions [1]	0	1 (5%)	Inf (0.08,Inf)	Inf (0.10,Inf)	0.05 (-0.08,0.23)	0.407
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Duration of Disease

Duration of Disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	1 (5%)	Inf (0.08,Inf)	Inf (0.10,Inf)	0.05 (-0.08,0.23)	0.407
Local Injection Site Reactions [3]	1 (3%)	0	0.00 (0.00,27.64)	0.00 (0.00,20.94)	-0.03 (-0.16,0.13)	>0.999
All Infections [4]	12 (38%)	14 (64%)	2.92 (0.83,10.51)	1.70 (0.96,3.14)	0.26 (-0.02,0.51)	0.096
Serious Infections	0	5 (23%)	Inf (2.01,Inf)	Inf (1.78,Inf)	0.23 (0.07,0.45)	0.008
Potential Opportunistic Infections [5]	1 (3%)	1 (5%)	1.48 (0.02,119.56)	1.45 (0.04,48.09)	0.01 (-0.13,0.20)	>0.999
Neoplasms [4]	1 (3%)	0	0.00 (0.00,27.64)	0.00 (0.00,20.94)	-0.03 (-0.16,0.13)	>0.999
Malignancies [6]	1 (3%)	0	0.00 (0.00,27.64)	0.00 (0.00,20.94)	-0.03 (-0.16,0.13)	>0.999

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Protocol: 200622
Population: Safety

Table 100.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Duration of Disease

Duration of Disease: <2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	1 (3%)	3 (14%)	4.89 (0.35,265.05)	4.36 (0.46,112.28)	0.11 (-0.05,0.32)	0.293
Serious Cardiac Disorders	1 (3%)	1 (5%)	1.48 (0.02,119.56)	1.45 (0.04,48.09)	0.01 (-0.13,0.20)	>0.999
Serious CVT Events [6]	2 (6%)	2 (9%)	1.50 (0.10,22.11)	1.45 (0.10,21.29)	0.03 (-0.13,0.23)	>0.999
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Protocol: 200622
Population: Safety

Table 100.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Duration of Disease

Duration of Disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	22	32				
Risks						
Serious Adverse Events	2 (9%)	3 (9%)	1.03 (0.11,13.43)	1.03 (0.18,10.20)	0.00 (-0.20,0.18)	>0.999
Systemic Reactions [1]	0	0				
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Duration of Disease

Duration of Disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	0				
Local Injection Site Reactions [3]	1 (5%)	4 (13%)	3.00 (0.27,154.66)	2.75 (0.40,69.72)	0.08 (-0.12,0.26)	0.638
All Infections [4]	16 (73%)	23 (72%)	0.96 (0.23,3.75)	0.99 (0.70,1.51)	-0.01 (-0.25,0.25)	>0.999
Serious Infections	0	2 (6%)	Inf (0.20,Inf)	Inf (0.26,Inf)	0.06 (-0.10,0.21)	0.508
Potential Opportunistic Infections [5]	3 (14%)	2 (6%)	0.42 (0.03,4.11)	0.46 (0.05,2.69)	-0.07 (-0.30,0.10)	0.388
Neoplasms [4]	1 (5%)	0	0.00 (0.00,13.06)	0.00 (0.00,9.96)	-0.05 (-0.23,0.08)	0.407
Malignancies [6]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.17
Summary and Analysis of Proportion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Duration of Disease

Duration of Disease: >=2.76 Years

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	1 (5%)	1 (3%)	0.68 (0.01,55.68)	0.69 (0.02,22.83)	-0.01 (-0.20,0.13)	>0.999
Serious Cardiac Disorders	0	0				
Serious CVT Events [6]	0	0				
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Protocol: 200622
Population: Safety

Table 100.18
Summary and Analysis of Proporion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Blood Eosinophils

Baseline Blood Eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	30	26				
Risks						
Serious Adverse Events	3 (10%)	6 (23%)	2.70 (0.49,18.39)	2.31 (0.64,16.95)	0.13 (-0.07,0.35)	0.277
Systemic Reactions [1]	0	0				
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

PPD

Table 100.18
Summary and Analysis of Proporion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Blood Eosinophils

Baseline Blood Eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	0				
Local Injection Site Reactions [3]	1 (3%)	2 (8%)	2.42 (0.12,147.40)	2.31 (0.21,62.53)	0.04 (-0.11,0.22)	0.592
All Infections [4]	16 (53%)	17 (65%)	1.65 (0.49,5.63)	1.23 (0.76,2.00)	0.12 (-0.15,0.37)	0.422
Serious Infections	0	3 (12%)	Inf (0.70,Inf)	Inf (0.81,Inf)	0.12 (-0.02,0.30)	0.094
Potential Opportunistic Infections [5]	1 (3%)	1 (4%)	1.16 (0.01,94.15)	1.15 (0.03,38.23)	0.01 (-0.15,0.17)	>0.999
Neoplasms [4]	0	0				
Malignancies [6]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.18
Summary and Analysis of Proporion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Blood Eosinophils

Baseline Blood Eosinophils: <1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	2 (7%)	3 (12%)	1.83 (0.19,23.36)	1.73 (0.29,17.06)	0.05 (-0.12,0.25)	0.655
Serious Cardiac Disorders	1 (3%)	1 (4%)	1.16 (0.01,94.15)	1.15 (0.03,38.23)	0.01 (-0.15,0.17)	>0.999
Serious CVT Events [6]	1 (3%)	2 (8%)	2.42 (0.12,147.40)	2.31 (0.21,62.53)	0.04 (-0.11,0.22)	0.592
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.18
Summary and Analysis of Proporion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Blood Eosinophils

Baseline Blood Eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Number of Subjects in Subgroup	24	28				
Risks						
Serious Adverse Events	5 (21%)	4 (14%)	0.63 (0.11,3.43)	0.69 (0.18,2.69)	-0.07 (-0.29,0.15)	0.716
Systemic Reactions [1]	0	1 (4%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.04 (-0.11,0.18)	>0.999
Anaphylaxis [2]	0	0				
Allergic (Type I) Hypersensitivity	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.18
Summary and Analysis of Proporion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Blood Eosinophils

Baseline Blood Eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Other Systemic	0	1 (4%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.04 (-0.11,0.18)	>0.999
Local Injection Site Reactions [3]	1 (4%)	2 (7%)	1.77 (0.09,108.85)	1.71 (0.16,46.47)	0.03 (-0.15,0.20)	>0.999
All Infections [4]	12 (50%)	20 (71%)	2.50 (0.69,9.22)	1.43 (0.90,2.68)	0.21 (-0.07,0.47)	0.156
Serious Infections	0	4 (14%)	Inf (0.81,Inf)	Inf (0.89,Inf)	0.14 (-0.02,0.33)	0.115
Potential Opportunistic Infections [5]	3 (13%)	2 (7%)	0.54 (0.04,5.22)	0.57 (0.06,3.35)	-0.05 (-0.26,0.13)	0.652
Neoplasms [4]	2 (8%)	0	0.00 (0.00,2.94)	0.00 (0.00,2.24)	-0.08 (-0.27,0.05)	0.208
Malignancies [6]	1 (4%)	0	0.00 (0.00,16.29)	0.00 (0.00,12.40)	-0.04 (-0.22,0.09)	0.462

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.

Table 100.18
Summary and Analysis of Proporion of Subjects with On-Treatment Serious Adverse Events and Adverse Events of Special Interest by Baseline Blood Eosinophils

Baseline Blood Eosinophils: >=1.5 10^9/L

	Placebo (N=54)	Mepolizumab 300mg SC (N=54)	Odds Ratio (Exact 95% CI)	Relative Risk (Exact 95% CI) [8]	Risk Difference (Exact 95% CI) [8]	p-value [9]
Cardiac Disorders [4]	0	1 (4%)	Inf (0.05,Inf)	Inf (0.06,Inf)	0.04 (-0.11,0.18)	>0.999
Serious Cardiac Disorders	0	0				
Serious CVT Events [6]	1 (4%)	0	0.00 (0.00,16.29)	0.00 (0.00,12.40)	-0.04 (-0.22,0.09)	0.462
Serious Ischemic Events [7]	0	0				

[1] Identified by the investigator in eCRF designed for collecting data on systemic reactions.
[2] Considered by the investigator to represent systemic reactions meeting Sampson's anaphylaxis criteria.
[3] Identified by the investigator in eCRF designed for collecting data on local injection site reactions.
[4] Infections from Infections and Infestations SOC; Neoplasms from Neoplasms Benign, Malignant and Unspecified (Including Cysts and Polyps) SOC; Cardiac disorders from Cardiac Disorders SOC. [5] Identified based on published list of pathogens and/or presentations of specific pathogens to be considered as potential opportunistic infections in the setting of biologic therapy (Winthrop, 2015). [6] Identified from prespecified standardised MedDRA queries (SMQs). [7] Subset of serious CVT events identified from prespecified standardised MedDRA queries (SMQs). [8] Score method, [9] 2-sided Fisher's Exact p-value.